[{"content": "No formal drug interaction studies of Aranesp? have been performed.", "metadata": {"original_id": "DrugDDI.d482.s0"}, "annotations": []}, {"content": "Hypertensive crises have resulted when sympathomimetic amines have been used concomitantly within14 days following use of monoamine oxidase inhibitors.", "metadata": {"original_id": "DrugDDI.d194.s0"}, "annotations": [{"start": 39, "end": 62, "tag": "drug"}, {"start": 122, "end": 151, "tag": "drug"}]}, {"content": "DIDREX should not be used concomitantly with other CNS stimulants.", "metadata": {"original_id": "DrugDDI.d194.s1"}, "annotations": [{"start": 0, "end": 7, "tag": "drug"}, {"start": 51, "end": 66, "tag": "drug"}]}, {"content": "Amphetamines may decrease the hypotensive effect of antihypertensives.", "metadata": {"original_id": "DrugDDI.d194.s2"}, "annotations": [{"start": 0, "end": 13, "tag": "drug"}, {"start": 52, "end": 70, "tag": "drug"}]}, {"content": "Amphetamines may enhance the effects of tricyclic antidepressants.", "metadata": {"original_id": "DrugDDI.d194.s3"}, "annotations": [{"start": 0, "end": 13, "tag": "drug"}, {"start": 40, "end": 66, "tag": "drug"}]}, {"content": "Urinary alkalinizing agents increase blood levels and decrease excretion of amphetamines.", "metadata": {"original_id": "DrugDDI.d194.s4"}, "annotations": [{"start": 8, "end": 28, "tag": "drug"}, {"start": 76, "end": 89, "tag": "drug"}]}, {"content": "Urinary acidifying agents decrease blood levels and increase excretion of amphetamines.", "metadata": {"original_id": "DrugDDI.d194.s5"}, "annotations": [{"start": 8, "end": 26, "tag": "drug"}, {"start": 74, "end": 87, "tag": "drug"}]}, {"content": "No drugs are known to interfere with the conversion of fosphenytoin to phenytoin.", "metadata": {"original_id": "DrugDDI.d466.s0"}, "annotations": [{"start": 3, "end": 9, "tag": "drug"}, {"start": 55, "end": 68, "tag": "drug"}, {"start": 71, "end": 81, "tag": "drug"}]}, {"content": "Conversion could be affected by alterations in the level of phosphatase activity, but given the abundance and wide distribution of phosphatases in the body it is unlikely that drugs would affect this activity enough to affect conversion of fosphenytoin to phenytoin.", "metadata": {"original_id": "DrugDDI.d466.s1"}, "annotations": [{"start": 131, "end": 144, "tag": "drug"}, {"start": 176, "end": 182, "tag": "drug"}, {"start": 240, "end": 253, "tag": "drug"}, {"start": 256, "end": 266, "tag": "drug"}]}, {"content": "Drugs highly bound to albumin could increase the unbound fraction of fosphenytoin.", "metadata": {"original_id": "DrugDDI.d466.s2"}, "annotations": [{"start": 0, "end": 6, "tag": "drug"}, {"start": 22, "end": 30, "tag": "drug"}, {"start": 69, "end": 82, "tag": "drug"}]}, {"content": "Although, it is unknown whether this could result in clinically significant effects, caution is advised when administering Cerebyx with other drugs that significantly bind to serum albumin.", "metadata": {"original_id": "DrugDDI.d466.s3"}, "annotations": [{"start": 123, "end": 131, "tag": "drug"}, {"start": 142, "end": 148, "tag": "drug"}, {"start": 175, "end": 189, "tag": "drug"}]}, {"content": "The pharmacokinetics and protein binding of fosphenytoin, phenytoin, and diazepam were not altered when diazepam and Cerebyx were concurrently administered in single submaximal doses.", "metadata": {"original_id": "DrugDDI.d466.s4"}, "annotations": [{"start": 44, "end": 57, "tag": "drug"}, {"start": 58, "end": 68, "tag": "drug"}, {"start": 73, "end": 82, "tag": "drug"}, {"start": 104, "end": 113, "tag": "drug"}, {"start": 117, "end": 125, "tag": "drug"}]}, {"content": "The most significant drug interactions following administration of Cerebyx are expected to occur with drugs that interact with phenytoin.", "metadata": {"original_id": "DrugDDI.d466.s5"}, "annotations": [{"start": 67, "end": 75, "tag": "drug"}, {"start": 102, "end": 108, "tag": "drug"}, {"start": 127, "end": 137, "tag": "drug"}]}, {"content": "Phenytoin is extensively bound to serum plasma proteins and is prone to competitive displacement.", "metadata": {"original_id": "DrugDDI.d466.s6"}, "annotations": [{"start": 0, "end": 10, "tag": "drug"}, {"start": 47, "end": 57, "tag": "drug"}]}, {"content": "Phenytoin is metabolized by hepatic cytochrome P450 enzymes and is particularly susceptible to inhibitory drug interactions because it is subject to saturable metabolism.", "metadata": {"original_id": "DrugDDI.d466.s7"}, "annotations": [{"start": 0, "end": 10, "tag": "drug"}, {"start": 28, "end": 59, "tag": "drug"}]}, {"content": "Inhibition of metabolism may produce significant increases in circulating phenytoin concentrations and enhance the risk of drug toxicity.", "metadata": {"original_id": "DrugDDI.d466.s8"}, "annotations": [{"start": 74, "end": 84, "tag": "drug"}]}, {"content": "Phenytoin is a potent inducer of hepatic drug-metabolizing enzymes.", "metadata": {"original_id": "DrugDDI.d466.s9"}, "annotations": [{"start": 0, "end": 10, "tag": "drug"}]}, {"content": "The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone", "metadata": {"original_id": "DrugDDI.d466.s10"}, "annotations": [{"start": 66, "end": 72, "tag": "drug"}, {"start": 97, "end": 107, "tag": "drug"}, {"start": 153, "end": 164, "tag": "drug"}, {"start": 182, "end": 199, "tag": "drug"}, {"start": 200, "end": 211, "tag": "drug"}, {"start": 212, "end": 221, "tag": "drug"}, {"start": 222, "end": 232, "tag": "drug"}, {"start": 233, "end": 244, "tag": "drug"}, {"start": 245, "end": 255, "tag": "drug"}, {"start": 256, "end": 269, "tag": "drug"}, {"start": 270, "end": 281, "tag": "drug"}, {"start": 298, "end": 308, "tag": "drug"}, {"start": 309, "end": 319, "tag": "drug"}, {"start": 320, "end": 336, "tag": "drug"}, {"start": 337, "end": 352, "tag": "drug"}, {"start": 353, "end": 368, "tag": "drug"}, {"start": 369, "end": 381, "tag": "drug"}, {"start": 382, "end": 395, "tag": "drug"}, {"start": 396, "end": 409, "tag": "drug"}, {"start": 410, "end": 422, "tag": "drug"}, {"start": 423, "end": 433, "tag": "drug"}]}, {"content": ".", "metadata": {"original_id": "DrugDDI.d466.s11"}, "annotations": []}, {"content": "- Drugs that may decrease plasma phenytoin concentrations include: carbamazepine, chronic alcohol abuse, reserpine", "metadata": {"original_id": "DrugDDI.d466.s12"}, "annotations": [{"start": 2, "end": 8, "tag": "drug"}, {"start": 33, "end": 43, "tag": "drug"}, {"start": 67, "end": 81, "tag": "drug"}, {"start": 105, "end": 115, "tag": "drug"}]}, {"content": ".", "metadata": {"original_id": "DrugDDI.d466.s13"}, "annotations": []}, {"content": "- Drugs that may either increase or decrease plasma phenytoin concentrations include: phenobarbital, vaiproic acid, and sodium valproate.", "metadata": {"original_id": "DrugDDI.d466.s14"}, "annotations": [{"start": 2, "end": 8, "tag": "drug"}, {"start": 52, "end": 62, "tag": "drug"}, {"start": 86, "end": 100, "tag": "drug"}, {"start": 120, "end": 137, "tag": "drug"}]}, {"content": "Similarly, the effects of phenytoin on phenobarbital, valproic acid and sodium plasma valproate concentrations are unpredictable", "metadata": {"original_id": "DrugDDI.d466.s15"}, "annotations": [{"start": 26, "end": 36, "tag": "drug"}, {"start": 39, "end": 53, "tag": "drug"}, {"start": 54, "end": 68, "tag": "drug"}, {"start": 86, "end": 97, "tag": "drug"}]}, {"content": ".", "metadata": {"original_id": "DrugDDI.d466.s16"}, "annotations": []}, {"content": "- Although not a true drug interaction, tricyclic antidepressants may precipitate seizures in susceptible patients and Cerebyx dosage may need to be adjusted", "metadata": {"original_id": "DrugDDI.d466.s17"}, "annotations": [{"start": 40, "end": 66, "tag": "drug"}, {"start": 119, "end": 127, "tag": "drug"}]}, {"content": ".", "metadata": {"original_id": "DrugDDI.d466.s18"}, "annotations": []}, {"content": "- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.", "metadata": {"original_id": "DrugDDI.d466.s19"}, "annotations": [{"start": 2, "end": 8, "tag": "drug"}, {"start": 38, "end": 48, "tag": "drug"}, {"start": 57, "end": 72, "tag": "drug"}, {"start": 73, "end": 89, "tag": "drug"}, {"start": 90, "end": 99, "tag": "drug"}, {"start": 100, "end": 110, "tag": "drug"}, {"start": 111, "end": 123, "tag": "drug"}, {"start": 124, "end": 134, "tag": "drug"}, {"start": 135, "end": 146, "tag": "drug"}, {"start": 147, "end": 167, "tag": "drug"}, {"start": 168, "end": 177, "tag": "drug"}, {"start": 178, "end": 188, "tag": "drug"}, {"start": 189, "end": 202, "tag": "drug"}, {"start": 203, "end": 213, "tag": "drug"}]}, {"content": "Monitoring of plasma phenytoin concentrations may be helpful when possible drug interactions are suspected.", "metadata": {"original_id": "DrugDDI.d466.s20"}, "annotations": [{"start": 21, "end": 31, "tag": "drug"}]}, {"content": "Drug/Laboratory Test Interactions Phenytoin may decrease serum concentrations of 14.", "metadata": {"original_id": "DrugDDI.d466.s21"}, "annotations": [{"start": 0, "end": 5, "tag": "drug"}, {"start": 34, "end": 44, "tag": "drug"}]}, {"content": "It may also produce artifactually low results in dexamethasone or metyrapone tests.", "metadata": {"original_id": "DrugDDI.d466.s22"}, "annotations": [{"start": 49, "end": 63, "tag": "drug"}]}, {"content": "Phenytoin may also cause increased serum concentrations of glucose, alkaline phosphatase, and gamma glutamyl transpeptidase (GGT).", "metadata": {"original_id": "DrugDDI.d466.s23"}, "annotations": [{"start": 0, "end": 10, "tag": "drug"}, {"start": 59, "end": 67, "tag": "drug"}, {"start": 68, "end": 89, "tag": "drug"}, {"start": 94, "end": 125, "tag": "drug"}]}, {"content": "Care should be taken when using immunoanalytical methods to measure plasma phenytoin concentrations following Cerebyx administration.", "metadata": {"original_id": "DrugDDI.d466.s24"}, "annotations": [{"start": 75, "end": 85, "tag": "drug"}, {"start": 110, "end": 118, "tag": "drug"}]}, {"content": "Aminoglycosides The mixing of piperacillin with an aminoglycoside in vitro can result in substantial inactivation of the aminoglycoside.", "metadata": {"original_id": "DrugDDI.d235.s0"}, "annotations": [{"start": 0, "end": 16, "tag": "drug"}, {"start": 30, "end": 43, "tag": "drug"}, {"start": 51, "end": 66, "tag": "drug"}, {"start": 121, "end": 136, "tag": "drug"}]}, {"content": "Vecuronium When used in the perioperative period, piperacillin has been implicated in the prolongation of the neuromuscular blockade of vecuronium.", "metadata": {"original_id": "DrugDDI.d235.s1"}, "annotations": [{"start": 0, "end": 11, "tag": "drug"}, {"start": 50, "end": 63, "tag": "drug"}, {"start": 136, "end": 147, "tag": "drug"}]}, {"content": "Caution is indicated when piperacillin is used perioperatively.", "metadata": {"original_id": "DrugDDI.d235.s2"}, "annotations": [{"start": 26, "end": 39, "tag": "drug"}]}, {"content": "In one controlled clinical study, the ureidopenicillins, including piperacillin, were reported to prolong the action of vecuronium.", "metadata": {"original_id": "DrugDDI.d235.s3"}, "annotations": [{"start": 67, "end": 80, "tag": "drug"}, {"start": 120, "end": 131, "tag": "drug"}]}, {"content": "Due to their similar mechanism of action, it is expected that the neuromuscular blockade produced by any of the non-depolarizing muscle relaxants could be prolonged in the presence of piperacillin.", "metadata": {"original_id": "DrugDDI.d235.s4"}, "annotations": [{"start": 112, "end": 146, "tag": "drug"}, {"start": 184, "end": 197, "tag": "drug"}]}, {"content": "Probenecid The oral combination of probenecid before intramuscular injection of PIPRACIL produces an increase in piperacillin peak serum level of about 30%.", "metadata": {"original_id": "DrugDDI.d235.s5"}, "annotations": [{"start": 0, "end": 11, "tag": "drug"}, {"start": 35, "end": 46, "tag": "drug"}, {"start": 80, "end": 89, "tag": "drug"}, {"start": 113, "end": 126, "tag": "drug"}]}, {"content": "Anticoagulants Coagulation parameters should be tested more frequently and monitored regularly during simultaneous administration of high doses of heparin, oral anticoagulants, or other drugs that may affect the blood coagulation system or the thrombocyte function.", "metadata": {"original_id": "DrugDDI.d235.s6"}, "annotations": [{"start": 0, "end": 15, "tag": "drug"}, {"start": 147, "end": 155, "tag": "drug"}, {"start": 156, "end": 176, "tag": "drug"}, {"start": 186, "end": 192, "tag": "drug"}]}, {"content": "Methotrexate Piperacillin sodium may reduce the excretion of methotrexate.", "metadata": {"original_id": "DrugDDI.d235.s7"}, "annotations": [{"start": 0, "end": 27, "tag": "drug"}, {"start": 61, "end": 74, "tag": "drug"}]}, {"content": "Therefore, serum levels of methotrexate should be monitored in patients to avoid drug toxicity.", "metadata": {"original_id": "DrugDDI.d235.s8"}, "annotations": [{"start": 27, "end": 40, "tag": "drug"}]}, {"content": "Drug/Laboratory Test Interactions As with other penicillins, the administration of PIPRACIL may result in a false-positive reaction for glucose in the urine using a copper-reduction method.", "metadata": {"original_id": "DrugDDI.d235.s9"}, "annotations": [{"start": 0, "end": 5, "tag": "drug"}, {"start": 42, "end": 60, "tag": "drug"}, {"start": 83, "end": 92, "tag": "drug"}, {"start": 136, "end": 144, "tag": "drug"}, {"start": 165, "end": 172, "tag": "drug"}]}, {"content": "It is recommended that glucose tests based on enzymatic glucose oxidase reactions be used.", "metadata": {"original_id": "DrugDDI.d235.s10"}, "annotations": [{"start": 56, "end": 72, "tag": "drug"}]}, {"content": "There have been reports of positive test results using the Bio-Rad Laboratories Platelia Aspergillus EIA test in patients receiving piperacillin/tazobactam injection who were subsequently found to be free of Aspergillus infection.", "metadata": {"original_id": "DrugDDI.d235.s11"}, "annotations": [{"start": 132, "end": 145, "tag": "drug"}, {"start": 145, "end": 156, "tag": "drug"}]}, {"content": "Cross-reactions with non-Aspergillus polysaccharides and polyfuranoses with the Bio-Rad Laboratories Platelia Aspergillus EIA test have been reported.", "metadata": {"original_id": "DrugDDI.d235.s12"}, "annotations": [{"start": 37, "end": 53, "tag": "drug"}]}, {"content": "Therefore, positive test results in patients receiving piperacillin should be interpreted cautiously and confirmed by other diagnostic methods.", "metadata": {"original_id": "DrugDDI.d235.s13"}, "annotations": [{"start": 55, "end": 68, "tag": "drug"}]}, {"content": "Studies in vitro show that caspofungin acetate is not an inhibitor of any enzyme in the cytochrome P450 (CYP) system.", "metadata": {"original_id": "DrugDDI.d59.s0"}, "annotations": [{"start": 27, "end": 47, "tag": "drug"}, {"start": 88, "end": 104, "tag": "drug"}, {"start": 105, "end": 109, "tag": "drug"}]}, {"content": "In clinical studies, caspofungin did not induce the CYP3A4 metabolism of other drugs.", "metadata": {"original_id": "DrugDDI.d59.s1"}, "annotations": [{"start": 21, "end": 33, "tag": "drug"}, {"start": 52, "end": 59, "tag": "drug"}, {"start": 79, "end": 85, "tag": "drug"}]}, {"content": "Caspofungin is not a substrate for P-glycoprotein and is a poor substrate for cytochrome P450 enzymes.", "metadata": {"original_id": "DrugDDI.d59.s2"}, "annotations": [{"start": 0, "end": 12, "tag": "drug"}, {"start": 37, "end": 50, "tag": "drug"}, {"start": 78, "end": 94, "tag": "drug"}]}, {"content": "Clinical studies in healthy volunteers show that the pharmacokinetics of CANCIDAS are not altered by itraconazole, amphotericin B, mycophenolate, nelfinavir, or tacrolimus.", "metadata": {"original_id": "DrugDDI.d59.s3"}, "annotations": [{"start": 73, "end": 82, "tag": "drug"}, {"start": 101, "end": 114, "tag": "drug"}, {"start": 115, "end": 130, "tag": "drug"}, {"start": 131, "end": 145, "tag": "drug"}, {"start": 146, "end": 157, "tag": "drug"}, {"start": 161, "end": 172, "tag": "drug"}]}, {"content": "CANCIDAS has no effect on the pharmacokinetics of itraconazole, amphotericin B, or the active metabolite of mycophenolate.", "metadata": {"original_id": "DrugDDI.d59.s4"}, "annotations": [{"start": 0, "end": 9, "tag": "drug"}, {"start": 50, "end": 63, "tag": "drug"}, {"start": 64, "end": 79, "tag": "drug"}, {"start": 87, "end": 105, "tag": "drug"}, {"start": 108, "end": 122, "tag": "drug"}]}, {"content": "CANCIDAS reduced the blood AUC0-12 of tacrolimus (FK-506, Prograf span class= c4 ?3) by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of CANCIDAS 70 mg daily, as compared to results from a control period in which tacrolimus was administered alone.", "metadata": {"original_id": "DrugDDI.d59.s5"}, "annotations": [{"start": 0, "end": 9, "tag": "drug"}, {"start": 38, "end": 49, "tag": "drug"}, {"start": 50, "end": 57, "tag": "drug"}, {"start": 78, "end": 81, "tag": "drug"}, {"start": 219, "end": 230, "tag": "drug"}, {"start": 304, "end": 313, "tag": "drug"}, {"start": 380, "end": 391, "tag": "drug"}]}, {"content": "For patients receiving both therapies, standard monitoring of tacrolimus blood concentrations and appropriate tacrolimus dosage adjustments are recommended.", "metadata": {"original_id": "DrugDDI.d59.s6"}, "annotations": [{"start": 62, "end": 73, "tag": "drug"}, {"start": 110, "end": 121, "tag": "drug"}]}, {"content": "In two clinical studies, cyclosporine (one 4 mg/kg dose or two 3 mg/kg doses) increased the AUC of caspofungin by approximately 35%.", "metadata": {"original_id": "DrugDDI.d59.s7"}, "annotations": [{"start": 25, "end": 38, "tag": "drug"}, {"start": 99, "end": 111, "tag": "drug"}]}, {"content": "CANCIDAS did not increase the plasma levels of cyclosporine.", "metadata": {"original_id": "DrugDDI.d59.s8"}, "annotations": [{"start": 0, "end": 9, "tag": "drug"}, {"start": 47, "end": 60, "tag": "drug"}]}, {"content": "There were transient increases in liver ALT and AST when CANCIDAS and cyclosporine were co-administered.", "metadata": {"original_id": "DrugDDI.d59.s9"}, "annotations": [{"start": 34, "end": 40, "tag": "drug"}, {"start": 48, "end": 52, "tag": "drug"}, {"start": 57, "end": 66, "tag": "drug"}, {"start": 70, "end": 83, "tag": "drug"}]}, {"content": "A drug-drug interaction study with rifampin in healthy volunteers has shown a 30% decrease in caspofungin trough concentrations.", "metadata": {"original_id": "DrugDDI.d59.s10"}, "annotations": [{"start": 35, "end": 44, "tag": "drug"}, {"start": 94, "end": 106, "tag": "drug"}]}, {"content": "Patients on rifampin should receive 70 mg of CANCIDAS daily.", "metadata": {"original_id": "DrugDDI.d59.s11"}, "annotations": [{"start": 12, "end": 21, "tag": "drug"}, {"start": 45, "end": 54, "tag": "drug"}]}, {"content": "In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.", "metadata": {"original_id": "DrugDDI.d59.s12"}, "annotations": [{"start": 146, "end": 156, "tag": "drug"}, {"start": 157, "end": 168, "tag": "drug"}, {"start": 169, "end": 179, "tag": "drug"}, {"start": 180, "end": 194, "tag": "drug"}, {"start": 198, "end": 212, "tag": "drug"}, {"start": 218, "end": 227, "tag": "drug"}, {"start": 277, "end": 289, "tag": "drug"}]}, {"content": "It is not known which drug clearance mechanism involved in caspofungin disposition may be inducible.", "metadata": {"original_id": "DrugDDI.d59.s13"}, "annotations": [{"start": 59, "end": 71, "tag": "drug"}]}, {"content": "When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered", "metadata": {"original_id": "DrugDDI.d59.s14"}, "annotations": [{"start": 5, "end": 14, "tag": "drug"}, {"start": 74, "end": 84, "tag": "drug"}, {"start": 85, "end": 96, "tag": "drug"}, {"start": 97, "end": 107, "tag": "drug"}, {"start": 108, "end": 122, "tag": "drug"}, {"start": 126, "end": 140, "tag": "drug"}, {"start": 173, "end": 182, "tag": "drug"}]}, {"content": ".", "metadata": {"original_id": "DrugDDI.d59.s15"}, "annotations": []}, {"content": "?", "metadata": {"original_id": "DrugDDI.d59.s16"}, "annotations": []}, {"content": "Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc).", "metadata": {"original_id": "DrugDDI.d337.s0"}, "annotations": [{"start": 0, "end": 30, "tag": "drug"}, {"start": 56, "end": 64, "tag": "drug"}, {"start": 74, "end": 90, "tag": "drug"}, {"start": 91, "end": 101, "tag": "drug"}, {"start": 102, "end": 112, "tag": "drug"}, {"start": 113, "end": 127, "tag": "drug"}]}, {"content": "MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines.", "metadata": {"original_id": "DrugDDI.d337.s1"}, "annotations": [{"start": 0, "end": 15, "tag": "drug"}, {"start": 41, "end": 57, "tag": "drug"}, {"start": 77, "end": 92, "tag": "drug"}]}, {"content": "May interact anticoagulants (altered hypo-prothrombinemic effect), barbiturates, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), corticosteroids (increased effect of corticosteroids).", "metadata": {"original_id": "DrugDDI.d15.s0"}, "annotations": [{"start": 13, "end": 28, "tag": "drug"}, {"start": 67, "end": 80, "tag": "drug"}, {"start": 81, "end": 90, "tag": "drug"}, {"start": 120, "end": 138, "tag": "drug"}, {"start": 176, "end": 195, "tag": "drug"}, {"start": 197, "end": 213, "tag": "drug"}, {"start": 234, "end": 250, "tag": "drug"}]}, {"content": "Inhibitors of CYP3A4-Eplerenone metabolism is predominantly mediated via CYP3A4.", "metadata": {"original_id": "DrugDDI.d578.s0"}, "annotations": [{"start": 14, "end": 21, "tag": "drug"}, {"start": 73, "end": 80, "tag": "drug"}]}, {"content": "A pharmacokinetic study evaluating the administration of a single dose of INSPRA 100 mg with ketoconazole 200 mg BID, a potent inhibitor of the CYP3A4 pathway, showed a 1.7-fold increase in Cmax of eplerenone and a 5.4-fold increase in AUC of eplerenone.", "metadata": {"original_id": "DrugDDI.d578.s1"}, "annotations": [{"start": 74, "end": 81, "tag": "drug"}, {"start": 93, "end": 113, "tag": "drug"}, {"start": 144, "end": 151, "tag": "drug"}, {"start": 198, "end": 209, "tag": "drug"}, {"start": 243, "end": 254, "tag": "drug"}]}, {"content": "INSPRA should not be used with drugs described as strong inhibitors of CYP3A4 in their labeling.", "metadata": {"original_id": "DrugDDI.d578.s2"}, "annotations": [{"start": 0, "end": 7, "tag": "drug"}, {"start": 31, "end": 37, "tag": "drug"}, {"start": 71, "end": 78, "tag": "drug"}]}, {"content": "Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.", "metadata": {"original_id": "DrugDDI.d578.s3"}, "annotations": [{"start": 18, "end": 29, "tag": "drug"}, {"start": 40, "end": 47, "tag": "drug"}, {"start": 65, "end": 85, "tag": "drug"}, {"start": 90, "end": 107, "tag": "drug"}, {"start": 111, "end": 122, "tag": "drug"}, {"start": 135, "end": 154, "tag": "drug"}, {"start": 191, "end": 202, "tag": "drug"}]}, {"content": "ACE Inhibitors and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or angiotensin II receptor antagonists (ACEI/ARB).", "metadata": {"original_id": "DrugDDI.d578.s4"}, "annotations": [{"start": 0, "end": 15, "tag": "drug"}, {"start": 19, "end": 55, "tag": "drug"}, {"start": 152, "end": 159, "tag": "drug"}, {"start": 185, "end": 200, "tag": "drug"}, {"start": 203, "end": 239, "tag": "drug"}]}, {"content": "Rates of patients with maximum potassium levels  5.5 mEq/L were similar regardless of the use of ACEI/ARB.", "metadata": {"original_id": "DrugDDI.d578.s5"}, "annotations": []}, {"content": "ACE Inhibitors and Angiotensin II Receptor Antagonists (Hypertension)- In clinical studies of patients with hypertension, the addition of INSPRA 50 to 100 mg to ACE inhibitors and angiotensin II receptor antagonists increased mean serum potassium slightly (about 0.09-0.13 mEq/L).", "metadata": {"original_id": "DrugDDI.d578.s6"}, "annotations": [{"start": 0, "end": 15, "tag": "drug"}, {"start": 19, "end": 55, "tag": "drug"}, {"start": 138, "end": 145, "tag": "drug"}, {"start": 161, "end": 176, "tag": "drug"}, {"start": 180, "end": 216, "tag": "drug"}]}, {"content": "In a study in diabetics with microalbuminuria INSPRA 200 mg combined with the ACE inhibitor enalapril 10 mg increased the frequency of hyperkalemia (serum potassium  5.5 mEq/L) from 17% on enalapril alone to 38%.", "metadata": {"original_id": "DrugDDI.d578.s7"}, "annotations": [{"start": 46, "end": 53, "tag": "drug"}, {"start": 92, "end": 108, "tag": "drug"}, {"start": 189, "end": 199, "tag": "drug"}]}, {"content": "Lithium-A drug interaction study of eplerenone with lithium has not been conducted.", "metadata": {"original_id": "DrugDDI.d578.s8"}, "annotations": [{"start": 0, "end": 8, "tag": "drug"}, {"start": 36, "end": 47, "tag": "drug"}, {"start": 52, "end": 60, "tag": "drug"}]}, {"content": "Lithium toxicity has been reported in patients receiving lithium concomitantly with diuretics and ACE inhibitors.", "metadata": {"original_id": "DrugDDI.d578.s9"}, "annotations": [{"start": 57, "end": 65, "tag": "drug"}, {"start": 84, "end": 94, "tag": "drug"}, {"start": 98, "end": 113, "tag": "drug"}]}, {"content": "Serum lithium levels should be monitored frequently if INSPRA is administered concomitantly with lithium.", "metadata": {"original_id": "DrugDDI.d578.s10"}, "annotations": [{"start": 55, "end": 62, "tag": "drug"}, {"start": 97, "end": 105, "tag": "drug"}]}, {"content": "Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)-A drug interaction study of eplerenone with an NSAID has not been conducted.", "metadata": {"original_id": "DrugDDI.d578.s11"}, "annotations": [{"start": 0, "end": 37, "tag": "drug"}, {"start": 38, "end": 45, "tag": "drug"}, {"start": 74, "end": 85, "tag": "drug"}, {"start": 93, "end": 99, "tag": "drug"}]}, {"content": "The administration of other potassium-sparing antihypertensives with NSAIDs has been shown to reduce the antihypertensive effect in some patients and result in severe hyperkalemia in patients with impaired renal function.", "metadata": {"original_id": "DrugDDI.d578.s12"}, "annotations": [{"start": 28, "end": 65, "tag": "drug"}, {"start": 69, "end": 76, "tag": "drug"}]}, {"content": "Therefore, when INSPRA and NSAIDs are used concomitantly, patients should be observed to determine whether the desired effect on blood pressure is obtained.", "metadata": {"original_id": "DrugDDI.d578.s13"}, "annotations": [{"start": 16, "end": 23, "tag": "drug"}, {"start": 27, "end": 34, "tag": "drug"}]}, {"content": "The physician should be alert for possible combined drug actions, desirable or undesirable, involving ifosfamide even though ifosfamide has been used successfully concurrently with other drugs, including other cytotoxic drugs.", "metadata": {"original_id": "DrugDDI.d470.s0"}, "annotations": [{"start": 102, "end": 113, "tag": "drug"}, {"start": 125, "end": 136, "tag": "drug"}, {"start": 187, "end": 193, "tag": "drug"}, {"start": 204, "end": 226, "tag": "drug"}]}, {"content": "No drug interactions have been observed with the Vitrasert Implant.", "metadata": {"original_id": "DrugDDI.d281.s0"}, "annotations": [{"start": 49, "end": 59, "tag": "drug"}]}, {"content": "There is limited experience with use of retinal tamponades in conjunction with the Vitrasert Implant.", "metadata": {"original_id": "DrugDDI.d281.s1"}, "annotations": [{"start": 83, "end": 93, "tag": "drug"}]}, {"content": "Co-administration of BOTOX? and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.", "metadata": {"original_id": "DrugDDI.d134.s0"}, "annotations": [{"start": 32, "end": 48, "tag": "drug"}, {"start": 115, "end": 122, "tag": "drug"}, {"start": 197, "end": 203, "tag": "drug"}]}, {"content": "The effect of administering different botulinum neurotoxin serotypes at the same time or within several months of each other is unknown.", "metadata": {"original_id": "DrugDDI.d134.s1"}, "annotations": [{"start": 38, "end": 59, "tag": "drug"}]}, {"content": "Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin.", "metadata": {"original_id": "DrugDDI.d134.s2"}, "annotations": [{"start": 81, "end": 98, "tag": "drug"}, {"start": 165, "end": 182, "tag": "drug"}]}, {"content": "General No clinical drug interaction studies were performed.", "metadata": {"original_id": "DrugDDI.d246.s0"}, "annotations": []}, {"content": "No evaluation of EXTRANEALs effects on the cytochrome P450 system was conducted.", "metadata": {"original_id": "DrugDDI.d246.s1"}, "annotations": [{"start": 17, "end": 27, "tag": "drug"}, {"start": 43, "end": 59, "tag": "drug"}]}, {"content": "As with other dialysis solutions, blood concentrations of dialyzable drugs may be reduced by dialysis.", "metadata": {"original_id": "DrugDDI.d246.s2"}, "annotations": [{"start": 14, "end": 33, "tag": "drug"}, {"start": 69, "end": 75, "tag": "drug"}]}, {"content": "Dosage adjustment of concomitant medications may be necessary.", "metadata": {"original_id": "DrugDDI.d246.s3"}, "annotations": [{"start": 33, "end": 45, "tag": "drug"}]}, {"content": "In patients using cardiac glycosides (digoxin and others), plasma levels of calcium, potassium and magnesium must be carefully monitored.", "metadata": {"original_id": "DrugDDI.d246.s4"}, "annotations": [{"start": 18, "end": 37, "tag": "drug"}, {"start": 38, "end": 46, "tag": "drug"}, {"start": 76, "end": 84, "tag": "drug"}, {"start": 85, "end": 95, "tag": "drug"}, {"start": 99, "end": 109, "tag": "drug"}]}, {"content": "Insulin A clinical study in 6 insulin-dependent diabetic patients demonstrated no effect of EXTRANEAL on insulin absorption from the peritoneal cavity or on insulins ability to control blood glucose when insulin was administered intraperitoneally with EXTRANEAL.", "metadata": {"original_id": "DrugDDI.d246.s5"}, "annotations": [{"start": 0, "end": 8, "tag": "drug"}, {"start": 92, "end": 102, "tag": "drug"}, {"start": 105, "end": 113, "tag": "drug"}, {"start": 157, "end": 165, "tag": "drug"}, {"start": 204, "end": 212, "tag": "drug"}, {"start": 252, "end": 262, "tag": "drug"}]}, {"content": "However, appropriate monitoring of blood glucose should be performed when initiating EXTRANEAL in diabetic patients and insulin dosage should be adjusted if needed.", "metadata": {"original_id": "DrugDDI.d246.s6"}, "annotations": [{"start": 85, "end": 95, "tag": "drug"}, {"start": 120, "end": 128, "tag": "drug"}]}, {"content": "Heparin No human drug interaction studies with heparin were conducted.", "metadata": {"original_id": "DrugDDI.d246.s7"}, "annotations": [{"start": 0, "end": 8, "tag": "drug"}, {"start": 47, "end": 55, "tag": "drug"}]}, {"content": "In vitro studies demonstrated no evidence of incompatibility of heparin with EXTRANEAL.", "metadata": {"original_id": "DrugDDI.d246.s8"}, "annotations": [{"start": 64, "end": 72, "tag": "drug"}, {"start": 77, "end": 87, "tag": "drug"}]}, {"content": "Antibiotics No human drug interaction studies with antibiotics were conducted.", "metadata": {"original_id": "DrugDDI.d246.s9"}, "annotations": [{"start": 0, "end": 12, "tag": "drug"}, {"start": 51, "end": 63, "tag": "drug"}]}, {"content": "In vitro studies evaluating the minimum inhibitory concentration (MIC) of vancomycin, cefazolin, ampicillin, ampicillin/flucoxacillin, ceftazidime, gentamicin, and amphotericin demonstrated no evidence of incompatibility of these antibiotics with EXTRANEAL.", "metadata": {"original_id": "DrugDDI.d246.s10"}, "annotations": [{"start": 74, "end": 85, "tag": "drug"}, {"start": 86, "end": 96, "tag": "drug"}, {"start": 97, "end": 108, "tag": "drug"}, {"start": 109, "end": 120, "tag": "drug"}, {"start": 135, "end": 147, "tag": "drug"}, {"start": 148, "end": 159, "tag": "drug"}, {"start": 164, "end": 177, "tag": "drug"}, {"start": 230, "end": 242, "tag": "drug"}, {"start": 247, "end": 257, "tag": "drug"}]}, {"content": "Drug/Laboratory Test Interactions Blood Glucose Blood glucose measurement must be done with a glucose-specific method to prevent maltose interference with test results.", "metadata": {"original_id": "DrugDDI.d246.s11"}, "annotations": [{"start": 0, "end": 5, "tag": "drug"}, {"start": 94, "end": 102, "tag": "drug"}, {"start": 121, "end": 129, "tag": "drug"}, {"start": 129, "end": 137, "tag": "drug"}]}, {"content": "Since falsely elevated glucose levels have been observed with blood glucose monitoring devices and test strips that use glucose dehydrogenase pyrroloquinolinequinone (GDH PQQ)-based methods, GDH PQQ-based methods should not be used to measure glucose levels in patients administered EXTRANEAL..", "metadata": {"original_id": "DrugDDI.d246.s12"}, "annotations": [{"start": 120, "end": 142, "tag": "drug"}, {"start": 167, "end": 171, "tag": "drug"}, {"start": 191, "end": 195, "tag": "drug"}, {"start": 283, "end": 293, "tag": "drug"}]}, {"content": "Serum Amylase An apparent decrease in serum amylase activity has been observed in patients administered EXTRANEAL.", "metadata": {"original_id": "DrugDDI.d246.s13"}, "annotations": [{"start": 104, "end": 114, "tag": "drug"}]}, {"content": "Preliminary investigations indicate that icodextrin and its metabolites interfere with enzymatic-based amylase assays, resulting in inaccurately low values.", "metadata": {"original_id": "DrugDDI.d246.s14"}, "annotations": [{"start": 41, "end": 52, "tag": "drug"}, {"start": 60, "end": 72, "tag": "drug"}, {"start": 103, "end": 111, "tag": "drug"}]}, {"content": "This should be taken into account when evaluating serum amylase levels for diagnosis or monitoring of pancreatitis in patients using EXTRANEAL.", "metadata": {"original_id": "DrugDDI.d246.s15"}, "annotations": [{"start": 133, "end": 143, "tag": "drug"}]}, {"content": "D.", "metadata": {"original_id": "DrugDDI.d388.s0"}, "annotations": []}, {"content": "Drug and Laboratory Test Interactions 1.", "metadata": {"original_id": "DrugDDI.d388.s1"}, "annotations": [{"start": 0, "end": 5, "tag": "drug"}]}, {"content": "Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time;", "metadata": {"original_id": "DrugDDI.d388.s2"}, "annotations": []}, {"content": "increased platelet count;", "metadata": {"original_id": "DrugDDI.d388.s3"}, "annotations": []}, {"content": "increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin;", "metadata": {"original_id": "DrugDDI.d388.s4"}, "annotations": [{"start": 10, "end": 22, "tag": "drug"}, {"start": 26, "end": 34, "tag": "drug"}, {"start": 40, "end": 48, "tag": "drug"}, {"start": 49, "end": 65, "tag": "drug"}, {"start": 123, "end": 144, "tag": "drug"}]}, {"content": "decreased levels of anti-factor Xa and antithrombin III, decreased antithrombin III activity;", "metadata": {"original_id": "DrugDDI.d388.s5"}, "annotations": [{"start": 20, "end": 36, "tag": "drug"}, {"start": 39, "end": 56, "tag": "drug"}, {"start": 67, "end": 84, "tag": "drug"}]}, {"content": "increased levels of fibrinogen and fibrinogen activity;", "metadata": {"original_id": "DrugDDI.d388.s6"}, "annotations": [{"start": 20, "end": 31, "tag": "drug"}]}, {"content": "increased plasminogen antigen and activity.", "metadata": {"original_id": "DrugDDI.d388.s7"}, "annotations": []}, {"content": "2.", "metadata": {"original_id": "DrugDDI.d388.s8"}, "annotations": []}, {"content": "Increased thyroid-binding globulin (TBG) leading to increased circulating total thyroid hormone levels, as measured by protein-bound iodine (PBI), T4 levels (by column or by radioimmunoassay) or T3 levels by radioimmunoassay.", "metadata": {"original_id": "DrugDDI.d388.s9"}, "annotations": [{"start": 119, "end": 140, "tag": "drug"}]}, {"content": "T3 resin uptake is decreased, reflecting the elevated TBG.", "metadata": {"original_id": "DrugDDI.d388.s10"}, "annotations": []}, {"content": "Free T4 and T3 concentrations are unaltered.", "metadata": {"original_id": "DrugDDI.d388.s11"}, "annotations": [{"start": 12, "end": 15, "tag": "drug"}]}, {"content": "Patients on thyroid replacement therapy may require higher doses of thyroid hormone.", "metadata": {"original_id": "DrugDDI.d388.s12"}, "annotations": [{"start": 12, "end": 20, "tag": "drug"}, {"start": 68, "end": 84, "tag": "drug"}]}, {"content": "3.", "metadata": {"original_id": "DrugDDI.d388.s13"}, "annotations": []}, {"content": "Other binding proteins may be elevated in serum, i.e., corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively.", "metadata": {"original_id": "DrugDDI.d388.s14"}, "annotations": [{"start": 6, "end": 23, "tag": "drug"}, {"start": 55, "end": 88, "tag": "drug"}, {"start": 88, "end": 92, "tag": "drug"}, {"start": 94, "end": 123, "tag": "drug"}, {"start": 170, "end": 186, "tag": "drug"}]}, {"content": "Free hormone concentrations may be decreased.", "metadata": {"original_id": "DrugDDI.d388.s15"}, "annotations": []}, {"content": "Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-1-antitrypsin, ceruloplasmin).", "metadata": {"original_id": "DrugDDI.d388.s16"}, "annotations": [{"start": 6, "end": 22, "tag": "drug"}, {"start": 40, "end": 56, "tag": "drug"}, {"start": 55, "end": 73, "tag": "drug"}, {"start": 73, "end": 94, "tag": "drug"}, {"start": 94, "end": 108, "tag": "drug"}]}, {"content": "4.", "metadata": {"original_id": "DrugDDI.d388.s17"}, "annotations": []}, {"content": "Increased plasma HDL and HDL2 cholesterol subfraction concentrations, reduced LDL cholesterol concentration, increased triglyceride levels.", "metadata": {"original_id": "DrugDDI.d388.s18"}, "annotations": [{"start": 30, "end": 42, "tag": "drug"}, {"start": 78, "end": 94, "tag": "drug"}]}, {"content": "5.", "metadata": {"original_id": "DrugDDI.d388.s19"}, "annotations": []}, {"content": "Impaired glucose tolerance.", "metadata": {"original_id": "DrugDDI.d388.s20"}, "annotations": []}, {"content": "6.", "metadata": {"original_id": "DrugDDI.d388.s21"}, "annotations": []}, {"content": "Reduced response to metyrapone test.", "metadata": {"original_id": "DrugDDI.d388.s22"}, "annotations": []}, {"content": "General In vitro studies in human liver microsomes demonstrated no evidence of cytochrome P450-mediated drug interactions that are likely to be of clinical relevance.", "metadata": {"original_id": "DrugDDI.d298.s0"}, "annotations": [{"start": 79, "end": 90, "tag": "drug"}]}, {"content": "Anesthetics/Sedatives/Hypnotics/Opioids Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.", "metadata": {"original_id": "DrugDDI.d298.s1"}, "annotations": [{"start": 0, "end": 12, "tag": "drug"}, {"start": 12, "end": 22, "tag": "drug"}, {"start": 22, "end": 32, "tag": "drug"}, {"start": 32, "end": 40, "tag": "drug"}, {"start": 61, "end": 70, "tag": "drug"}, {"start": 75, "end": 87, "tag": "drug"}, {"start": 88, "end": 98, "tag": "drug"}, {"start": 99, "end": 109, "tag": "drug"}, {"start": 114, "end": 122, "tag": "drug"}]}, {"content": "Specific studies have confirmed these effects with sevoflurane, isoflurane, propofol, alfentanil, and midazolam.", "metadata": {"original_id": "DrugDDI.d298.s2"}, "annotations": [{"start": 51, "end": 63, "tag": "drug"}, {"start": 64, "end": 75, "tag": "drug"}, {"start": 76, "end": 85, "tag": "drug"}, {"start": 86, "end": 97, "tag": "drug"}, {"start": 102, "end": 112, "tag": "drug"}]}, {"content": "No pharmacokinetic interactions between dexmedetomidine and isoflurane, propofol, alfentanil, and midazolam have been demonstrated.", "metadata": {"original_id": "DrugDDI.d298.s3"}, "annotations": [{"start": 40, "end": 56, "tag": "drug"}, {"start": 60, "end": 71, "tag": "drug"}, {"start": 72, "end": 81, "tag": "drug"}, {"start": 82, "end": 93, "tag": "drug"}, {"start": 98, "end": 108, "tag": "drug"}]}, {"content": "However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of PRECEDEX on the concomitant anesthetic, sedative, hypnotic or opioid may be required.", "metadata": {"original_id": "DrugDDI.d298.s4"}, "annotations": [{"start": 81, "end": 90, "tag": "drug"}, {"start": 116, "end": 125, "tag": "drug"}, {"start": 144, "end": 156, "tag": "drug"}, {"start": 166, "end": 175, "tag": "drug"}, {"start": 178, "end": 185, "tag": "drug"}]}, {"content": "Neuromuscular Blockers In one study of 10 healthy volunteers, administration of PRECEDEX for 45 minutes at a plasma concentration of 1 (one) ng/mL resulted in no clinically meaningful increases in the magnitude or neuromuscular blockade associated with rocuronium administration.", "metadata": {"original_id": "DrugDDI.d298.s5"}, "annotations": [{"start": 0, "end": 23, "tag": "drug"}, {"start": 80, "end": 89, "tag": "drug"}, {"start": 253, "end": 264, "tag": "drug"}]}, {"content": "No formal drug interaction studies have been conducted with VELCADE.", "metadata": {"original_id": "DrugDDI.d222.s0"}, "annotations": [{"start": 60, "end": 68, "tag": "drug"}]}, {"content": "In vitro studies with human liver microsomes indicate that bortezomib is primarily a substrate for cytochrome P450 3A4, 2C19, and 1A2.", "metadata": {"original_id": "DrugDDI.d222.s1"}, "annotations": [{"start": 59, "end": 70, "tag": "drug"}, {"start": 99, "end": 119, "tag": "drug"}]}, {"content": "Patients who are concomitantly receiving VELCADE and drugs that are inhibitors or inducers of cytochrome P450 3A4 should be closely monitored for either toxicities or reduced efficacy .", "metadata": {"original_id": "DrugDDI.d222.s2"}, "annotations": [{"start": 41, "end": 49, "tag": "drug"}, {"start": 53, "end": 59, "tag": "drug"}, {"start": 94, "end": 114, "tag": "drug"}]}, {"content": "During clinical trials, hypoglycemia and hyperglycemia were reported in diabetic patients receiving oral hypoglycemics.", "metadata": {"original_id": "DrugDDI.d222.s3"}, "annotations": [{"start": 100, "end": 119, "tag": "drug"}]}, {"content": "Patients on oral antidiabetic agents receiving VELCADE treatment may require close monitoring of their blood glucose levels and adjustment of the dose of their antidiabetic medication.", "metadata": {"original_id": "DrugDDI.d222.s4"}, "annotations": [{"start": 17, "end": 37, "tag": "drug"}, {"start": 47, "end": 55, "tag": "drug"}, {"start": 160, "end": 173, "tag": "drug"}]}, {"content": "Drug Laboratory Test Interactions None known.", "metadata": {"original_id": "DrugDDI.d222.s5"}, "annotations": []}, {"content": "In clinical studies, Tilade has been co-administered with other anti-asthma medications, including inhaled and oral bronchodilators, and inhaled corticosteroids, with no evidence of increased frequency of adverse events or laboratory abnormalities.", "metadata": {"original_id": "DrugDDI.d312.s0"}, "annotations": [{"start": 21, "end": 28, "tag": "drug"}, {"start": 64, "end": 88, "tag": "drug"}, {"start": 116, "end": 132, "tag": "drug"}, {"start": 145, "end": 161, "tag": "drug"}]}, {"content": "No formal drug-drug interaction studies, however, have been conducted.", "metadata": {"original_id": "DrugDDI.d312.s1"}, "annotations": []}, {"content": "Probenecid decreases the renal tubular secretion of amoxicillin.", "metadata": {"original_id": "DrugDDI.d117.s0"}, "annotations": [{"start": 0, "end": 11, "tag": "drug"}, {"start": 52, "end": 64, "tag": "drug"}]}, {"content": "Concurrent use of amoxicillin and probenecid may result in increased and prolonged blood levels of amoxicillin.", "metadata": {"original_id": "DrugDDI.d117.s1"}, "annotations": [{"start": 18, "end": 30, "tag": "drug"}, {"start": 34, "end": 45, "tag": "drug"}, {"start": 99, "end": 111, "tag": "drug"}]}, {"content": "Chloramphenicol, macrolides, sulfonamides, and tetracy-clines may interfere with the bactericidal effects of penicillin.", "metadata": {"original_id": "DrugDDI.d117.s2"}, "annotations": [{"start": 0, "end": 16, "tag": "drug"}, {"start": 17, "end": 28, "tag": "drug"}, {"start": 29, "end": 42, "tag": "drug"}, {"start": 109, "end": 120, "tag": "drug"}]}, {"content": "This has been demonstrated in vitro;", "metadata": {"original_id": "DrugDDI.d117.s3"}, "annotations": []}, {"content": "however, the clinical significance of this interaction is not well documented.", "metadata": {"original_id": "DrugDDI.d117.s4"}, "annotations": []}, {"content": "Drug/Laboratory Test Interactions: High urine concentrations of ampicillin may result in false-positive reactions when testing for the presence of glucose in urine using CLINITEST?, Benedict?s Solution, or Fehling?s Solution.", "metadata": {"original_id": "DrugDDI.d117.s5"}, "annotations": [{"start": 0, "end": 5, "tag": "drug"}, {"start": 64, "end": 75, "tag": "drug"}, {"start": 147, "end": 155, "tag": "drug"}]}, {"content": "Since this effect may also occur with amoxicillin, it is recommended that glucose tests based on enzymatic glucose oxi-dase reactions (such as CLINISTIX?) be used.", "metadata": {"original_id": "DrugDDI.d117.s6"}, "annotations": [{"start": 38, "end": 50, "tag": "drug"}, {"start": 97, "end": 125, "tag": "drug"}]}, {"content": "Following administration of ampicillin to pregnant women, a transient decrease in plasma concentration of total conjugated estriol, estriol-glucuronide, conjugated estrone, and estradiol has been noted.", "metadata": {"original_id": "DrugDDI.d117.s7"}, "annotations": [{"start": 28, "end": 39, "tag": "drug"}, {"start": 123, "end": 131, "tag": "drug"}, {"start": 164, "end": 172, "tag": "drug"}, {"start": 177, "end": 187, "tag": "drug"}]}, {"content": "This effect may also occur with amoxicillin.", "metadata": {"original_id": "DrugDDI.d117.s8"}, "annotations": [{"start": 32, "end": 44, "tag": "drug"}]}, {"content": "Carcinogenesis, Mutagenesis, Impairment of Fertility: Long-term studies in animals have not been performed to evaluate carcinogenic potential.", "metadata": {"original_id": "DrugDDI.d117.s9"}, "annotations": []}, {"content": "Studies to detect mutagenic potential of amoxicillin alone have not been conducted;", "metadata": {"original_id": "DrugDDI.d117.s10"}, "annotations": [{"start": 41, "end": 53, "tag": "drug"}]}, {"content": "however, the following information is available from tests on a 4:1 mixture of amoxicillin and potassium clavulanate (AUGMENTIN).", "metadata": {"original_id": "DrugDDI.d117.s11"}, "annotations": [{"start": 79, "end": 91, "tag": "drug"}, {"start": 95, "end": 117, "tag": "drug"}, {"start": 118, "end": 128, "tag": "drug"}]}, {"content": "AUGMENTIN was non-mutagenic in the Ames bacterial mutation assay, and the yeast gene conversion assay.", "metadata": {"original_id": "DrugDDI.d117.s12"}, "annotations": [{"start": 0, "end": 10, "tag": "drug"}, {"start": 35, "end": 39, "tag": "drug"}]}, {"content": "AUGMENTIN was weakly positive in the mouse lymphoma assay, but the trend toward increased mutation frequencies in this assay occurred at doses that were also associated with decreased cell survival.", "metadata": {"original_id": "DrugDDI.d117.s13"}, "annotations": [{"start": 0, "end": 10, "tag": "drug"}]}, {"content": "AUGMENTIN was negative in the mouse micronucleus test, and in the dominant lethal assay in mice.", "metadata": {"original_id": "DrugDDI.d117.s14"}, "annotations": [{"start": 0, "end": 10, "tag": "drug"}]}, {"content": "Potassium clavulanate alone was tested in the Ames bacterial mutation assay and in the mouse micronucleus test, and was negative in each of these assays.", "metadata": {"original_id": "DrugDDI.d117.s15"}, "annotations": [{"start": 0, "end": 22, "tag": "drug"}, {"start": 46, "end": 50, "tag": "drug"}]}, {"content": "In a multi-generation reproduction study in rats, no impairment of fertility or other adverse reproductive effects were seen at doses up to 500 mg/kg (approximately 3 times the human dose in mg/m2).", "metadata": {"original_id": "DrugDDI.d117.s16"}, "annotations": []}, {"content": "Pregnancy: Teratogenic Effects: Pregnancy Category B.", "metadata": {"original_id": "DrugDDI.d117.s17"}, "annotations": []}, {"content": "Reproduction studies have been performed in mice and rats at doses up to 10 times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to amoxicillin.", "metadata": {"original_id": "DrugDDI.d117.s18"}, "annotations": [{"start": 177, "end": 189, "tag": "drug"}]}, {"content": "There are, however, no adequate and well-controlled studies in pregnant women.", "metadata": {"original_id": "DrugDDI.d117.s19"}, "annotations": []}, {"content": "Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.", "metadata": {"original_id": "DrugDDI.d117.s20"}, "annotations": [{"start": 86, "end": 91, "tag": "drug"}]}, {"content": "Labor and Delivery: Oral ampicillin-class antibiotics are poorly absorbed during labor.", "metadata": {"original_id": "DrugDDI.d117.s21"}, "annotations": [{"start": 20, "end": 36, "tag": "drug"}]}, {"content": "Studies in guinea pigs showed that intravenous administration of ampicillin slightly decreased the uterine tone and frequency of contractions but moderately increased the height and duration of contractions.", "metadata": {"original_id": "DrugDDI.d117.s22"}, "annotations": [{"start": 65, "end": 76, "tag": "drug"}]}, {"content": "However, it is not known whether use of amoxicillin in humans during labor or delivery has immediate or delayed adverse effects on the fetus, prolongs the duration of labor, or increases the likelihood that forceps delivery or other obstetrical intervention or resuscitation of the newborn will be necessary.", "metadata": {"original_id": "DrugDDI.d117.s23"}, "annotations": [{"start": 40, "end": 52, "tag": "drug"}]}, {"content": "Nursing Mothers: Penicillins have been shown to be excreted in human milk.", "metadata": {"original_id": "DrugDDI.d117.s24"}, "annotations": [{"start": 17, "end": 29, "tag": "drug"}]}, {"content": "Amoxicillin use by nursing mothers may lead to sensitization of infants.", "metadata": {"original_id": "DrugDDI.d117.s25"}, "annotations": [{"start": 0, "end": 12, "tag": "drug"}]}, {"content": "Caution should be exercised when amoxicillin is administered to a nursing woman.", "metadata": {"original_id": "DrugDDI.d117.s26"}, "annotations": [{"start": 33, "end": 45, "tag": "drug"}]}, {"content": "Pediatric Use: Because of incompletely developed renal function in neonates and young infants, the elimination of amoxicillin may be delayed.", "metadata": {"original_id": "DrugDDI.d117.s27"}, "annotations": [{"start": 0, "end": 10, "tag": "drug"}, {"start": 114, "end": 126, "tag": "drug"}]}, {"content": "Dosing of AMOXIL should be modified in pediatric patients 12 weeks or younger (?3 months).", "metadata": {"original_id": "DrugDDI.d117.s28"}, "annotations": [{"start": 10, "end": 17, "tag": "drug"}, {"start": 39, "end": 49, "tag": "drug"}]}, {"content": "(See DOSAGE AND ADMINISTRATION?Neonates and infants.)", "metadata": {"original_id": "DrugDDI.d117.s29"}, "annotations": []}, {"content": "Antacids: Administration of flurbiprofen to volunteers under fasting conditions, or with antacid suspension yielded similar serum flurbiprofen time profiles in young subjects (n=12).", "metadata": {"original_id": "DrugDDI.d332.s0"}, "annotations": [{"start": 0, "end": 9, "tag": "drug"}, {"start": 28, "end": 41, "tag": "drug"}, {"start": 89, "end": 108, "tag": "drug"}, {"start": 130, "end": 143, "tag": "drug"}]}, {"content": "In geriatric subjects (n=7) there was a reduction in the rate but not the extent of flurbiprofen absorption.", "metadata": {"original_id": "DrugDDI.d332.s1"}, "annotations": [{"start": 23, "end": 28, "tag": "drug"}, {"start": 84, "end": 97, "tag": "drug"}]}, {"content": "Anticoagulants: Flurbiprofen like other nonsteroidal anti-inflammatory drugs, has been shown to affect bleeding parameters in patients receiving anti-coagulants, and serious clinical bleeding has been reported.", "metadata": {"original_id": "DrugDDI.d332.s2"}, "annotations": [{"start": 0, "end": 15, "tag": "drug"}, {"start": 16, "end": 29, "tag": "drug"}, {"start": 40, "end": 77, "tag": "drug"}, {"start": 145, "end": 162, "tag": "drug"}]}, {"content": "The physician should be cautious when administering flurbiprofen to patients taking anticoagulants.", "metadata": {"original_id": "DrugDDI.d332.s3"}, "annotations": [{"start": 52, "end": 65, "tag": "drug"}, {"start": 84, "end": 99, "tag": "drug"}]}, {"content": "Aspirin: Concurrent administration of aspirin and flurbiprofen resulted in 50% lower serum flurbiprofen concentrations.", "metadata": {"original_id": "DrugDDI.d332.s4"}, "annotations": [{"start": 0, "end": 8, "tag": "drug"}, {"start": 38, "end": 46, "tag": "drug"}, {"start": 50, "end": 63, "tag": "drug"}, {"start": 91, "end": 104, "tag": "drug"}]}, {"content": "This effect of aspirin (which also lowers serum concentrations of other nonsteroidal anti-inflammatory drugs given with it) has been demonstrated in patients with rheumatoid arthritis (n= 15) as well as normal volunteers (n= 16).", "metadata": {"original_id": "DrugDDI.d332.s5"}, "annotations": [{"start": 15, "end": 23, "tag": "drug"}, {"start": 72, "end": 109, "tag": "drug"}]}, {"content": "Concurrent use of flurbiprofen and aspirin is therefore not recommended.", "metadata": {"original_id": "DrugDDI.d332.s6"}, "annotations": [{"start": 18, "end": 31, "tag": "drug"}, {"start": 35, "end": 43, "tag": "drug"}]}, {"content": "Beta-adrenergic Blocking Agents: The effect of flurbiprofen on blood pressure response to propranolol and atenolol was evaluated in men with mild uncomplicated hypertension (n = 10).", "metadata": {"original_id": "DrugDDI.d332.s7"}, "annotations": [{"start": 0, "end": 32, "tag": "drug"}, {"start": 47, "end": 60, "tag": "drug"}, {"start": 90, "end": 102, "tag": "drug"}, {"start": 106, "end": 115, "tag": "drug"}]}, {"content": "Flurbiprofen pretreatment attenuated the hypotensive effect of a single dose of propranolol but not atenolol.", "metadata": {"original_id": "DrugDDI.d332.s8"}, "annotations": [{"start": 0, "end": 13, "tag": "drug"}, {"start": 80, "end": 92, "tag": "drug"}, {"start": 100, "end": 109, "tag": "drug"}]}, {"content": "Flurbiprofen did not appear to affect the beta-blocker-mediated reduction in heart rate.", "metadata": {"original_id": "DrugDDI.d332.s9"}, "annotations": [{"start": 0, "end": 13, "tag": "drug"}, {"start": 42, "end": 55, "tag": "drug"}]}, {"content": "Flurbiprofen did not affect the pharmacokinetic profile of either drug, and the mechanism under lying the interference with propranolols hypotensive effect is unknown.", "metadata": {"original_id": "DrugDDI.d332.s10"}, "annotations": [{"start": 0, "end": 13, "tag": "drug"}, {"start": 66, "end": 71, "tag": "drug"}, {"start": 124, "end": 136, "tag": "drug"}]}, {"content": "Patients taking both flurbiprofen and a beta-blocker should be monitored to ensure that a satisfactory hypotensive effect is achieved.", "metadata": {"original_id": "DrugDDI.d332.s11"}, "annotations": [{"start": 21, "end": 34, "tag": "drug"}, {"start": 40, "end": 53, "tag": "drug"}]}, {"content": "Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.", "metadata": {"original_id": "DrugDDI.d332.s12"}, "annotations": [{"start": 0, "end": 11, "tag": "drug"}, {"start": 12, "end": 23, "tag": "drug"}, {"start": 46, "end": 51, "tag": "drug"}, {"start": 70, "end": 81, "tag": "drug"}, {"start": 84, "end": 95, "tag": "drug"}, {"start": 110, "end": 123, "tag": "drug"}, {"start": 257, "end": 270, "tag": "drug"}, {"start": 284, "end": 295, "tag": "drug"}]}, {"content": "Digoxin: Studies of concomitant administration of flurbiprofen and digoxin to healthy men (n= 14) did not show a change in the steady state serum levels of either drug.", "metadata": {"original_id": "DrugDDI.d332.s13"}, "annotations": [{"start": 0, "end": 8, "tag": "drug"}, {"start": 50, "end": 63, "tag": "drug"}, {"start": 67, "end": 75, "tag": "drug"}, {"start": 163, "end": 168, "tag": "drug"}]}, {"content": "Diuretics: Studies in normal volunteers have shown that flurbiprofen like other nonsteroidal anti-inflammatory drugs, can interfere with the effects of furosemide.", "metadata": {"original_id": "DrugDDI.d332.s14"}, "annotations": [{"start": 0, "end": 10, "tag": "drug"}, {"start": 56, "end": 69, "tag": "drug"}, {"start": 80, "end": 117, "tag": "drug"}, {"start": 152, "end": 164, "tag": "drug"}]}, {"content": "Although results have varied from study to study, effects have been shown on furosemide-stimulated diuresis, natriuresis, and kaliuresis.", "metadata": {"original_id": "DrugDDI.d332.s15"}, "annotations": [{"start": 77, "end": 109, "tag": "drug"}]}, {"content": "Other nonsteroidal anti-inflammatory drugs that inhibit prostaglandin synthesis have been shown to interfere with thiazide diuretics in some studies and with potassium-sparing diuretics.", "metadata": {"original_id": "DrugDDI.d332.s16"}, "annotations": [{"start": 6, "end": 43, "tag": "drug"}, {"start": 56, "end": 70, "tag": "drug"}, {"start": 114, "end": 133, "tag": "drug"}, {"start": 158, "end": 186, "tag": "drug"}]}, {"content": "Patients receiving flurbiprofen and furosemide or other diuretics should be observed closely to determine if the desired effect is obtained.", "metadata": {"original_id": "DrugDDI.d332.s17"}, "annotations": [{"start": 19, "end": 32, "tag": "drug"}, {"start": 36, "end": 47, "tag": "drug"}, {"start": 56, "end": 66, "tag": "drug"}]}, {"content": "Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) chlorpropamide with phenformin (n= 3) or glyburide with phenformin (n=6).", "metadata": {"original_id": "DrugDDI.d332.s18"}, "annotations": [{"start": 5, "end": 25, "tag": "drug"}, {"start": 40, "end": 53, "tag": "drug"}, {"start": 109, "end": 119, "tag": "drug"}, {"start": 126, "end": 136, "tag": "drug"}, {"start": 142, "end": 157, "tag": "drug"}, {"start": 162, "end": 174, "tag": "drug"}, {"start": 174, "end": 180, "tag": "drug"}, {"start": 183, "end": 193, "tag": "drug"}, {"start": 198, "end": 210, "tag": "drug"}]}, {"content": "Although there was a slight reduction in blood sugar concentrations during concomitant administration of flurbiprofen and hypoglycemic agents, there were no signs or symptoms of hypoglycemia.", "metadata": {"original_id": "DrugDDI.d332.s19"}, "annotations": [{"start": 105, "end": 118, "tag": "drug"}, {"start": 122, "end": 142, "tag": "drug"}]}, {"content": "Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.", "metadata": {"original_id": "DrugDDI.d535.s0"}, "annotations": [{"start": 0, "end": 11, "tag": "drug"}, {"start": 57, "end": 66, "tag": "drug"}, {"start": 67, "end": 81, "tag": "drug"}, {"start": 82, "end": 93, "tag": "drug"}, {"start": 94, "end": 105, "tag": "drug"}, {"start": 109, "end": 120, "tag": "drug"}]}, {"content": "Because the tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.", "metadata": {"original_id": "DrugDDI.d492.s0"}, "annotations": [{"start": 12, "end": 26, "tag": "drug"}, {"start": 165, "end": 179, "tag": "drug"}]}, {"content": "Since bacteriostatic drugs, such as the tetracycline class of antibiotics, may interfere with the bactericidal action of penicillins, it is not advisable to administer these drugs concomitantly.", "metadata": {"original_id": "DrugDDI.d492.s1"}, "annotations": [{"start": 6, "end": 19, "tag": "drug"}, {"start": 40, "end": 53, "tag": "drug"}, {"start": 62, "end": 74, "tag": "drug"}, {"start": 121, "end": 133, "tag": "drug"}, {"start": 174, "end": 180, "tag": "drug"}]}, {"content": "Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.", "metadata": {"original_id": "DrugDDI.d492.s2"}, "annotations": [{"start": 18, "end": 32, "tag": "drug"}, {"start": 37, "end": 57, "tag": "drug"}, {"start": 68, "end": 100, "tag": "drug"}]}, {"content": "Breakthrough bleeding has been reported", "metadata": {"original_id": "DrugDDI.d492.s3"}, "annotations": []}, {"content": "Clinical trials have indicated that Pulmozyme can be effectively and safely used in conjunction with standard cystic fibrosis therapies including oral, inhaled and/or parenteral antibiotics, bronchodilators, enzyme supplements, vitamins, oral or inhaled corticosteroids, and analgesics.", "metadata": {"original_id": "DrugDDI.d212.s0"}, "annotations": [{"start": 36, "end": 46, "tag": "drug"}, {"start": 178, "end": 190, "tag": "drug"}, {"start": 191, "end": 207, "tag": "drug"}, {"start": 228, "end": 237, "tag": "drug"}, {"start": 254, "end": 270, "tag": "drug"}, {"start": 275, "end": 286, "tag": "drug"}]}, {"content": "No formal drug interaction studies have been performed.", "metadata": {"original_id": "DrugDDI.d212.s1"}, "annotations": []}, {"content": "Immunosuppressive Drugs, Fibric Acid Derivatives, Niacin (Nicotinic Acid, Erythromycin, Azole Antifungals: Skeletal Muscle.", "metadata": {"original_id": "DrugDDI.d169.s0"}, "annotations": [{"start": 0, "end": 18, "tag": "drug"}, {"start": 37, "end": 49, "tag": "drug"}, {"start": 50, "end": 57, "tag": "drug"}, {"start": 58, "end": 73, "tag": "drug"}, {"start": 74, "end": 87, "tag": "drug"}, {"start": 88, "end": 106, "tag": "drug"}]}, {"content": "ANTACID (Magnesium-Aluminum Hydroxide): Cerivastatin plasma concentrations were not affected by co-administration of antacid.", "metadata": {"original_id": "DrugDDI.d169.s1"}, "annotations": [{"start": 0, "end": 8, "tag": "drug"}, {"start": 9, "end": 39, "tag": "drug"}, {"start": 40, "end": 53, "tag": "drug"}, {"start": 117, "end": 125, "tag": "drug"}]}, {"content": "CIMETlDINE: Cerivastatin plasma concentrations were not affected by co-administration of cimetidine.", "metadata": {"original_id": "DrugDDI.d169.s2"}, "annotations": [{"start": 12, "end": 25, "tag": "drug"}, {"start": 89, "end": 100, "tag": "drug"}]}, {"content": "CHOLESTYRAMINE: The influence of the bile-acidsequestering agent cholestyramine on the pharmacokinetits of cerivastatin sodium was evaluated in 12 healthy males in 2 separate randomized crossover studies.", "metadata": {"original_id": "DrugDDI.d169.s3"}, "annotations": [{"start": 0, "end": 15, "tag": "drug"}, {"start": 37, "end": 65, "tag": "drug"}, {"start": 107, "end": 127, "tag": "drug"}]}, {"content": "In the first study, concomitant administration of 0.2 mg cerivastatin sodium and 12 g cholestyramine resulted in decreases of more than 22% for AUC and 40% for Cmax when compared to dosing cerivastatin sodium alone.", "metadata": {"original_id": "DrugDDI.d169.s4"}, "annotations": [{"start": 57, "end": 77, "tag": "drug"}, {"start": 86, "end": 101, "tag": "drug"}, {"start": 189, "end": 209, "tag": "drug"}]}, {"content": "However, in the second study, administration of 12 g cholestyramine 1 hour before the evening meal and 0.3 mg cerivastatin sodium approximately 4 hours after the same evening meal resulted in a decrease in the cerivastatin AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing cerivastatin sodium alone.", "metadata": {"original_id": "DrugDDI.d169.s5"}, "annotations": [{"start": 53, "end": 69, "tag": "drug"}, {"start": 110, "end": 130, "tag": "drug"}, {"start": 210, "end": 223, "tag": "drug"}, {"start": 304, "end": 324, "tag": "drug"}]}, {"content": "Therefore, it would be expected that a dosing schedule of cerivastatin sodium given at bedtime and cholestyramine given before the evening meal would not result in a significant decrease in the clinical effect of cerivastatin sodium.", "metadata": {"original_id": "DrugDDI.d169.s6"}, "annotations": [{"start": 58, "end": 78, "tag": "drug"}, {"start": 99, "end": 114, "tag": "drug"}, {"start": 213, "end": 233, "tag": "drug"}]}, {"content": "DIGOXIN: Plasma digoxin levels and digoxin clearance at steady-state were not affected by co-administration of 0.2 mg cerivastatin sodium.", "metadata": {"original_id": "DrugDDI.d169.s7"}, "annotations": [{"start": 0, "end": 8, "tag": "drug"}, {"start": 35, "end": 43, "tag": "drug"}, {"start": 118, "end": 138, "tag": "drug"}]}, {"content": "Cerivastatin plasma concentrations were also not affected by co-administration of digoxin.", "metadata": {"original_id": "DrugDDI.d169.s8"}, "annotations": [{"start": 0, "end": 13, "tag": "drug"}, {"start": 82, "end": 90, "tag": "drug"}]}, {"content": "WARFARIN: Co- administration of warfarin and cerivastatin to healthy volunteers did not result in any changes in prothrombin time or clotting factor VII when compared to co-administration of warfarin and placebo.", "metadata": {"original_id": "DrugDDI.d169.s9"}, "annotations": [{"start": 0, "end": 9, "tag": "drug"}, {"start": 32, "end": 41, "tag": "drug"}, {"start": 45, "end": 58, "tag": "drug"}, {"start": 142, "end": 153, "tag": "drug"}, {"start": 191, "end": 200, "tag": "drug"}]}, {"content": "The AUC and Cmax of both the (R) and (S) isomers of warfarin were unaffected by concurrent dosing of 0.3 mg cerivastatin sodium.", "metadata": {"original_id": "DrugDDI.d169.s10"}, "annotations": [{"start": 52, "end": 61, "tag": "drug"}, {"start": 108, "end": 128, "tag": "drug"}]}, {"content": "Co-administration of warfarin and cerivastatin did not alter the pharmacokinetics of cerivastatin sodium.", "metadata": {"original_id": "DrugDDI.d169.s11"}, "annotations": [{"start": 21, "end": 30, "tag": "drug"}, {"start": 34, "end": 47, "tag": "drug"}, {"start": 85, "end": 105, "tag": "drug"}]}, {"content": "ERYTHROMYCIN: In hypercholesterolemic patients, steady-state cerivastatin AUC and Cmax increased approximately 50% and 24% respectively after 10 days with co-administration of erythromycin, a known inhibitor of cytochrome P450 3A4.", "metadata": {"original_id": "DrugDDI.d169.s12"}, "annotations": [{"start": 0, "end": 13, "tag": "drug"}, {"start": 61, "end": 74, "tag": "drug"}, {"start": 176, "end": 189, "tag": "drug"}, {"start": 211, "end": 231, "tag": "drug"}]}, {"content": "OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, calcium-channel blockers, diuretics, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.", "metadata": {"original_id": "DrugDDI.d169.s13"}, "annotations": [{"start": 106, "end": 126, "tag": "drug"}, {"start": 154, "end": 185, "tag": "drug"}, {"start": 217, "end": 242, "tag": "drug"}, {"start": 243, "end": 253, "tag": "drug"}, {"start": 258, "end": 295, "tag": "drug"}, {"start": 296, "end": 303, "tag": "drug"}]}, {"content": "Caution should be taken in concurrent or serial use of other neurotoxic and/ or nephrotoxic drugs because of possible enhancement of the nephrotoxicity and/or ototoxicity of neomycin.", "metadata": {"original_id": "DrugDDI.d336.s0"}, "annotations": [{"start": 92, "end": 98, "tag": "drug"}, {"start": 174, "end": 183, "tag": "drug"}]}, {"content": "Caution should also be taken in concurrent or serial use of other aminoglycosides and polymyxins because they may enhance neomycin?s nephrotoxicity and/or ototoxicity and potentiate neomycin sulfate?s neuromuscular blocking effects.", "metadata": {"original_id": "DrugDDI.d336.s1"}, "annotations": [{"start": 66, "end": 82, "tag": "drug"}, {"start": 86, "end": 97, "tag": "drug"}, {"start": 182, "end": 191, "tag": "drug"}]}, {"content": "Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorouracil.", "metadata": {"original_id": "DrugDDI.d336.s2"}, "annotations": [{"start": 0, "end": 14, "tag": "drug"}, {"start": 58, "end": 71, "tag": "drug"}, {"start": 72, "end": 91, "tag": "drug"}, {"start": 91, "end": 104, "tag": "drug"}, {"start": 108, "end": 123, "tag": "drug"}]}, {"content": "The gastrointestinal absorption of digoxin also appears to be inhibited.", "metadata": {"original_id": "DrugDDI.d336.s3"}, "annotations": [{"start": 35, "end": 43, "tag": "drug"}]}, {"content": "Therefore, digoxin serum levels should be monitored.", "metadata": {"original_id": "DrugDDI.d336.s4"}, "annotations": []}, {"content": "Oral neomycin sulfate may enhance the effect of coumarin in anticoagulants by decreasing vitamin K availability.", "metadata": {"original_id": "DrugDDI.d336.s5"}, "annotations": [{"start": 0, "end": 14, "tag": "drug"}, {"start": 48, "end": 57, "tag": "drug"}, {"start": 60, "end": 75, "tag": "drug"}]}, {"content": "No information available.", "metadata": {"original_id": "DrugDDI.d107.s0"}, "annotations": []}, {"content": "Digitalis toxicity may be aggravated by the initial release of norepinephrine caused by Bretylium Tosylate Injection.", "metadata": {"original_id": "DrugDDI.d398.s0"}, "annotations": [{"start": 63, "end": 78, "tag": "drug"}, {"start": 88, "end": 117, "tag": "drug"}]}, {"content": "The pressor effects of catecholamines such as dopamine or norepinephrine are enhanced by Bretylium Tosylate.", "metadata": {"original_id": "DrugDDI.d398.s1"}, "annotations": [{"start": 4, "end": 20, "tag": "drug"}, {"start": 46, "end": 55, "tag": "drug"}, {"start": 58, "end": 73, "tag": "drug"}, {"start": 89, "end": 108, "tag": "drug"}]}, {"content": "When catecholamines are administered, dilute solutions should be used and blood pressure should be monitored closely.", "metadata": {"original_id": "DrugDDI.d398.s2"}, "annotations": []}, {"content": "Although there is little published information on concomitant administration of lidocaine and Bretylium Tosylate, these drugs are often administered concurrently without any evidence of interactions resulting in adverse effects or diminished efficacy.", "metadata": {"original_id": "DrugDDI.d398.s3"}, "annotations": [{"start": 80, "end": 90, "tag": "drug"}, {"start": 94, "end": 113, "tag": "drug"}, {"start": 120, "end": 126, "tag": "drug"}]}, {"content": "A number of substances affect glucose metabolism and may require insulin dose adjustment and particularly close monitoring.", "metadata": {"original_id": "DrugDDI.d395.s0"}, "annotations": [{"start": 65, "end": 73, "tag": "drug"}]}, {"content": "?? ? The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.", "metadata": {"original_id": "DrugDDI.d395.s1"}, "annotations": [{"start": 139, "end": 152, "tag": "drug"}, {"start": 162, "end": 177, "tag": "drug"}, {"start": 178, "end": 191, "tag": "drug"}, {"start": 192, "end": 201, "tag": "drug"}, {"start": 202, "end": 213, "tag": "drug"}, {"start": 214, "end": 232, "tag": "drug"}, {"start": 250, "end": 263, "tag": "drug"}, {"start": 264, "end": 276, "tag": "drug"}, {"start": 277, "end": 297, "tag": "drug"}, {"start": 304, "end": 315, "tag": "drug"}, {"start": 317, "end": 329, "tag": "drug"}]}, {"content": "?? ? The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).", "metadata": {"original_id": "DrugDDI.d395.s2"}, "annotations": [{"start": 97, "end": 113, "tag": "drug"}, {"start": 114, "end": 121, "tag": "drug"}, {"start": 122, "end": 130, "tag": "drug"}, {"start": 131, "end": 141, "tag": "drug"}, {"start": 142, "end": 165, "tag": "drug"}, {"start": 172, "end": 184, "tag": "drug"}, {"start": 185, "end": 196, "tag": "drug"}, {"start": 197, "end": 209, "tag": "drug"}, {"start": 211, "end": 221, "tag": "drug"}, {"start": 222, "end": 248, "tag": "drug"}, {"start": 249, "end": 260, "tag": "drug"}, {"start": 261, "end": 278, "tag": "drug"}, {"start": 279, "end": 289, "tag": "drug"}, {"start": 290, "end": 303, "tag": "drug"}, {"start": 313, "end": 333, "tag": "drug"}]}, {"content": "?? ? Beta-blockers, clonidine, lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin.", "metadata": {"original_id": "DrugDDI.d395.s3"}, "annotations": [{"start": 0, "end": 20, "tag": "drug"}, {"start": 20, "end": 30, "tag": "drug"}, {"start": 31, "end": 44, "tag": "drug"}, {"start": 50, "end": 58, "tag": "drug"}, {"start": 127, "end": 135, "tag": "drug"}]}, {"content": "Pentamidine may cause hypoglycemia, which may sometimes be followed by hyperglycemia.", "metadata": {"original_id": "DrugDDI.d395.s4"}, "annotations": [{"start": 0, "end": 12, "tag": "drug"}]}, {"content": "?? ? In addition, under the influence of sympatholytic medicinal products such as beta-blockers, clonidine, guanethidine, and reserpine, the signs of hypoglycemia may be reduced or absent.", "metadata": {"original_id": "DrugDDI.d395.s5"}, "annotations": [{"start": 41, "end": 55, "tag": "drug"}, {"start": 82, "end": 97, "tag": "drug"}, {"start": 97, "end": 107, "tag": "drug"}, {"start": 108, "end": 121, "tag": "drug"}, {"start": 126, "end": 136, "tag": "drug"}]}, {"content": "Mixing of Insulins", "metadata": {"original_id": "DrugDDI.d395.s6"}, "annotations": [{"start": 10, "end": 19, "tag": "drug"}]}, {"content": "?? ? A clinical study in healthy male volunteers (n=24) demonstrated that mixing NovoLog with NPH human insulin immediately before injection produced some attenuation in the peak concentration of NovoLog, but that the time to peak and the total bioavailability of NovoLog were not significantly affected.", "metadata": {"original_id": "DrugDDI.d395.s7"}, "annotations": [{"start": 81, "end": 89, "tag": "drug"}, {"start": 98, "end": 112, "tag": "drug"}, {"start": 196, "end": 204, "tag": "drug"}, {"start": 264, "end": 272, "tag": "drug"}]}, {"content": "If NovoLog is mixed with NPH human insulin, NovoLog should be drawn into the syringe first.", "metadata": {"original_id": "DrugDDI.d395.s8"}, "annotations": [{"start": 3, "end": 11, "tag": "drug"}, {"start": 29, "end": 43, "tag": "drug"}, {"start": 44, "end": 52, "tag": "drug"}]}, {"content": "The injection should be made immediately after mixing.", "metadata": {"original_id": "DrugDDI.d395.s9"}, "annotations": []}, {"content": "Because there are no data on the compatibility of NovoLog and crystalline zinc insulin preparations, NovoLog should not be mixed with these preparations.", "metadata": {"original_id": "DrugDDI.d395.s10"}, "annotations": [{"start": 50, "end": 58, "tag": "drug"}, {"start": 62, "end": 99, "tag": "drug"}, {"start": 101, "end": 109, "tag": "drug"}]}, {"content": "?? ? The effects of mixing NovoLog with insulins of animal source or insulin preparations produced by other manufacturers have not been studied .", "metadata": {"original_id": "DrugDDI.d395.s11"}, "annotations": [{"start": 27, "end": 35, "tag": "drug"}, {"start": 40, "end": 49, "tag": "drug"}, {"start": 69, "end": 90, "tag": "drug"}]}, {"content": "?? ? Mixtures should not be administered intravenously.", "metadata": {"original_id": "DrugDDI.d395.s12"}, "annotations": []}, {"content": "?? ? When used in external subcutaneous infusion pumps for insulin, NovoLog should not be mixed with any other insulins or diluent.", "metadata": {"original_id": "DrugDDI.d395.s13"}, "annotations": [{"start": 59, "end": 67, "tag": "drug"}, {"start": 68, "end": 76, "tag": "drug"}, {"start": 111, "end": 120, "tag": "drug"}]}, {"content": "Ethinyl estradiol: Substrate of CYP3A4 (major), 3A5-7 (minor);", "metadata": {"original_id": "DrugDDI.d132.s0"}, "annotations": [{"start": 0, "end": 18, "tag": "drug"}, {"start": 32, "end": 39, "tag": "drug"}]}, {"content": "Inhibits CYP1A2 (weak), 2B6 (weak), 2C19 (weak), 3A4 (weak).", "metadata": {"original_id": "DrugDDI.d132.s1"}, "annotations": [{"start": 9, "end": 16, "tag": "drug"}]}, {"content": "Acetaminophen: May increase plasma concentration of synthetic estrogens, possibly by inhibiting conjugation.", "metadata": {"original_id": "DrugDDI.d132.s2"}, "annotations": [{"start": 0, "end": 14, "tag": "drug"}, {"start": 52, "end": 73, "tag": "drug"}]}, {"content": "Combination hormonal contraceptives may also decrease the plasma concentration of acetaminophen.", "metadata": {"original_id": "DrugDDI.d132.s3"}, "annotations": [{"start": 21, "end": 36, "tag": "drug"}, {"start": 82, "end": 96, "tag": "drug"}]}, {"content": "Acitretin: Interferes with the contraceptive effect of microdosed progestin-containing minipill preparations.", "metadata": {"original_id": "DrugDDI.d132.s4"}, "annotations": [{"start": 0, "end": 10, "tag": "drug"}, {"start": 31, "end": 45, "tag": "drug"}, {"start": 66, "end": 76, "tag": "drug"}]}, {"content": "The effect on other progestational contraceptives (eg, implants, injectables) is unknown.", "metadata": {"original_id": "DrugDDI.d132.s5"}, "annotations": [{"start": 35, "end": 50, "tag": "drug"}]}, {"content": "Aminoglutethimide: May increase CYP metabolism of progestins leading to possible decrease in contraceptive effectiveness.", "metadata": {"original_id": "DrugDDI.d132.s6"}, "annotations": [{"start": 0, "end": 18, "tag": "drug"}, {"start": 32, "end": 36, "tag": "drug"}, {"start": 50, "end": 61, "tag": "drug"}, {"start": 93, "end": 107, "tag": "drug"}]}, {"content": "Use of a nonhormonal contraceptive product is recommended.", "metadata": {"original_id": "DrugDDI.d132.s7"}, "annotations": [{"start": 21, "end": 35, "tag": "drug"}]}, {"content": "Antibiotics (ampicillin, tetracycline): Pregnancy has been reported following concomitant use, however, pharmacokinetic studies have not shown consistent effects with these antibiotics on plasma concentrations of synthetic steroids.", "metadata": {"original_id": "DrugDDI.d132.s8"}, "annotations": [{"start": 0, "end": 12, "tag": "drug"}, {"start": 13, "end": 24, "tag": "drug"}, {"start": 25, "end": 38, "tag": "drug"}, {"start": 173, "end": 185, "tag": "drug"}]}, {"content": "Use of a nonhormonal contraceptive product is recommended.", "metadata": {"original_id": "DrugDDI.d132.s9"}, "annotations": [{"start": 21, "end": 35, "tag": "drug"}]}, {"content": "Anticoagulants: Combination hormonal contraceptives may increase or decrease the effects of coumarin derivatives.", "metadata": {"original_id": "DrugDDI.d132.s10"}, "annotations": [{"start": 0, "end": 15, "tag": "drug"}, {"start": 37, "end": 52, "tag": "drug"}, {"start": 92, "end": 101, "tag": "drug"}]}, {"content": "Combination hormonal contraceptives may also increase risk of thromboembolic disorders.", "metadata": {"original_id": "DrugDDI.d132.s11"}, "annotations": [{"start": 21, "end": 36, "tag": "drug"}]}, {"content": "Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.", "metadata": {"original_id": "DrugDDI.d132.s12"}, "annotations": [{"start": 0, "end": 16, "tag": "drug"}, {"start": 17, "end": 31, "tag": "drug"}, {"start": 32, "end": 42, "tag": "drug"}, {"start": 43, "end": 57, "tag": "drug"}, {"start": 58, "end": 68, "tag": "drug"}, {"start": 69, "end": 80, "tag": "drug"}, {"start": 109, "end": 127, "tag": "drug"}, {"start": 139, "end": 150, "tag": "drug"}, {"start": 183, "end": 197, "tag": "drug"}]}, {"content": "Use of a nonhormonal contraceptive product is recommended.", "metadata": {"original_id": "DrugDDI.d132.s13"}, "annotations": [{"start": 21, "end": 35, "tag": "drug"}]}, {"content": "Ascorbic acid: Doses of ascorbic acid (vitamin C) 1 g/day have been reported to increase plasma concentration of synthetic estrogens by ~47%, possibly by inhibiting conjugation;", "metadata": {"original_id": "DrugDDI.d132.s14"}, "annotations": [{"start": 0, "end": 14, "tag": "drug"}, {"start": 24, "end": 38, "tag": "drug"}, {"start": 39, "end": 49, "tag": "drug"}, {"start": 113, "end": 134, "tag": "drug"}]}, {"content": "clinical implications are unclear.", "metadata": {"original_id": "DrugDDI.d132.s15"}, "annotations": []}, {"content": "Atorvastatin: Atorvastatin increases the AUC for norethindrone and ethinyl estradiol.", "metadata": {"original_id": "DrugDDI.d132.s16"}, "annotations": [{"start": 0, "end": 13, "tag": "drug"}, {"start": 14, "end": 27, "tag": "drug"}, {"start": 49, "end": 63, "tag": "drug"}, {"start": 67, "end": 85, "tag": "drug"}]}, {"content": "Benzodiazepines: Combination hormonal contraceptives may decrease the clearance of some benzodiazepines (alprazolam, chlordiazepoxide, diazepam) and increase the clearance of others (lorazepam, oxazepam, temazepam).", "metadata": {"original_id": "DrugDDI.d132.s17"}, "annotations": [{"start": 0, "end": 16, "tag": "drug"}, {"start": 38, "end": 53, "tag": "drug"}, {"start": 88, "end": 104, "tag": "drug"}, {"start": 105, "end": 116, "tag": "drug"}, {"start": 117, "end": 134, "tag": "drug"}, {"start": 135, "end": 144, "tag": "drug"}, {"start": 183, "end": 193, "tag": "drug"}, {"start": 194, "end": 203, "tag": "drug"}, {"start": 204, "end": 214, "tag": "drug"}]}, {"content": "Clofibric acid: Combination hormonal contraceptives may increase the clearance of clofibric acid.", "metadata": {"original_id": "DrugDDI.d132.s18"}, "annotations": [{"start": 0, "end": 15, "tag": "drug"}, {"start": 37, "end": 52, "tag": "drug"}, {"start": 82, "end": 97, "tag": "drug"}]}, {"content": "Cyclosporine: Combination hormonal contraceptives may inhibit the metabolism of cyclosporine, leading to increased plasma concentrations;", "metadata": {"original_id": "DrugDDI.d132.s19"}, "annotations": [{"start": 0, "end": 13, "tag": "drug"}, {"start": 35, "end": 50, "tag": "drug"}, {"start": 80, "end": 93, "tag": "drug"}]}, {"content": "monitor cyclosporine levels.", "metadata": {"original_id": "DrugDDI.d132.s20"}, "annotations": [{"start": 8, "end": 21, "tag": "drug"}]}, {"content": "CYP3A4 inducers: CYP3A4 inducers may decrease the levels/effects of ethinyl estradiol.", "metadata": {"original_id": "DrugDDI.d132.s21"}, "annotations": [{"start": 0, "end": 7, "tag": "drug"}, {"start": 17, "end": 24, "tag": "drug"}, {"start": 68, "end": 86, "tag": "drug"}]}, {"content": "Example inducers include aminoglutethimide, carbamazepine, nafcillin, nevirapine, phenobarbital, phenytoin, and rifamycins.", "metadata": {"original_id": "DrugDDI.d132.s22"}, "annotations": [{"start": 25, "end": 43, "tag": "drug"}, {"start": 44, "end": 58, "tag": "drug"}, {"start": 59, "end": 69, "tag": "drug"}, {"start": 70, "end": 81, "tag": "drug"}, {"start": 82, "end": 96, "tag": "drug"}, {"start": 97, "end": 107, "tag": "drug"}, {"start": 112, "end": 123, "tag": "drug"}]}, {"content": "Griseofulvin: Griseofulvin may induce the metabolism of combination hormonal contraceptives causing menstrual changes;", "metadata": {"original_id": "DrugDDI.d132.s23"}, "annotations": [{"start": 0, "end": 13, "tag": "drug"}, {"start": 14, "end": 27, "tag": "drug"}, {"start": 77, "end": 92, "tag": "drug"}]}, {"content": "pregnancies have been reported.", "metadata": {"original_id": "DrugDDI.d132.s24"}, "annotations": []}, {"content": "Use of barrier form of contraception is suggested while on griseofulvin therapy.", "metadata": {"original_id": "DrugDDI.d132.s25"}, "annotations": [{"start": 59, "end": 72, "tag": "drug"}]}, {"content": "Morphine: Combination hormonal contraceptives may increase the clearance of morphine.", "metadata": {"original_id": "DrugDDI.d132.s26"}, "annotations": [{"start": 0, "end": 9, "tag": "drug"}, {"start": 31, "end": 46, "tag": "drug"}, {"start": 76, "end": 85, "tag": "drug"}]}, {"content": "Non-nucleoside reverse transcriptase inhibitors (NNRTIs): Nevirapine may decrease plasma levels of combination hormonal contraceptives;", "metadata": {"original_id": "DrugDDI.d132.s27"}, "annotations": [{"start": 0, "end": 48, "tag": "drug"}, {"start": 58, "end": 69, "tag": "drug"}, {"start": 120, "end": 135, "tag": "drug"}]}, {"content": "use of a nonhormonal contraceptive product is recommended.", "metadata": {"original_id": "DrugDDI.d132.s28"}, "annotations": [{"start": 21, "end": 35, "tag": "drug"}]}, {"content": "No data for delavirdine;", "metadata": {"original_id": "DrugDDI.d132.s29"}, "annotations": [{"start": 12, "end": 24, "tag": "drug"}]}, {"content": "incomplete data for efavirenz.", "metadata": {"original_id": "DrugDDI.d132.s30"}, "annotations": [{"start": 20, "end": 30, "tag": "drug"}]}, {"content": "Prednisolone: Ethinyl estradiol may inhibit the metabolism of prednisolone, leading to increased plasma concentrations.", "metadata": {"original_id": "DrugDDI.d132.s31"}, "annotations": [{"start": 0, "end": 13, "tag": "drug"}, {"start": 14, "end": 32, "tag": "drug"}, {"start": 62, "end": 75, "tag": "drug"}]}, {"content": "Protease inhibitors: Amprenavir, lopinavir, nelfinavir, and ritonavir have been shown to decrease plasma levels of combination hormonal contraceptives;", "metadata": {"original_id": "DrugDDI.d132.s32"}, "annotations": [{"start": 0, "end": 20, "tag": "drug"}, {"start": 21, "end": 32, "tag": "drug"}, {"start": 33, "end": 43, "tag": "drug"}, {"start": 44, "end": 55, "tag": "drug"}, {"start": 60, "end": 70, "tag": "drug"}, {"start": 136, "end": 151, "tag": "drug"}]}, {"content": "use of a nonhormonal contraceptive product is recommended.", "metadata": {"original_id": "DrugDDI.d132.s33"}, "annotations": [{"start": 21, "end": 35, "tag": "drug"}]}, {"content": "Indinavir has been shown to increase plasma levels of combination hormonal contraceptives.", "metadata": {"original_id": "DrugDDI.d132.s34"}, "annotations": [{"start": 0, "end": 10, "tag": "drug"}, {"start": 75, "end": 90, "tag": "drug"}]}, {"content": "No data for saquinavir.", "metadata": {"original_id": "DrugDDI.d132.s35"}, "annotations": [{"start": 12, "end": 23, "tag": "drug"}]}, {"content": "Rifampin: Rifampin increases the metabolism of ethinyl estradiol and some progestins (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.", "metadata": {"original_id": "DrugDDI.d132.s36"}, "annotations": [{"start": 0, "end": 9, "tag": "drug"}, {"start": 10, "end": 19, "tag": "drug"}, {"start": 47, "end": 65, "tag": "drug"}, {"start": 74, "end": 85, "tag": "drug"}, {"start": 86, "end": 100, "tag": "drug"}, {"start": 124, "end": 138, "tag": "drug"}]}, {"content": "Use of a nonhormonal contraceptive product is recommended.", "metadata": {"original_id": "DrugDDI.d132.s37"}, "annotations": [{"start": 21, "end": 35, "tag": "drug"}]}, {"content": "Salicylic acid: Combination hormonal contraceptives may increase the clearance of salicylic acid.", "metadata": {"original_id": "DrugDDI.d132.s38"}, "annotations": [{"start": 0, "end": 15, "tag": "drug"}, {"start": 37, "end": 52, "tag": "drug"}, {"start": 82, "end": 97, "tag": "drug"}]}, {"content": "Selegiline: Combination hormonal contraceptives may increase the serum concentration of selegiline.", "metadata": {"original_id": "DrugDDI.d132.s39"}, "annotations": [{"start": 0, "end": 11, "tag": "drug"}, {"start": 33, "end": 48, "tag": "drug"}, {"start": 88, "end": 99, "tag": "drug"}]}, {"content": "Theophylline: Ethinyl estradiol may inhibit the metabolism of theophylline, leading to increased plasma concentrations.", "metadata": {"original_id": "DrugDDI.d132.s40"}, "annotations": [{"start": 0, "end": 13, "tag": "drug"}, {"start": 14, "end": 32, "tag": "drug"}, {"start": 62, "end": 75, "tag": "drug"}]}, {"content": "Tricyclic antidepressants (amitriptyline, imipramine, nortriptyline): Metabolism may be inhibited by combination hormonal contraceptives, increasing plasma levels of antidepressant;", "metadata": {"original_id": "DrugDDI.d132.s41"}, "annotations": [{"start": 0, "end": 26, "tag": "drug"}, {"start": 27, "end": 41, "tag": "drug"}, {"start": 42, "end": 53, "tag": "drug"}, {"start": 54, "end": 68, "tag": "drug"}, {"start": 122, "end": 137, "tag": "drug"}, {"start": 166, "end": 181, "tag": "drug"}]}, {"content": "use caution.", "metadata": {"original_id": "DrugDDI.d132.s42"}, "annotations": []}, {"content": "ETHANOL / NUTRITION / HERB INTERACTIONS: Food: CNS effects of caffeine may be enhanced if combination hormonal contraceptives are used concurrently with caffeine.", "metadata": {"original_id": "DrugDDI.d132.s43"}, "annotations": [{"start": 0, "end": 8, "tag": "drug"}, {"start": 62, "end": 71, "tag": "drug"}, {"start": 111, "end": 126, "tag": "drug"}, {"start": 153, "end": 162, "tag": "drug"}]}, {"content": "Grapefruit juice increases ethinyl estradiol concentrations and would be expected to increase progesterone serum levels as well;", "metadata": {"original_id": "DrugDDI.d132.s44"}, "annotations": [{"start": 27, "end": 45, "tag": "drug"}]}, {"content": "clinical implications are unclear.", "metadata": {"original_id": "DrugDDI.d132.s45"}, "annotations": []}, {"content": "Herb/Nutraceutical: St Johns wort may decrease the effectiveness of combination hormonal contraceptives by inducing hepatic enzymes.", "metadata": {"original_id": "DrugDDI.d132.s46"}, "annotations": [{"start": 89, "end": 104, "tag": "drug"}]}, {"content": "Avoid dong quai and black cohosh (have estrogen activity).", "metadata": {"original_id": "DrugDDI.d132.s47"}, "annotations": [{"start": 6, "end": 16, "tag": "drug"}, {"start": 20, "end": 33, "tag": "drug"}, {"start": 39, "end": 48, "tag": "drug"}]}, {"content": "Avoid saw palmetto, red clover, ginseng.", "metadata": {"original_id": "DrugDDI.d132.s48"}, "annotations": [{"start": 6, "end": 19, "tag": "drug"}, {"start": 20, "end": 31, "tag": "drug"}, {"start": 32, "end": 40, "tag": "drug"}]}, {"content": "Prior administration of succinylcholine has no clinically important effect on the neuromuscular blocking action of NUROMAX.", "metadata": {"original_id": "DrugDDI.d43.s0"}, "annotations": [{"start": 24, "end": 40, "tag": "drug"}, {"start": 115, "end": 123, "tag": "drug"}]}, {"content": "The use of NUROMAX before succinylcholine to attenuate some of the side effects of succinylcholine has not been studied.", "metadata": {"original_id": "DrugDDI.d43.s1"}, "annotations": [{"start": 11, "end": 19, "tag": "drug"}, {"start": 26, "end": 42, "tag": "drug"}, {"start": 83, "end": 99, "tag": "drug"}]}, {"content": "There are no clinical data on concomitant use of NUROMAX and other nondepolarizing neuromuscular blocking agents.", "metadata": {"original_id": "DrugDDI.d43.s2"}, "annotations": [{"start": 49, "end": 57, "tag": "drug"}, {"start": 83, "end": 113, "tag": "drug"}]}, {"content": "Isoflurane, enflurane, and halothane decrease the ED50 of NUROMAX by 30% to 45%.", "metadata": {"original_id": "DrugDDI.d43.s3"}, "annotations": [{"start": 0, "end": 11, "tag": "drug"}, {"start": 12, "end": 22, "tag": "drug"}, {"start": 27, "end": 37, "tag": "drug"}, {"start": 58, "end": 66, "tag": "drug"}]}, {"content": "These agents may also prolong the clinically effective duration of action by up to 25%.", "metadata": {"original_id": "DrugDDI.d43.s4"}, "annotations": []}, {"content": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "metadata": {"original_id": "DrugDDI.d43.s5"}, "annotations": [{"start": 6, "end": 12, "tag": "drug"}, {"start": 67, "end": 89, "tag": "drug"}, {"start": 98, "end": 106, "tag": "drug"}, {"start": 122, "end": 134, "tag": "drug"}, {"start": 142, "end": 158, "tag": "drug"}, {"start": 159, "end": 173, "tag": "drug"}, {"start": 174, "end": 185, "tag": "drug"}, {"start": 186, "end": 197, "tag": "drug"}, {"start": 198, "end": 209, "tag": "drug"}, {"start": 210, "end": 222, "tag": "drug"}, {"start": 223, "end": 232, "tag": "drug"}, {"start": 237, "end": 244, "tag": "drug"}, {"start": 261, "end": 276, "tag": "drug"}, {"start": 278, "end": 286, "tag": "drug"}, {"start": 287, "end": 305, "tag": "drug"}, {"start": 306, "end": 319, "tag": "drug"}, {"start": 324, "end": 334, "tag": "drug"}]}, {"content": "As with some other nondepolarizing neuromuscular blocking agents, the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving phenytoin or carbamazepine.", "metadata": {"original_id": "DrugDDI.d43.s6"}, "annotations": [{"start": 35, "end": 65, "tag": "drug"}, {"start": 118, "end": 126, "tag": "drug"}, {"start": 201, "end": 211, "tag": "drug"}, {"start": 214, "end": 228, "tag": "drug"}]}, {"content": "Medroxyprogesterone Acetate - L-histidine was observed to enhance (in tissue culture) the effect of medroxyprogesterone acetate in reducing the number of human breast cancer cells that were in the S phase.", "metadata": {"original_id": "DrugDDI.d415.s0"}, "annotations": [{"start": 0, "end": 28, "tag": "drug"}, {"start": 100, "end": 128, "tag": "drug"}]}, {"content": "H1 and H2 Blockers - Although not reported, L-histidine, via its metabolism to histamine, might decrease the efficacy of H1 and H2 blockers.", "metadata": {"original_id": "DrugDDI.d415.s1"}, "annotations": [{"start": 7, "end": 19, "tag": "drug"}, {"start": 44, "end": 56, "tag": "drug"}, {"start": 128, "end": 140, "tag": "drug"}]}, {"content": "When administered concurrently, the following drugs may interact with beta-adrenergic receptor blocking agents: Anesthetics, general: exaggeration of the hypotension induced by general anesthetics.", "metadata": {"original_id": "DrugDDI.d464.s0"}, "annotations": [{"start": 46, "end": 52, "tag": "drug"}, {"start": 70, "end": 111, "tag": "drug"}, {"start": 112, "end": 124, "tag": "drug"}, {"start": 177, "end": 197, "tag": "drug"}]}, {"content": "Antidiabetic drugs (oral agents and insulin): hypoglycemia or hyperglycemia;", "metadata": {"original_id": "DrugDDI.d464.s1"}, "annotations": [{"start": 0, "end": 19, "tag": "drug"}, {"start": 36, "end": 44, "tag": "drug"}]}, {"content": "adjust dosage of antidiabetic drug accordingly.", "metadata": {"original_id": "DrugDDI.d464.s2"}, "annotations": [{"start": 17, "end": 35, "tag": "drug"}]}, {"content": "Catecholamine-depleting drugs (e.g., reserpine): additive effect;", "metadata": {"original_id": "DrugDDI.d464.s3"}, "annotations": [{"start": 24, "end": 30, "tag": "drug"}, {"start": 37, "end": 47, "tag": "drug"}]}, {"content": "monitor closely for evidence of hypotension and/or excessive bradycardia (e.g., vertigo, syncope, postural hypotension).", "metadata": {"original_id": "DrugDDI.d464.s4"}, "annotations": []}, {"content": "Response to Treatment for Anaphylactic Reaction: While taking beta-blockers, patients with a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic.", "metadata": {"original_id": "DrugDDI.d464.s5"}, "annotations": [{"start": 62, "end": 77, "tag": "drug"}]}, {"content": "Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction.", "metadata": {"original_id": "DrugDDI.d464.s6"}, "annotations": [{"start": 56, "end": 68, "tag": "drug"}]}, {"content": "Although no clinical drug-drug interaction studies have been conducted to date, on the basis of the in vitro studies, cytochrome p450 inhibitors and inducers are unlikely to affect the metabolism of clofarabine.", "metadata": {"original_id": "DrugDDI.d118.s0"}, "annotations": [{"start": 118, "end": 134, "tag": "drug"}, {"start": 199, "end": 211, "tag": "drug"}]}, {"content": "The effect of clofarabine on the metabolism of cytochrome p450 substrates has not been studied.", "metadata": {"original_id": "DrugDDI.d118.s1"}, "annotations": [{"start": 14, "end": 26, "tag": "drug"}, {"start": 47, "end": 63, "tag": "drug"}]}, {"content": "Drug/Laboratory Tests Interactions There are no known clinically significant interactions of CLOLAR? with other medications or laboratory tests.", "metadata": {"original_id": "DrugDDI.d118.s2"}, "annotations": [{"start": 0, "end": 5, "tag": "drug"}, {"start": 112, "end": 124, "tag": "drug"}]}, {"content": "No formal drug/laboratory test interaction studies have been conducted with CLOLAR? .", "metadata": {"original_id": "DrugDDI.d118.s3"}, "annotations": [{"start": 10, "end": 15, "tag": "drug"}]}, {"content": "In vitro drug metabolism studies indicate that Starlix is predominantly metabolized by the cytochrome P450 isozyme CYP2C9 (70%) and to a lesser extent CYP3A4 (30%).", "metadata": {"original_id": "DrugDDI.d249.s0"}, "annotations": [{"start": 47, "end": 55, "tag": "drug"}, {"start": 91, "end": 107, "tag": "drug"}, {"start": 151, "end": 158, "tag": "drug"}]}, {"content": "Starlix is a potential inhibitor of the CYP2C9 isoenzyme in vivo as indicated by its ability to inhibit the in vitro metabolism of tolbutamide.", "metadata": {"original_id": "DrugDDI.d249.s1"}, "annotations": [{"start": 0, "end": 8, "tag": "drug"}, {"start": 40, "end": 58, "tag": "drug"}, {"start": 131, "end": 143, "tag": "drug"}]}, {"content": "Inhibition of CYP3A4 metabolic reactions was not detected in in vitro experiments.", "metadata": {"original_id": "DrugDDI.d249.s2"}, "annotations": [{"start": 14, "end": 21, "tag": "drug"}]}, {"content": "Glyburide: In a randomized, multiple-dose crossover study, patients with Type 2 diabetes were administered 120 mg Starlix three times a day before meals for 1 day in combination with glyburide 10 mg daily.", "metadata": {"original_id": "DrugDDI.d249.s3"}, "annotations": [{"start": 0, "end": 10, "tag": "drug"}, {"start": 114, "end": 122, "tag": "drug"}, {"start": 183, "end": 193, "tag": "drug"}]}, {"content": "There were no clinically relevant alterations in the pharmacokinetics of either agent.", "metadata": {"original_id": "DrugDDI.d249.s4"}, "annotations": []}, {"content": "Metformin: When Starlix 120 mg three times daily before meals was administered in combination with metformin 500 mg three times daily to patients with Type 2 diabetes, there were no clinically relevant changes in the pharmacokinetics of either agent.", "metadata": {"original_id": "DrugDDI.d249.s5"}, "annotations": [{"start": 0, "end": 10, "tag": "drug"}, {"start": 16, "end": 24, "tag": "drug"}, {"start": 99, "end": 116, "tag": "drug"}]}, {"content": "Digoxin: When Starlix 120 mg before meals was administered in combination with a single 1-mg dose of digoxin to healthy volunteers, there were no clinically relevant changes in the pharmacokinetics of either agent.", "metadata": {"original_id": "DrugDDI.d249.s6"}, "annotations": [{"start": 0, "end": 8, "tag": "drug"}, {"start": 14, "end": 22, "tag": "drug"}, {"start": 101, "end": 109, "tag": "drug"}]}, {"content": "Warfarin: When healthy subjects were administered Starlix 120 mg three times daily before meals for four days in combination with a single dose of warfarin 30 mg on day 2, there were no alterations in the pharmacokinetics of either agent.", "metadata": {"original_id": "DrugDDI.d249.s7"}, "annotations": [{"start": 0, "end": 9, "tag": "drug"}, {"start": 50, "end": 58, "tag": "drug"}, {"start": 147, "end": 156, "tag": "drug"}]}, {"content": "Prothrombin time was not affected.", "metadata": {"original_id": "DrugDDI.d249.s8"}, "annotations": []}, {"content": "Diclofenac: Administration of morning and lunch doses of Starlix 120 mg in combination with a single 75-mg dose of diclofenac in healthy volunteers resulted in no significant changes to the pharmacokinetics of either agent.", "metadata": {"original_id": "DrugDDI.d249.s9"}, "annotations": [{"start": 0, "end": 11, "tag": "drug"}, {"start": 57, "end": 65, "tag": "drug"}, {"start": 115, "end": 126, "tag": "drug"}]}, {"content": "Nateglinide is highly bound to plasma proteins (98%), mainly albumin.", "metadata": {"original_id": "DrugDDI.d249.s10"}, "annotations": [{"start": 0, "end": 12, "tag": "drug"}, {"start": 31, "end": 47, "tag": "drug"}, {"start": 61, "end": 69, "tag": "drug"}]}, {"content": "In vitro displacement studies with highly protein-bound drugs such as furosemide, propranolol, captopril, nicardipine, pravastatin, glyburide, warfarin, phenytoin, acetylsalicylic acid, tolbutamide, and metformin showed no influence on the extent of nateglinide protein binding.", "metadata": {"original_id": "DrugDDI.d249.s11"}, "annotations": [{"start": 42, "end": 50, "tag": "drug"}, {"start": 70, "end": 82, "tag": "drug"}, {"start": 82, "end": 94, "tag": "drug"}, {"start": 95, "end": 105, "tag": "drug"}, {"start": 106, "end": 118, "tag": "drug"}, {"start": 119, "end": 131, "tag": "drug"}, {"start": 132, "end": 142, "tag": "drug"}, {"start": 143, "end": 152, "tag": "drug"}, {"start": 153, "end": 163, "tag": "drug"}, {"start": 164, "end": 185, "tag": "drug"}, {"start": 186, "end": 198, "tag": "drug"}, {"start": 203, "end": 213, "tag": "drug"}, {"start": 250, "end": 262, "tag": "drug"}]}, {"content": "Similarly, nateglinide had no influence on the serum protein binding of propranolol, glyburide, nicardipine, warfarin, phenytoin, acetylsalicylic acid, and tolbutamide in vitro .", "metadata": {"original_id": "DrugDDI.d249.s12"}, "annotations": [{"start": 11, "end": 23, "tag": "drug"}, {"start": 53, "end": 70, "tag": "drug"}, {"start": 72, "end": 84, "tag": "drug"}, {"start": 85, "end": 95, "tag": "drug"}, {"start": 96, "end": 108, "tag": "drug"}, {"start": 109, "end": 118, "tag": "drug"}, {"start": 119, "end": 129, "tag": "drug"}, {"start": 130, "end": 151, "tag": "drug"}, {"start": 156, "end": 168, "tag": "drug"}]}, {"content": "However, prudent evaluation of individual cases is warranted in the clinical setting.", "metadata": {"original_id": "DrugDDI.d249.s13"}, "annotations": []}, {"content": "Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.", "metadata": {"original_id": "DrugDDI.d249.s14"}, "annotations": [{"start": 8, "end": 14, "tag": "drug"}, {"start": 25, "end": 63, "tag": "drug"}, {"start": 64, "end": 71, "tag": "drug"}, {"start": 73, "end": 85, "tag": "drug"}, {"start": 86, "end": 115, "tag": "drug"}, {"start": 120, "end": 166, "tag": "drug"}, {"start": 185, "end": 205, "tag": "drug"}, {"start": 208, "end": 216, "tag": "drug"}, {"start": 231, "end": 250, "tag": "drug"}]}, {"content": "Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.", "metadata": {"original_id": "DrugDDI.d249.s15"}, "annotations": [{"start": 8, "end": 14, "tag": "drug"}, {"start": 24, "end": 34, "tag": "drug"}, {"start": 35, "end": 51, "tag": "drug"}, {"start": 52, "end": 60, "tag": "drug"}, {"start": 74, "end": 91, "tag": "drug"}, {"start": 106, "end": 126, "tag": "drug"}, {"start": 129, "end": 137, "tag": "drug"}, {"start": 152, "end": 171, "tag": "drug"}]}, {"content": "When these drugs are administered to or withdrawn from patients receiving Starlix, the patient should be observed closely for changes in glycemic control.", "metadata": {"original_id": "DrugDDI.d249.s16"}, "annotations": [{"start": 11, "end": 17, "tag": "drug"}, {"start": 74, "end": 82, "tag": "drug"}]}, {"content": "Drug interaction studies with Xigris have not been performed in patients with severe sepsis.", "metadata": {"original_id": "DrugDDI.d93.s0"}, "annotations": [{"start": 30, "end": 37, "tag": "drug"}]}, {"content": "However, since there is an increased risk of bleeding with Xigris, caution should be employed when Xigris is used with other drugs that affect hemostasis.", "metadata": {"original_id": "DrugDDI.d93.s1"}, "annotations": [{"start": 59, "end": 66, "tag": "drug"}, {"start": 99, "end": 106, "tag": "drug"}, {"start": 125, "end": 131, "tag": "drug"}]}, {"content": "Approximately 2/3 of the patients in the Phase 3 study received either prophylactic low dose heparin (unfractionated heparin up to 15,000 units/day) or prophylactic doses of low molecular weight heparins as indicated in the prescribing information for the specific products.", "metadata": {"original_id": "DrugDDI.d93.s2"}, "annotations": [{"start": 93, "end": 101, "tag": "drug"}, {"start": 102, "end": 125, "tag": "drug"}, {"start": 152, "end": 165, "tag": "drug"}, {"start": 174, "end": 204, "tag": "drug"}]}, {"content": "Concomitant use of prophylactic low dose heparin did not appear to affect safety, however, its effects on the efficacy of Xigris have not been evaluated in an adequate and well-controlled clinical trial.", "metadata": {"original_id": "DrugDDI.d93.s3"}, "annotations": [{"start": 41, "end": 49, "tag": "drug"}, {"start": 122, "end": 129, "tag": "drug"}]}, {"content": "Drug/Laboratory Test Interaction Because Xigris may affect the APTT assay, Xigris present in plasma samples may interfere with one-stage coagulation assays based on the APTT (such as factor VIII, IX, and XI assays).", "metadata": {"original_id": "DrugDDI.d93.s4"}, "annotations": [{"start": 0, "end": 5, "tag": "drug"}, {"start": 41, "end": 48, "tag": "drug"}, {"start": 75, "end": 82, "tag": "drug"}, {"start": 183, "end": 195, "tag": "drug"}]}, {"content": "This interference may result in an apparent factor concentration that is lower than the true concentration.", "metadata": {"original_id": "DrugDDI.d93.s5"}, "annotations": []}, {"content": "Xigris present in plasma samples does not interfere with one-stage factor assays based on the PT (such as factor II, V, VII, and X assays).", "metadata": {"original_id": "DrugDDI.d93.s6"}, "annotations": [{"start": 0, "end": 7, "tag": "drug"}, {"start": 106, "end": 116, "tag": "drug"}]}, {"content": "Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control.", "metadata": {"original_id": "DrugDDI.d103.s0"}, "annotations": [{"start": 8, "end": 14, "tag": "drug"}]}, {"content": "These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and isoniazid.", "metadata": {"original_id": "DrugDDI.d103.s1"}, "annotations": [{"start": 6, "end": 12, "tag": "drug"}, {"start": 24, "end": 34, "tag": "drug"}, {"start": 44, "end": 54, "tag": "drug"}, {"start": 55, "end": 71, "tag": "drug"}, {"start": 72, "end": 87, "tag": "drug"}, {"start": 88, "end": 96, "tag": "drug"}, {"start": 106, "end": 116, "tag": "drug"}, {"start": 117, "end": 137, "tag": "drug"}, {"start": 138, "end": 148, "tag": "drug"}, {"start": 149, "end": 164, "tag": "drug"}, {"start": 165, "end": 182, "tag": "drug"}, {"start": 183, "end": 214, "tag": "drug"}, {"start": 219, "end": 229, "tag": "drug"}]}, {"content": "When such drugs are administered to a patient receiving Acarbose, the patient should be closely observed for loss of blood glucose control.", "metadata": {"original_id": "DrugDDI.d103.s2"}, "annotations": [{"start": 10, "end": 16, "tag": "drug"}, {"start": 56, "end": 65, "tag": "drug"}]}, {"content": "When such drugs are withdrawn from patients receiving Acarbose in combination with sulfonylureas or insulin, patients should be observed closely for any evidence of hypoglycemia.", "metadata": {"original_id": "DrugDDI.d103.s3"}, "annotations": [{"start": 10, "end": 16, "tag": "drug"}, {"start": 54, "end": 63, "tag": "drug"}, {"start": 83, "end": 97, "tag": "drug"}, {"start": 100, "end": 108, "tag": "drug"}]}, {"content": "Intestinal adsorbents (e. g., charcoal) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., amylase, pancreatin) may reduce the effect of Acarbose and should not be taken concomitantly.", "metadata": {"original_id": "DrugDDI.d103.s4"}, "annotations": [{"start": 11, "end": 22, "tag": "drug"}, {"start": 30, "end": 39, "tag": "drug"}, {"start": 44, "end": 74, "tag": "drug"}, {"start": 124, "end": 132, "tag": "drug"}, {"start": 133, "end": 144, "tag": "drug"}, {"start": 170, "end": 179, "tag": "drug"}]}, {"content": "Acarbose has been shown to change the bioavailabillty digoxin when they are co-administered, which may require digoxin dose adjustment.", "metadata": {"original_id": "DrugDDI.d103.s5"}, "annotations": [{"start": 0, "end": 9, "tag": "drug"}, {"start": 54, "end": 62, "tag": "drug"}]}, {"content": "Studies in healthy volunteers have shown that Acarbose has no effect on either the pharmacokinetics or pharmacodynamics of digoxin, nifedipine, propranolol, or ranitidine.", "metadata": {"original_id": "DrugDDI.d103.s6"}, "annotations": [{"start": 46, "end": 55, "tag": "drug"}, {"start": 123, "end": 131, "tag": "drug"}, {"start": 132, "end": 143, "tag": "drug"}, {"start": 144, "end": 156, "tag": "drug"}, {"start": 160, "end": 171, "tag": "drug"}]}, {"content": "Acarbose did not interfere with the absorption or disposition of the sulfonylurea glyburide in diabetic patients.", "metadata": {"original_id": "DrugDDI.d103.s7"}, "annotations": [{"start": 0, "end": 9, "tag": "drug"}, {"start": 69, "end": 82, "tag": "drug"}]}, {"content": "Acarbose may affect digoxin bioavailabillty and may require dose adjustment of digoxin by 16% (90% confidence interval: 8-23%), decrease mean C max digoxin by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of digoxin by 9% (90% confidence limit: 19% decrease to 2% increase).", "metadata": {"original_id": "DrugDDI.d103.s8"}, "annotations": [{"start": 0, "end": 9, "tag": "drug"}, {"start": 20, "end": 28, "tag": "drug"}, {"start": 79, "end": 87, "tag": "drug"}, {"start": 144, "end": 148, "tag": "drug"}, {"start": 240, "end": 248, "tag": "drug"}]}, {"content": "The amount of metformin absorbed while taking Acarbose was bioequivalent to the amount absorbed when taking placebo, as indicated by the plasma AUC values.", "metadata": {"original_id": "DrugDDI.d103.s9"}, "annotations": [{"start": 14, "end": 24, "tag": "drug"}, {"start": 46, "end": 55, "tag": "drug"}]}, {"content": "However, the peak plasma level of metformin was reduced by approximately 20% when taking Acarbose due to a slight delay in the absorption of metformin.", "metadata": {"original_id": "DrugDDI.d103.s10"}, "annotations": [{"start": 34, "end": 44, "tag": "drug"}, {"start": 89, "end": 98, "tag": "drug"}, {"start": 141, "end": 151, "tag": "drug"}]}, {"content": "There is little if any clinically significant interaction between Acarbose and metformin.", "metadata": {"original_id": "DrugDDI.d103.s11"}, "annotations": [{"start": 66, "end": 75, "tag": "drug"}, {"start": 79, "end": 89, "tag": "drug"}]}, {"content": "Effects of Lapatinib on Drug Metabolizing Enzymes and Drug Transport Systems Lapatinib inhibits CYP3A4 and CYP2C8 in vitro at clinically relevant concentrations.", "metadata": {"original_id": "DrugDDI.d201.s0"}, "annotations": [{"start": 11, "end": 21, "tag": "drug"}, {"start": 24, "end": 29, "tag": "drug"}, {"start": 77, "end": 87, "tag": "drug"}, {"start": 96, "end": 103, "tag": "drug"}, {"start": 107, "end": 114, "tag": "drug"}]}, {"content": "Caution should be exercised and dose reduction of the concomitant substrate drug should be considered when dosing lapatinib concurrently with medications with narrow therapeutic windows that are substrates of CYP3A4 or CYP2C8.", "metadata": {"original_id": "DrugDDI.d201.s1"}, "annotations": [{"start": 76, "end": 81, "tag": "drug"}, {"start": 114, "end": 124, "tag": "drug"}, {"start": 142, "end": 154, "tag": "drug"}, {"start": 209, "end": 216, "tag": "drug"}, {"start": 219, "end": 226, "tag": "drug"}]}, {"content": "Lapatinib did not significantly inhibit the following enzymes in human liver microsomes: CYP1A2, CYP2C9, CYP2C19, and CYP2D6 or UGT enzymes in vitro, however, the clinical significance is unknown.", "metadata": {"original_id": "DrugDDI.d201.s2"}, "annotations": [{"start": 0, "end": 10, "tag": "drug"}, {"start": 89, "end": 96, "tag": "drug"}, {"start": 97, "end": 104, "tag": "drug"}, {"start": 105, "end": 113, "tag": "drug"}, {"start": 118, "end": 125, "tag": "drug"}]}, {"content": "Lapatinib inhibits human P-glycoprotein.", "metadata": {"original_id": "DrugDDI.d201.s3"}, "annotations": [{"start": 0, "end": 10, "tag": "drug"}, {"start": 27, "end": 40, "tag": "drug"}]}, {"content": "If TYKERB is administered with drugs that are substrates of Pgp, increased concentrations of the substrate drug are likely, and caution should be exercised.", "metadata": {"original_id": "DrugDDI.d201.s4"}, "annotations": [{"start": 31, "end": 37, "tag": "drug"}, {"start": 107, "end": 112, "tag": "drug"}]}, {"content": "Drugs that Inhibit or Induce Cytochrome P450 3A4 Enzymes Lapatinib undergoes extensive metabolism by CYP3A4, and concomitant administration of strong inhibitors or inducers of CYP3A4 alter lapatinib concentrations significantly.", "metadata": {"original_id": "DrugDDI.d201.s5"}, "annotations": [{"start": 0, "end": 6, "tag": "drug"}, {"start": 29, "end": 49, "tag": "drug"}, {"start": 101, "end": 108, "tag": "drug"}, {"start": 176, "end": 183, "tag": "drug"}, {"start": 189, "end": 199, "tag": "drug"}]}, {"content": "Dose adjustment of lapatinib should be considered for patients who must receive concomitant strong inhibitors or concomitant strong inducers of CYP3A4 enzymes.", "metadata": {"original_id": "DrugDDI.d201.s6"}, "annotations": [{"start": 19, "end": 29, "tag": "drug"}, {"start": 144, "end": 151, "tag": "drug"}]}, {"content": "Ketoconazole: In healthy subjects receiving ketoconazole, a CYP3A4 inhibitor, at 200 mg twice daily for 7 days, systemic exposure (AUC) to lapatinib was increased to approximately 3.6-fold of control and half-life increased to 1.7-fold of control.", "metadata": {"original_id": "DrugDDI.d201.s7"}, "annotations": [{"start": 0, "end": 13, "tag": "drug"}, {"start": 44, "end": 57, "tag": "drug"}, {"start": 60, "end": 67, "tag": "drug"}, {"start": 139, "end": 149, "tag": "drug"}]}, {"content": "Carbamazepine: In healthy subjects receiving the CYP3A4 inducer, carbamazepine, at 100 mg twice daily for 3 days and 200 mg twice daily for 17 days, systemic exposure (AUC) to lapatinib was decreased approximately 72%.", "metadata": {"original_id": "DrugDDI.d201.s8"}, "annotations": [{"start": 0, "end": 14, "tag": "drug"}, {"start": 49, "end": 56, "tag": "drug"}, {"start": 65, "end": 79, "tag": "drug"}, {"start": 176, "end": 186, "tag": "drug"}]}, {"content": "Drugs that Inhibit Drug Transport Systems Lapatinib is a substrate of the efflux transporter P-glycoprotein (Pgp, ABCB1).", "metadata": {"original_id": "DrugDDI.d201.s9"}, "annotations": [{"start": 0, "end": 6, "tag": "drug"}, {"start": 42, "end": 52, "tag": "drug"}, {"start": 81, "end": 93, "tag": "drug"}, {"start": 114, "end": 120, "tag": "drug"}]}, {"content": "If TYKERB is administered with drugs that inhibit Pgp, increased concentrations of lapatinib are likely, and caution should be exercised.", "metadata": {"original_id": "DrugDDI.d201.s10"}, "annotations": [{"start": 31, "end": 37, "tag": "drug"}, {"start": 83, "end": 93, "tag": "drug"}]}, {"content": "Other Chemotherapy Agents In a separate study, concomitant administration of lapatinib with capecitabine did not meaningfully alter the pharmacokinetics of either agent (or the metabolites of capecitabine).", "metadata": {"original_id": "DrugDDI.d201.s11"}, "annotations": [{"start": 77, "end": 87, "tag": "drug"}, {"start": 92, "end": 105, "tag": "drug"}, {"start": 177, "end": 189, "tag": "drug"}, {"start": 192, "end": 205, "tag": "drug"}]}, {"content": "Warfarin Concomitant administration of daptomycin (6 mg/kg once every 24 hours for 5 days) and warfarin (25 mg single oral dose) had no significant effect on the pharmacokinetics of either drug, and the INR was not significantly altered.", "metadata": {"original_id": "DrugDDI.d168.s0"}, "annotations": [{"start": 0, "end": 9, "tag": "drug"}, {"start": 39, "end": 50, "tag": "drug"}, {"start": 95, "end": 104, "tag": "drug"}, {"start": 189, "end": 194, "tag": "drug"}]}, {"content": "As experience with the concomitant administration of daptomycin and warfarin is limited to volunteer studies, anticoagulant activity in patients receiving daptomycin and warfarin should be monitored for the first several days after initiating therapy with Fentanyl.", "metadata": {"original_id": "DrugDDI.d168.s1"}, "annotations": [{"start": 53, "end": 64, "tag": "drug"}, {"start": 68, "end": 77, "tag": "drug"}, {"start": 155, "end": 166, "tag": "drug"}, {"start": 170, "end": 179, "tag": "drug"}, {"start": 256, "end": 265, "tag": "drug"}]}, {"content": "HMG-CoA Reductase Inhibitors Inhibitors of HMG-CoA reductase may cause myopathy, which is manifested as muscle pain or weakness associated with elevated levels of CPK.", "metadata": {"original_id": "DrugDDI.d168.s2"}, "annotations": [{"start": 0, "end": 29, "tag": "drug"}, {"start": 43, "end": 61, "tag": "drug"}]}, {"content": "There were no reports of skeletal myopathy in a placebo-controlled Phase I trial in which 10 healthy subjects on stable simvastatin therapy were treated concurrently with daptomycin (4 mg/kg once every 24 hours) for 14 days.", "metadata": {"original_id": "DrugDDI.d168.s3"}, "annotations": [{"start": 120, "end": 132, "tag": "drug"}, {"start": 171, "end": 182, "tag": "drug"}]}, {"content": "Experience with co-administration of HMG-CoA reduc-tase inhibitors and Fentanyl in patients is limited,therefore,consideration should be given to temporarily suspending use of HMG-CoA reductase inhibitors in patients receiving Fentanyl.", "metadata": {"original_id": "DrugDDI.d168.s4"}, "annotations": [{"start": 37, "end": 45, "tag": "drug"}, {"start": 71, "end": 80, "tag": "drug"}, {"start": 176, "end": 205, "tag": "drug"}, {"start": 227, "end": 236, "tag": "drug"}]}, {"content": "Drug-Laboratory Test Interactions: There are no reported drug-laboratory test interactions.", "metadata": {"original_id": "DrugDDI.d168.s5"}, "annotations": []}, {"content": "Fenfluramine may increase slightly the effect of antihypertensive drugs, e.g., guanethidine, methyldopa, reserpine.", "metadata": {"original_id": "DrugDDI.d210.s0"}, "annotations": [{"start": 0, "end": 13, "tag": "drug"}, {"start": 49, "end": 72, "tag": "drug"}, {"start": 79, "end": 92, "tag": "drug"}, {"start": 93, "end": 104, "tag": "drug"}, {"start": 105, "end": 115, "tag": "drug"}]}, {"content": "Other CNS depressant drugs should be used with caution in patients taking fenfluramine, since the effects may be additive.", "metadata": {"original_id": "DrugDDI.d210.s1"}, "annotations": [{"start": 6, "end": 27, "tag": "drug"}, {"start": 74, "end": 87, "tag": "drug"}]}, {"content": "Special consideration should be given to the administration of ETHYOL? in patients receiving antihypertensive medications or other drugs that could cause or potentiate hypotension.", "metadata": {"original_id": "DrugDDI.d0.s0"}, "annotations": [{"start": 93, "end": 110, "tag": "drug"}, {"start": 131, "end": 137, "tag": "drug"}]}, {"content": "Caution should be observed when anileridine is coadministered with other opioids, sedatives, phenothiazines, or anesthetics, as these agents may increase respiratory and circulatory depression.", "metadata": {"original_id": "DrugDDI.d290.s0"}, "annotations": [{"start": 32, "end": 44, "tag": "drug"}, {"start": 73, "end": 81, "tag": "drug"}, {"start": 82, "end": 92, "tag": "drug"}, {"start": 93, "end": 108, "tag": "drug"}, {"start": 112, "end": 124, "tag": "drug"}]}, {"content": "Tizoxanide is highly bound to plasma protein ( 99.9%).", "metadata": {"original_id": "DrugDDI.d306.s0"}, "annotations": [{"start": 0, "end": 11, "tag": "drug"}, {"start": 30, "end": 45, "tag": "drug"}]}, {"content": "Therefore, caution should be used when administering nitazoxanide concurrently with other highly plasma protein-bound drugs with narrow therapeutic indices, as competition for binding sites may occur (e.g., warfarin).", "metadata": {"original_id": "DrugDDI.d306.s1"}, "annotations": [{"start": 53, "end": 66, "tag": "drug"}, {"start": 207, "end": 216, "tag": "drug"}]}, {"content": "In vitro metabolism studies have demonstrated that tizoxanide has no significant inhibitory effect on cytochrome P450 enzymes.", "metadata": {"original_id": "DrugDDI.d306.s2"}, "annotations": [{"start": 51, "end": 62, "tag": "drug"}, {"start": 102, "end": 118, "tag": "drug"}]}, {"content": "Although no drug-drug interaction studies have been conducted in vivo, it is expected that no significant interaction would occur when nitazoxanide is co-administered with drugs that either are metabolized by or inhibit cytochrome P450 enzymes.", "metadata": {"original_id": "DrugDDI.d306.s3"}, "annotations": [{"start": 135, "end": 148, "tag": "drug"}, {"start": 172, "end": 178, "tag": "drug"}, {"start": 220, "end": 236, "tag": "drug"}]}, {"content": "In occasional susceptible patients or in those receiving anticholinergic drugs (including antiparkinsonism agents) in addition, the atropine-like effects may become more pronounced (e.g., paralytic ileus).", "metadata": {"original_id": "DrugDDI.d188.s0"}, "annotations": [{"start": 57, "end": 79, "tag": "drug"}, {"start": 132, "end": 141, "tag": "drug"}]}, {"content": "Close supervision and careful adjustment of dosage is required when this drug is administered concomitantly with anticholinergic drugs.", "metadata": {"original_id": "DrugDDI.d188.s1"}, "annotations": [{"start": 73, "end": 78, "tag": "drug"}, {"start": 113, "end": 135, "tag": "drug"}]}, {"content": "Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.", "metadata": {"original_id": "DrugDDI.d188.s2"}, "annotations": [{"start": 38, "end": 52, "tag": "drug"}, {"start": 56, "end": 74, "tag": "drug"}, {"start": 92, "end": 115, "tag": "drug"}, {"start": 121, "end": 133, "tag": "drug"}, {"start": 134, "end": 149, "tag": "drug"}, {"start": 183, "end": 209, "tag": "drug"}]}, {"content": "Caution should be exercised when imipramine hydrochloride is used with agents that lower blood pressure.", "metadata": {"original_id": "DrugDDI.d188.s3"}, "annotations": [{"start": 33, "end": 58, "tag": "drug"}]}, {"content": "Imipramine hydrochloride may potentiate the effects of CNS depressant drugs.", "metadata": {"original_id": "DrugDDI.d188.s4"}, "annotations": [{"start": 0, "end": 25, "tag": "drug"}, {"start": 55, "end": 76, "tag": "drug"}]}, {"content": "The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary.", "metadata": {"original_id": "DrugDDI.d188.s5"}, "annotations": [{"start": 28, "end": 39, "tag": "drug"}, {"start": 61, "end": 66, "tag": "drug"}, {"start": 102, "end": 120, "tag": "drug"}, {"start": 127, "end": 138, "tag": "drug"}, {"start": 139, "end": 150, "tag": "drug"}, {"start": 228, "end": 241, "tag": "drug"}, {"start": 242, "end": 252, "tag": "drug"}, {"start": 286, "end": 297, "tag": "drug"}]}, {"content": "Drugs Metabolized by P450 2D6 The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the caucasian population (about 7 to 10% of caucasians are so called poor metabolizers);", "metadata": {"original_id": "DrugDDI.d188.s6"}, "annotations": [{"start": 0, "end": 6, "tag": "drug"}, {"start": 21, "end": 31, "tag": "drug"}, {"start": 62, "end": 67, "tag": "drug"}, {"start": 109, "end": 134, "tag": "drug"}]}, {"content": "reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available.", "metadata": {"original_id": "DrugDDI.d188.s7"}, "annotations": [{"start": 48, "end": 66, "tag": "drug"}]}, {"content": "Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses.", "metadata": {"original_id": "DrugDDI.d188.s8"}, "annotations": [{"start": 69, "end": 95, "tag": "drug"}]}, {"content": "Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA).", "metadata": {"original_id": "DrugDDI.d188.s9"}, "annotations": [{"start": 29, "end": 34, "tag": "drug"}, {"start": 49, "end": 59, "tag": "drug"}]}, {"content": "In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble p.o.", "metadata": {"original_id": "DrugDDI.d188.s10"}, "annotations": [{"start": 21, "end": 27, "tag": "drug"}, {"start": 56, "end": 64, "tag": "drug"}]}, {"content": "metabolizers.", "metadata": {"original_id": "DrugDDI.d188.s11"}, "annotations": []}, {"content": "An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy.", "metadata": {"original_id": "DrugDDI.d188.s12"}, "annotations": [{"start": 112, "end": 118, "tag": "drug"}]}, {"content": "The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine;", "metadata": {"original_id": "DrugDDI.d188.s13"}, "annotations": [{"start": 4, "end": 10, "tag": "drug"}, {"start": 23, "end": 43, "tag": "drug"}, {"start": 96, "end": 106, "tag": "drug"}]}, {"content": "cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide).", "metadata": {"original_id": "DrugDDI.d188.s14"}, "annotations": [{"start": 0, "end": 11, "tag": "drug"}, {"start": 45, "end": 55, "tag": "drug"}, {"start": 66, "end": 82, "tag": "drug"}, {"start": 83, "end": 98, "tag": "drug"}, {"start": 131, "end": 143, "tag": "drug"}, {"start": 147, "end": 158, "tag": "drug"}]}, {"content": "While all the selective serotonin reuptake inhibitors (SSRIs), e. g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.", "metadata": {"original_id": "DrugDDI.d188.s15"}, "annotations": [{"start": 24, "end": 54, "tag": "drug"}, {"start": 70, "end": 81, "tag": "drug"}, {"start": 82, "end": 93, "tag": "drug"}, {"start": 98, "end": 109, "tag": "drug"}, {"start": 118, "end": 128, "tag": "drug"}]}, {"content": "The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition, and the pharmacokinetics of the SSRI involved.", "metadata": {"original_id": "DrugDDI.d188.s16"}, "annotations": []}, {"content": "Nevertheless, caution is indicated in the co-administration of TCA5 with any of the SSRIs and also in switching from one class to the other.", "metadata": {"original_id": "DrugDDI.d188.s17"}, "annotations": []}, {"content": "Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).", "metadata": {"original_id": "DrugDDI.d188.s18"}, "annotations": [{"start": 120, "end": 131, "tag": "drug"}, {"start": 175, "end": 193, "tag": "drug"}]}, {"content": "Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug.", "metadata": {"original_id": "DrugDDI.d188.s19"}, "annotations": [{"start": 19, "end": 45, "tag": "drug"}, {"start": 50, "end": 56, "tag": "drug"}, {"start": 73, "end": 93, "tag": "drug"}, {"start": 156, "end": 181, "tag": "drug"}, {"start": 194, "end": 199, "tag": "drug"}]}, {"content": "Furthermore, whenever one of these other drugs is withdrawn from cotherapy, an increased dose of tricyclic antidepressant may be required.", "metadata": {"original_id": "DrugDDI.d188.s20"}, "annotations": [{"start": 41, "end": 47, "tag": "drug"}, {"start": 97, "end": 122, "tag": "drug"}]}, {"content": "It is desirable to monitor TCA plasma levels whenever a TCA is going to be co-administered with another drug known to be an inhibitor of P450 2D6.", "metadata": {"original_id": "DrugDDI.d188.s21"}, "annotations": [{"start": 104, "end": 109, "tag": "drug"}, {"start": 137, "end": 147, "tag": "drug"}]}, {"content": "Certain endocrine and liver function tests may be affected by estrogen-containing oral contraceptives.", "metadata": {"original_id": "DrugDDI.d9.s0"}, "annotations": [{"start": 62, "end": 71, "tag": "drug"}, {"start": 82, "end": 102, "tag": "drug"}]}, {"content": "The following similar changes may be expected with larger doses of estrogen: Increased sulfobromophthalein retention;", "metadata": {"original_id": "DrugDDI.d9.s1"}, "annotations": [{"start": 67, "end": 76, "tag": "drug"}]}, {"content": "increased prothrombin and factors VII, VIII, IX, and X;", "metadata": {"original_id": "DrugDDI.d9.s2"}, "annotations": [{"start": 10, "end": 22, "tag": "drug"}, {"start": 26, "end": 39, "tag": "drug"}]}, {"content": "decreased antithrombin 3;", "metadata": {"original_id": "DrugDDI.d9.s3"}, "annotations": [{"start": 10, "end": 23, "tag": "drug"}]}, {"content": "increased norepinephrine-induced platel et aggregation;", "metadata": {"original_id": "DrugDDI.d9.s4"}, "annotations": [{"start": 10, "end": 25, "tag": "drug"}]}, {"content": "increased thyroid binding globulin (TBG) leading to increased circulating total thyroid hormone, as measured by PBI, T4 by column, or T4 by radioimmunoassay.", "metadata": {"original_id": "DrugDDI.d9.s5"}, "annotations": [{"start": 80, "end": 96, "tag": "drug"}, {"start": 117, "end": 120, "tag": "drug"}, {"start": 134, "end": 137, "tag": "drug"}]}, {"content": "Free T3 resin uptake is decreased, reflecting the elevated TBG;", "metadata": {"original_id": "DrugDDI.d9.s6"}, "annotations": []}, {"content": "free T4 concentration is unaltered: impaired glucose tolerance;", "metadata": {"original_id": "DrugDDI.d9.s7"}, "annotations": []}, {"content": "decreased pregnanediol excretion;", "metadata": {"original_id": "DrugDDI.d9.s8"}, "annotations": []}, {"content": "reduced response to metyrapone test;", "metadata": {"original_id": "DrugDDI.d9.s9"}, "annotations": []}, {"content": "reduced serum folate concentration;", "metadata": {"original_id": "DrugDDI.d9.s10"}, "annotations": []}, {"content": "increased serum triglyceride and phospholipid concentration.", "metadata": {"original_id": "DrugDDI.d9.s11"}, "annotations": [{"start": 33, "end": 46, "tag": "drug"}]}, {"content": "Plasma levels of anticonvulsant agents may become subtherapeutic during cisplatin therapy.", "metadata": {"original_id": "DrugDDI.d12.s0"}, "annotations": [{"start": 17, "end": 38, "tag": "drug"}, {"start": 72, "end": 82, "tag": "drug"}]}, {"content": "In a randomized trial in advanced ovarian cancer, response duration was adversely affected when pyridoxine was used in combination with altretamine (hexamethylmelamine) and cisplatin.1", "metadata": {"original_id": "DrugDDI.d12.s1"}, "annotations": [{"start": 96, "end": 107, "tag": "drug"}, {"start": 136, "end": 148, "tag": "drug"}, {"start": 149, "end": 168, "tag": "drug"}, {"start": 173, "end": 183, "tag": "drug"}]}, {"content": "In vitro data indicate that NORVASC has no effect on the human plasma protein binding of digoxin, phenytoin, warfarin, and indomethacin.", "metadata": {"original_id": "DrugDDI.d539.s0"}, "annotations": [{"start": 28, "end": 36, "tag": "drug"}, {"start": 57, "end": 70, "tag": "drug"}, {"start": 89, "end": 97, "tag": "drug"}, {"start": 98, "end": 108, "tag": "drug"}, {"start": 109, "end": 118, "tag": "drug"}, {"start": 123, "end": 136, "tag": "drug"}]}, {"content": "Effect of other agents on NORVASC.", "metadata": {"original_id": "DrugDDI.d539.s1"}, "annotations": [{"start": 26, "end": 34, "tag": "drug"}]}, {"content": "CIMETIDINE: Co-administration of NORVASC with cimetidine did not alter the pharmacokinetics of NORVASC.", "metadata": {"original_id": "DrugDDI.d539.s2"}, "annotations": [{"start": 0, "end": 11, "tag": "drug"}, {"start": 33, "end": 41, "tag": "drug"}, {"start": 46, "end": 57, "tag": "drug"}, {"start": 95, "end": 103, "tag": "drug"}]}, {"content": "GRAPEFRUIT JUICE: Co-administration of 240 mL of grapefruit juice with a single oral dose of amlodipine 10 mg in 20 healthy volunteers had no significant effect on the pharmacokinetics of amlodipine.", "metadata": {"original_id": "DrugDDI.d539.s3"}, "annotations": [{"start": 93, "end": 110, "tag": "drug"}, {"start": 188, "end": 199, "tag": "drug"}]}, {"content": "MAALOX (antacid): Co-administration of the antacid Maalox with a single dose of NORVASC had no significant effect on the pharmacokinetics of NORVASC.", "metadata": {"original_id": "DrugDDI.d539.s4"}, "annotations": [{"start": 0, "end": 7, "tag": "drug"}, {"start": 8, "end": 16, "tag": "drug"}, {"start": 51, "end": 58, "tag": "drug"}, {"start": 80, "end": 88, "tag": "drug"}, {"start": 141, "end": 149, "tag": "drug"}]}, {"content": "SILDENAFIL: A single 100 mg dose of sildenafil (Viagra?) in subjects with essential hypertension had no effect on the pharmacokinetic parameters of NORVASC.", "metadata": {"original_id": "DrugDDI.d539.s5"}, "annotations": [{"start": 0, "end": 11, "tag": "drug"}, {"start": 36, "end": 47, "tag": "drug"}, {"start": 148, "end": 156, "tag": "drug"}]}, {"content": "When NORVASC and sildenafil were used in combination, each agent independently exerted its own blood pressure lowering effect.", "metadata": {"original_id": "DrugDDI.d539.s6"}, "annotations": [{"start": 5, "end": 13, "tag": "drug"}, {"start": 17, "end": 28, "tag": "drug"}]}, {"content": "Effect of NORVASC on other agents.", "metadata": {"original_id": "DrugDDI.d539.s7"}, "annotations": [{"start": 10, "end": 18, "tag": "drug"}]}, {"content": "ATORVASTATIN: Co-administration of multiple 10 mg doses of NORVASC with 80 mg of atorvastatin resulted in no significant change in the steady state pharmacokinetic parameters of atorvastatin.", "metadata": {"original_id": "DrugDDI.d539.s8"}, "annotations": [{"start": 0, "end": 13, "tag": "drug"}, {"start": 59, "end": 67, "tag": "drug"}, {"start": 81, "end": 94, "tag": "drug"}, {"start": 178, "end": 191, "tag": "drug"}]}, {"content": "DIGOXIN: Co-administration of NORVASC with digoxin did not change serum digoxin levels or digoxin renal clearance in normal volunteers.", "metadata": {"original_id": "DrugDDI.d539.s9"}, "annotations": [{"start": 0, "end": 8, "tag": "drug"}, {"start": 30, "end": 38, "tag": "drug"}, {"start": 43, "end": 51, "tag": "drug"}, {"start": 90, "end": 98, "tag": "drug"}]}, {"content": "ETHANOL (alcohol): Single and multiple 10 mg doses of NORVASC had no significant effect on the pharmacokinetics of ethanol.", "metadata": {"original_id": "DrugDDI.d539.s10"}, "annotations": [{"start": 0, "end": 8, "tag": "drug"}, {"start": 9, "end": 17, "tag": "drug"}, {"start": 54, "end": 62, "tag": "drug"}, {"start": 115, "end": 123, "tag": "drug"}]}, {"content": "WARFARIN: Co-administration of NORVASC with warfarin did not change the warfarin prothrombin response time.", "metadata": {"original_id": "DrugDDI.d539.s11"}, "annotations": [{"start": 0, "end": 9, "tag": "drug"}, {"start": 31, "end": 39, "tag": "drug"}, {"start": 44, "end": 53, "tag": "drug"}, {"start": 81, "end": 93, "tag": "drug"}]}, {"content": "In clinical trials, NORVASC has been safely administered with thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual nitroglycerin, digoxin, warfarin, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs.", "metadata": {"original_id": "DrugDDI.d539.s12"}, "annotations": [{"start": 20, "end": 28, "tag": "drug"}, {"start": 62, "end": 81, "tag": "drug"}, {"start": 82, "end": 97, "tag": "drug"}, {"start": 97, "end": 138, "tag": "drug"}, {"start": 151, "end": 160, "tag": "drug"}, {"start": 172, "end": 186, "tag": "drug"}, {"start": 187, "end": 195, "tag": "drug"}, {"start": 196, "end": 205, "tag": "drug"}, {"start": 206, "end": 244, "tag": "drug"}, {"start": 245, "end": 257, "tag": "drug"}, {"start": 262, "end": 286, "tag": "drug"}]}, {"content": "Drug/Laboratory Test Interactions: None known.", "metadata": {"original_id": "DrugDDI.d539.s13"}, "annotations": [{"start": 0, "end": 5, "tag": "drug"}]}, {"content": "Oral Anticoagulants CAUTION SHOULD BE EXERCISED WHEN COUMARIN ANTICOAGULANTS ARE GIVEN IN CONJUNCTION WITH TRICOR.", "metadata": {"original_id": "DrugDDI.d199.s0"}, "annotations": [{"start": 0, "end": 20, "tag": "drug"}, {"start": 53, "end": 76, "tag": "drug"}, {"start": 107, "end": 114, "tag": "drug"}]}, {"content": "THE DOSAGE OF THE ANTICOAGULANTS SHOULD BE REDUCED TO MAINTAIN THE PROTHROMBIN TIME/INR AT THE DESIRED LEVEL TO PREVENT BLEEDING COMPLICATIONS.", "metadata": {"original_id": "DrugDDI.d199.s1"}, "annotations": [{"start": 18, "end": 33, "tag": "drug"}, {"start": 112, "end": 120, "tag": "drug"}]}, {"content": "FREQUENT PROTHROMBIN TIME/INR DETERMINATIONS ARE ADVISABLE UNTIL IT HAS BEEN DEFINITELY DETERMINED THAT THE PROTHROMBIN TIME/INR HAS STABILIZED.", "metadata": {"original_id": "DrugDDI.d199.s2"}, "annotations": []}, {"content": "HMG-CoA reductase inhibitors The combined use of TRICOR and HMG-CoA reductase inhibitors should be avoided unless the benefit of further alterations in lipid levels is likely to outweigh the increased risk of this drug combination.", "metadata": {"original_id": "DrugDDI.d199.s3"}, "annotations": [{"start": 0, "end": 29, "tag": "drug"}, {"start": 49, "end": 56, "tag": "drug"}, {"start": 60, "end": 89, "tag": "drug"}, {"start": 214, "end": 219, "tag": "drug"}]}, {"content": "Resins Since bile acid sequestrants may bind other drugs given concurrently, patients should take TRICOR at least 1 hour before or 4-6 hours after a bile acid binding resin to avoid impeding its absorption.", "metadata": {"original_id": "DrugDDI.d199.s4"}, "annotations": [{"start": 0, "end": 7, "tag": "drug"}, {"start": 13, "end": 36, "tag": "drug"}, {"start": 51, "end": 57, "tag": "drug"}, {"start": 98, "end": 105, "tag": "drug"}, {"start": 149, "end": 159, "tag": "drug"}]}, {"content": "Cyclosporine Because cyclosporine can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate drugs including TRICOR, there is a risk that an interaction will lead to deterioration.", "metadata": {"original_id": "DrugDDI.d199.s5"}, "annotations": [{"start": 0, "end": 13, "tag": "drug"}, {"start": 21, "end": 34, "tag": "drug"}, {"start": 104, "end": 111, "tag": "drug"}, {"start": 195, "end": 209, "tag": "drug"}, {"start": 219, "end": 226, "tag": "drug"}]}, {"content": "The benefits and risks of using TRICOR with immunosuppressants and other potentially nephrotoxic agents should be carefully considered, and the lowest effective dose employed", "metadata": {"original_id": "DrugDDI.d199.s6"}, "annotations": [{"start": 32, "end": 39, "tag": "drug"}, {"start": 44, "end": 63, "tag": "drug"}]}, {"content": ".", "metadata": {"original_id": "DrugDDI.d199.s7"}, "annotations": []}, {"content": "? Drug-drug interactions In vitro studies using human liver microsomes indicate that fenofibrate and fenofibric acid are not inhibitors of cytochrome (CYP) P450 isoforms CYP3A4, CYP2D6, CYP2E1, or CYP1A2.", "metadata": {"original_id": "DrugDDI.d199.s8"}, "annotations": [{"start": 85, "end": 97, "tag": "drug"}, {"start": 101, "end": 117, "tag": "drug"}, {"start": 139, "end": 150, "tag": "drug"}, {"start": 151, "end": 155, "tag": "drug"}, {"start": 156, "end": 161, "tag": "drug"}, {"start": 178, "end": 185, "tag": "drug"}, {"start": 186, "end": 193, "tag": "drug"}, {"start": 197, "end": 204, "tag": "drug"}]}, {"content": "They are weak inhibitors of CYP2C19 and CYP2A6, and mild-to-moderate inhibitors of CYP2C9 at therapeutic concentrations.", "metadata": {"original_id": "DrugDDI.d199.s9"}, "annotations": [{"start": 28, "end": 36, "tag": "drug"}, {"start": 40, "end": 47, "tag": "drug"}, {"start": 83, "end": 90, "tag": "drug"}]}, {"content": "Potentiation of coumarin-type anticoagulants has been observed with prolongation of the prothrombin time/INR.", "metadata": {"original_id": "DrugDDI.d199.s10"}, "annotations": [{"start": 16, "end": 45, "tag": "drug"}]}, {"content": "Bile acid sequestrants have been shown to bind other drugs given concurrently.", "metadata": {"original_id": "DrugDDI.d199.s11"}, "annotations": [{"start": 0, "end": 23, "tag": "drug"}, {"start": 53, "end": 59, "tag": "drug"}]}, {"content": "Therefore, fenofibrate should be taken at least 1 hour before or 4-6 hours after a bile acid binding resin to avoid impeding its absorption .", "metadata": {"original_id": "DrugDDI.d199.s12"}, "annotations": [{"start": 11, "end": 23, "tag": "drug"}, {"start": 83, "end": 93, "tag": "drug"}]}, {"content": "Concomitant administration of fenofibrate (equivalent to 145mg TRICOR) with pravastatin (40 mg) once daily for 10 days has been shown to increase the mean Cmax and AUC values for pravastatin by 36% (range from 69% decrease to 321% increase) and 28% (range from 54% decrease to 128% increase), respectively, and for 3?-hydroxy-iso-pravastatin by 55% (range from 32% decrease to 314% increase) and 39% (range from 24% decrease to 261% increase), respectively in 23 healthy adults.", "metadata": {"original_id": "DrugDDI.d199.s13"}, "annotations": [{"start": 30, "end": 42, "tag": "drug"}, {"start": 63, "end": 70, "tag": "drug"}, {"start": 76, "end": 88, "tag": "drug"}, {"start": 179, "end": 191, "tag": "drug"}, {"start": 330, "end": 342, "tag": "drug"}]}, {"content": "A single dose of pravastatin had no clinically important effect on the pharmacokinetics of fenofibric acid.", "metadata": {"original_id": "DrugDDI.d199.s14"}, "annotations": [{"start": 17, "end": 29, "tag": "drug"}, {"start": 91, "end": 107, "tag": "drug"}]}, {"content": "Concomitant administration of fenofibrate (equivalent to 145 mg TRICOR) with atorvastatin (20 mg) once daily for 10 days resulted in approximately 17% decrease (range from 67% decrease to 44% increase) in atorvastatin AUC values in 22 healthy males.", "metadata": {"original_id": "DrugDDI.d199.s15"}, "annotations": [{"start": 30, "end": 42, "tag": "drug"}, {"start": 64, "end": 71, "tag": "drug"}, {"start": 77, "end": 90, "tag": "drug"}, {"start": 205, "end": 218, "tag": "drug"}]}, {"content": "The atorvastatin Cmax values were not significantly affected by fenofibrate.", "metadata": {"original_id": "DrugDDI.d199.s16"}, "annotations": [{"start": 4, "end": 17, "tag": "drug"}, {"start": 64, "end": 76, "tag": "drug"}]}, {"content": "The pharmacokinetics of fenofibric acid were not significantly affected by atorvastatin", "metadata": {"original_id": "DrugDDI.d199.s17"}, "annotations": [{"start": 24, "end": 40, "tag": "drug"}, {"start": 75, "end": 88, "tag": "drug"}]}, {"content": ".", "metadata": {"original_id": "DrugDDI.d199.s18"}, "annotations": []}, {"content": "?", "metadata": {"original_id": "DrugDDI.d199.s19"}, "annotations": []}, {"content": "Substances that are inducers of CYP3A4 activity increase the metabolism of gefitinib and decrease its plasma concentrations.", "metadata": {"original_id": "DrugDDI.d178.s0"}, "annotations": [{"start": 32, "end": 39, "tag": "drug"}, {"start": 75, "end": 85, "tag": "drug"}]}, {"content": "In patients receiving a potent CYP3A4 inducer such as rifampicin or phenytoin, a dose increase to 500 mg daily should be considered in the absence of severe adverse drug reaction, and clinical response and adverse events should be carefully monitored (see CLINICAL PHARMACOLOGY-Pharmacokinetics-Drug-Drug Interactions and DOSAGE AND ADMINISTRATION-Dosage Adjustment sections).", "metadata": {"original_id": "DrugDDI.d178.s1"}, "annotations": [{"start": 31, "end": 38, "tag": "drug"}, {"start": 54, "end": 65, "tag": "drug"}, {"start": 68, "end": 78, "tag": "drug"}]}, {"content": "International Normalized Ratio (INR) elevations and/or bleeding events have been reported in some patients taking warfarin while on IRESSA therapy.", "metadata": {"original_id": "DrugDDI.d178.s2"}, "annotations": [{"start": 114, "end": 123, "tag": "drug"}, {"start": 132, "end": 139, "tag": "drug"}]}, {"content": "Patients taking warfarin should be monitored regularly for changes in prothrombin time or INR.", "metadata": {"original_id": "DrugDDI.d178.s3"}, "annotations": [{"start": 16, "end": 25, "tag": "drug"}]}, {"content": "Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole) decrease gefitinib metabolism and increase gefitinib plasma concentrations.", "metadata": {"original_id": "DrugDDI.d178.s4"}, "annotations": [{"start": 41, "end": 48, "tag": "drug"}, {"start": 62, "end": 75, "tag": "drug"}, {"start": 79, "end": 92, "tag": "drug"}, {"start": 102, "end": 112, "tag": "drug"}, {"start": 136, "end": 146, "tag": "drug"}]}, {"content": "This increase may be clinically relevant as adverse experiences are related to dose and exposure;", "metadata": {"original_id": "DrugDDI.d178.s5"}, "annotations": []}, {"content": "therefore, caution should be used when administering CYP3A4 inhibitors with IRESSA.", "metadata": {"original_id": "DrugDDI.d178.s6"}, "annotations": [{"start": 53, "end": 60, "tag": "drug"}, {"start": 76, "end": 83, "tag": "drug"}]}, {"content": "Drugs that cause significant sustained elevation in gastric pH (histamine H2-receptor antagonists such as ranitidine or cimetidine) may reduce plasma concentrations of IRESSA and therefore potentially may reduce efficacy.", "metadata": {"original_id": "DrugDDI.d178.s7"}, "annotations": [{"start": 0, "end": 6, "tag": "drug"}, {"start": 64, "end": 98, "tag": "drug"}, {"start": 106, "end": 117, "tag": "drug"}, {"start": 120, "end": 131, "tag": "drug"}, {"start": 168, "end": 175, "tag": "drug"}]}, {"content": "Phase II clinical trial data, where IRESSA and vinorelbine have been used concomitantly, indicate that IRESSA may exacerbate the neutropenic effect of vinorelbine.", "metadata": {"original_id": "DrugDDI.d178.s8"}, "annotations": [{"start": 36, "end": 43, "tag": "drug"}, {"start": 47, "end": 59, "tag": "drug"}, {"start": 103, "end": 110, "tag": "drug"}, {"start": 151, "end": 163, "tag": "drug"}]}, {"content": "No formal drug interaction studies with anti-neoplastic agents have been conducted.", "metadata": {"original_id": "DrugDDI.d285.s0"}, "annotations": [{"start": 40, "end": 63, "tag": "drug"}]}, {"content": "In Study 1, patients with colorectal cancer were given irinotecan/5-FU/leucovorin (bolus-IFL) with or without AVASTIN.", "metadata": {"original_id": "DrugDDI.d285.s1"}, "annotations": [{"start": 55, "end": 66, "tag": "drug"}, {"start": 110, "end": 118, "tag": "drug"}]}, {"content": "Irinotecan concentrations were similar in patients receiving bolus-IFL alone and in combination with AVASTIN.", "metadata": {"original_id": "DrugDDI.d285.s2"}, "annotations": [{"start": 0, "end": 11, "tag": "drug"}, {"start": 101, "end": 109, "tag": "drug"}]}, {"content": "The concentrations of SN38, the active metabolite of irinotecan, were on average 33% higher in patients receiving bolus-IFL in combination with AVASTIN when compared with bolus-IFL alone.", "metadata": {"original_id": "DrugDDI.d285.s3"}, "annotations": [{"start": 32, "end": 50, "tag": "drug"}, {"start": 53, "end": 64, "tag": "drug"}, {"start": 144, "end": 152, "tag": "drug"}]}, {"content": "In Study 1, patients receiving bolus-IFL plus AVASTIN had a higher incidence of Grade 3-4 diarrhea and neutropenia.", "metadata": {"original_id": "DrugDDI.d285.s4"}, "annotations": [{"start": 46, "end": 54, "tag": "drug"}]}, {"content": "Due to high inter-patient variability and limited sampling, the extent of the increase in SN38 levels in patients receiving concurrent irinotecan and AVASTIN is uncertain.", "metadata": {"original_id": "DrugDDI.d285.s5"}, "annotations": [{"start": 135, "end": 146, "tag": "drug"}, {"start": 150, "end": 158, "tag": "drug"}]}, {"content": "Dicumarol and warfarin may decrease hypoprothrombinemic effect.", "metadata": {"original_id": "DrugDDI.d174.s0"}, "annotations": [{"start": 0, "end": 10, "tag": "drug"}, {"start": 14, "end": 23, "tag": "drug"}]}, {"content": "Other depressasnts such as alcohol, barbiturates, and MAOIs may enhance CNS depression when administered with ethchlorvynol.", "metadata": {"original_id": "DrugDDI.d174.s1"}, "annotations": [{"start": 27, "end": 35, "tag": "drug"}, {"start": 36, "end": 49, "tag": "drug"}, {"start": 110, "end": 125, "tag": "drug"}]}, {"content": "Effect of other drugs on Vardenafil", "metadata": {"original_id": "DrugDDI.d253.s0"}, "annotations": [{"start": 16, "end": 22, "tag": "drug"}, {"start": 25, "end": 36, "tag": "drug"}]}, {"content": "In vitro studies: Studies in human liver microsomes showed that vardenafil is metabolized primarily by cytochrome P450 (CYP) isoforms 3A4/5, and to a lesser degree by CYP2C9.", "metadata": {"original_id": "DrugDDI.d253.s1"}, "annotations": [{"start": 64, "end": 75, "tag": "drug"}, {"start": 103, "end": 119, "tag": "drug"}, {"start": 120, "end": 124, "tag": "drug"}, {"start": 125, "end": 134, "tag": "drug"}, {"start": 167, "end": 174, "tag": "drug"}]}, {"content": "Therefore, inhibitors of these enzymes are expected to reduce vardenafil clearance.", "metadata": {"original_id": "DrugDDI.d253.s2"}, "annotations": [{"start": 62, "end": 73, "tag": "drug"}]}, {"content": "In vivo studies: Cytochrome P450 Inhibitors", "metadata": {"original_id": "DrugDDI.d253.s3"}, "annotations": [{"start": 17, "end": 33, "tag": "drug"}]}, {"content": "Cimetidine (400 mg b.i.d.) had no effect on vardenafil bioavailability (AUC) and maximum concentration (Cmax) of vardenafil when co-administered with 20 mg Vardenafil in healthy volunteers.", "metadata": {"original_id": "DrugDDI.d253.s4"}, "annotations": [{"start": 0, "end": 11, "tag": "drug"}, {"start": 44, "end": 55, "tag": "drug"}, {"start": 113, "end": 124, "tag": "drug"}, {"start": 156, "end": 167, "tag": "drug"}]}, {"content": "Erythromycin (500 mg t.i.d) produced a 4-fold increase in vardenafil AUC and a 3-fold increase in Cmax when co-administered with Vardenafil 5 mg in healthy volunteers.", "metadata": {"original_id": "DrugDDI.d253.s5"}, "annotations": [{"start": 0, "end": 13, "tag": "drug"}, {"start": 14, "end": 19, "tag": "drug"}, {"start": 58, "end": 69, "tag": "drug"}, {"start": 129, "end": 145, "tag": "drug"}]}, {"content": "It is recommended not to exceed a single 5 mg dose of Vardenafil in a 24-hour period when used in combination with erythromycin.", "metadata": {"original_id": "DrugDDI.d253.s6"}, "annotations": [{"start": 54, "end": 65, "tag": "drug"}, {"start": 115, "end": 128, "tag": "drug"}]}, {"content": "Ketoconazole (200 mg once daily) produced a 10-fold increase in vardenafil AUC and a 4-fold increase in Cmax when co-administered with Vardenafil (5 mg) in healthy volunteers.", "metadata": {"original_id": "DrugDDI.d253.s7"}, "annotations": [{"start": 0, "end": 13, "tag": "drug"}, {"start": 64, "end": 75, "tag": "drug"}, {"start": 135, "end": 146, "tag": "drug"}]}, {"content": "A 5-mg Vardenafil dose should not be exceeded when used in combination with 200 mg once daily ketoconazole.", "metadata": {"original_id": "DrugDDI.d253.s8"}, "annotations": [{"start": 7, "end": 18, "tag": "drug"}, {"start": 94, "end": 107, "tag": "drug"}]}, {"content": "Since higher doses of ketoconazole (400 mg daily) may result in higher increases in Cmax and AUC, a single 2.5 mg dose of Vardenafil should not be exceeded in a 24-hour period when used in combination with ketoconazole 400 mg daily.", "metadata": {"original_id": "DrugDDI.d253.s9"}, "annotations": [{"start": 22, "end": 35, "tag": "drug"}, {"start": 122, "end": 133, "tag": "drug"}, {"start": 206, "end": 226, "tag": "drug"}]}, {"content": "HIV Protease Inhibitors: Indinavir (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life.", "metadata": {"original_id": "DrugDDI.d253.s10"}, "annotations": [{"start": 0, "end": 24, "tag": "drug"}, {"start": 25, "end": 35, "tag": "drug"}, {"start": 36, "end": 41, "tag": "drug"}, {"start": 72, "end": 89, "tag": "drug"}, {"start": 123, "end": 134, "tag": "drug"}, {"start": 160, "end": 171, "tag": "drug"}, {"start": 201, "end": 212, "tag": "drug"}]}, {"content": "It is recommended not to exceed a single 2.5 mg Vardenafil dose in a 24-hour period when used in combination with indinavir.", "metadata": {"original_id": "DrugDDI.d253.s11"}, "annotations": [{"start": 114, "end": 124, "tag": "drug"}]}, {"content": "Ritonavir (600 mg b.i.d.) co-administered with Vardenafil 5 mg resulted in a 49-fold increase in vardenafil AUC and a 13-fold increase in vardenafil Cmax.", "metadata": {"original_id": "DrugDDI.d253.s12"}, "annotations": [{"start": 0, "end": 10, "tag": "drug"}, {"start": 47, "end": 63, "tag": "drug"}, {"start": 97, "end": 108, "tag": "drug"}, {"start": 138, "end": 149, "tag": "drug"}]}, {"content": "The interaction is a consequence of blocking hepatic metabolism of vardenafil by ritonavir, a highly potent CYP3A4 inhibitor, which also inhibits CYP2C9.", "metadata": {"original_id": "DrugDDI.d253.s13"}, "annotations": [{"start": 67, "end": 78, "tag": "drug"}, {"start": 81, "end": 91, "tag": "drug"}, {"start": 108, "end": 115, "tag": "drug"}, {"start": 146, "end": 153, "tag": "drug"}]}, {"content": "Ritonavir significantly prolonged the half-life of vardenafil to 26 hours.", "metadata": {"original_id": "DrugDDI.d253.s14"}, "annotations": [{"start": 0, "end": 10, "tag": "drug"}, {"start": 51, "end": 62, "tag": "drug"}]}, {"content": "Consequently, it is recommended not to exceed a single 2.5 mg Vardenafil dose in a 72-hour period when used in combination with ritonavir.", "metadata": {"original_id": "DrugDDI.d253.s15"}, "annotations": [{"start": 128, "end": 138, "tag": "drug"}]}, {"content": "Other Drug Interactions: No pharmacokinetic interactions were observed between vardenafil and the following drugs: glyburide, warfarin, digoxin, Maalox, and ranitidine.", "metadata": {"original_id": "DrugDDI.d253.s16"}, "annotations": [{"start": 79, "end": 90, "tag": "drug"}, {"start": 108, "end": 114, "tag": "drug"}, {"start": 115, "end": 125, "tag": "drug"}, {"start": 126, "end": 135, "tag": "drug"}, {"start": 136, "end": 144, "tag": "drug"}, {"start": 145, "end": 152, "tag": "drug"}, {"start": 157, "end": 168, "tag": "drug"}]}, {"content": "In the warfarin study, vardenafil had no effect on the prothrombin time or other pharmacodynamic parameters.", "metadata": {"original_id": "DrugDDI.d253.s17"}, "annotations": [{"start": 7, "end": 16, "tag": "drug"}, {"start": 23, "end": 34, "tag": "drug"}]}, {"content": "Effects of Vardenafil on other drugs", "metadata": {"original_id": "DrugDDI.d253.s18"}, "annotations": [{"start": 11, "end": 22, "tag": "drug"}, {"start": 31, "end": 37, "tag": "drug"}]}, {"content": "In vitro studies: Vardenafil and its metabolites had no effect on CYP1A2, 2A6, and 2E1 (Ki   100uM).", "metadata": {"original_id": "DrugDDI.d253.s19"}, "annotations": [{"start": 18, "end": 29, "tag": "drug"}, {"start": 37, "end": 49, "tag": "drug"}, {"start": 66, "end": 73, "tag": "drug"}, {"start": 88, "end": 100, "tag": "drug"}]}, {"content": "Weak inhibitory effects toward other isoforms (CYP2C8, 2C9, 2C19, 2D6, 3A4) were found, but Ki values were in excess of plasma concentrations achieved following dosing.", "metadata": {"original_id": "DrugDDI.d253.s20"}, "annotations": [{"start": 37, "end": 46, "tag": "drug"}, {"start": 47, "end": 54, "tag": "drug"}]}, {"content": "The most potent inhibitory activity was observed for vardenafil metabolite M1, which had a Ki of 1.4 uM toward CYP3A4, which is about 20 times higher than the M1 Cmax values after an 80 mg Vardenafil dose.", "metadata": {"original_id": "DrugDDI.d253.s21"}, "annotations": [{"start": 53, "end": 64, "tag": "drug"}, {"start": 111, "end": 118, "tag": "drug"}, {"start": 189, "end": 200, "tag": "drug"}]}, {"content": "In vivo studies: Nitrates: The blood pressure lowering effects of sublingual nitrates (0.4 mg) taken 1 and 4 hours after vardenafil and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of Vardenafil in healthy middle-aged subjects.", "metadata": {"original_id": "DrugDDI.d253.s22"}, "annotations": [{"start": 17, "end": 26, "tag": "drug"}, {"start": 77, "end": 86, "tag": "drug"}, {"start": 121, "end": 132, "tag": "drug"}, {"start": 227, "end": 238, "tag": "drug"}]}, {"content": "These effects were not observed when Vardenafil 20 mg was taken 24 hours before the NTG.", "metadata": {"original_id": "DrugDDI.d253.s23"}, "annotations": [{"start": 37, "end": 54, "tag": "drug"}]}, {"content": "Potentiation of the hypotensive effects of nitrates for patients with ischemic heart disease has not been evaluated, and concomitant use of Vardenafil and nitrates is contraindicated.", "metadata": {"original_id": "DrugDDI.d253.s24"}, "annotations": [{"start": 43, "end": 52, "tag": "drug"}, {"start": 140, "end": 151, "tag": "drug"}, {"start": 155, "end": 164, "tag": "drug"}]}, {"content": "Nifedipine: Vardenafil 20 mg, when co-administered with slow-release nifedipine 30 mg or 60 mg once daily, did not affect the relative bioavailability (AUC) or maximum concentration (Cmax) of nifedipine, a drug that is metabolized via CYP3A4.", "metadata": {"original_id": "DrugDDI.d253.s25"}, "annotations": [{"start": 0, "end": 11, "tag": "drug"}, {"start": 12, "end": 29, "tag": "drug"}, {"start": 69, "end": 86, "tag": "drug"}, {"start": 192, "end": 203, "tag": "drug"}, {"start": 206, "end": 211, "tag": "drug"}, {"start": 235, "end": 242, "tag": "drug"}]}, {"content": "Nifedipine did not alter the plasma levels of Vardenafil when taken in combination.", "metadata": {"original_id": "DrugDDI.d253.s26"}, "annotations": [{"start": 0, "end": 11, "tag": "drug"}, {"start": 46, "end": 57, "tag": "drug"}]}, {"content": "In these patients whose hypertension was controlled with nifedipine, Vardenafil 20 mg produced mean additional supine systolic/diastolic blood pressure reductions of 6/5 mm Hg compared to placebo.", "metadata": {"original_id": "DrugDDI.d253.s27"}, "annotations": [{"start": 57, "end": 68, "tag": "drug"}, {"start": 69, "end": 86, "tag": "drug"}]}, {"content": "Alpha-blockers: When Vardenafil 10 or 20 mg was given to healthy volunteers either simultaneously or 6 hours after a 10 mg dose of terazosin, significant hypotension developed in a substantial number of subjects.", "metadata": {"original_id": "DrugDDI.d253.s28"}, "annotations": [{"start": 21, "end": 32, "tag": "drug"}, {"start": 131, "end": 141, "tag": "drug"}]}, {"content": "With simultaneous dosing of Vardenafil 10 mg and terazosin 10 mg, 6 of 8 subjects experienced a standing systolic blood pressure of less than 85 mm Hg.", "metadata": {"original_id": "DrugDDI.d253.s29"}, "annotations": [{"start": 28, "end": 45, "tag": "drug"}, {"start": 49, "end": 63, "tag": "drug"}]}, {"content": "With simultaneous dosing of Vardenafil 20 mg and terazosin 10 mg, 2 of 9 subjects experienced a standing systolic blood pressure of less than 85 mm Hg.", "metadata": {"original_id": "DrugDDI.d253.s30"}, "annotations": [{"start": 28, "end": 45, "tag": "drug"}, {"start": 49, "end": 63, "tag": "drug"}]}, {"content": "When Vardenafil dosing was separated from terazosin 10 mg by 6 hours, 7 of 28 subjects who received 20 mg of Vardenafil experienced a decrease in standing systolic blood pressure below 85 mm Hg.", "metadata": {"original_id": "DrugDDI.d253.s31"}, "annotations": [{"start": 5, "end": 16, "tag": "drug"}, {"start": 42, "end": 56, "tag": "drug"}, {"start": 109, "end": 120, "tag": "drug"}]}, {"content": "In a similar study with tamsulosin in healthy volunteers, 1 of 24 subjects dosed with Vardenafil 20 mg and tamsulosin 0.4 mg separated by 6 hours experienced a standing systolic blood pressure below 85 mm Hg.", "metadata": {"original_id": "DrugDDI.d253.s32"}, "annotations": [{"start": 24, "end": 35, "tag": "drug"}, {"start": 86, "end": 103, "tag": "drug"}, {"start": 107, "end": 125, "tag": "drug"}]}, {"content": "Two of 16 subjects dosed simultaneously with Vardenafil 10 mg and tamsulosin 0.4 mg experienced a standing systolic blood pressure below 85 mm Hg.", "metadata": {"original_id": "DrugDDI.d253.s33"}, "annotations": [{"start": 45, "end": 62, "tag": "drug"}, {"start": 66, "end": 84, "tag": "drug"}]}, {"content": "The administration of lower doses of Vardenafil with alpha-blockers has not been completely evaluated to determine if they can be safely administered together.", "metadata": {"original_id": "DrugDDI.d253.s34"}, "annotations": [{"start": 37, "end": 48, "tag": "drug"}]}, {"content": "Based on these data, Vardenafil should not be used in patients on alpha-blocker therapy.", "metadata": {"original_id": "DrugDDI.d253.s35"}, "annotations": [{"start": 21, "end": 32, "tag": "drug"}, {"start": 66, "end": 81, "tag": "drug"}]}, {"content": "Ritonavir and indinavir: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir, the Cmax and AUC of ritonavir were reduced by approximately 20%.", "metadata": {"original_id": "DrugDDI.d253.s36"}, "annotations": [{"start": 0, "end": 10, "tag": "drug"}, {"start": 14, "end": 24, "tag": "drug"}, {"start": 68, "end": 79, "tag": "drug"}, {"start": 95, "end": 105, "tag": "drug"}, {"start": 126, "end": 136, "tag": "drug"}]}, {"content": "Upon administration of 10 mg of Vardenafil with 800 mg TID indinavir, the Cmax and AUC of indinavir were reduced by 40% and 30%, respectively.", "metadata": {"original_id": "DrugDDI.d253.s37"}, "annotations": [{"start": 32, "end": 43, "tag": "drug"}, {"start": 59, "end": 69, "tag": "drug"}, {"start": 90, "end": 100, "tag": "drug"}]}, {"content": "Alcohol: Alcohol (0.5 g/kg body weight: approximately 40 mL of absolute alcohol in a 70 kg person) and vardenafil plasma levels were not altered when dosed simultaneously.", "metadata": {"original_id": "DrugDDI.d253.s38"}, "annotations": [{"start": 0, "end": 8, "tag": "drug"}, {"start": 9, "end": 17, "tag": "drug"}, {"start": 103, "end": 114, "tag": "drug"}]}, {"content": "Vardenafil (20 mg) did not potentiate the hypotensive effects of alcohol during the 4-hour observation period in healthy volunteers when administered with alcohol (0.5 g/kg body weight).", "metadata": {"original_id": "DrugDDI.d253.s39"}, "annotations": [{"start": 0, "end": 11, "tag": "drug"}, {"start": 65, "end": 73, "tag": "drug"}, {"start": 155, "end": 163, "tag": "drug"}]}, {"content": "Aspirin: Vardenafil (10 mg and 20 mg) did not potentiate the increase in bleeding time caused by aspirin (two 81 mg tablets).", "metadata": {"original_id": "DrugDDI.d253.s40"}, "annotations": [{"start": 0, "end": 8, "tag": "drug"}, {"start": 9, "end": 20, "tag": "drug"}, {"start": 97, "end": 105, "tag": "drug"}]}, {"content": "Other interactions: Vardenafil had no effect on the pharmacodynamics of glyburide (glucose and insulin concentrations) and warfarin (prothrombin time or other pharmacodynamic parameters).", "metadata": {"original_id": "DrugDDI.d253.s41"}, "annotations": [{"start": 20, "end": 31, "tag": "drug"}, {"start": 72, "end": 82, "tag": "drug"}, {"start": 83, "end": 91, "tag": "drug"}, {"start": 95, "end": 103, "tag": "drug"}, {"start": 123, "end": 132, "tag": "drug"}]}, {"content": "CYP3A4 Inhibitors?Felodipine is metabolized by CYP3A4.", "metadata": {"original_id": "DrugDDI.d411.s0"}, "annotations": [{"start": 0, "end": 7, "tag": "drug"}, {"start": 47, "end": 54, "tag": "drug"}]}, {"content": "Co-administration of CYP3A4 inhibitors (eg, ketoconazole, itraconazole, erythromycin, grapefruit juice, cimetidine) with felodipine may lead to several- fold increases in the plasma levels of felodipine, either due to an increase in bioavailability or due to a decrease in metabolism.", "metadata": {"original_id": "DrugDDI.d411.s1"}, "annotations": [{"start": 21, "end": 28, "tag": "drug"}, {"start": 44, "end": 57, "tag": "drug"}, {"start": 58, "end": 71, "tag": "drug"}, {"start": 72, "end": 85, "tag": "drug"}, {"start": 104, "end": 115, "tag": "drug"}, {"start": 121, "end": 132, "tag": "drug"}, {"start": 192, "end": 203, "tag": "drug"}]}, {"content": "These increases in concentration may lead to increased effects, (lower blood pressure and increased heart rate).", "metadata": {"original_id": "DrugDDI.d411.s2"}, "annotations": []}, {"content": "These effects have been observed with co-administration of itraconazole (a potent CYP3A4 inhibitor).", "metadata": {"original_id": "DrugDDI.d411.s3"}, "annotations": [{"start": 59, "end": 72, "tag": "drug"}, {"start": 82, "end": 89, "tag": "drug"}]}, {"content": "Caution should be used when CYP3A4 inhibitors are co-administered with felodipine.", "metadata": {"original_id": "DrugDDI.d411.s4"}, "annotations": [{"start": 28, "end": 35, "tag": "drug"}, {"start": 71, "end": 82, "tag": "drug"}]}, {"content": "A conservative approach to dosing felodipine should be taken.", "metadata": {"original_id": "DrugDDI.d411.s5"}, "annotations": [{"start": 34, "end": 45, "tag": "drug"}]}, {"content": "The following specific interactions have been reported: Itraconazole?Co-administration of another extended release formulation of felodipine with itraconazole resulted in approximately 8-fold increase in the AUC, more than 6- fold increase in the Cmax, and 2-fold prolongation in the half- life of felodipine.", "metadata": {"original_id": "DrugDDI.d411.s6"}, "annotations": [{"start": 130, "end": 141, "tag": "drug"}, {"start": 146, "end": 159, "tag": "drug"}, {"start": 298, "end": 309, "tag": "drug"}]}, {"content": "Erythromycin?Co-administration of felodipine (PLENDIL) with erythromycin resulted in approximately 2.5- fold increase in the AUC and Cmax, and about 2- fold prolongation in the half- life of felodipine.", "metadata": {"original_id": "DrugDDI.d411.s7"}, "annotations": [{"start": 34, "end": 45, "tag": "drug"}, {"start": 46, "end": 54, "tag": "drug"}, {"start": 60, "end": 73, "tag": "drug"}, {"start": 191, "end": 202, "tag": "drug"}]}, {"content": "Grapefruit juice?Co-administration of felodipine with grapefruit juice resulted in more than 2-fold increase in the AUC and Cmax, but no prolongation in the half- life of felodipine.", "metadata": {"original_id": "DrugDDI.d411.s8"}, "annotations": [{"start": 0, "end": 11, "tag": "drug"}, {"start": 38, "end": 49, "tag": "drug"}, {"start": 171, "end": 182, "tag": "drug"}]}, {"content": "Cimetidine?Co-administration of felodipine with cimetidine (a non-specific CYP-450 inhibitor) resulted in an increase of approximately 50% in the AUC and the Cmax, of felodipine.", "metadata": {"original_id": "DrugDDI.d411.s9"}, "annotations": [{"start": 32, "end": 43, "tag": "drug"}, {"start": 48, "end": 59, "tag": "drug"}, {"start": 167, "end": 178, "tag": "drug"}]}, {"content": "Beta-Blocking Agents? A pharmacokinetic study of felodipine in conjunction with metoprolol demonstrated no significant effects on the pharmacokinetics of felodipine.", "metadata": {"original_id": "DrugDDI.d411.s10"}, "annotations": [{"start": 49, "end": 60, "tag": "drug"}, {"start": 80, "end": 91, "tag": "drug"}, {"start": 154, "end": 165, "tag": "drug"}]}, {"content": "The AUC and Cmax of metoprolol, however, were increased approximately 31 and 38%, respectively.", "metadata": {"original_id": "DrugDDI.d411.s11"}, "annotations": [{"start": 20, "end": 31, "tag": "drug"}]}, {"content": "In controlled clinical trials, however, beta blockers including metoprolol were concurrently administered with felodipine and were well tolerated.", "metadata": {"original_id": "DrugDDI.d411.s12"}, "annotations": [{"start": 40, "end": 54, "tag": "drug"}, {"start": 64, "end": 75, "tag": "drug"}, {"start": 111, "end": 122, "tag": "drug"}]}, {"content": "Digoxin? When given concomitantly with PLENDIL the pharmacokinetics of digoxin in patients with heart failure were not significantly altered.", "metadata": {"original_id": "DrugDDI.d411.s13"}, "annotations": [{"start": 39, "end": 47, "tag": "drug"}, {"start": 71, "end": 79, "tag": "drug"}]}, {"content": "Anticonvulsants? In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers.", "metadata": {"original_id": "DrugDDI.d411.s14"}, "annotations": [{"start": 78, "end": 89, "tag": "drug"}, {"start": 176, "end": 186, "tag": "drug"}, {"start": 187, "end": 201, "tag": "drug"}, {"start": 205, "end": 219, "tag": "drug"}]}, {"content": "In such patients, the mean area under the felodipine plasma concentration-time curve was also reduced to approximately 6% of that observed in healthy volunteers.", "metadata": {"original_id": "DrugDDI.d411.s15"}, "annotations": [{"start": 42, "end": 53, "tag": "drug"}]}, {"content": "Since a clinically significant interaction may be anticipated, alternative antihypertensive therapy should be considered in these patients.", "metadata": {"original_id": "DrugDDI.d411.s16"}, "annotations": [{"start": 75, "end": 92, "tag": "drug"}]}, {"content": "Tacrolimus? Felodipine may increase the blood concentration of tacrolimus.", "metadata": {"original_id": "DrugDDI.d411.s17"}, "annotations": [{"start": 12, "end": 23, "tag": "drug"}, {"start": 63, "end": 74, "tag": "drug"}]}, {"content": "When given concomitantly with felodipine, the tacrolimus blood concentration should be followed and the tacrolimus dose may need to be adjusted.", "metadata": {"original_id": "DrugDDI.d411.s18"}, "annotations": [{"start": 30, "end": 41, "tag": "drug"}, {"start": 46, "end": 57, "tag": "drug"}]}, {"content": "Other Concomitant Therapy? In healthy subjects there were no clinically significant interactions when felodipine was given concomitantly with indomethacin or spironolactone.", "metadata": {"original_id": "DrugDDI.d411.s19"}, "annotations": [{"start": 102, "end": 113, "tag": "drug"}, {"start": 142, "end": 155, "tag": "drug"}, {"start": 158, "end": 173, "tag": "drug"}]}, {"content": "Interaction with Food? See CLINICAL PHARMACOLOGY, Pharmacokinetics and Metabolism.", "metadata": {"original_id": "DrugDDI.d411.s20"}, "annotations": []}, {"content": "Elevated plasma levels of theophylline have been reported with concomitant use of some quinolones.", "metadata": {"original_id": "DrugDDI.d462.s0"}, "annotations": [{"start": 26, "end": 39, "tag": "drug"}, {"start": 87, "end": 98, "tag": "drug"}]}, {"content": "There have been reports of theophylline-related side-effects in patients on concomitant theophylline-quinolone therapy.", "metadata": {"original_id": "DrugDDI.d462.s1"}, "annotations": [{"start": 27, "end": 40, "tag": "drug"}, {"start": 88, "end": 101, "tag": "drug"}]}, {"content": "Therefore, monitoring of theophylline plasma levels should be considered and dosage of theophylline adjusted as required.", "metadata": {"original_id": "DrugDDI.d462.s2"}, "annotations": [{"start": 25, "end": 38, "tag": "drug"}]}, {"content": "Quinolones have also been shown to interfere with the metabolism of caffeine.", "metadata": {"original_id": "DrugDDI.d462.s3"}, "annotations": [{"start": 0, "end": 11, "tag": "drug"}, {"start": 68, "end": 77, "tag": "drug"}]}, {"content": "This may lead to reduced clearance of caffeine and a prolongation of its plasma half-life.", "metadata": {"original_id": "DrugDDI.d462.s4"}, "annotations": [{"start": 38, "end": 47, "tag": "drug"}]}, {"content": "Although this interaction has not been reported with cinoxacin, caution should be exercised when cinoxacin is given concomitantly with caffeine-containing products.", "metadata": {"original_id": "DrugDDI.d462.s5"}, "annotations": [{"start": 53, "end": 63, "tag": "drug"}, {"start": 97, "end": 107, "tag": "drug"}, {"start": 135, "end": 156, "tag": "drug"}]}, {"content": "Antacids or sucralfate substantially interfere with the absorption of some quinolones, resulting in low urine levels.", "metadata": {"original_id": "DrugDDI.d462.s6"}, "annotations": [{"start": 0, "end": 9, "tag": "drug"}, {"start": 12, "end": 23, "tag": "drug"}, {"start": 75, "end": 86, "tag": "drug"}]}, {"content": "Also, concomitant administration of quinolones with products containing iron, multivitamins containing zinc, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels.", "metadata": {"original_id": "DrugDDI.d462.s7"}, "annotations": [{"start": 36, "end": 47, "tag": "drug"}, {"start": 72, "end": 77, "tag": "drug"}, {"start": 78, "end": 92, "tag": "drug"}, {"start": 103, "end": 108, "tag": "drug"}, {"start": 112, "end": 118, "tag": "drug"}, {"start": 119, "end": 130, "tag": "drug"}, {"start": 140, "end": 147, "tag": "drug"}, {"start": 164, "end": 174, "tag": "drug"}]}, {"content": "Quinolones, including cinoxacin, may enhance the effects of oral anticoagulants, such as warfarin or its derivatives.", "metadata": {"original_id": "DrugDDI.d462.s8"}, "annotations": [{"start": 0, "end": 11, "tag": "drug"}, {"start": 22, "end": 32, "tag": "drug"}, {"start": 60, "end": 80, "tag": "drug"}, {"start": 89, "end": 98, "tag": "drug"}, {"start": 105, "end": 117, "tag": "drug"}]}, {"content": "When these products are administered concomitantly, prothrombin time or other suitable coagulation tests should be closely monitored.", "metadata": {"original_id": "DrugDDI.d462.s9"}, "annotations": []}, {"content": "Seizures have been reported in patients taking another quinolone class antimicrobial and the nonsteroidal anti-inflammatory drug fenbufen concurrently.", "metadata": {"original_id": "DrugDDI.d462.s10"}, "annotations": [{"start": 55, "end": 86, "tag": "drug"}, {"start": 93, "end": 129, "tag": "drug"}]}, {"content": "Animal studies also suggest an increased potential for seizures when these 2 drugs are given concomitantly.", "metadata": {"original_id": "DrugDDI.d462.s11"}, "annotations": [{"start": 77, "end": 83, "tag": "drug"}]}, {"content": "Fenbufen is not approved in the United States at this time.", "metadata": {"original_id": "DrugDDI.d462.s12"}, "annotations": [{"start": 0, "end": 9, "tag": "drug"}]}, {"content": "Physicians are provided this information to increase awareness of the potential for serious interactions when cinoxacin and certain nonsteroidal anti-inflammatory agents are administered concomitantly.", "metadata": {"original_id": "DrugDDI.d462.s13"}, "annotations": [{"start": 110, "end": 120, "tag": "drug"}, {"start": 132, "end": 170, "tag": "drug"}]}, {"content": "Elevated cyclosporine serum levels have been reported with the concomitant use of quinolones and cyclosporine.", "metadata": {"original_id": "DrugDDI.d462.s14"}, "annotations": [{"start": 9, "end": 22, "tag": "drug"}, {"start": 82, "end": 93, "tag": "drug"}, {"start": 97, "end": 110, "tag": "drug"}]}, {"content": "Clinical interaction studies with cimetidine and warfarin indicated that the coadministration of Femara with these drugs does not result in clinically- significant drug interactions.", "metadata": {"original_id": "DrugDDI.d379.s0"}, "annotations": [{"start": 34, "end": 45, "tag": "drug"}, {"start": 49, "end": 58, "tag": "drug"}, {"start": 97, "end": 104, "tag": "drug"}, {"start": 115, "end": 121, "tag": "drug"}]}, {"content": "(See CLINICAL PHARMACOLOGY) Coadministration of Femara and tamoxifen 20 mg daily resulted in a reduction of letrozole plasma levels by 38% on average.", "metadata": {"original_id": "DrugDDI.d379.s1"}, "annotations": [{"start": 48, "end": 55, "tag": "drug"}, {"start": 59, "end": 75, "tag": "drug"}, {"start": 108, "end": 118, "tag": "drug"}]}, {"content": "There is no clinical experience to date on the use of Femara in combination with other anticancer agents.", "metadata": {"original_id": "DrugDDI.d379.s2"}, "annotations": [{"start": 54, "end": 61, "tag": "drug"}]}, {"content": "Drug/Laboratory Test-Interactions None observed.", "metadata": {"original_id": "DrugDDI.d379.s3"}, "annotations": [{"start": 0, "end": 5, "tag": "drug"}]}, {"content": "Renal clearance measurements of PAH cannot be made with any significant accuracy in patients receiving sulfonamides, procaine, or thiazolesulfone.", "metadata": {"original_id": "DrugDDI.d153.s0"}, "annotations": [{"start": 103, "end": 116, "tag": "drug"}, {"start": 117, "end": 126, "tag": "drug"}]}, {"content": "These compounds interfere with chemical color development essential to the analytical procedures.", "metadata": {"original_id": "DrugDDI.d153.s1"}, "annotations": []}, {"content": "Probenecid depresses tubular secretion of certain weak acids such as PAH.", "metadata": {"original_id": "DrugDDI.d153.s2"}, "annotations": [{"start": 0, "end": 11, "tag": "drug"}]}, {"content": "Therefore, patients receiving probenecid will have erroneously low ERPF and Tm PAH values.", "metadata": {"original_id": "DrugDDI.d153.s3"}, "annotations": [{"start": 30, "end": 41, "tag": "drug"}]}, {"content": "Concomitant oral administration of ketoconazole (a known inhibitor of CYP3A4 activity in the liver and in the intestinal mucosa) caused an eight-fold increase of the systemic exposure to oral budesonide.", "metadata": {"original_id": "DrugDDI.d316.s0"}, "annotations": [{"start": 35, "end": 48, "tag": "drug"}, {"start": 70, "end": 77, "tag": "drug"}, {"start": 93, "end": 99, "tag": "drug"}, {"start": 187, "end": 203, "tag": "drug"}]}, {"content": "If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.", "metadata": {"original_id": "DrugDDI.d316.s1"}, "annotations": [{"start": 32, "end": 39, "tag": "drug"}, {"start": 57, "end": 70, "tag": "drug"}, {"start": 86, "end": 96, "tag": "drug"}, {"start": 97, "end": 107, "tag": "drug"}, {"start": 108, "end": 119, "tag": "drug"}, {"start": 120, "end": 133, "tag": "drug"}, {"start": 171, "end": 182, "tag": "drug"}]}, {"content": "After extensive intake of grapefruit juice (which inhibits CYP3A4 activity predominantly in the intestinal mucosa), the systemic exposure for oral budesonide increased about two times.", "metadata": {"original_id": "DrugDDI.d316.s2"}, "annotations": [{"start": 59, "end": 66, "tag": "drug"}, {"start": 142, "end": 158, "tag": "drug"}]}, {"content": "As with other drugs primarily being metabolized through CYP3A4, ingestion of grapefruit or grapefruit juice should be avoided in connection with budesonide administration.", "metadata": {"original_id": "DrugDDI.d316.s3"}, "annotations": [{"start": 14, "end": 20, "tag": "drug"}, {"start": 56, "end": 63, "tag": "drug"}, {"start": 77, "end": 88, "tag": "drug"}, {"start": 145, "end": 156, "tag": "drug"}]}, {"content": "The following drug interactions were studied with ketoprofen doses of 200 mg/day.", "metadata": {"original_id": "DrugDDI.d347.s0"}, "annotations": [{"start": 50, "end": 61, "tag": "drug"}]}, {"content": "The possibility of increased interaction should be kept in mind when Orudis doses greater than 50 mg as a single dose or 200 mg of ketoprofen per day are used concomitantly with highly bound drugs.", "metadata": {"original_id": "DrugDDI.d347.s1"}, "annotations": [{"start": 69, "end": 76, "tag": "drug"}, {"start": 131, "end": 142, "tag": "drug"}]}, {"content": "1.", "metadata": {"original_id": "DrugDDI.d347.s2"}, "annotations": []}, {"content": "Antacids: Concomitant administration of magnesium hydroxide and aluminum hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as Orudis.", "metadata": {"original_id": "DrugDDI.d347.s3"}, "annotations": [{"start": 0, "end": 9, "tag": "drug"}, {"start": 40, "end": 60, "tag": "drug"}, {"start": 64, "end": 83, "tag": "drug"}, {"start": 147, "end": 158, "tag": "drug"}, {"start": 174, "end": 181, "tag": "drug"}]}, {"content": "2.", "metadata": {"original_id": "DrugDDI.d347.s4"}, "annotations": []}, {"content": "Aspirin: Ketoprofen does not alter aspirin absorption;", "metadata": {"original_id": "DrugDDI.d347.s5"}, "annotations": [{"start": 0, "end": 8, "tag": "drug"}, {"start": 9, "end": 20, "tag": "drug"}, {"start": 35, "end": 43, "tag": "drug"}]}, {"content": "however, in a study of 12 normal subjects, concurrent administration of aspirin decreased ketoprofen protein binding and increased ketoprofen plasma clearance from 0.07 L/kg/h without aspirin to 0.11 L/kg/h with aspirin.", "metadata": {"original_id": "DrugDDI.d347.s6"}, "annotations": [{"start": 72, "end": 80, "tag": "drug"}, {"start": 90, "end": 101, "tag": "drug"}, {"start": 131, "end": 142, "tag": "drug"}, {"start": 184, "end": 192, "tag": "drug"}, {"start": 212, "end": 220, "tag": "drug"}]}, {"content": "The clinical significance of these changes has not been adequately studied.", "metadata": {"original_id": "DrugDDI.d347.s7"}, "annotations": []}, {"content": "Therefore, concurrent use of aspirin and ketoprofen is not recommended.", "metadata": {"original_id": "DrugDDI.d347.s8"}, "annotations": [{"start": 29, "end": 37, "tag": "drug"}, {"start": 41, "end": 52, "tag": "drug"}]}, {"content": "3.", "metadata": {"original_id": "DrugDDI.d347.s9"}, "annotations": []}, {"content": "Diuretic: Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone.", "metadata": {"original_id": "DrugDDI.d347.s10"}, "annotations": [{"start": 0, "end": 9, "tag": "drug"}, {"start": 10, "end": 30, "tag": "drug"}, {"start": 56, "end": 67, "tag": "drug"}, {"start": 145, "end": 165, "tag": "drug"}]}, {"content": "Patients taking diuretics are at a greater risk of developing renal failure secondary to a decrease in renal blood flow caused by prostaglandin inhibition.", "metadata": {"original_id": "DrugDDI.d347.s11"}, "annotations": [{"start": 16, "end": 26, "tag": "drug"}]}, {"content": "4.", "metadata": {"original_id": "DrugDDI.d347.s12"}, "annotations": []}, {"content": "Digoxin: In a study in 12 patients with congestive heart failure where ketoprofen and digoxin were concomitantly administered, ketoprofen did not alter the serum levels of digoxin.", "metadata": {"original_id": "DrugDDI.d347.s13"}, "annotations": [{"start": 0, "end": 8, "tag": "drug"}, {"start": 71, "end": 82, "tag": "drug"}, {"start": 86, "end": 94, "tag": "drug"}, {"start": 127, "end": 138, "tag": "drug"}, {"start": 172, "end": 180, "tag": "drug"}]}, {"content": "5.", "metadata": {"original_id": "DrugDDI.d347.s14"}, "annotations": []}, {"content": "Warfarin: In a short-term controlled study in 14 normal volunteers, ketoprofen did not significantly interfere with the effect of warfarin on prothrombin time.", "metadata": {"original_id": "DrugDDI.d347.s15"}, "annotations": [{"start": 0, "end": 9, "tag": "drug"}, {"start": 68, "end": 79, "tag": "drug"}, {"start": 130, "end": 139, "tag": "drug"}]}, {"content": "Bleeding from a number of sites may be a complication of warfarin treatment and GI bleeding a complication of ketoprofen treatment.", "metadata": {"original_id": "DrugDDI.d347.s16"}, "annotations": [{"start": 110, "end": 121, "tag": "drug"}]}, {"content": "Because prostaglandina play an important role in hemostasis and ketoprofen has an effect on platelet function as well, concurent therapy with ketoprofen and warfarin requires close monitoring of patients on both drugs.", "metadata": {"original_id": "DrugDDI.d347.s17"}, "annotations": [{"start": 64, "end": 75, "tag": "drug"}, {"start": 142, "end": 153, "tag": "drug"}, {"start": 157, "end": 166, "tag": "drug"}, {"start": 212, "end": 218, "tag": "drug"}]}, {"content": "6.", "metadata": {"original_id": "DrugDDI.d347.s18"}, "annotations": []}, {"content": "Probenecid: Probenecid increases both free and bound ketoprofen by reducing the plasma clearance of ketoprofen to about one-third, as well as decreasing its protein binding.", "metadata": {"original_id": "DrugDDI.d347.s19"}, "annotations": [{"start": 0, "end": 11, "tag": "drug"}, {"start": 12, "end": 23, "tag": "drug"}, {"start": 53, "end": 64, "tag": "drug"}, {"start": 100, "end": 111, "tag": "drug"}]}, {"content": "Therefore, the combination of ketoprofen and probenecid is not recommended.", "metadata": {"original_id": "DrugDDI.d347.s20"}, "annotations": [{"start": 30, "end": 41, "tag": "drug"}, {"start": 45, "end": 56, "tag": "drug"}]}, {"content": "7.", "metadata": {"original_id": "DrugDDI.d347.s21"}, "annotations": []}, {"content": "Methotrexate: Ketoprofen, like other NSAIDs, may cause changes in the elimination of methotrexate leading to elevated serum levels of the drug and increased toxicity.", "metadata": {"original_id": "DrugDDI.d347.s22"}, "annotations": [{"start": 0, "end": 13, "tag": "drug"}, {"start": 14, "end": 25, "tag": "drug"}, {"start": 37, "end": 44, "tag": "drug"}, {"start": 85, "end": 98, "tag": "drug"}, {"start": 138, "end": 143, "tag": "drug"}]}, {"content": "8.", "metadata": {"original_id": "DrugDDI.d347.s23"}, "annotations": []}, {"content": "Lithium: Nonsteroidal anti-inflammatory agents have been reported to increase steadystate plasma lithium levels.", "metadata": {"original_id": "DrugDDI.d347.s24"}, "annotations": [{"start": 0, "end": 8, "tag": "drug"}, {"start": 9, "end": 47, "tag": "drug"}]}, {"content": "It is recommended that plasma lithium levels be monitored when ketoprofen is coadministered with lithium.", "metadata": {"original_id": "DrugDDI.d347.s25"}, "annotations": [{"start": 63, "end": 74, "tag": "drug"}, {"start": 97, "end": 105, "tag": "drug"}]}, {"content": "DRUG/LABORATORY TEST INTERACTIONS: EFFECT ON BLOOD COAGULATION Ketoprofen decreases platelet adhesion and aggregation.", "metadata": {"original_id": "DrugDDI.d347.s26"}, "annotations": [{"start": 0, "end": 5, "tag": "drug"}, {"start": 63, "end": 74, "tag": "drug"}]}, {"content": "Therefore, it can prolong bleeding time by approximately 3 to 4 minutes from baseline values.", "metadata": {"original_id": "DrugDDI.d347.s27"}, "annotations": []}, {"content": "There is no significant change in platelet count, prothrombin time, partial thromboplastin time, or thrombin time.", "metadata": {"original_id": "DrugDDI.d347.s28"}, "annotations": []}, {"content": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.", "metadata": {"original_id": "DrugDDI.d261.s0"}, "annotations": [{"start": 22, "end": 39, "tag": "drug"}, {"start": 60, "end": 72, "tag": "drug"}, {"start": 75, "end": 90, "tag": "drug"}, {"start": 112, "end": 141, "tag": "drug"}, {"start": 142, "end": 168, "tag": "drug"}, {"start": 171, "end": 186, "tag": "drug"}]}, {"content": "Concurrent use of these agents should generally be avoided.", "metadata": {"original_id": "DrugDDI.d261.s1"}, "annotations": []}, {"content": "In situations when concurrent therapy is necessary, careful patient monitoring is essential.", "metadata": {"original_id": "DrugDDI.d261.s2"}, "annotations": []}, {"content": "Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents.", "metadata": {"original_id": "DrugDDI.d261.s3"}, "annotations": [{"start": 29, "end": 47, "tag": "drug"}, {"start": 125, "end": 140, "tag": "drug"}]}, {"content": "The para-aminobenzoic acid metabolite of chloroprocaine inhibits the action of sulfonamides.", "metadata": {"original_id": "DrugDDI.d261.s4"}, "annotations": [{"start": 4, "end": 27, "tag": "drug"}, {"start": 41, "end": 56, "tag": "drug"}, {"start": 79, "end": 92, "tag": "drug"}]}, {"content": "Therefore, chloroprocaine should not be used in any condition in which a sulfonamide drug is being employed.", "metadata": {"original_id": "DrugDDI.d261.s5"}, "annotations": [{"start": 11, "end": 26, "tag": "drug"}, {"start": 73, "end": 85, "tag": "drug"}]}, {"content": "In normal volunteers receiving indomethacin, the administration of diflunisal decreased the renal clearance and significantly increased the plasma levels of indomethacin.", "metadata": {"original_id": "DrugDDI.d83.s0"}, "annotations": [{"start": 31, "end": 44, "tag": "drug"}, {"start": 67, "end": 78, "tag": "drug"}, {"start": 157, "end": 170, "tag": "drug"}]}, {"content": "In some patients, combined use of INDOCIN and diflunisal has been associated with fatal gastrointestinal hemorrhage.", "metadata": {"original_id": "DrugDDI.d83.s1"}, "annotations": [{"start": 34, "end": 42, "tag": "drug"}, {"start": 46, "end": 57, "tag": "drug"}]}, {"content": "Therefore, diflunisal and INDOCIN should not be used concomitantly.", "metadata": {"original_id": "DrugDDI.d83.s2"}, "annotations": [{"start": 11, "end": 22, "tag": "drug"}, {"start": 26, "end": 34, "tag": "drug"}]}, {"content": "In a study in normal volunteers, it was found that chronic concurrent administration of 3.6 g of aspirin per day decreases indomethacin blood levels approximately 20%.", "metadata": {"original_id": "DrugDDI.d83.s3"}, "annotations": [{"start": 97, "end": 105, "tag": "drug"}, {"start": 123, "end": 136, "tag": "drug"}]}, {"content": "The concomitant use of INDOCIN with other NSAIDs is not recommended due to the increased possibility of gastrointestinal toxicity, with little or no increase in efficacy.", "metadata": {"original_id": "DrugDDI.d83.s4"}, "annotations": [{"start": 23, "end": 31, "tag": "drug"}, {"start": 42, "end": 49, "tag": "drug"}]}, {"content": "Clinical studies have shown that INDOCIN does not influence the hypoprothrombinemia produced by anticoagulants.", "metadata": {"original_id": "DrugDDI.d83.s5"}, "annotations": [{"start": 33, "end": 41, "tag": "drug"}, {"start": 96, "end": 111, "tag": "drug"}]}, {"content": "However, when any additional drug, including INDOCIN, is added to the treatment of patients on anticoagulant therapy, the patients should be observed for alterations of the prothrombin time.", "metadata": {"original_id": "DrugDDI.d83.s6"}, "annotations": [{"start": 29, "end": 34, "tag": "drug"}, {"start": 45, "end": 53, "tag": "drug"}]}, {"content": "In post-marketing experience, bleeding has been reported in patients on concomitant treatment with anticoagulants and INDOCIN.", "metadata": {"original_id": "DrugDDI.d83.s7"}, "annotations": [{"start": 99, "end": 114, "tag": "drug"}, {"start": 118, "end": 126, "tag": "drug"}]}, {"content": "Caution should be exercised when INDOCIN and anticoagulants are administered concomitantly.", "metadata": {"original_id": "DrugDDI.d83.s8"}, "annotations": [{"start": 33, "end": 41, "tag": "drug"}, {"start": 45, "end": 60, "tag": "drug"}]}, {"content": "When INDOCIN is given to patients receiving probenecid, the plasma levels of indomethacin are likely to be increased.", "metadata": {"original_id": "DrugDDI.d83.s9"}, "annotations": [{"start": 5, "end": 13, "tag": "drug"}, {"start": 44, "end": 55, "tag": "drug"}, {"start": 77, "end": 90, "tag": "drug"}]}, {"content": "Therefore, a lower total daily dosage of INDOCIN may produce a satisfactory therapeutic effect.", "metadata": {"original_id": "DrugDDI.d83.s10"}, "annotations": [{"start": 41, "end": 49, "tag": "drug"}]}, {"content": "When increases in the dose of INDOCIN are made, they should be made carefully and in small increments.", "metadata": {"original_id": "DrugDDI.d83.s11"}, "annotations": [{"start": 30, "end": 38, "tag": "drug"}]}, {"content": "Caution should be used if INDOCIN is administered simultaneously with methotrexate.", "metadata": {"original_id": "DrugDDI.d83.s12"}, "annotations": [{"start": 26, "end": 34, "tag": "drug"}, {"start": 70, "end": 83, "tag": "drug"}]}, {"content": "INDOCIN has been reported to decrease the tubular secretion of methotrexate and to potentiate its toxicity.", "metadata": {"original_id": "DrugDDI.d83.s13"}, "annotations": [{"start": 0, "end": 8, "tag": "drug"}, {"start": 63, "end": 76, "tag": "drug"}]}, {"content": "Administration of non-steroidal anti-inflammatory drugs concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.", "metadata": {"original_id": "DrugDDI.d83.s14"}, "annotations": [{"start": 18, "end": 56, "tag": "drug"}, {"start": 75, "end": 88, "tag": "drug"}, {"start": 204, "end": 217, "tag": "drug"}]}, {"content": "NSAIDs should be used with caution in patients taking cyclosporine, and renal function should be carefully monitored.", "metadata": {"original_id": "DrugDDI.d83.s15"}, "annotations": [{"start": 0, "end": 7, "tag": "drug"}, {"start": 54, "end": 67, "tag": "drug"}]}, {"content": "Capsules INDOCIN 50 mg t.i.d. produced a clinically relevant elevation of plasma lithium and reduction in renal lithium clearance in psychiatric patients and normal subjects with steady state plasma lithium concentrations.", "metadata": {"original_id": "DrugDDI.d83.s16"}, "annotations": [{"start": 81, "end": 89, "tag": "drug"}, {"start": 112, "end": 120, "tag": "drug"}, {"start": 199, "end": 207, "tag": "drug"}]}, {"content": "This effect has been attributed to inhibition of prostaglandin synthesis.", "metadata": {"original_id": "DrugDDI.d83.s17"}, "annotations": [{"start": 49, "end": 63, "tag": "drug"}]}, {"content": "As a consequence, when INDOCIN and lithium are given concomitantly, the patient should be carefully observed for signs of lithium toxicity.", "metadata": {"original_id": "DrugDDI.d83.s18"}, "annotations": [{"start": 23, "end": 31, "tag": "drug"}, {"start": 35, "end": 43, "tag": "drug"}]}, {"content": "(Read circulars for lithium preparations before use of such concomitant therapy.)", "metadata": {"original_id": "DrugDDI.d83.s19"}, "annotations": [{"start": 20, "end": 40, "tag": "drug"}]}, {"content": "In addition, the frequency of monitoring serum lithium concentration should be increased at the outset of such combination drug treatment.", "metadata": {"original_id": "DrugDDI.d83.s20"}, "annotations": [{"start": 47, "end": 55, "tag": "drug"}, {"start": 123, "end": 128, "tag": "drug"}]}, {"content": "INDOCIN given concomitantly with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin.", "metadata": {"original_id": "DrugDDI.d83.s21"}, "annotations": [{"start": 0, "end": 8, "tag": "drug"}, {"start": 33, "end": 41, "tag": "drug"}, {"start": 124, "end": 132, "tag": "drug"}]}, {"content": "Therefore, when INDOCIN and digoxin are used concomitantly, serum digoxin levels should be closely monitored.", "metadata": {"original_id": "DrugDDI.d83.s22"}, "annotations": [{"start": 16, "end": 24, "tag": "drug"}, {"start": 28, "end": 36, "tag": "drug"}]}, {"content": "In some patients, the administration of INDOCIN can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing, and thiazide diuretics.", "metadata": {"original_id": "DrugDDI.d83.s23"}, "annotations": [{"start": 40, "end": 48, "tag": "drug"}, {"start": 63, "end": 72, "tag": "drug"}, {"start": 90, "end": 107, "tag": "drug"}, {"start": 124, "end": 134, "tag": "drug"}, {"start": 147, "end": 166, "tag": "drug"}]}, {"content": "Therefore, when INDOCIN and INDOCIN.", "metadata": {"original_id": "DrugDDI.d83.s24"}, "annotations": [{"start": 16, "end": 24, "tag": "drug"}, {"start": 28, "end": 36, "tag": "drug"}]}, {"content": "(Indomethacin) diuretics are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.", "metadata": {"original_id": "DrugDDI.d83.s25"}, "annotations": [{"start": 1, "end": 14, "tag": "drug"}, {"start": 15, "end": 25, "tag": "drug"}, {"start": 130, "end": 139, "tag": "drug"}]}, {"content": "INDOCIN reduces basal plasma renin activity (PRA), as well as those elevations of PRA induced by furosemide administration, or salt or volume depletion.", "metadata": {"original_id": "DrugDDI.d83.s26"}, "annotations": [{"start": 0, "end": 8, "tag": "drug"}, {"start": 97, "end": 109, "tag": "drug"}, {"start": 127, "end": 132, "tag": "drug"}]}, {"content": "These facts should be considered when evaluating plasma renin activity in hypertensive patients.", "metadata": {"original_id": "DrugDDI.d83.s27"}, "annotations": []}, {"content": "It has been reported that the addition of triamterene to a maintenance schedule of INDOCIN resulted in reversible acute renal failure in two of four healthy volunteers.", "metadata": {"original_id": "DrugDDI.d83.s28"}, "annotations": [{"start": 42, "end": 54, "tag": "drug"}, {"start": 83, "end": 91, "tag": "drug"}]}, {"content": "INDOCIN and triamterene should not be administered together.", "metadata": {"original_id": "DrugDDI.d83.s29"}, "annotations": [{"start": 0, "end": 8, "tag": "drug"}, {"start": 12, "end": 24, "tag": "drug"}]}, {"content": "INDOCIN and potassium-sparing diuretics each may be associated with increased serum potassium levels.", "metadata": {"original_id": "DrugDDI.d83.s30"}, "annotations": [{"start": 0, "end": 8, "tag": "drug"}, {"start": 12, "end": 40, "tag": "drug"}]}, {"content": "The potential effects of INDOCIN and potassium-sparing diuretics on potassium kinetics and renal function should be considered when these agents are administered concurrently.", "metadata": {"original_id": "DrugDDI.d83.s31"}, "annotations": [{"start": 25, "end": 33, "tag": "drug"}, {"start": 37, "end": 65, "tag": "drug"}, {"start": 68, "end": 78, "tag": "drug"}]}, {"content": "Most of the above effects concerning diuretics have been attributed, at least in part, to mechanisms involving inhibition of prostaglandin synthesis by INDOCIN.", "metadata": {"original_id": "DrugDDI.d83.s32"}, "annotations": [{"start": 37, "end": 47, "tag": "drug"}, {"start": 125, "end": 139, "tag": "drug"}, {"start": 152, "end": 160, "tag": "drug"}]}, {"content": "Blunting of the antihypertensive effect of beta-adrenoceptor blocking agents by non-steroidal antiinflammatory drugs including INDOCIN has been reported.", "metadata": {"original_id": "DrugDDI.d83.s33"}, "annotations": [{"start": 16, "end": 33, "tag": "drug"}, {"start": 43, "end": 76, "tag": "drug"}, {"start": 80, "end": 117, "tag": "drug"}, {"start": 127, "end": 135, "tag": "drug"}]}, {"content": "Therefore, when using these blocking agents to treat hypertension, patients should be observed carefully in order to confirm that the desired therapeutic effect has been obtained.", "metadata": {"original_id": "DrugDDI.d83.s34"}, "annotations": []}, {"content": "INDOCIN can reduce the antihypertensive effects of captopril and losartan.", "metadata": {"original_id": "DrugDDI.d83.s35"}, "annotations": [{"start": 0, "end": 8, "tag": "drug"}, {"start": 23, "end": 40, "tag": "drug"}, {"start": 51, "end": 61, "tag": "drug"}, {"start": 65, "end": 74, "tag": "drug"}]}, {"content": "False-negative results in the dexamethasone suppression test (DST) in patients being treated with INDOCIN have been reported.", "metadata": {"original_id": "DrugDDI.d83.s36"}, "annotations": [{"start": 98, "end": 106, "tag": "drug"}]}, {"content": "Thus, results of the DST should be interpreted with caution in these patients.", "metadata": {"original_id": "DrugDDI.d83.s37"}, "annotations": []}, {"content": "There is no known drug interference with standard clinical laboratory tests.", "metadata": {"original_id": "DrugDDI.d522.s0"}, "annotations": []}, {"content": "Steroids enhance the renal toxicity of edetate calcium disodium in animals. 7 Edetate calcium disodium interferes with the action of zinc insulin preparations by chelating the zinc. 7", "metadata": {"original_id": "DrugDDI.d522.s1"}, "annotations": [{"start": 39, "end": 64, "tag": "drug"}, {"start": 78, "end": 103, "tag": "drug"}, {"start": 133, "end": 138, "tag": "drug"}, {"start": 176, "end": 182, "tag": "drug"}]}, {"content": "Ketorolac is highly bound to human plasma protein (mean 99.2%).", "metadata": {"original_id": "DrugDDI.d334.s0"}, "annotations": [{"start": 0, "end": 10, "tag": "drug"}, {"start": 35, "end": 50, "tag": "drug"}]}, {"content": "Warfarin, Digoxin, Salicylate, and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.", "metadata": {"original_id": "DrugDDI.d334.s1"}, "annotations": [{"start": 0, "end": 9, "tag": "drug"}, {"start": 10, "end": 18, "tag": "drug"}, {"start": 19, "end": 30, "tag": "drug"}, {"start": 67, "end": 76, "tag": "drug"}, {"start": 79, "end": 95, "tag": "drug"}, {"start": 123, "end": 146, "tag": "drug"}, {"start": 176, "end": 186, "tag": "drug"}, {"start": 214, "end": 222, "tag": "drug"}]}, {"content": "Ketorolac does not alter digoxin protein binding.", "metadata": {"original_id": "DrugDDI.d334.s2"}, "annotations": [{"start": 0, "end": 10, "tag": "drug"}, {"start": 25, "end": 33, "tag": "drug"}]}, {"content": "In vitro studies indicate that, at therapeutic concentrations of salicylate (300 m g/mL), the binding of ketorolac was reduced from approximately 99.2% to 97.5%, representing a potential twofold increase in unbound ketorolac plasma levels.", "metadata": {"original_id": "DrugDDI.d334.s3"}, "annotations": [{"start": 65, "end": 76, "tag": "drug"}, {"start": 105, "end": 115, "tag": "drug"}, {"start": 215, "end": 225, "tag": "drug"}]}, {"content": "Therapeutic concentrations of digoxin, warfarin, ibuprofen, naproxen, piroxicam, acetaminophen, phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.", "metadata": {"original_id": "DrugDDI.d334.s4"}, "annotations": [{"start": 30, "end": 38, "tag": "drug"}, {"start": 39, "end": 48, "tag": "drug"}, {"start": 49, "end": 59, "tag": "drug"}, {"start": 60, "end": 69, "tag": "drug"}, {"start": 70, "end": 80, "tag": "drug"}, {"start": 81, "end": 95, "tag": "drug"}, {"start": 96, "end": 106, "tag": "drug"}, {"start": 135, "end": 158, "tag": "drug"}]}, {"content": "In a study involving 12 adult volunteers, TORADOLORAL was coadministered with a single dose of 25 mg warfarin, causing no significant changes in pharmacokinetics or pharmacodynamics of warfarin.", "metadata": {"original_id": "DrugDDI.d334.s5"}, "annotations": [{"start": 101, "end": 110, "tag": "drug"}, {"start": 185, "end": 194, "tag": "drug"}]}, {"content": "In another study, TORADOLIV/IM was given with two doses of 5000 U of heparin to 11 healthy volunteers, resulting in a mean template bleeding time of 6.4 minutes (3.2 to 11.4 min) compared to a mean of 6.0 minutes (3.4 to 7.5 min) for heparin alone and 5.1 minutes (3.5 to 8.5 min) for placebo.", "metadata": {"original_id": "DrugDDI.d334.s6"}, "annotations": [{"start": 69, "end": 77, "tag": "drug"}, {"start": 234, "end": 242, "tag": "drug"}]}, {"content": "Although these results do not indicate a significant interaction between TORADOL and warfarin or heparin, the administration of TORADOL to patients taking anticoagulants should be done extremely cautiously, and patients should be closely monitored.", "metadata": {"original_id": "DrugDDI.d334.s7"}, "annotations": [{"start": 73, "end": 81, "tag": "drug"}, {"start": 85, "end": 94, "tag": "drug"}, {"start": 97, "end": 105, "tag": "drug"}, {"start": 128, "end": 136, "tag": "drug"}, {"start": 155, "end": 170, "tag": "drug"}]}, {"content": "Furosemide TORADOLIV/IM reduced the diuretic response to furosemide in normovolemic healthy subjects by approximately 20% (mean sodium and urinary output decreased 17%).", "metadata": {"original_id": "DrugDDI.d334.s8"}, "annotations": [{"start": 0, "end": 22, "tag": "drug"}, {"start": 36, "end": 45, "tag": "drug"}, {"start": 57, "end": 69, "tag": "drug"}, {"start": 128, "end": 135, "tag": "drug"}]}, {"content": "Probenecid Concomitant administration of TORADOLORAL and probenecid resulted in decreased clearance of ketorolac and significant increases in ketorolac plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.", "metadata": {"original_id": "DrugDDI.d334.s9"}, "annotations": [{"start": 0, "end": 11, "tag": "drug"}, {"start": 57, "end": 68, "tag": "drug"}, {"start": 103, "end": 113, "tag": "drug"}, {"start": 142, "end": 152, "tag": "drug"}]}, {"content": "Therefore, concomitant use of TORADOL and probenecid is contraindicated.", "metadata": {"original_id": "DrugDDI.d334.s10"}, "annotations": [{"start": 30, "end": 38, "tag": "drug"}, {"start": 42, "end": 53, "tag": "drug"}]}, {"content": "Lithium Inhibition of renal lithium clearance, leading to an increase in plasma lithium concentration, has been reported with some prostaglandin synthesis-inhibiting drugs.", "metadata": {"original_id": "DrugDDI.d334.s11"}, "annotations": [{"start": 0, "end": 8, "tag": "drug"}, {"start": 28, "end": 36, "tag": "drug"}, {"start": 80, "end": 88, "tag": "drug"}, {"start": 131, "end": 145, "tag": "drug"}, {"start": 166, "end": 172, "tag": "drug"}]}, {"content": "The effect of TORADOL on plasma lithium has not been studied, but cases of increased lithium plasma levels during TORADOL therapy have been reported.", "metadata": {"original_id": "DrugDDI.d334.s12"}, "annotations": [{"start": 14, "end": 22, "tag": "drug"}, {"start": 32, "end": 40, "tag": "drug"}, {"start": 114, "end": 122, "tag": "drug"}]}, {"content": "Methotrexate Concomitant administration of methotrexate and some NSAIDs has been reported to reduce the clearance of methotrexate, enhancing the toxicity of methotrexate.", "metadata": {"original_id": "DrugDDI.d334.s13"}, "annotations": [{"start": 0, "end": 13, "tag": "drug"}, {"start": 43, "end": 56, "tag": "drug"}, {"start": 65, "end": 72, "tag": "drug"}, {"start": 117, "end": 130, "tag": "drug"}, {"start": 157, "end": 170, "tag": "drug"}]}, {"content": "The effect of TORADOL on methotrexate clearance has not been studied.", "metadata": {"original_id": "DrugDDI.d334.s14"}, "annotations": [{"start": 14, "end": 22, "tag": "drug"}, {"start": 25, "end": 38, "tag": "drug"}]}, {"content": "Nondepolarizing Muscle Relaxants In postmarketing experience there have been reports of a possible interaction between TORADOLIV/IM and nondepolarizing muscle relaxants that resulted in apnea.", "metadata": {"original_id": "DrugDDI.d334.s15"}, "annotations": [{"start": 16, "end": 33, "tag": "drug"}, {"start": 152, "end": 169, "tag": "drug"}]}, {"content": "The concurrent use of TORADOL with muscle relaxants has not been formally studied.", "metadata": {"original_id": "DrugDDI.d334.s16"}, "annotations": [{"start": 22, "end": 30, "tag": "drug"}, {"start": 35, "end": 52, "tag": "drug"}]}, {"content": "ACE Inhibitors Concomitant use of ACE inhibitors may increase the risk of renal impairment, particularly in volume-depleted patients.", "metadata": {"original_id": "DrugDDI.d334.s17"}, "annotations": [{"start": 0, "end": 15, "tag": "drug"}, {"start": 34, "end": 49, "tag": "drug"}]}, {"content": "Antiepileptic Drugs Sporadic cases of seizures have been reported during concomitant use of TORADOL and antiepileptic drugs (phenytoin, carbamazepine).", "metadata": {"original_id": "DrugDDI.d334.s18"}, "annotations": [{"start": 0, "end": 20, "tag": "drug"}, {"start": 92, "end": 100, "tag": "drug"}, {"start": 104, "end": 124, "tag": "drug"}, {"start": 125, "end": 135, "tag": "drug"}, {"start": 136, "end": 150, "tag": "drug"}]}, {"content": "Psychoactive Drugs Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (fluoxetine, thiothixene, alprazolam).", "metadata": {"original_id": "DrugDDI.d334.s19"}, "annotations": [{"start": 0, "end": 19, "tag": "drug"}, {"start": 58, "end": 66, "tag": "drug"}, {"start": 94, "end": 113, "tag": "drug"}, {"start": 114, "end": 125, "tag": "drug"}, {"start": 126, "end": 138, "tag": "drug"}, {"start": 139, "end": 150, "tag": "drug"}]}, {"content": "Morphine TORADOLIV/IM has been administered concurrently with morphine in several clinical trials of postoperative pain without evidence of adverse interactions.", "metadata": {"original_id": "DrugDDI.d334.s20"}, "annotations": [{"start": 0, "end": 9, "tag": "drug"}, {"start": 62, "end": 71, "tag": "drug"}]}, {"content": "Do not mix TORADOL and morphine in the same syringe.", "metadata": {"original_id": "DrugDDI.d334.s21"}, "annotations": [{"start": 11, "end": 19, "tag": "drug"}, {"start": 23, "end": 32, "tag": "drug"}]}, {"content": "There is no evidence in animal or human studies that TORADOL induces or inhibits hepatic enzymes capable of metabolizing itself or other drugs", "metadata": {"original_id": "DrugDDI.d334.s22"}, "annotations": [{"start": 53, "end": 61, "tag": "drug"}, {"start": 137, "end": 143, "tag": "drug"}]}, {"content": ".", "metadata": {"original_id": "DrugDDI.d334.s23"}, "annotations": []}, {"content": "?", "metadata": {"original_id": "DrugDDI.d334.s24"}, "annotations": []}, {"content": "Probenecid may decrease renal tubular secretion of cephalosporins when used concurrently, resulting in increased and more prolonged cephalosporin blood levels.", "metadata": {"original_id": "DrugDDI.d67.s0"}, "annotations": [{"start": 0, "end": 11, "tag": "drug"}, {"start": 51, "end": 66, "tag": "drug"}, {"start": 132, "end": 146, "tag": "drug"}]}, {"content": "Drug/Laboratory Test Interactions A false positive reaction for glucose in the urine may occur with Benedicts solution, Fehlings solution or with CLINITEST? tablets, but not with enzyme-based tests such as CLINISTIX?.", "metadata": {"original_id": "DrugDDI.d67.s1"}, "annotations": [{"start": 0, "end": 5, "tag": "drug"}, {"start": 64, "end": 72, "tag": "drug"}]}, {"content": "Positive direct and indirect antiglobulin (Coombs) tests have occurred;", "metadata": {"original_id": "DrugDDI.d67.s2"}, "annotations": [{"start": 29, "end": 43, "tag": "drug"}]}, {"content": "these may also occur in neonates whose mothers received cephalosporins before delivery.", "metadata": {"original_id": "DrugDDI.d67.s3"}, "annotations": [{"start": 56, "end": 71, "tag": "drug"}]}, {"content": "As DIFFERIN Gel has the potential to produce local irritation in some patients, concomitant use of other potentially irritating topical products (medicated or abrasive soaps and cleansers, soaps and cosmetics that have a strong drying effect, and products with high concentrations of alcohol, astringents, spices or lime) should be approached with caution.", "metadata": {"original_id": "DrugDDI.d60.s0"}, "annotations": [{"start": 3, "end": 12, "tag": "drug"}, {"start": 284, "end": 292, "tag": "drug"}, {"start": 293, "end": 305, "tag": "drug"}, {"start": 316, "end": 321, "tag": "drug"}]}, {"content": "Particular caution should be exercised in using preparations containing sulfur, resorcinol, or salicylic acid in combination with DIFFERIN Gel.", "metadata": {"original_id": "DrugDDI.d60.s1"}, "annotations": [{"start": 72, "end": 79, "tag": "drug"}, {"start": 80, "end": 91, "tag": "drug"}, {"start": 95, "end": 110, "tag": "drug"}, {"start": 130, "end": 139, "tag": "drug"}]}, {"content": "If these preparations have been used it is advisable not to start therapy with DIFFERIN Gel until the effects of such preparations in the skin have subsided.", "metadata": {"original_id": "DrugDDI.d60.s2"}, "annotations": [{"start": 79, "end": 88, "tag": "drug"}]}, {"content": "Amiodarone is metabolized to desethylamiodarone by the cytochrome P450 (CYP450) enzyme group, specifically cytochromes P450 3A4 (CYP3A4) and CYP2C8.", "metadata": {"original_id": "DrugDDI.d63.s0"}, "annotations": [{"start": 0, "end": 11, "tag": "drug"}, {"start": 29, "end": 48, "tag": "drug"}, {"start": 55, "end": 71, "tag": "drug"}, {"start": 107, "end": 129, "tag": "drug"}, {"start": 129, "end": 136, "tag": "drug"}, {"start": 141, "end": 148, "tag": "drug"}]}, {"content": "The CYP3A4 isoenzyme is present in both the liver and intestines.", "metadata": {"original_id": "DrugDDI.d63.s1"}, "annotations": [{"start": 4, "end": 22, "tag": "drug"}, {"start": 44, "end": 50, "tag": "drug"}]}, {"content": "Amiodarone is also known to be an inhibitor of CYP3A4.", "metadata": {"original_id": "DrugDDI.d63.s2"}, "annotations": [{"start": 0, "end": 11, "tag": "drug"}, {"start": 47, "end": 54, "tag": "drug"}]}, {"content": "Therefore, amiodarone has the potential for interactions with drugs or substances that may be substrates, inhibitors or inducers of CYP3A4.", "metadata": {"original_id": "DrugDDI.d63.s3"}, "annotations": [{"start": 11, "end": 22, "tag": "drug"}, {"start": 62, "end": 68, "tag": "drug"}, {"start": 132, "end": 139, "tag": "drug"}]}, {"content": "While only a limited number of in vivo drug-drug interactions with amiodarone have been reported, chiefly with the oral formulation, the potential for other interactions should be anticipated.", "metadata": {"original_id": "DrugDDI.d63.s4"}, "annotations": [{"start": 67, "end": 78, "tag": "drug"}]}, {"content": "This is especially important for drugs associated with serious toxicity, such as other antiarrhythmics.", "metadata": {"original_id": "DrugDDI.d63.s5"}, "annotations": [{"start": 33, "end": 39, "tag": "drug"}, {"start": 87, "end": 103, "tag": "drug"}]}, {"content": "If such drugs are needed, their dose should be reassessed and, where appropriate, plasma concentration measured.", "metadata": {"original_id": "DrugDDI.d63.s6"}, "annotations": [{"start": 8, "end": 14, "tag": "drug"}]}, {"content": "In view of the long and variable half-life of amiodarone, potential for drug interactions exists not only with concomitant medication but also with drugs administered after discontinuation of amiodarone.", "metadata": {"original_id": "DrugDDI.d63.s7"}, "annotations": [{"start": 46, "end": 57, "tag": "drug"}, {"start": 123, "end": 135, "tag": "drug"}, {"start": 148, "end": 154, "tag": "drug"}, {"start": 192, "end": 203, "tag": "drug"}]}, {"content": "Since amiodarone is a substrate for CYP3A4 and CYP2C8, drugs/substances that inhibit these isoenzymes may decrease the metabolism and increase serum concentration of amiodarone.", "metadata": {"original_id": "DrugDDI.d63.s8"}, "annotations": [{"start": 6, "end": 17, "tag": "drug"}, {"start": 36, "end": 43, "tag": "drug"}, {"start": 47, "end": 54, "tag": "drug"}, {"start": 55, "end": 61, "tag": "drug"}, {"start": 91, "end": 102, "tag": "drug"}, {"start": 166, "end": 177, "tag": "drug"}]}, {"content": "Reported examples include the following: Protease Inhibitors: Protease inhibitors are known to inhibit CYP3A4 to varying degrees.", "metadata": {"original_id": "DrugDDI.d63.s9"}, "annotations": [{"start": 41, "end": 61, "tag": "drug"}, {"start": 62, "end": 82, "tag": "drug"}, {"start": 103, "end": 110, "tag": "drug"}]}, {"content": "A case report of one patient taking amiodarone 200 mg and indinavir 800 mg three times a day resulted in increases in amiodarone concentrations from 0.9 mg/L to 1.3 mg/L.", "metadata": {"original_id": "DrugDDI.d63.s10"}, "annotations": [{"start": 36, "end": 54, "tag": "drug"}, {"start": 58, "end": 68, "tag": "drug"}, {"start": 118, "end": 129, "tag": "drug"}]}, {"content": "DEA concentrations were not affected.", "metadata": {"original_id": "DrugDDI.d63.s11"}, "annotations": []}, {"content": "There was no evidence of toxicity.", "metadata": {"original_id": "DrugDDI.d63.s12"}, "annotations": []}, {"content": "Monitoring for amiodarone toxicity and serial measurement of amiodarone serum concentration during concomitant protease inhibitor therapy should be considered.", "metadata": {"original_id": "DrugDDI.d63.s13"}, "annotations": [{"start": 15, "end": 26, "tag": "drug"}, {"start": 61, "end": 72, "tag": "drug"}, {"start": 111, "end": 130, "tag": "drug"}]}, {"content": "Histamine H2 antagonists: Cimetidine inhibits CYP3A4 and can increase serum amiodarone levels.", "metadata": {"original_id": "DrugDDI.d63.s14"}, "annotations": [{"start": 0, "end": 25, "tag": "drug"}, {"start": 26, "end": 37, "tag": "drug"}, {"start": 46, "end": 53, "tag": "drug"}]}, {"content": "Other substances: Grapefruit juice given to healthy volunteers increased amiodarone AUC by 50% and Cmax by 84%, resulting in increased plasma levels of amiodarone.", "metadata": {"original_id": "DrugDDI.d63.s15"}, "annotations": [{"start": 73, "end": 84, "tag": "drug"}, {"start": 152, "end": 163, "tag": "drug"}]}, {"content": "Grapefruit juice should not be taken during treatment with oral amiodarone.", "metadata": {"original_id": "DrugDDI.d63.s16"}, "annotations": [{"start": 64, "end": 75, "tag": "drug"}]}, {"content": "This information should be considered when changing from intravenous amiodarone to oral amiodarone .", "metadata": {"original_id": "DrugDDI.d63.s17"}, "annotations": [{"start": 69, "end": 80, "tag": "drug"}, {"start": 88, "end": 99, "tag": "drug"}]}, {"content": "Amiodarone may suppress certain CYP450 enzymes, including CYP1A2, CYP2C9, CYP2D6, and CYP3A4.", "metadata": {"original_id": "DrugDDI.d63.s18"}, "annotations": [{"start": 0, "end": 11, "tag": "drug"}, {"start": 58, "end": 65, "tag": "drug"}, {"start": 66, "end": 73, "tag": "drug"}, {"start": 74, "end": 81, "tag": "drug"}, {"start": 86, "end": 93, "tag": "drug"}]}, {"content": "This inhibition can result in unexpectedly high plasma levels of other drugs which are metabolized by those CYP450 enzymes.", "metadata": {"original_id": "DrugDDI.d63.s19"}, "annotations": [{"start": 71, "end": 77, "tag": "drug"}]}, {"content": "Reported examples of this interaction include the following: Immunosuppressives: Cyclosporine (CYP3A4 substrate) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine, despite reduction in dose of cyclosporine.", "metadata": {"original_id": "DrugDDI.d63.s20"}, "annotations": [{"start": 61, "end": 79, "tag": "drug"}, {"start": 81, "end": 94, "tag": "drug"}, {"start": 95, "end": 102, "tag": "drug"}, {"start": 151, "end": 162, "tag": "drug"}, {"start": 238, "end": 251, "tag": "drug"}, {"start": 314, "end": 327, "tag": "drug"}]}, {"content": "HMG-CoA Reductase Inhibitors: Simvastatin (CYP3A4 substrate) in combination with amiodarone has been associated with reports of myopathy/rhabdomyolysis.", "metadata": {"original_id": "DrugDDI.d63.s21"}, "annotations": [{"start": 0, "end": 29, "tag": "drug"}, {"start": 30, "end": 42, "tag": "drug"}, {"start": 43, "end": 50, "tag": "drug"}, {"start": 81, "end": 92, "tag": "drug"}]}, {"content": "Cardiovasculars: Cardiac glycosides: In patients receiving digoxin therapy, administration of oral amiodarone regularly results in an increase in serum digoxin concentration that may reach toxic levels with resultant clinical toxicity.", "metadata": {"original_id": "DrugDDI.d63.s22"}, "annotations": [{"start": 17, "end": 36, "tag": "drug"}, {"start": 59, "end": 67, "tag": "drug"}, {"start": 99, "end": 110, "tag": "drug"}, {"start": 152, "end": 160, "tag": "drug"}]}, {"content": "Amiodarone taken concomitantly with digoxin increases the serum digoxin concentration by 70% after one day.", "metadata": {"original_id": "DrugDDI.d63.s23"}, "annotations": [{"start": 0, "end": 11, "tag": "drug"}, {"start": 36, "end": 44, "tag": "drug"}, {"start": 64, "end": 72, "tag": "drug"}]}, {"content": "On administration of oral amiodarone, the need for digitalis therapy should be reviewed and the dose reduced by approximately 50% or discontinued.", "metadata": {"original_id": "DrugDDI.d63.s24"}, "annotations": [{"start": 26, "end": 37, "tag": "drug"}]}, {"content": "If digitalis treatment is continued, serum levels should be closely monitored and patients observed for clinical evidence of toxicity.", "metadata": {"original_id": "DrugDDI.d63.s25"}, "annotations": [{"start": 3, "end": 13, "tag": "drug"}]}, {"content": "These precautions probably should apply to digitoxin administration as well.", "metadata": {"original_id": "DrugDDI.d63.s26"}, "annotations": [{"start": 43, "end": 53, "tag": "drug"}]}, {"content": "Antiarrhythmics: Other antiarrhythmic drugs, such as quinidine, procainamide, disopyramide, and phenytoin, have been used concurrently with amiodarone.", "metadata": {"original_id": "DrugDDI.d63.s27"}, "annotations": [{"start": 0, "end": 16, "tag": "drug"}, {"start": 23, "end": 44, "tag": "drug"}, {"start": 53, "end": 63, "tag": "drug"}, {"start": 64, "end": 77, "tag": "drug"}, {"start": 78, "end": 91, "tag": "drug"}, {"start": 96, "end": 106, "tag": "drug"}, {"start": 140, "end": 151, "tag": "drug"}]}, {"content": "There have been case reports of increased steady-state levels of quinidine, procainamide, and phenytoin during concomitant therapy with amiodarone.", "metadata": {"original_id": "DrugDDI.d63.s28"}, "annotations": [{"start": 65, "end": 75, "tag": "drug"}, {"start": 76, "end": 89, "tag": "drug"}, {"start": 94, "end": 104, "tag": "drug"}, {"start": 136, "end": 147, "tag": "drug"}]}, {"content": "Phenytoin decreases serum amiodarone levels.", "metadata": {"original_id": "DrugDDI.d63.s29"}, "annotations": [{"start": 0, "end": 10, "tag": "drug"}]}, {"content": "Amiodarone taken concomitantly with quinidine increases quinidine serum concentration by 33% after two days.", "metadata": {"original_id": "DrugDDI.d63.s30"}, "annotations": [{"start": 0, "end": 11, "tag": "drug"}, {"start": 36, "end": 46, "tag": "drug"}, {"start": 56, "end": 66, "tag": "drug"}]}, {"content": "Amiodarone taken concomitantly with procainamide for less than seven days increases plasma concentrations of procainamide and n-acetyl procainamide by 55% and 33%, respectively.", "metadata": {"original_id": "DrugDDI.d63.s31"}, "annotations": [{"start": 0, "end": 11, "tag": "drug"}, {"start": 36, "end": 49, "tag": "drug"}, {"start": 109, "end": 122, "tag": "drug"}, {"start": 135, "end": 148, "tag": "drug"}]}, {"content": "Quinidine and procainamide doses should be reduced by one-third when either is administered with amiodarone.", "metadata": {"original_id": "DrugDDI.d63.s32"}, "annotations": [{"start": 0, "end": 10, "tag": "drug"}, {"start": 97, "end": 108, "tag": "drug"}]}, {"content": "Plasma levels of flecainide have been reported to increase in the presence of oral amiodarone;", "metadata": {"original_id": "DrugDDI.d63.s33"}, "annotations": [{"start": 17, "end": 28, "tag": "drug"}, {"start": 83, "end": 94, "tag": "drug"}]}, {"content": "because of this, the dosage of flecainide should be adjusted when these drugs are administered concomitantly.", "metadata": {"original_id": "DrugDDI.d63.s34"}, "annotations": [{"start": 31, "end": 42, "tag": "drug"}, {"start": 72, "end": 78, "tag": "drug"}]}, {"content": "In general, any added antiarrhythmic drug should be initiated at a lower than usual dose with careful monitoring.", "metadata": {"original_id": "DrugDDI.d63.s35"}, "annotations": [{"start": 22, "end": 42, "tag": "drug"}]}, {"content": "Combination of amiodarone with other antiarrhythmic therapy should be reserved for patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent or incompletely responsive to amiodarone.", "metadata": {"original_id": "DrugDDI.d63.s36"}, "annotations": [{"start": 15, "end": 26, "tag": "drug"}, {"start": 37, "end": 53, "tag": "drug"}, {"start": 218, "end": 229, "tag": "drug"}]}, {"content": "During transfer to oral amiodarone, the dose levels of previously administered agents should be reduced by 30 to 50% several days after the addition of oral amiodarone.", "metadata": {"original_id": "DrugDDI.d63.s37"}, "annotations": [{"start": 24, "end": 35, "tag": "drug"}, {"start": 157, "end": 168, "tag": "drug"}]}, {"content": "The continued need for the other antiarrhythmic agent should be reviewed after the effects of amiodarone have been established, and discontinuation ordinarily should be attempted.", "metadata": {"original_id": "DrugDDI.d63.s38"}, "annotations": [{"start": 33, "end": 54, "tag": "drug"}, {"start": 94, "end": 105, "tag": "drug"}]}, {"content": "If the treatment is continued, these patients should be particularly carefully monitored for adverse effects, especially conduction disturbances and exacerbation of tachyarrhythmias, as amiodarone is continued.", "metadata": {"original_id": "DrugDDI.d63.s39"}, "annotations": [{"start": 186, "end": 197, "tag": "drug"}]}, {"content": "In amiodarone-treated patients who require additional antiarrhythmic therapy, the initial dose of such agents should be approximately half of the usual recommended dose.", "metadata": {"original_id": "DrugDDI.d63.s40"}, "annotations": [{"start": 3, "end": 14, "tag": "drug"}, {"start": 54, "end": 70, "tag": "drug"}]}, {"content": "Antihypertensives: Amiodarone should be used with caution in patients receiving ?-receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;", "metadata": {"original_id": "DrugDDI.d63.s41"}, "annotations": [{"start": 0, "end": 18, "tag": "drug"}, {"start": 19, "end": 30, "tag": "drug"}, {"start": 82, "end": 91, "tag": "drug"}, {"start": 114, "end": 126, "tag": "drug"}, {"start": 129, "end": 136, "tag": "drug"}, {"start": 150, "end": 166, "tag": "drug"}, {"start": 185, "end": 195, "tag": "drug"}, {"start": 198, "end": 205, "tag": "drug"}, {"start": 220, "end": 230, "tag": "drug"}, {"start": 233, "end": 240, "tag": "drug"}]}, {"content": "if necessary, amiodarone can continue to be used after insertion of a pacemaker in patients with severe bradycardia or sinus arrest.", "metadata": {"original_id": "DrugDDI.d63.s42"}, "annotations": [{"start": 14, "end": 25, "tag": "drug"}]}, {"content": "Anticoagulants: Potentiation of warfarin-type (CYP2C9 and CYP3A4 substrate) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.", "metadata": {"original_id": "DrugDDI.d63.s43"}, "annotations": [{"start": 0, "end": 15, "tag": "drug"}, {"start": 32, "end": 41, "tag": "drug"}, {"start": 47, "end": 54, "tag": "drug"}, {"start": 58, "end": 65, "tag": "drug"}, {"start": 76, "end": 90, "tag": "drug"}, {"start": 143, "end": 154, "tag": "drug"}]}, {"content": "Since the concomitant administration of warfarin with amiodarone increases the prothrombin time by 100% after 3 to 4 days, the dose of the anticoagulant should be reduced by one-third to one-half, and prothrombin times should be monitored closely.", "metadata": {"original_id": "DrugDDI.d63.s44"}, "annotations": [{"start": 40, "end": 49, "tag": "drug"}, {"start": 54, "end": 65, "tag": "drug"}, {"start": 139, "end": 153, "tag": "drug"}]}, {"content": "Some drugs/substances are known to accelerate the metabolism of amiodarone by stimulating the synthesis of CYP3A4 (enzyme induction).", "metadata": {"original_id": "DrugDDI.d63.s45"}, "annotations": [{"start": 5, "end": 11, "tag": "drug"}, {"start": 64, "end": 75, "tag": "drug"}, {"start": 107, "end": 114, "tag": "drug"}]}, {"content": "This may lead to low amiodarone serum levels and potential decrease in efficacy.", "metadata": {"original_id": "DrugDDI.d63.s46"}, "annotations": [{"start": 21, "end": 32, "tag": "drug"}]}, {"content": "Reported examples of this interaction include the following: Antibiotics: Rifampin is a potent inducer of CYP3A4.", "metadata": {"original_id": "DrugDDI.d63.s47"}, "annotations": [{"start": 61, "end": 73, "tag": "drug"}, {"start": 74, "end": 83, "tag": "drug"}, {"start": 106, "end": 113, "tag": "drug"}]}, {"content": "Administration of rifampin concomitantly with oral amiodarone has been shown to result in decreases in serum concentrations of amiodarone and desethylamiodarone.", "metadata": {"original_id": "DrugDDI.d63.s48"}, "annotations": [{"start": 18, "end": 27, "tag": "drug"}, {"start": 51, "end": 62, "tag": "drug"}, {"start": 127, "end": 138, "tag": "drug"}, {"start": 142, "end": 161, "tag": "drug"}]}, {"content": "Other substances, including herbal preparations: St. John?s Wort (Hypericum perforatum) induces CYP3A4.", "metadata": {"original_id": "DrugDDI.d63.s49"}, "annotations": [{"start": 28, "end": 48, "tag": "drug"}, {"start": 66, "end": 87, "tag": "drug"}, {"start": 96, "end": 103, "tag": "drug"}]}, {"content": "Since amiodarone is a substrate for CYP3A4, there is the potential that the use of St. John?s Wort in patients receiving amiodarone could result in reduced amiodarone levels.", "metadata": {"original_id": "DrugDDI.d63.s50"}, "annotations": [{"start": 6, "end": 17, "tag": "drug"}, {"start": 36, "end": 43, "tag": "drug"}, {"start": 121, "end": 132, "tag": "drug"}, {"start": 156, "end": 167, "tag": "drug"}]}, {"content": "Other reported interactions with amiodarone: Fentanyl (CYP3A4 substrate) in combination with amiodarone may cause hypotension, bradycardia, and decreased cardiac output.", "metadata": {"original_id": "DrugDDI.d63.s51"}, "annotations": [{"start": 33, "end": 44, "tag": "drug"}, {"start": 45, "end": 54, "tag": "drug"}, {"start": 55, "end": 62, "tag": "drug"}, {"start": 93, "end": 104, "tag": "drug"}]}, {"content": "Sinus bradycardia has been reported with oral amiodarone in combination with lidocaine (CYP3A4 substrate) given for local anesthesia.", "metadata": {"original_id": "DrugDDI.d63.s52"}, "annotations": [{"start": 46, "end": 57, "tag": "drug"}, {"start": 77, "end": 87, "tag": "drug"}, {"start": 88, "end": 95, "tag": "drug"}, {"start": 116, "end": 133, "tag": "drug"}]}, {"content": "Seizure, associated with increased lidocaine concentrations, has been reported with concomitant administration of intravenous amiodarone.", "metadata": {"original_id": "DrugDDI.d63.s53"}, "annotations": [{"start": 35, "end": 45, "tag": "drug"}, {"start": 126, "end": 137, "tag": "drug"}]}, {"content": "Dextromethorphan is a substrate for both CYP2D6 and CYP3A4.", "metadata": {"original_id": "DrugDDI.d63.s54"}, "annotations": [{"start": 0, "end": 17, "tag": "drug"}, {"start": 41, "end": 48, "tag": "drug"}, {"start": 52, "end": 59, "tag": "drug"}]}, {"content": "Amiodarone inhibits CYP2D6.", "metadata": {"original_id": "DrugDDI.d63.s55"}, "annotations": [{"start": 0, "end": 11, "tag": "drug"}, {"start": 20, "end": 27, "tag": "drug"}]}, {"content": "Cholestyramine increases enterohepatic elimination of amiodarone and may reduce its serum levels and t1/2.", "metadata": {"original_id": "DrugDDI.d63.s56"}, "annotations": [{"start": 0, "end": 15, "tag": "drug"}, {"start": 54, "end": 65, "tag": "drug"}, {"start": 101, "end": 104, "tag": "drug"}]}, {"content": "Disopyramide increases QT prolongation which could cause arrhythmia.", "metadata": {"original_id": "DrugDDI.d63.s57"}, "annotations": [{"start": 0, "end": 13, "tag": "drug"}]}, {"content": "Fluoroquinolones, macrolide antibiotics, and azoles are known to cause QTc prolongation.", "metadata": {"original_id": "DrugDDI.d63.s58"}, "annotations": [{"start": 0, "end": 17, "tag": "drug"}, {"start": 18, "end": 40, "tag": "drug"}]}, {"content": "There have been reports of QTc prolongation, with or without TdP, in patients taking amiodarone when fluoroquinolones, macrolide antibiotics, or azoles were administered concomitantly.", "metadata": {"original_id": "DrugDDI.d63.s59"}, "annotations": [{"start": 85, "end": 96, "tag": "drug"}, {"start": 101, "end": 118, "tag": "drug"}, {"start": 119, "end": 141, "tag": "drug"}]}, {"content": "Hemodynamic and electrophysiologic interactions have also been observed after concomitant administration with propranolol, diltiazem, and verapamil.", "metadata": {"original_id": "DrugDDI.d63.s60"}, "annotations": [{"start": 110, "end": 122, "tag": "drug"}, {"start": 123, "end": 133, "tag": "drug"}, {"start": 138, "end": 148, "tag": "drug"}]}, {"content": "Volatile Anesthetic Agents:.", "metadata": {"original_id": "DrugDDI.d63.s61"}, "annotations": [{"start": 9, "end": 27, "tag": "drug"}]}, {"content": "In addition to the interactions noted above, chronic (  2 weeks) oral Cordarone administration impairs metabolism of phenytoin, dextromethorphan, and methotrexate.", "metadata": {"original_id": "DrugDDI.d63.s62"}, "annotations": [{"start": 70, "end": 80, "tag": "drug"}, {"start": 117, "end": 127, "tag": "drug"}, {"start": 128, "end": 145, "tag": "drug"}, {"start": 150, "end": 163, "tag": "drug"}]}, {"content": "Electrolyte Disturbances Patients with hypokalemia or hypomagnesemia should have the condition corrected whenever possible before being treated with Cordarone I.V., as these disorders can exaggerate the degree of QTc prolongation and increase the potential for TdP.", "metadata": {"original_id": "DrugDDI.d63.s63"}, "annotations": [{"start": 149, "end": 164, "tag": "drug"}]}, {"content": "Special attention should be given to electrolyte and acid-base balance in patients experiencing severe or prolonged diarrhea or in patients receiving concomitant diuretics.", "metadata": {"original_id": "DrugDDI.d63.s64"}, "annotations": [{"start": 162, "end": 172, "tag": "drug"}]}, {"content": "Atovaquone is highly bound to plasma protein (99.9%).", "metadata": {"original_id": "DrugDDI.d582.s0"}, "annotations": [{"start": 0, "end": 11, "tag": "drug"}, {"start": 30, "end": 45, "tag": "drug"}]}, {"content": "Therefore, caution should be used when administering MEPRON concurrently with other highly plasma protein- bound drugs with narrow therapeutic indices, as competition for binding sites may occur.", "metadata": {"original_id": "DrugDDI.d582.s1"}, "annotations": [{"start": 53, "end": 60, "tag": "drug"}]}, {"content": "The extent of plasma protein binding of atovaquone in human plasma is not affected by the presence of therapeutic concentrations of phenytoin (15 mcg/ mL), nor is the binding of phenytoin affected by the presence of atovaquone.", "metadata": {"original_id": "DrugDDI.d582.s2"}, "annotations": [{"start": 14, "end": 29, "tag": "drug"}, {"start": 40, "end": 51, "tag": "drug"}, {"start": 54, "end": 67, "tag": "drug"}, {"start": 132, "end": 142, "tag": "drug"}, {"start": 178, "end": 188, "tag": "drug"}, {"start": 216, "end": 227, "tag": "drug"}]}, {"content": "Rifampin: Coadministration of rifampin and MEPRON Suspension results in a significant decrease in average steady- state plasma atovaquone concentrations.", "metadata": {"original_id": "DrugDDI.d582.s3"}, "annotations": [{"start": 0, "end": 9, "tag": "drug"}, {"start": 30, "end": 39, "tag": "drug"}, {"start": 43, "end": 50, "tag": "drug"}, {"start": 127, "end": 138, "tag": "drug"}]}, {"content": "Alternatives to rifampin should be considered during the course of PCP treatment with MEPRON.", "metadata": {"original_id": "DrugDDI.d582.s4"}, "annotations": [{"start": 16, "end": 25, "tag": "drug"}, {"start": 86, "end": 93, "tag": "drug"}]}, {"content": "Rifabutin, another rifamycin, is structurally similar to rifampin and may possibly have some of the same drug interactions as rifampin.", "metadata": {"original_id": "DrugDDI.d582.s5"}, "annotations": [{"start": 0, "end": 10, "tag": "drug"}, {"start": 19, "end": 29, "tag": "drug"}, {"start": 57, "end": 66, "tag": "drug"}, {"start": 126, "end": 135, "tag": "drug"}]}, {"content": "No interaction trials have been conducted with MEPRON and rifabutin.", "metadata": {"original_id": "DrugDDI.d582.s6"}, "annotations": [{"start": 47, "end": 54, "tag": "drug"}, {"start": 58, "end": 68, "tag": "drug"}]}, {"content": "Drug/ Laboratory Test Interactions: It is not known if MEPRON interferes with clinical laboratory test or assay results.", "metadata": {"original_id": "DrugDDI.d582.s7"}, "annotations": [{"start": 0, "end": 5, "tag": "drug"}, {"start": 55, "end": 62, "tag": "drug"}]}, {"content": "In vitro studies have shown CASODEX can displace coumarin anticoagulants, such as warfarin, from their protein-binding sites.", "metadata": {"original_id": "DrugDDI.d498.s0"}, "annotations": [{"start": 28, "end": 36, "tag": "drug"}, {"start": 49, "end": 72, "tag": "drug"}, {"start": 82, "end": 91, "tag": "drug"}, {"start": 103, "end": 111, "tag": "drug"}]}, {"content": "It is recommended that if CASODEX is started in patients already receiving coumarin anticoagulants, prothrombin times should be closely monitored and adjustment of the anticoagulant dose may be necessary.", "metadata": {"original_id": "DrugDDI.d498.s1"}, "annotations": [{"start": 26, "end": 34, "tag": "drug"}, {"start": 75, "end": 98, "tag": "drug"}, {"start": 168, "end": 182, "tag": "drug"}]}, {"content": "No significant drug-drug pharmacokinetic interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, cimetidine and phenobarbital.", "metadata": {"original_id": "DrugDDI.d112.s0"}, "annotations": [{"start": 98, "end": 118, "tag": "drug"}, {"start": 119, "end": 127, "tag": "drug"}, {"start": 128, "end": 137, "tag": "drug"}, {"start": 138, "end": 149, "tag": "drug"}, {"start": 153, "end": 167, "tag": "drug"}]}, {"content": "Rifampin, an inducer of drug metabolism, decreased the concentrations of losartan and its active metabolite.", "metadata": {"original_id": "DrugDDI.d112.s1"}, "annotations": [{"start": 0, "end": 9, "tag": "drug"}, {"start": 73, "end": 82, "tag": "drug"}, {"start": 90, "end": 108, "tag": "drug"}]}, {"content": "In humans, two inhibitors of P450 3A4 have been studied.", "metadata": {"original_id": "DrugDDI.d112.s2"}, "annotations": [{"start": 29, "end": 38, "tag": "drug"}]}, {"content": "Ketoconazole did not affect the conversion of losartan to the active metabolite after intravenous administration of losartan, and erythromycin had no clinically significant effect after oral administration.", "metadata": {"original_id": "DrugDDI.d112.s3"}, "annotations": [{"start": 0, "end": 13, "tag": "drug"}, {"start": 46, "end": 55, "tag": "drug"}, {"start": 62, "end": 80, "tag": "drug"}, {"start": 116, "end": 125, "tag": "drug"}, {"start": 130, "end": 143, "tag": "drug"}]}, {"content": "Fluconazole, an inhibitor of P450 2C9, decreased active metabolite concentration and increased losartan concentration.", "metadata": {"original_id": "DrugDDI.d112.s4"}, "annotations": [{"start": 0, "end": 12, "tag": "drug"}, {"start": 29, "end": 34, "tag": "drug"}, {"start": 49, "end": 67, "tag": "drug"}, {"start": 95, "end": 104, "tag": "drug"}]}, {"content": "The pharmacodynamic consequences of concomitant use of losartan and inhibitors of P450 2C9 have not been examined.", "metadata": {"original_id": "DrugDDI.d112.s5"}, "annotations": [{"start": 55, "end": 64, "tag": "drug"}, {"start": 82, "end": 87, "tag": "drug"}]}, {"content": "Subjects who do not metabolize losartan to active metabolite have been shown to have a specific, rare defect in cytochrome P450 2C9.", "metadata": {"original_id": "DrugDDI.d112.s6"}, "annotations": [{"start": 31, "end": 40, "tag": "drug"}, {"start": 43, "end": 61, "tag": "drug"}, {"start": 112, "end": 132, "tag": "drug"}]}, {"content": "These data suggest that the conversion of losartan to its active metabolite is mediated primarily by P450 2C9 and not P450 3A4.", "metadata": {"original_id": "DrugDDI.d112.s7"}, "annotations": [{"start": 42, "end": 51, "tag": "drug"}, {"start": 58, "end": 76, "tag": "drug"}, {"start": 101, "end": 106, "tag": "drug"}, {"start": 118, "end": 127, "tag": "drug"}]}, {"content": "As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.", "metadata": {"original_id": "DrugDDI.d112.s8"}, "annotations": [{"start": 14, "end": 20, "tag": "drug"}, {"start": 31, "end": 46, "tag": "drug"}, {"start": 81, "end": 109, "tag": "drug"}, {"start": 116, "end": 131, "tag": "drug"}, {"start": 132, "end": 144, "tag": "drug"}, {"start": 145, "end": 155, "tag": "drug"}, {"start": 157, "end": 178, "tag": "drug"}, {"start": 183, "end": 188, "tag": "drug"}, {"start": 211, "end": 221, "tag": "drug"}]}, {"content": "As with other antihypertensive agents, the antihypertensive effect of losartan may be blunted by the non-steroidal anti-inflammatory drug indomethacin", "metadata": {"original_id": "DrugDDI.d112.s9"}, "annotations": [{"start": 14, "end": 38, "tag": "drug"}, {"start": 43, "end": 60, "tag": "drug"}, {"start": 70, "end": 79, "tag": "drug"}, {"start": 101, "end": 138, "tag": "drug"}]}, {"content": ".", "metadata": {"original_id": "DrugDDI.d112.s10"}, "annotations": []}, {"content": "?", "metadata": {"original_id": "DrugDDI.d112.s11"}, "annotations": []}, {"content": "Administration of thiazide diuretics to hypoparathyroid patients who are concurrently being treated with dihydrotachysterol may cause hypercalcemia.", "metadata": {"original_id": "DrugDDI.d62.s0"}, "annotations": [{"start": 18, "end": 37, "tag": "drug"}, {"start": 105, "end": 124, "tag": "drug"}]}, {"content": "Injection There is inadequate systematic experience with the use of baclofen injection in combination with other medications to predict specific drug-drug interactions.", "metadata": {"original_id": "DrugDDI.d517.s0"}, "annotations": [{"start": 68, "end": 77, "tag": "drug"}, {"start": 107, "end": 125, "tag": "drug"}]}, {"content": "Interactions attributed to the combined use of baclofen injection and epidural morphine include hypotension and dyspnea.", "metadata": {"original_id": "DrugDDI.d517.s1"}, "annotations": [{"start": 47, "end": 56, "tag": "drug"}, {"start": 79, "end": 88, "tag": "drug"}]}, {"content": "SIDE EFFECTS (KEMSTRO) The most common adverse reaction during treatment with baclofen is transient drowsiness (10-63%).", "metadata": {"original_id": "DrugDDI.d517.s2"}, "annotations": [{"start": 78, "end": 87, "tag": "drug"}]}, {"content": "In one controlled study of 175 patients, transient drowsiness was observed in 63% of those receiving baclofen tablets compared to 36% of those in the placebo group.", "metadata": {"original_id": "DrugDDI.d517.s3"}, "annotations": [{"start": 101, "end": 118, "tag": "drug"}]}, {"content": "Other common adverse reactions are dizziness (5-15%), weakness (5-15%) and fatigue (2-4%).", "metadata": {"original_id": "DrugDDI.d517.s4"}, "annotations": []}, {"content": "Others reported: Neuropsychiatric: Confusion (1-11%), headache (4-8%), insomnia (2-7%);", "metadata": {"original_id": "DrugDDI.d517.s5"}, "annotations": []}, {"content": "and, rarely, euphoria, excitement, depression, hallucinations, paresthesia, muscle pain, tinnitus, slurred speech, coordination disorder, tremor, rigidity, dystonia, ataxia, blurred vision, nystagmus, strabismus, miosis, mydriasis, diplopia, dysarthria, epileptic seizure.", "metadata": {"original_id": "DrugDDI.d517.s6"}, "annotations": []}, {"content": "Cardiovascular: Hypotension (0-9%).", "metadata": {"original_id": "DrugDDI.d517.s7"}, "annotations": []}, {"content": "Rare instances of dyspnea, palpitation, chest pain, syncope.", "metadata": {"original_id": "DrugDDI.d517.s8"}, "annotations": []}, {"content": "Gastrointestinal: Nausea (4-12%), constipation (2-6%);", "metadata": {"original_id": "DrugDDI.d517.s9"}, "annotations": []}, {"content": "and, rarely, dry mouth, anorexia, taste disorder, abdominal pain, vomiting, diarrhea, and positive test for occult blood in stool.", "metadata": {"original_id": "DrugDDI.d517.s10"}, "annotations": []}, {"content": "Genitourinary: Urinary frequency (2-6%);", "metadata": {"original_id": "DrugDDI.d517.s11"}, "annotations": []}, {"content": "and, rarely, enuresis, urinary retention, dysuria, impotence, inability to ejaculate, nocturia, hematuria.", "metadata": {"original_id": "DrugDDI.d517.s12"}, "annotations": []}, {"content": "Other: Instances of rash, pruritus, ankle edema, excessive perspiration, weight gain, nasal congestion.", "metadata": {"original_id": "DrugDDI.d517.s13"}, "annotations": []}, {"content": "Some of the CNS and genitourinary symptoms may be related to the underlying disease rather than to drug therapy.", "metadata": {"original_id": "DrugDDI.d517.s14"}, "annotations": []}, {"content": "The following laboratory tests have been found to be abnormal in a few patients receiving baclofen: increased SGOT, elevated alkaline phosphatase, and elevation of blood sugar.", "metadata": {"original_id": "DrugDDI.d517.s15"}, "annotations": [{"start": 90, "end": 99, "tag": "drug"}, {"start": 125, "end": 146, "tag": "drug"}]}, {"content": "The adverse experience profile seen with KEMSTROTM was similar to that seen with baclofen tablets.", "metadata": {"original_id": "DrugDDI.d517.s16"}, "annotations": [{"start": 81, "end": 98, "tag": "drug"}]}, {"content": "Preliminary data which suggest that dapsone may inhibit the anti-inflammatory activity of Lamprene have not been confirmed.", "metadata": {"original_id": "DrugDDI.d558.s0"}, "annotations": [{"start": 36, "end": 44, "tag": "drug"}, {"start": 90, "end": 99, "tag": "drug"}]}, {"content": "If leprosy-associated inflammatory reactions develop in patients being treated with dapsone and clofazimine, it is still advisable to continue treatment with both drugs.", "metadata": {"original_id": "DrugDDI.d558.s1"}, "annotations": [{"start": 3, "end": 11, "tag": "drug"}, {"start": 84, "end": 92, "tag": "drug"}, {"start": 96, "end": 108, "tag": "drug"}, {"start": 163, "end": 169, "tag": "drug"}]}, {"content": "No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.", "metadata": {"original_id": "DrugDDI.d396.s0"}, "annotations": [{"start": 15, "end": 20, "tag": "drug"}, {"start": 119, "end": 139, "tag": "drug"}, {"start": 140, "end": 148, "tag": "drug"}, {"start": 149, "end": 158, "tag": "drug"}, {"start": 163, "end": 174, "tag": "drug"}]}, {"content": "In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.", "metadata": {"original_id": "DrugDDI.d396.s1"}, "annotations": [{"start": 74, "end": 85, "tag": "drug"}, {"start": 123, "end": 131, "tag": "drug"}, {"start": 167, "end": 179, "tag": "drug"}, {"start": 183, "end": 194, "tag": "drug"}]}, {"content": "However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.", "metadata": {"original_id": "DrugDDI.d396.s2"}, "annotations": [{"start": 61, "end": 72, "tag": "drug"}, {"start": 99, "end": 108, "tag": "drug"}]}, {"content": "Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isozymes 1A1, 1A2,2A6,2B6,2D6,2E1,or 3A4.", "metadata": {"original_id": "DrugDDI.d396.s3"}, "annotations": [{"start": 62, "end": 68, "tag": "drug"}, {"start": 103, "end": 133, "tag": "drug"}]}, {"content": "In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of digoxin.", "metadata": {"original_id": "DrugDDI.d396.s4"}, "annotations": [{"start": 63, "end": 72, "tag": "drug"}, {"start": 73, "end": 93, "tag": "drug"}, {"start": 97, "end": 105, "tag": "drug"}, {"start": 106, "end": 117, "tag": "drug"}, {"start": 184, "end": 193, "tag": "drug"}, {"start": 235, "end": 243, "tag": "drug"}]}, {"content": "The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide", "metadata": {"original_id": "DrugDDI.d396.s5"}, "annotations": [{"start": 24, "end": 35, "tag": "drug"}, {"start": 76, "end": 87, "tag": "drug"}, {"start": 90, "end": 110, "tag": "drug"}]}, {"content": ".", "metadata": {"original_id": "DrugDDI.d396.s6"}, "annotations": []}, {"content": "?", "metadata": {"original_id": "DrugDDI.d396.s7"}, "annotations": []}, {"content": "Geocillin (carbenicillin indanyl sodium) blood levels may be increased and prolonged by concurrent administration of probenecid.", "metadata": {"original_id": "DrugDDI.d303.s0"}, "annotations": [{"start": 0, "end": 10, "tag": "drug"}, {"start": 11, "end": 40, "tag": "drug"}, {"start": 117, "end": 128, "tag": "drug"}]}, {"content": "When ertapenem is co-administered with probenecid (500 mg p.o. every 6 hours), probenecid competes for active tubular secretion and reduces the renal clearance of ertapenem.", "metadata": {"original_id": "DrugDDI.d124.s0"}, "annotations": [{"start": 5, "end": 15, "tag": "drug"}, {"start": 39, "end": 50, "tag": "drug"}, {"start": 51, "end": 56, "tag": "drug"}, {"start": 79, "end": 90, "tag": "drug"}, {"start": 163, "end": 173, "tag": "drug"}]}, {"content": "Based on total ertapenem concentrations, probenecid increased the AUC by 25% and reduced the plasma and renal clearances by 20% and 35%, respectively.", "metadata": {"original_id": "DrugDDI.d124.s1"}, "annotations": [{"start": 15, "end": 25, "tag": "drug"}, {"start": 41, "end": 52, "tag": "drug"}]}, {"content": "The half-life increased from 4.0 to 4.8 hours.", "metadata": {"original_id": "DrugDDI.d124.s2"}, "annotations": []}, {"content": "Because of the small effect on half-life, the coadministration with probenecid to extend the half-life of ertapenem is not recommended.", "metadata": {"original_id": "DrugDDI.d124.s3"}, "annotations": [{"start": 68, "end": 79, "tag": "drug"}, {"start": 106, "end": 116, "tag": "drug"}]}, {"content": "In vitro studies indicate that ertapenem does not inhibit P-glycoprotein-mediated transport of digoxin or vinblastine and that ertapenem is not a substrate for P-glycoprotein-mediated transport.", "metadata": {"original_id": "DrugDDI.d124.s4"}, "annotations": [{"start": 31, "end": 41, "tag": "drug"}, {"start": 60, "end": 73, "tag": "drug"}, {"start": 95, "end": 103, "tag": "drug"}, {"start": 106, "end": 118, "tag": "drug"}, {"start": 127, "end": 137, "tag": "drug"}, {"start": 162, "end": 175, "tag": "drug"}]}, {"content": "In vitro studies in human liver microsomes indicate that ertapenem does not inhibit metabolism mediated by any of the following six cytochrome p450 (CYP) isoforms: 1A2, 2C9, 2C19, 2D6, 2E1 and 3A4.", "metadata": {"original_id": "DrugDDI.d124.s5"}, "annotations": [{"start": 57, "end": 67, "tag": "drug"}, {"start": 132, "end": 148, "tag": "drug"}, {"start": 149, "end": 153, "tag": "drug"}, {"start": 154, "end": 163, "tag": "drug"}]}, {"content": "Drug interactions caused by inhibition of P-glycoprotein-mediated drug clearance or CYP-mediated drug clearance with the listed isoforms are unlikely.", "metadata": {"original_id": "DrugDDI.d124.s6"}, "annotations": [{"start": 44, "end": 57, "tag": "drug"}, {"start": 84, "end": 88, "tag": "drug"}, {"start": 128, "end": 137, "tag": "drug"}]}, {"content": "Other than with probenecid, no specific clinical drug interaction studies have been conducted", "metadata": {"original_id": "DrugDDI.d124.s7"}, "annotations": [{"start": 16, "end": 27, "tag": "drug"}]}, {"content": ".", "metadata": {"original_id": "DrugDDI.d124.s8"}, "annotations": []}, {"content": "? ?", "metadata": {"original_id": "DrugDDI.d124.s9"}, "annotations": []}, {"content": "Co-administration of nelfinavir at steady-state with a single dose of azithromycin (2  span class= c94 ??", "metadata": {"original_id": "DrugDDI.d554.s0"}, "annotations": [{"start": 21, "end": 32, "tag": "drug"}, {"start": 70, "end": 83, "tag": "drug"}]}, {"content": "600 mg tablets) results in increased azithromycin serum concentrations.", "metadata": {"original_id": "DrugDDI.d554.s1"}, "annotations": [{"start": 37, "end": 50, "tag": "drug"}]}, {"content": "Although a dose adjustment of azithromycin is not recommended when administered in combination with nelfinavir, close monitoring for known side effects of azithromycin, such as liver enzyme abnormalities and hearing impairment, is warranted.", "metadata": {"original_id": "DrugDDI.d554.s2"}, "annotations": [{"start": 30, "end": 43, "tag": "drug"}, {"start": 100, "end": 111, "tag": "drug"}, {"start": 155, "end": 168, "tag": "drug"}]}, {"content": "Azithromycin did not affect the prothrombin time response to a single dose of warfarin.", "metadata": {"original_id": "DrugDDI.d554.s3"}, "annotations": [{"start": 0, "end": 13, "tag": "drug"}, {"start": 78, "end": 87, "tag": "drug"}]}, {"content": "However, prudent medical practice dictates careful monitoring of prothrombin time in all patients treated with azithromycin and warfarin concomitantly.", "metadata": {"original_id": "DrugDDI.d554.s4"}, "annotations": [{"start": 111, "end": 124, "tag": "drug"}, {"start": 128, "end": 137, "tag": "drug"}]}, {"content": "Concurrent use of macrolides and warfarin in clinical practice has been associated with increased anticoagulant effects.", "metadata": {"original_id": "DrugDDI.d554.s5"}, "annotations": [{"start": 18, "end": 29, "tag": "drug"}, {"start": 33, "end": 42, "tag": "drug"}]}, {"content": "Drug interaction studies were performed with azithromycin and other drugs likely to be co-administered.", "metadata": {"original_id": "DrugDDI.d554.s6"}, "annotations": [{"start": 45, "end": 58, "tag": "drug"}, {"start": 68, "end": 74, "tag": "drug"}]}, {"content": "When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.", "metadata": {"original_id": "DrugDDI.d554.s7"}, "annotations": [{"start": 32, "end": 45, "tag": "drug"}, {"start": 92, "end": 105, "tag": "drug"}, {"start": 106, "end": 120, "tag": "drug"}, {"start": 121, "end": 132, "tag": "drug"}, {"start": 133, "end": 144, "tag": "drug"}, {"start": 145, "end": 155, "tag": "drug"}, {"start": 156, "end": 168, "tag": "drug"}, {"start": 169, "end": 179, "tag": "drug"}, {"start": 180, "end": 190, "tag": "drug"}, {"start": 191, "end": 201, "tag": "drug"}, {"start": 202, "end": 213, "tag": "drug"}, {"start": 214, "end": 227, "tag": "drug"}, {"start": 251, "end": 261, "tag": "drug"}, {"start": 262, "end": 275, "tag": "drug"}, {"start": 275, "end": 292, "tag": "drug"}, {"start": 295, "end": 306, "tag": "drug"}]}, {"content": "Co-administration with efavirenz or fluconazole had a modest effect on the pharmacokinetics of azithromycin.", "metadata": {"original_id": "DrugDDI.d554.s8"}, "annotations": [{"start": 23, "end": 33, "tag": "drug"}, {"start": 36, "end": 48, "tag": "drug"}, {"start": 95, "end": 108, "tag": "drug"}]}, {"content": "No dosage adjustment of either drug is recommended when azithromycin is co administered with any of the above agents.", "metadata": {"original_id": "DrugDDI.d554.s9"}, "annotations": [{"start": 31, "end": 36, "tag": "drug"}, {"start": 56, "end": 69, "tag": "drug"}]}, {"content": "Interactions with the drugs listed below have not been reported in clinical trials with azithromycin;", "metadata": {"original_id": "DrugDDI.d554.s10"}, "annotations": [{"start": 22, "end": 28, "tag": "drug"}, {"start": 88, "end": 101, "tag": "drug"}]}, {"content": "however, no specific drug interaction studies have been performed to evaluate potential drug-drug interaction.", "metadata": {"original_id": "DrugDDI.d554.s11"}, "annotations": []}, {"content": "Nonetheless, they have been observed with macrolide products.", "metadata": {"original_id": "DrugDDI.d554.s12"}, "annotations": [{"start": 42, "end": 52, "tag": "drug"}]}, {"content": "Until further data are developed regarding drug interactions when azithromycin and these drugs are used concomitantly, careful monitoring of patients is advised: Digoxin?elevated digoxin concentrations.", "metadata": {"original_id": "DrugDDI.d554.s13"}, "annotations": [{"start": 66, "end": 79, "tag": "drug"}, {"start": 89, "end": 95, "tag": "drug"}, {"start": 162, "end": 170, "tag": "drug"}]}, {"content": "Ergotamine or dihydroergotamine?acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.", "metadata": {"original_id": "DrugDDI.d554.s14"}, "annotations": [{"start": 0, "end": 11, "tag": "drug"}, {"start": 21, "end": 27, "tag": "drug"}]}, {"content": "Cyclosporine, hexobarbital and phenytoin concentrations.", "metadata": {"original_id": "DrugDDI.d554.s15"}, "annotations": [{"start": 0, "end": 13, "tag": "drug"}, {"start": 14, "end": 27, "tag": "drug"}, {"start": 31, "end": 41, "tag": "drug"}]}, {"content": "Laboratory Test Interactions There are no reported laboratory test interactions.", "metadata": {"original_id": "DrugDDI.d554.s16"}, "annotations": []}, {"content": "Repeat Treatment Studies evaluating the use of repeated courses of Zmax have not been conducted.", "metadata": {"original_id": "DrugDDI.d554.s17"}, "annotations": [{"start": 67, "end": 72, "tag": "drug"}]}, {"content": "Isoflurane potentiates the muscle relaxant effect of all muscle relaxants, most notably nondepolarizing muscle relaxants, and MAC (minimum alveolar concentration) is reduced by concomitant administration of N span class= c13 2O.", "metadata": {"original_id": "DrugDDI.d171.s0"}, "annotations": [{"start": 0, "end": 11, "tag": "drug"}, {"start": 27, "end": 43, "tag": "drug"}, {"start": 57, "end": 74, "tag": "drug"}, {"start": 104, "end": 121, "tag": "drug"}]}, {"content": "See CLINICAL PHARMACOLOGY.", "metadata": {"original_id": "DrugDDI.d171.s1"}, "annotations": []}, {"content": "No formal drug/drug interaction studies with Plenaxis? were performed.", "metadata": {"original_id": "DrugDDI.d505.s0"}, "annotations": [{"start": 10, "end": 15, "tag": "drug"}]}, {"content": "Cytochrome P-450 is not known to be involved in the metabolism of Plenaxis?.", "metadata": {"original_id": "DrugDDI.d505.s1"}, "annotations": [{"start": 0, "end": 17, "tag": "drug"}]}, {"content": "Plenaxis? is highly bound to plasma proteins (96 to 99%).", "metadata": {"original_id": "DrugDDI.d505.s2"}, "annotations": [{"start": 29, "end": 45, "tag": "drug"}]}, {"content": "Laboratory Tests Response to Plenaxis? should be monitored by measuring serum total testosterone concentrations just prior to administration on Day 29 and every 8 weeks thereafter.", "metadata": {"original_id": "DrugDDI.d505.s3"}, "annotations": [{"start": 78, "end": 97, "tag": "drug"}]}, {"content": "Serum transaminase levels should be obtained before starting treatment with Plenaxis? and periodically during treatment.", "metadata": {"original_id": "DrugDDI.d505.s4"}, "annotations": [{"start": 6, "end": 19, "tag": "drug"}]}, {"content": "Periodic measurement of serum PSA levels may also be considered.", "metadata": {"original_id": "DrugDDI.d505.s5"}, "annotations": []}, {"content": "Although clinical studies have not established a cause and effect relationship, physicians should be aware that variable effects an blood coagulation have been reported very rarely in patients receiving oral anticoagulants and chlordiazepoxide.", "metadata": {"original_id": "DrugDDI.d125.s0"}, "annotations": [{"start": 203, "end": 223, "tag": "drug"}, {"start": 227, "end": 244, "tag": "drug"}]}, {"content": "The concomitant use of alcohol or other central nervous system depressants may have an additive effect.", "metadata": {"original_id": "DrugDDI.d125.s1"}, "annotations": [{"start": 23, "end": 31, "tag": "drug"}, {"start": 40, "end": 75, "tag": "drug"}]}, {"content": "Drug Interaction with Erythromycin and Ketoconazole Fexofenadine has been shown to exhibit minimal (ca. 5%) metabolism.", "metadata": {"original_id": "DrugDDI.d95.s0"}, "annotations": [{"start": 22, "end": 35, "tag": "drug"}, {"start": 39, "end": 52, "tag": "drug"}]}, {"content": "However, co? administration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine.", "metadata": {"original_id": "DrugDDI.d95.s1"}, "annotations": [{"start": 31, "end": 58, "tag": "drug"}, {"start": 70, "end": 83, "tag": "drug"}, {"start": 86, "end": 99, "tag": "drug"}, {"start": 141, "end": 154, "tag": "drug"}]}, {"content": "Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.", "metadata": {"original_id": "DrugDDI.d95.s2"}, "annotations": [{"start": 0, "end": 13, "tag": "drug"}, {"start": 61, "end": 74, "tag": "drug"}, {"start": 77, "end": 90, "tag": "drug"}]}, {"content": "In 2 separate studies, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was co-administered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy volunteers (n=24, each study).", "metadata": {"original_id": "DrugDDI.d95.s3"}, "annotations": [{"start": 23, "end": 55, "tag": "drug"}, {"start": 127, "end": 147, "tag": "drug"}, {"start": 164, "end": 184, "tag": "drug"}]}, {"content": "No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.", "metadata": {"original_id": "DrugDDI.d95.s4"}, "annotations": [{"start": 95, "end": 122, "tag": "drug"}, {"start": 158, "end": 171, "tag": "drug"}, {"start": 174, "end": 187, "tag": "drug"}]}, {"content": "The findings of these studies are summarized in the following table: Effects on steady-state fexofenadine pharmacokinetics after 7 days of co-administration with fexofenadine hydrochloride 120 mg every 12 hours (two times the recommended twice daily dose) in healthy volunteers (n=24)", "metadata": {"original_id": "DrugDDI.d95.s5"}, "annotations": [{"start": 93, "end": 106, "tag": "drug"}, {"start": 162, "end": 194, "tag": "drug"}]}, {"content": "Concomitant Drug", "metadata": {"original_id": "DrugDDI.d95.s6"}, "annotations": [{"start": 12, "end": 17, "tag": "drug"}]}, {"content": "cmaxSS (Peak plasma concentration)", "metadata": {"original_id": "DrugDDI.d95.s7"}, "annotations": []}, {"content": "AUCss(0-12h) (Extent of systemic exposure)", "metadata": {"original_id": "DrugDDI.d95.s8"}, "annotations": []}, {"content": "Erythromycin (500 mg every 8 hrs)", "metadata": {"original_id": "DrugDDI.d95.s9"}, "annotations": [{"start": 0, "end": 13, "tag": "drug"}]}, {"content": "+82%", "metadata": {"original_id": "DrugDDI.d95.s10"}, "annotations": []}, {"content": "+109%", "metadata": {"original_id": "DrugDDI.d95.s11"}, "annotations": []}, {"content": "Ketoconazole (400 mg once daily)", "metadata": {"original_id": "DrugDDI.d95.s12"}, "annotations": [{"start": 0, "end": 13, "tag": "drug"}]}, {"content": "+135%", "metadata": {"original_id": "DrugDDI.d95.s13"}, "annotations": []}, {"content": "+164%", "metadata": {"original_id": "DrugDDI.d95.s14"}, "annotations": []}, {"content": "The changes in plasma levels were within the range of plasma levels achieved in adequate and well-controlled clinical trials.", "metadata": {"original_id": "DrugDDI.d95.s15"}, "annotations": []}, {"content": "The mechanism of these interactions has been evaluated in in vitro, in situ, and in vivo animal models.", "metadata": {"original_id": "DrugDDI.d95.s16"}, "annotations": []}, {"content": "These studies indicate that ketoconazole or erythromycin co-administration enhances fexofenadine gastrointestinal absorption.", "metadata": {"original_id": "DrugDDI.d95.s17"}, "annotations": [{"start": 28, "end": 41, "tag": "drug"}, {"start": 44, "end": 57, "tag": "drug"}, {"start": 84, "end": 97, "tag": "drug"}]}, {"content": "This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein. in vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.", "metadata": {"original_id": "DrugDDI.d95.s18"}, "annotations": [{"start": 49, "end": 62, "tag": "drug"}, {"start": 113, "end": 126, "tag": "drug"}, {"start": 205, "end": 218, "tag": "drug"}, {"start": 228, "end": 241, "tag": "drug"}, {"start": 275, "end": 288, "tag": "drug"}]}, {"content": "Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox?) decreased fexofenadine AUC by 41% and cmax by 43%.", "metadata": {"original_id": "DrugDDI.d95.s19"}, "annotations": [{"start": 23, "end": 32, "tag": "drug"}, {"start": 60, "end": 87, "tag": "drug"}, {"start": 144, "end": 174, "tag": "drug"}, {"start": 193, "end": 206, "tag": "drug"}]}, {"content": "ALLEGRA should not be taken closely in time with aluminum and magnesium containing antacids.", "metadata": {"original_id": "DrugDDI.d95.s20"}, "annotations": [{"start": 0, "end": 8, "tag": "drug"}, {"start": 62, "end": 92, "tag": "drug"}]}, {"content": "Interactions with Fruit Juices Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.", "metadata": {"original_id": "DrugDDI.d95.s21"}, "annotations": [{"start": 52, "end": 63, "tag": "drug"}, {"start": 128, "end": 141, "tag": "drug"}]}, {"content": "This is based on the results from 3 clinical studies using histamine induced skin wheals and flares coupled with population pharmacokinetic analysis.", "metadata": {"original_id": "DrugDDI.d95.s22"}, "annotations": []}, {"content": "The size of wheal and flare were significantly larger when fexofenadine hydrochloride was administered with either grapefruit or orange juices compared to water.", "metadata": {"original_id": "DrugDDI.d95.s23"}, "annotations": [{"start": 59, "end": 86, "tag": "drug"}, {"start": 115, "end": 126, "tag": "drug"}, {"start": 155, "end": 161, "tag": "drug"}]}, {"content": "Based on the literature reports, the same effects may be extrapolated to other fruit juices such as apple juice.", "metadata": {"original_id": "DrugDDI.d95.s24"}, "annotations": []}, {"content": "The clinical significance of these observations is unknown.", "metadata": {"original_id": "DrugDDI.d95.s25"}, "annotations": []}, {"content": "In addition, based on the population pharmacokinetics analysis of the combined data from grapefruit and orange juices studies with the data from a bioequivalence study, the bioavailability of fexofenadine was reduced by 36%.", "metadata": {"original_id": "DrugDDI.d95.s26"}, "annotations": [{"start": 89, "end": 100, "tag": "drug"}, {"start": 192, "end": 205, "tag": "drug"}]}, {"content": "Therefore, to maximize the effects of fexofenadine, it is recommended that ALLEGRA should be taken with water", "metadata": {"original_id": "DrugDDI.d95.s27"}, "annotations": [{"start": 38, "end": 51, "tag": "drug"}, {"start": 75, "end": 83, "tag": "drug"}, {"start": 104, "end": 110, "tag": "drug"}]}, {"content": ".", "metadata": {"original_id": "DrugDDI.d95.s28"}, "annotations": []}, {"content": "?", "metadata": {"original_id": "DrugDDI.d95.s29"}, "annotations": []}, {"content": "Amantadine, tricyclic antidepressants, and MAOIs may increase anticholinergic effect of clidinium.", "metadata": {"original_id": "DrugDDI.d425.s0"}, "annotations": [{"start": 0, "end": 11, "tag": "drug"}, {"start": 12, "end": 38, "tag": "drug"}, {"start": 62, "end": 78, "tag": "drug"}, {"start": 88, "end": 98, "tag": "drug"}]}, {"content": "Clidinium may decrease the effect of phenothiazines, levodopa, and ketoconazole.", "metadata": {"original_id": "DrugDDI.d425.s1"}, "annotations": [{"start": 0, "end": 10, "tag": "drug"}, {"start": 37, "end": 52, "tag": "drug"}, {"start": 53, "end": 62, "tag": "drug"}, {"start": 67, "end": 80, "tag": "drug"}]}, {"content": "Cholestyramine and Charcoal Administration of cholestyramine or activated charcoal in patients (n=13) and volunteers (n=96) resulted in a rapid and significant decrease in plasma M1 (the active metabolite of leflunomide) concentration .", "metadata": {"original_id": "DrugDDI.d581.s0"}, "annotations": [{"start": 0, "end": 15, "tag": "drug"}, {"start": 19, "end": 28, "tag": "drug"}, {"start": 46, "end": 61, "tag": "drug"}, {"start": 64, "end": 83, "tag": "drug"}, {"start": 187, "end": 205, "tag": "drug"}, {"start": 208, "end": 220, "tag": "drug"}]}, {"content": "Hepatotoxic Drugs Increased side effects may occur when leflunomide is given concomitantly with hepatotoxic substances.", "metadata": {"original_id": "DrugDDI.d581.s1"}, "annotations": [{"start": 12, "end": 18, "tag": "drug"}, {"start": 56, "end": 68, "tag": "drug"}]}, {"content": "This is also to be considered when leflunomide treatment is followed by such drugs without a drug elimination procedure.", "metadata": {"original_id": "DrugDDI.d581.s2"}, "annotations": [{"start": 35, "end": 47, "tag": "drug"}, {"start": 77, "end": 83, "tag": "drug"}]}, {"content": "In a small (n=30) combination study of ARAVA with methotrexate, a 2- to 3-fold elevation in liver enzymes was seen in 5 of 30 patients.", "metadata": {"original_id": "DrugDDI.d581.s3"}, "annotations": [{"start": 39, "end": 45, "tag": "drug"}, {"start": 50, "end": 63, "tag": "drug"}, {"start": 92, "end": 106, "tag": "drug"}]}, {"content": "All elevations resolved, 2 with continuation of both drugs and 3 after discontinuation of leflunomide.", "metadata": {"original_id": "DrugDDI.d581.s4"}, "annotations": [{"start": 53, "end": 59, "tag": "drug"}, {"start": 90, "end": 102, "tag": "drug"}]}, {"content": "A  3-fold increase was seen in another 5 patients.", "metadata": {"original_id": "DrugDDI.d581.s5"}, "annotations": []}, {"content": "All of these also resolved, 2 with continuation of both drugs and 3 after discontinuation of leflunomide.", "metadata": {"original_id": "DrugDDI.d581.s6"}, "annotations": [{"start": 56, "end": 62, "tag": "drug"}, {"start": 93, "end": 105, "tag": "drug"}]}, {"content": "Three patients met ACR criteria for liver biopsy (1: Roegnik Grade I, 2: Roegnik Grade IIIa).", "metadata": {"original_id": "DrugDDI.d581.s7"}, "annotations": [{"start": 15, "end": 19, "tag": "drug"}]}, {"content": "No pharmacokinetic interaction was identified.", "metadata": {"original_id": "DrugDDI.d581.s8"}, "annotations": []}, {"content": "NSAIDs In in vitro studies, M1 was shown to cause increases ranging from 13 - 50% in the free fraction of diclofenac and ibuprofen at concentrations in the clinical range.", "metadata": {"original_id": "DrugDDI.d581.s9"}, "annotations": [{"start": 0, "end": 7, "tag": "drug"}, {"start": 106, "end": 117, "tag": "drug"}, {"start": 121, "end": 131, "tag": "drug"}]}, {"content": "The clinical significance of this finding is unknown;", "metadata": {"original_id": "DrugDDI.d581.s10"}, "annotations": []}, {"content": "however, there was extensive concomitant use of NSAIDs in clinical studies and no differential effect was observed.", "metadata": {"original_id": "DrugDDI.d581.s11"}, "annotations": [{"start": 48, "end": 55, "tag": "drug"}]}, {"content": "Tolbutamide In in vitro studies, M1 was shown to cause increases ranging from 13 - 50% in the free fraction of tolbutamide at concentrations in the clinical range.", "metadata": {"original_id": "DrugDDI.d581.s12"}, "annotations": [{"start": 0, "end": 12, "tag": "drug"}, {"start": 111, "end": 123, "tag": "drug"}]}, {"content": "The clinical significance of this finding is unknown.", "metadata": {"original_id": "DrugDDI.d581.s13"}, "annotations": []}, {"content": "Rifampin Following concomitant administration of a single dose of ARAVA to subjects receiving multiple doses of rifampin, M1 peak levels were increased (~40%) over those seen when ARAVA was given alone.", "metadata": {"original_id": "DrugDDI.d581.s14"}, "annotations": [{"start": 0, "end": 9, "tag": "drug"}, {"start": 66, "end": 72, "tag": "drug"}, {"start": 112, "end": 121, "tag": "drug"}, {"start": 180, "end": 186, "tag": "drug"}]}, {"content": "Because of the potential for ARAVA levels to continue to increase with multiple dosing, caution should be used if patients are to be receiving both ARAVA and rifampin.", "metadata": {"original_id": "DrugDDI.d581.s15"}, "annotations": [{"start": 29, "end": 35, "tag": "drug"}, {"start": 148, "end": 154, "tag": "drug"}, {"start": 158, "end": 167, "tag": "drug"}]}, {"content": "Warfarin Increased INR (International Normalized Ratio) when ARAVA and warfarin were co-administered has been rarely reported.", "metadata": {"original_id": "DrugDDI.d581.s16"}, "annotations": [{"start": 0, "end": 9, "tag": "drug"}, {"start": 61, "end": 67, "tag": "drug"}, {"start": 71, "end": 80, "tag": "drug"}]}, {"content": "CNS depression?producing medications - concurrent use may potentiate the effects of either these medications or diphenidol;", "metadata": {"original_id": "DrugDDI.d189.s0"}, "annotations": [{"start": 97, "end": 109, "tag": "drug"}, {"start": 112, "end": 123, "tag": "drug"}]}, {"content": "anticholinergics or other medications with anticholinergic activity - anticholinergic effects may be potentiated when these medications are used concurrently with diphenidol;", "metadata": {"original_id": "DrugDDI.d189.s1"}, "annotations": [{"start": 0, "end": 17, "tag": "drug"}, {"start": 20, "end": 38, "tag": "drug"}, {"start": 43, "end": 59, "tag": "drug"}, {"start": 124, "end": 136, "tag": "drug"}, {"start": 163, "end": 175, "tag": "drug"}]}, {"content": "apomorphine - prior ingestion of diphenidol may decrease the emetic response to apomorphine in the treatment of poisoning.", "metadata": {"original_id": "DrugDDI.d189.s2"}, "annotations": [{"start": 0, "end": 12, "tag": "drug"}, {"start": 33, "end": 45, "tag": "drug"}, {"start": 61, "end": 68, "tag": "drug"}, {"start": 80, "end": 92, "tag": "drug"}]}, {"content": "No specific drug interaction studies have been conducted.", "metadata": {"original_id": "DrugDDI.d147.s0"}, "annotations": []}, {"content": "For information on the pharmacokinetics of Gemzar and cisplatin in combination, see Drug Interactions under CLINICAL PHARMACOLOGY section.", "metadata": {"original_id": "DrugDDI.d147.s1"}, "annotations": [{"start": 43, "end": 50, "tag": "drug"}, {"start": 54, "end": 64, "tag": "drug"}]}, {"content": "Administration of doxapram to patients who are receiving sympathomimetic or monoamine oxidase inhibiting drugs may result in an additive pressor effect .", "metadata": {"original_id": "DrugDDI.d55.s0"}, "annotations": [{"start": 18, "end": 27, "tag": "drug"}, {"start": 57, "end": 73, "tag": "drug"}, {"start": 76, "end": 94, "tag": "drug"}, {"start": 128, "end": 152, "tag": "drug"}]}, {"content": "In patients who have received muscle relaxants, doxapram may temporarily mask the residual effects of muscle relaxant drugs.", "metadata": {"original_id": "DrugDDI.d55.s1"}, "annotations": [{"start": 30, "end": 47, "tag": "drug"}, {"start": 48, "end": 57, "tag": "drug"}, {"start": 118, "end": 124, "tag": "drug"}]}, {"content": "In patients who have received general anesthesia utilizing a volatile agent known to sensitize the myocardium to catecholamines, administration of doxapram should be delayed until the volatile agent has been excreted in order to lessen the potential for arrhythmias, including ventricular tachycardia and ventricular fibrillation.", "metadata": {"original_id": "DrugDDI.d55.s2"}, "annotations": [{"start": 147, "end": 156, "tag": "drug"}]}, {"content": "Diuretics: Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium.", "metadata": {"original_id": "DrugDDI.d561.s0"}, "annotations": [{"start": 0, "end": 10, "tag": "drug"}, {"start": 23, "end": 33, "tag": "drug"}, {"start": 190, "end": 208, "tag": "drug"}]}, {"content": "The possibility of hypotensive effects can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium.", "metadata": {"original_id": "DrugDDI.d561.s1"}, "annotations": [{"start": 84, "end": 93, "tag": "drug"}, {"start": 157, "end": 175, "tag": "drug"}]}, {"content": "If this is not possible, the starting dose should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION.)", "metadata": {"original_id": "DrugDDI.d561.s2"}, "annotations": []}, {"content": "Potassium Supplements and Potassium-Sparing Diuretics: Fosinopril sodium can attenuate potassium loss caused by thiazide diuretics.", "metadata": {"original_id": "DrugDDI.d561.s3"}, "annotations": [{"start": 0, "end": 21, "tag": "drug"}, {"start": 26, "end": 54, "tag": "drug"}, {"start": 55, "end": 73, "tag": "drug"}, {"start": 87, "end": 97, "tag": "drug"}, {"start": 112, "end": 131, "tag": "drug"}]}, {"content": "Potassium-sparing diuretics (spironolactone, amiloride,triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.", "metadata": {"original_id": "DrugDDI.d561.s4"}, "annotations": [{"start": 0, "end": 28, "tag": "drug"}, {"start": 29, "end": 44, "tag": "drug"}, {"start": 45, "end": 55, "tag": "drug"}, {"start": 55, "end": 67, "tag": "drug"}, {"start": 83, "end": 104, "tag": "drug"}]}, {"content": "Therefore, if concomitant use of such agents is indicated, they should be given with caution, and the patients serum potassium should be monitored frequently.", "metadata": {"original_id": "DrugDDI.d561.s5"}, "annotations": []}, {"content": "Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.", "metadata": {"original_id": "DrugDDI.d561.s6"}, "annotations": [{"start": 0, "end": 8, "tag": "drug"}, {"start": 114, "end": 129, "tag": "drug"}, {"start": 149, "end": 157, "tag": "drug"}]}, {"content": "These drugs should be coadministered with caution, and frequent monitoring of serum lithium levels is recommended.", "metadata": {"original_id": "DrugDDI.d561.s7"}, "annotations": [{"start": 6, "end": 12, "tag": "drug"}]}, {"content": "If a diuretic is also used, the risk of lithium toxicity may be increased.", "metadata": {"original_id": "DrugDDI.d561.s8"}, "annotations": [{"start": 5, "end": 14, "tag": "drug"}]}, {"content": "Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.", "metadata": {"original_id": "DrugDDI.d561.s9"}, "annotations": [{"start": 0, "end": 9, "tag": "drug"}, {"start": 67, "end": 75, "tag": "drug"}, {"start": 76, "end": 96, "tag": "drug"}, {"start": 96, "end": 116, "tag": "drug"}, {"start": 121, "end": 133, "tag": "drug"}, {"start": 139, "end": 150, "tag": "drug"}, {"start": 196, "end": 209, "tag": "drug"}, {"start": 226, "end": 237, "tag": "drug"}, {"start": 273, "end": 282, "tag": "drug"}, {"start": 307, "end": 318, "tag": "drug"}]}, {"content": "Therefore, if concomitant administration of these agents is indicated, dosing should be separated by 2 hours.", "metadata": {"original_id": "DrugDDI.d561.s10"}, "annotations": []}, {"content": "Other: Neither fosinopril sodium nor its metabolites have been found to interact with food.", "metadata": {"original_id": "DrugDDI.d561.s11"}, "annotations": [{"start": 15, "end": 33, "tag": "drug"}, {"start": 41, "end": 53, "tag": "drug"}]}, {"content": "In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.", "metadata": {"original_id": "DrugDDI.d561.s12"}, "annotations": [{"start": 77, "end": 93, "tag": "drug"}, {"start": 93, "end": 104, "tag": "drug"}, {"start": 105, "end": 116, "tag": "drug"}, {"start": 117, "end": 137, "tag": "drug"}, {"start": 138, "end": 149, "tag": "drug"}, {"start": 150, "end": 165, "tag": "drug"}, {"start": 166, "end": 180, "tag": "drug"}, {"start": 181, "end": 189, "tag": "drug"}, {"start": 194, "end": 203, "tag": "drug"}, {"start": 227, "end": 240, "tag": "drug"}, {"start": 279, "end": 290, "tag": "drug"}, {"start": 312, "end": 318, "tag": "drug"}]}, {"content": "In a study with concomitant administration of aspirin and fosinopril sodium, the bioavailability of unbound fosinoprilat was not altered.", "metadata": {"original_id": "DrugDDI.d561.s13"}, "annotations": [{"start": 46, "end": 54, "tag": "drug"}, {"start": 58, "end": 76, "tag": "drug"}, {"start": 108, "end": 121, "tag": "drug"}]}, {"content": "In a pharmacokinetic interaction study with warfarin, bioavailability parameters, the degree of protein binding, and the anticoagulant effect (measured by prothrombin time) of warfarin were not significantly changed.", "metadata": {"original_id": "DrugDDI.d561.s14"}, "annotations": [{"start": 44, "end": 53, "tag": "drug"}, {"start": 176, "end": 185, "tag": "drug"}]}, {"content": "Drug/Laboratory Test Interaction Fosinopril may cause a false low measurement of serum digoxin levels with the Digi- Tab? RIA Kit for Digoxin.", "metadata": {"original_id": "DrugDDI.d561.s15"}, "annotations": [{"start": 0, "end": 5, "tag": "drug"}, {"start": 33, "end": 44, "tag": "drug"}, {"start": 134, "end": 142, "tag": "drug"}]}, {"content": "Other kits, such as the Coat-A-Count? RIA Kit, may be used.", "metadata": {"original_id": "DrugDDI.d561.s16"}, "annotations": []}, {"content": "Increased nephrotoxicity has been reported following concomitant administration of cephalosporins and aminoglycoside antibiotics.", "metadata": {"original_id": "DrugDDI.d373.s0"}, "annotations": [{"start": 83, "end": 98, "tag": "drug"}, {"start": 102, "end": 129, "tag": "drug"}]}, {"content": "Drug/Laboratory Test Interactions As with cephalothin, high concentrations of cefoxitin ( 100 micrograms/mL) may interfere with measurement of serum and urine creatinine levels by the Jaff? reaction, and produce false increases of modest degree in the levels of creatinine reported.", "metadata": {"original_id": "DrugDDI.d373.s1"}, "annotations": [{"start": 0, "end": 5, "tag": "drug"}, {"start": 42, "end": 54, "tag": "drug"}, {"start": 78, "end": 88, "tag": "drug"}, {"start": 262, "end": 273, "tag": "drug"}]}, {"content": "Serum samples from patients treated with cefoxitin should not be analyzed for creatinine if withdrawn within 2 hours of drug administration.", "metadata": {"original_id": "DrugDDI.d373.s2"}, "annotations": [{"start": 41, "end": 51, "tag": "drug"}, {"start": 78, "end": 89, "tag": "drug"}]}, {"content": "High concentrations of cefoxitin in the urine may interfere with measurement of urinary 17-hydroxy-corticosteroids by the Porter-Silber reaction, and produce false increases of modest degree in the levels reported.", "metadata": {"original_id": "DrugDDI.d373.s3"}, "annotations": [{"start": 23, "end": 33, "tag": "drug"}, {"start": 99, "end": 115, "tag": "drug"}]}, {"content": "A false-positive reaction for glucose in the urine may occur.", "metadata": {"original_id": "DrugDDI.d373.s4"}, "annotations": [{"start": 30, "end": 38, "tag": "drug"}]}, {"content": "This has been observed with CLINITEST? reagent tablets", "metadata": {"original_id": "DrugDDI.d373.s5"}, "annotations": []}, {"content": ".", "metadata": {"original_id": "DrugDDI.d373.s6"}, "annotations": []}, {"content": "? Registered trademark of Ames Company, Division of Miles Laboratories, Inc.", "metadata": {"original_id": "DrugDDI.d373.s7"}, "annotations": [{"start": 26, "end": 30, "tag": "drug"}]}, {"content": "Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, vancomycin.", "metadata": {"original_id": "DrugDDI.d409.s0"}, "annotations": [{"start": 18, "end": 30, "tag": "drug"}, {"start": 138, "end": 154, "tag": "drug"}, {"start": 161, "end": 172, "tag": "drug"}, {"start": 173, "end": 182, "tag": "drug"}, {"start": 184, "end": 199, "tag": "drug"}, {"start": 200, "end": 213, "tag": "drug"}, {"start": 214, "end": 252, "tag": "drug"}, {"start": 259, "end": 269, "tag": "drug"}, {"start": 271, "end": 282, "tag": "drug"}, {"start": 283, "end": 294, "tag": "drug"}]}, {"content": "Do not start or stop any medicine without doctor or pharmacist approval.", "metadata": {"original_id": "DrugDDI.d409.s1"}, "annotations": [{"start": 25, "end": 34, "tag": "drug"}]}, {"content": "DIAMOX modifies phenytoin metabolism with increased serum levels of phenytoin.", "metadata": {"original_id": "DrugDDI.d452.s0"}, "annotations": [{"start": 0, "end": 7, "tag": "drug"}, {"start": 16, "end": 26, "tag": "drug"}, {"start": 68, "end": 78, "tag": "drug"}]}, {"content": "This may increase or enhance the occurrence of osteomalacia in some patients receiving chronic phenytoin therapy.", "metadata": {"original_id": "DrugDDI.d452.s1"}, "annotations": [{"start": 95, "end": 105, "tag": "drug"}]}, {"content": "Caution is advised in patients receiving chronic concomitant therapy.", "metadata": {"original_id": "DrugDDI.d452.s2"}, "annotations": []}, {"content": "By decreasing the gastrointestinal absorption of primidone, DIAMOX may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect.", "metadata": {"original_id": "DrugDDI.d452.s3"}, "annotations": [{"start": 49, "end": 59, "tag": "drug"}, {"start": 60, "end": 67, "tag": "drug"}, {"start": 104, "end": 114, "tag": "drug"}, {"start": 122, "end": 134, "tag": "drug"}, {"start": 174, "end": 189, "tag": "drug"}]}, {"content": "Caution is advised when beginning, discontinuing, or changing the dose of DIAMOX in patients receiving primidone.", "metadata": {"original_id": "DrugDDI.d452.s4"}, "annotations": [{"start": 74, "end": 81, "tag": "drug"}, {"start": 103, "end": 113, "tag": "drug"}]}, {"content": "Because of possible additive effects with other carbonic anhydrase inhibitors, concomitant use is not advisable.", "metadata": {"original_id": "DrugDDI.d452.s5"}, "annotations": [{"start": 48, "end": 78, "tag": "drug"}]}, {"content": "Acetazolamide may increase the effects of other folic acid antagonists.", "metadata": {"original_id": "DrugDDI.d452.s6"}, "annotations": [{"start": 0, "end": 14, "tag": "drug"}, {"start": 48, "end": 71, "tag": "drug"}]}, {"content": "Acetazolamide may increase or decrease blood glucose levels.", "metadata": {"original_id": "DrugDDI.d452.s7"}, "annotations": [{"start": 0, "end": 14, "tag": "drug"}]}, {"content": "Consideration should be taken in patients being treated with antidiabetic agents.", "metadata": {"original_id": "DrugDDI.d452.s8"}, "annotations": [{"start": 61, "end": 81, "tag": "drug"}]}, {"content": "Acetazolamide decreases urinary excretion of amphetamine and may enhance the magnitude and duration of their effect.", "metadata": {"original_id": "DrugDDI.d452.s9"}, "annotations": [{"start": 0, "end": 14, "tag": "drug"}, {"start": 45, "end": 58, "tag": "drug"}]}, {"content": "Acetazolamide reduces urinary excretion of quinidine and may enhance its effect.", "metadata": {"original_id": "DrugDDI.d452.s10"}, "annotations": [{"start": 0, "end": 14, "tag": "drug"}, {"start": 43, "end": 53, "tag": "drug"}]}, {"content": "Acetazolamide may prevent the urinary antiseptic effect of methenamine.", "metadata": {"original_id": "DrugDDI.d452.s11"}, "annotations": [{"start": 0, "end": 14, "tag": "drug"}, {"start": 18, "end": 26, "tag": "drug"}, {"start": 38, "end": 49, "tag": "drug"}, {"start": 59, "end": 71, "tag": "drug"}]}, {"content": "Acetazolamide increases lithium excretion and the lithium may be decreased.", "metadata": {"original_id": "DrugDDI.d452.s12"}, "annotations": [{"start": 0, "end": 14, "tag": "drug"}, {"start": 24, "end": 32, "tag": "drug"}, {"start": 50, "end": 58, "tag": "drug"}]}, {"content": "Acetazolamide and sodium bicarbonate used concurrently increases the risk of renal calculus formation.", "metadata": {"original_id": "DrugDDI.d452.s13"}, "annotations": [{"start": 0, "end": 14, "tag": "drug"}, {"start": 18, "end": 37, "tag": "drug"}]}, {"content": "Acetazolamide may elevate cyclosporine levels.", "metadata": {"original_id": "DrugDDI.d452.s14"}, "annotations": [{"start": 0, "end": 14, "tag": "drug"}, {"start": 26, "end": 39, "tag": "drug"}]}, {"content": "The vasodilating effects of isosorbide dinitrate may be additive with those of other vasodilators.", "metadata": {"original_id": "DrugDDI.d250.s0"}, "annotations": [{"start": 28, "end": 49, "tag": "drug"}, {"start": 85, "end": 98, "tag": "drug"}]}, {"content": "Alcohol, in particular, has been found to exhibit additive effects of this variety.", "metadata": {"original_id": "DrugDDI.d250.s1"}, "annotations": [{"start": 0, "end": 8, "tag": "drug"}]}, {"content": "Drug interaction studies with decitabine have not been conducted.", "metadata": {"original_id": "DrugDDI.d157.s0"}, "annotations": [{"start": 30, "end": 41, "tag": "drug"}]}, {"content": "In vitro studies in human liver microsomes suggest that decitabine is unlikely to inhibit or induce cytochrome P450 enzymes.", "metadata": {"original_id": "DrugDDI.d157.s1"}, "annotations": [{"start": 56, "end": 67, "tag": "drug"}, {"start": 100, "end": 116, "tag": "drug"}]}, {"content": "In vitro metabolism studies have suggested that decitabine is not a substrate for the human liver cytochrome P450 enzymes.", "metadata": {"original_id": "DrugDDI.d157.s2"}, "annotations": [{"start": 48, "end": 59, "tag": "drug"}, {"start": 98, "end": 121, "tag": "drug"}]}, {"content": "As plasma protein binding of decitabine is negligible ( 1%), interactions due to displacement of more highly protein bound drugs from plasma proteins are not expected.", "metadata": {"original_id": "DrugDDI.d157.s3"}, "annotations": [{"start": 3, "end": 18, "tag": "drug"}, {"start": 29, "end": 40, "tag": "drug"}, {"start": 134, "end": 150, "tag": "drug"}]}, {"content": "Drug Interaction During Pregnancy: Cromolyn sodium and isoproterenol were studied following subcutaneous injections in pregnant mice.", "metadata": {"original_id": "DrugDDI.d25.s0"}, "annotations": [{"start": 35, "end": 51, "tag": "drug"}, {"start": 55, "end": 69, "tag": "drug"}]}, {"content": "Cromolyn sodium alone in doses up to 540 mg/kg/day (approximately 340 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis) did not cause significant increases in resorptions or major malformations.", "metadata": {"original_id": "DrugDDI.d25.s1"}, "annotations": [{"start": 0, "end": 16, "tag": "drug"}]}, {"content": "Isoproterenol alone at a dose of 2.7 mg/kg/day (approximately 7 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis) increased both resorptions and malformations.", "metadata": {"original_id": "DrugDDI.d25.s2"}, "annotations": [{"start": 0, "end": 14, "tag": "drug"}]}, {"content": "The addition of 540 mg/kg/day of cromolyn sodium (approximately 340 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis) to 2.7 mg/kg/day of isoproterenol (approximately 7 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis) appears to have increased the incidence of both resorptions and malformations.", "metadata": {"original_id": "DrugDDI.d25.s3"}, "annotations": [{"start": 33, "end": 49, "tag": "drug"}, {"start": 168, "end": 182, "tag": "drug"}]}, {"content": "Iodine or iodine excess may decrease the effect of Carbimazole, and an iodine deficiency can increase the effect of Carbimazole.", "metadata": {"original_id": "DrugDDI.d156.s0"}, "annotations": [{"start": 0, "end": 7, "tag": "drug"}, {"start": 10, "end": 17, "tag": "drug"}, {"start": 51, "end": 63, "tag": "drug"}, {"start": 116, "end": 128, "tag": "drug"}]}, {"content": "Serum concentration of digoxin and digitoxin may increase when patients take antithyroid agents.", "metadata": {"original_id": "DrugDDI.d156.s1"}, "annotations": [{"start": 23, "end": 31, "tag": "drug"}, {"start": 35, "end": 45, "tag": "drug"}, {"start": 77, "end": 96, "tag": "drug"}]}, {"content": "A decrease of the dosage may be necessary when patient becomes euthyroid.", "metadata": {"original_id": "DrugDDI.d156.s2"}, "annotations": []}, {"content": "Antithyroid agents may decrease thyroidal uptake of sodium iodide I131, a rebound in uptake may occur up to 5 days after sudden withdrawal of Carbimazole.", "metadata": {"original_id": "DrugDDI.d156.s3"}, "annotations": [{"start": 0, "end": 19, "tag": "drug"}, {"start": 32, "end": 40, "tag": "drug"}, {"start": 52, "end": 71, "tag": "drug"}, {"start": 142, "end": 154, "tag": "drug"}]}, {"content": "Patients response to oral anticoagulants may be affected by his/her thyroid and metabolic status.", "metadata": {"original_id": "DrugDDI.d156.s4"}, "annotations": [{"start": 21, "end": 41, "tag": "drug"}, {"start": 68, "end": 76, "tag": "drug"}]}, {"content": "An evaluation of prothrombin time and an adjustment of anticoagulant dosage are recommended", "metadata": {"original_id": "DrugDDI.d156.s5"}, "annotations": [{"start": 55, "end": 69, "tag": "drug"}]}, {"content": "No specific information available", "metadata": {"original_id": "DrugDDI.d126.s0"}, "annotations": []}, {"content": ".", "metadata": {"original_id": "DrugDDI.d126.s1"}, "annotations": []}, {"content": "?", "metadata": {"original_id": "DrugDDI.d126.s2"}, "annotations": []}, {"content": "DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthines, or metoclopramide.", "metadata": {"original_id": "DrugDDI.d218.s0"}, "annotations": [{"start": 0, "end": 9, "tag": "drug"}, {"start": 78, "end": 93, "tag": "drug"}, {"start": 94, "end": 109, "tag": "drug"}, {"start": 128, "end": 143, "tag": "drug"}]}, {"content": "Alcohol (increases bioavailability by 50%), cimetidine, and valproates.", "metadata": {"original_id": "DrugDDI.d119.s0"}, "annotations": [{"start": 0, "end": 8, "tag": "drug"}, {"start": 44, "end": 55, "tag": "drug"}]}, {"content": "No drug interaction studies have been performed.", "metadata": {"original_id": "DrugDDI.d220.s0"}, "annotations": []}, {"content": "Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;", "metadata": {"original_id": "DrugDDI.d113.s0"}, "annotations": [{"start": 38, "end": 49, "tag": "drug"}, {"start": 50, "end": 61, "tag": "drug"}, {"start": 62, "end": 73, "tag": "drug"}, {"start": 78, "end": 88, "tag": "drug"}, {"start": 90, "end": 105, "tag": "drug"}, {"start": 106, "end": 121, "tag": "drug"}]}, {"content": "as such it may impair intestinal absorption of any of vitamin D.", "metadata": {"original_id": "DrugDDI.d113.s1"}, "annotations": [{"start": 54, "end": 64, "tag": "drug"}]}, {"content": "Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.", "metadata": {"original_id": "DrugDDI.d113.s2"}, "annotations": [{"start": 0, "end": 10, "tag": "drug"}, {"start": 10, "end": 24, "tag": "drug"}, {"start": 49, "end": 59, "tag": "drug"}, {"start": 62, "end": 76, "tag": "drug"}, {"start": 117, "end": 127, "tag": "drug"}, {"start": 171, "end": 182, "tag": "drug"}]}, {"content": "Since blood level of calcitriol/ergocalcitriol will be reduced, higher doses of Rocaltrol may be necessary if these drugs are administered simultaneously.", "metadata": {"original_id": "DrugDDI.d113.s3"}, "annotations": [{"start": 21, "end": 32, "tag": "drug"}, {"start": 80, "end": 90, "tag": "drug"}, {"start": 116, "end": 122, "tag": "drug"}]}, {"content": "Thiazides: Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine.", "metadata": {"original_id": "DrugDDI.d113.s4"}, "annotations": [{"start": 0, "end": 10, "tag": "drug"}, {"start": 11, "end": 21, "tag": "drug"}, {"start": 75, "end": 83, "tag": "drug"}]}, {"content": "Some reports have shown that the concomitant administration of thiazides with vitamin D causes hypercalcemia.", "metadata": {"original_id": "DrugDDI.d113.s5"}, "annotations": [{"start": 63, "end": 73, "tag": "drug"}, {"start": 78, "end": 88, "tag": "drug"}]}, {"content": "Therefore, precaution should be taken when coadministration is necessary.", "metadata": {"original_id": "DrugDDI.d113.s6"}, "annotations": []}, {"content": "Digitalis: Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias.", "metadata": {"original_id": "DrugDDI.d113.s7"}, "annotations": [{"start": 0, "end": 10, "tag": "drug"}, {"start": 11, "end": 21, "tag": "drug"}, {"start": 95, "end": 105, "tag": "drug"}]}, {"content": "Ketoconazole: Ketoconazole may inhibit both synthetic and catabolic enzymes of vitamin D.", "metadata": {"original_id": "DrugDDI.d113.s8"}, "annotations": [{"start": 0, "end": 13, "tag": "drug"}, {"start": 14, "end": 27, "tag": "drug"}, {"start": 79, "end": 89, "tag": "drug"}]}, {"content": "Reductions in serum endogenous vitamin D concentrations have been observed following the administration of 300 mg/day to 1200 mg/day ketoconazole for a week to healthy men.", "metadata": {"original_id": "DrugDDI.d113.s9"}, "annotations": [{"start": 133, "end": 146, "tag": "drug"}]}, {"content": "However, in vivo drug interaction studies of ketoconazole with vitamin D have not been investigated.", "metadata": {"original_id": "DrugDDI.d113.s10"}, "annotations": [{"start": 45, "end": 58, "tag": "drug"}, {"start": 63, "end": 73, "tag": "drug"}]}, {"content": "Corticosteroids: A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption.", "metadata": {"original_id": "DrugDDI.d113.s11"}, "annotations": [{"start": 0, "end": 16, "tag": "drug"}, {"start": 107, "end": 115, "tag": "drug"}, {"start": 131, "end": 147, "tag": "drug"}, {"start": 162, "end": 170, "tag": "drug"}]}, {"content": "Phosphate-Binding Agents: Since vitamin D also has an effect on phosphate transport in the intestine, kidneys and bones, the dosage of phosphate-binding agents must be adjusted in accordance with the serum phosphate concentration.", "metadata": {"original_id": "DrugDDI.d113.s12"}, "annotations": [{"start": 0, "end": 25, "tag": "drug"}, {"start": 32, "end": 42, "tag": "drug"}, {"start": 135, "end": 160, "tag": "drug"}]}, {"content": "Vitamin D: The coadministration of any of the vitamin D analogues should be avoided as this could create possible additive effects and hypercalcemia.", "metadata": {"original_id": "DrugDDI.d113.s13"}, "annotations": [{"start": 0, "end": 10, "tag": "drug"}]}, {"content": "Calcium Supplements: Uncontrolled intake of additional calcium-containing preparations should be avoided.", "metadata": {"original_id": "DrugDDI.d113.s14"}, "annotations": [{"start": 0, "end": 8, "tag": "drug"}, {"start": 55, "end": 87, "tag": "drug"}]}, {"content": "Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.", "metadata": {"original_id": "DrugDDI.d113.s15"}, "annotations": [{"start": 0, "end": 10, "tag": "drug"}, {"start": 11, "end": 45, "tag": "drug"}, {"start": 50, "end": 59, "tag": "drug"}, {"start": 140, "end": 150, "tag": "drug"}]}, {"content": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "metadata": {"original_id": "DrugDDI.d570.s0"}, "annotations": [{"start": 22, "end": 39, "tag": "drug"}, {"start": 60, "end": 72, "tag": "drug"}, {"start": 75, "end": 90, "tag": "drug"}, {"start": 112, "end": 141, "tag": "drug"}, {"start": 144, "end": 170, "tag": "drug"}]}, {"content": "Concurrent use of these agents should generally be avoided.", "metadata": {"original_id": "DrugDDI.d570.s1"}, "annotations": []}, {"content": "In situations in which concurrent therapy is necessary, careful patient monitoring is essential.", "metadata": {"original_id": "DrugDDI.d570.s2"}, "annotations": []}, {"content": "Concurrent administration of vasopressor drugs and of ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents.", "metadata": {"original_id": "DrugDDI.d570.s3"}, "annotations": [{"start": 29, "end": 47, "tag": "drug"}, {"start": 65, "end": 80, "tag": "drug"}]}, {"content": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine.", "metadata": {"original_id": "DrugDDI.d570.s4"}, "annotations": [{"start": 0, "end": 15, "tag": "drug"}, {"start": 19, "end": 34, "tag": "drug"}, {"start": 60, "end": 75, "tag": "drug"}, {"start": 78, "end": 90, "tag": "drug"}]}, {"content": "No clinically relevant drug-drug interactions have been observed with drugs likely to be co-administered with anidulafungin.", "metadata": {"original_id": "DrugDDI.d552.s0"}, "annotations": [{"start": 70, "end": 76, "tag": "drug"}, {"start": 110, "end": 124, "tag": "drug"}]}, {"content": "Calcium Supplements/Antacids", "metadata": {"original_id": "DrugDDI.d184.s0"}, "annotations": [{"start": 0, "end": 8, "tag": "drug"}, {"start": 20, "end": 29, "tag": "drug"}]}, {"content": "Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of Ibandronate.", "metadata": {"original_id": "DrugDDI.d184.s1"}, "annotations": [{"start": 20, "end": 28, "tag": "drug"}, {"start": 50, "end": 58, "tag": "drug"}, {"start": 77, "end": 87, "tag": "drug"}, {"start": 88, "end": 93, "tag": "drug"}, {"start": 137, "end": 149, "tag": "drug"}]}, {"content": "Ibandronate should be taken at least 60 minutes before any oral medications containing multivalent cations (including antacids, supplements or vitamins).", "metadata": {"original_id": "DrugDDI.d184.s2"}, "annotations": [{"start": 0, "end": 12, "tag": "drug"}, {"start": 99, "end": 107, "tag": "drug"}, {"start": 118, "end": 127, "tag": "drug"}, {"start": 143, "end": 152, "tag": "drug"}]}, {"content": "H2 Blockers and Proton Pump Inhibitors (PPIs)", "metadata": {"original_id": "DrugDDI.d184.s3"}, "annotations": [{"start": 0, "end": 12, "tag": "drug"}, {"start": 16, "end": 39, "tag": "drug"}]}, {"content": "Of over 3500 patients enrolled in the Ibandronate osteoporosis Treatment and Prevention Studies, 15% used anti-peptic agents (primarily H2 blockers and PPIs).", "metadata": {"original_id": "DrugDDI.d184.s4"}, "annotations": [{"start": 38, "end": 50, "tag": "drug"}, {"start": 106, "end": 125, "tag": "drug"}, {"start": 136, "end": 148, "tag": "drug"}]}, {"content": "Among these patients, the incidence of upper gastrointestinal adverse experiences in the patients treated with Ibandronate was similar to that in placebo-treated patients.", "metadata": {"original_id": "DrugDDI.d184.s5"}, "annotations": [{"start": 111, "end": 123, "tag": "drug"}]}, {"content": "Similarly, of over 1600 patients enrolled in a study comparing once-monthly with daily dosing regimens of ibandronate, 14% of patients used anti-peptic agents.", "metadata": {"original_id": "DrugDDI.d184.s6"}, "annotations": [{"start": 106, "end": 118, "tag": "drug"}, {"start": 140, "end": 159, "tag": "drug"}]}, {"content": "Among these patients, the incidence of upper gastrointestinal adverse experiences in the patients treated with Ibandronate 150 mg once monthly was similar to that in patients treated with Ibandronate 2.5 mg once daily.", "metadata": {"original_id": "DrugDDI.d184.s7"}, "annotations": [{"start": 111, "end": 130, "tag": "drug"}, {"start": 188, "end": 207, "tag": "drug"}]}, {"content": "Aspirin/Nonsteroidal Antiinflammatory Drugs (NSAIDs)", "metadata": {"original_id": "DrugDDI.d184.s8"}, "annotations": [{"start": 0, "end": 8, "tag": "drug"}, {"start": 8, "end": 43, "tag": "drug"}, {"start": 45, "end": 52, "tag": "drug"}]}, {"content": "In the large, placebo-controlled osteoporosis Treatment Study, aspirin and nonsteroidal anti-inflammatory drugs were taken by 62% of the 2946 patients.", "metadata": {"original_id": "DrugDDI.d184.s9"}, "annotations": [{"start": 63, "end": 71, "tag": "drug"}, {"start": 75, "end": 112, "tag": "drug"}]}, {"content": "Among aspirin or NSAID users, the incidence of upper gastrointestinal adverse events in patients treated with ibandronate 2.5 mg daily (28.9%) was similar to that in placebo-treated patients (30.7%).", "metadata": {"original_id": "DrugDDI.d184.s10"}, "annotations": [{"start": 6, "end": 14, "tag": "drug"}, {"start": 17, "end": 23, "tag": "drug"}, {"start": 110, "end": 129, "tag": "drug"}]}, {"content": "Similarly, in the 1-year monthly comparison study, aspirin and nonsteroidal anti-inflammatory drugs were taken by 39% of the 1602 patients.", "metadata": {"original_id": "DrugDDI.d184.s11"}, "annotations": [{"start": 51, "end": 59, "tag": "drug"}, {"start": 63, "end": 100, "tag": "drug"}]}, {"content": "The incidence of upper gastrointestinal events in patients concomitantly taking aspirin or NSAIDs was similar in patients taking ibandronate 2.5 mg daily (21.7%) and 150 mg once monthly (22.0%).", "metadata": {"original_id": "DrugDDI.d184.s12"}, "annotations": [{"start": 80, "end": 88, "tag": "drug"}, {"start": 91, "end": 98, "tag": "drug"}, {"start": 129, "end": 148, "tag": "drug"}]}, {"content": "However, since aspirin, NSAIDs, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with Ibandronate.", "metadata": {"original_id": "DrugDDI.d184.s13"}, "annotations": [{"start": 15, "end": 23, "tag": "drug"}, {"start": 24, "end": 31, "tag": "drug"}, {"start": 36, "end": 52, "tag": "drug"}, {"start": 159, "end": 167, "tag": "drug"}, {"start": 170, "end": 177, "tag": "drug"}, {"start": 182, "end": 194, "tag": "drug"}]}, {"content": "Drug/Laboratory Test Interactions", "metadata": {"original_id": "DrugDDI.d184.s14"}, "annotations": [{"start": 0, "end": 5, "tag": "drug"}]}, {"content": "Bisphosphonates are known to interfere with the use of bone-imaging agents.", "metadata": {"original_id": "DrugDDI.d184.s15"}, "annotations": [{"start": 0, "end": 16, "tag": "drug"}]}, {"content": "Specific studies with ibandronate have not been performed.", "metadata": {"original_id": "DrugDDI.d184.s16"}, "annotations": [{"start": 22, "end": 34, "tag": "drug"}]}, {"content": "Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.", "metadata": {"original_id": "DrugDDI.d236.s0"}, "annotations": [{"start": 0, "end": 13, "tag": "drug"}, {"start": 31, "end": 39, "tag": "drug"}, {"start": 40, "end": 54, "tag": "drug"}, {"start": 56, "end": 75, "tag": "drug"}, {"start": 101, "end": 111, "tag": "drug"}, {"start": 122, "end": 128, "tag": "drug"}, {"start": 129, "end": 137, "tag": "drug"}, {"start": 138, "end": 153, "tag": "drug"}, {"start": 154, "end": 161, "tag": "drug"}, {"start": 166, "end": 172, "tag": "drug"}, {"start": 175, "end": 185, "tag": "drug"}, {"start": 210, "end": 222, "tag": "drug"}]}, {"content": "Central nervous system depressant (CNS) drugs including alcohol, antidepressants, antihistamines, antipsychotics, blood pressure medications (reserpine, methyldopa, beta-blockers), motion sickness medications, muscle relaxants, narcotics, sedatives, sleeping pills and tranquilizers", "metadata": {"original_id": "DrugDDI.d430.s0"}, "annotations": [{"start": 0, "end": 34, "tag": "drug"}, {"start": 40, "end": 46, "tag": "drug"}, {"start": 56, "end": 64, "tag": "drug"}, {"start": 65, "end": 81, "tag": "drug"}, {"start": 82, "end": 97, "tag": "drug"}, {"start": 98, "end": 113, "tag": "drug"}, {"start": 129, "end": 141, "tag": "drug"}, {"start": 142, "end": 152, "tag": "drug"}, {"start": 153, "end": 164, "tag": "drug"}, {"start": 165, "end": 180, "tag": "drug"}, {"start": 197, "end": 209, "tag": "drug"}, {"start": 210, "end": 227, "tag": "drug"}, {"start": 228, "end": 238, "tag": "drug"}, {"start": 239, "end": 249, "tag": "drug"}, {"start": 269, "end": 283, "tag": "drug"}]}, {"content": "Ketoconazole/Itraconazole, Macrolides, Including Erythromycin", "metadata": {"original_id": "DrugDDI.d224.s0"}, "annotations": [{"start": 0, "end": 13, "tag": "drug"}, {"start": 13, "end": 26, "tag": "drug"}, {"start": 27, "end": 38, "tag": "drug"}, {"start": 49, "end": 62, "tag": "drug"}]}, {"content": "May interact with wthionamide (Trecator-SC) and isoniazid (Nydrazid).", "metadata": {"original_id": "DrugDDI.d230.s0"}, "annotations": [{"start": 31, "end": 43, "tag": "drug"}, {"start": 48, "end": 58, "tag": "drug"}, {"start": 59, "end": 68, "tag": "drug"}]}, {"content": "Co-treatment with the potent CYP3A4 inhibitor ketoconazole increases erlotinib AUC by 2/3.", "metadata": {"original_id": "DrugDDI.d145.s0"}, "annotations": [{"start": 46, "end": 59, "tag": "drug"}, {"start": 69, "end": 79, "tag": "drug"}]}, {"content": "Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .", "metadata": {"original_id": "DrugDDI.d145.s1"}, "annotations": [{"start": 52, "end": 60, "tag": "drug"}, {"start": 65, "end": 78, "tag": "drug"}, {"start": 95, "end": 102, "tag": "drug"}, {"start": 142, "end": 153, "tag": "drug"}, {"start": 154, "end": 169, "tag": "drug"}, {"start": 170, "end": 180, "tag": "drug"}, {"start": 181, "end": 194, "tag": "drug"}, {"start": 195, "end": 206, "tag": "drug"}, {"start": 207, "end": 218, "tag": "drug"}, {"start": 219, "end": 229, "tag": "drug"}, {"start": 230, "end": 241, "tag": "drug"}, {"start": 242, "end": 256, "tag": "drug"}, {"start": 257, "end": 272, "tag": "drug"}, {"start": 273, "end": 278, "tag": "drug"}, {"start": 283, "end": 296, "tag": "drug"}]}, {"content": "Pre-treatment with the CYP3A4 inducer rifampicin decreased erlotinib AUC by about 2/3.", "metadata": {"original_id": "DrugDDI.d145.s2"}, "annotations": [{"start": 38, "end": 49, "tag": "drug"}, {"start": 59, "end": 69, "tag": "drug"}]}, {"content": "Alternate treatments lacking CYP3A4 inducing activity should be considered.", "metadata": {"original_id": "DrugDDI.d145.s3"}, "annotations": [{"start": 29, "end": 36, "tag": "drug"}]}, {"content": "If an alternative treatment is unavailable, a TARCEVA dose greater than 150 mg should be considered for NSCLC patients, and greater than 100 mg considered for pancreatic cancer patients.", "metadata": {"original_id": "DrugDDI.d145.s4"}, "annotations": [{"start": 46, "end": 54, "tag": "drug"}]}, {"content": "If the TARCEVA dose is adjusted upward, the dose will need to be reduced upon discontinuation of rifampicin or other inducers.", "metadata": {"original_id": "DrugDDI.d145.s5"}, "annotations": [{"start": 7, "end": 15, "tag": "drug"}, {"start": 97, "end": 108, "tag": "drug"}]}, {"content": "Other CYP3A4 inducers include, but are not limited to, rifabutin, rifapentine, phenytoin, carbamazepine, phenobarbital and St. Johns Wort.", "metadata": {"original_id": "DrugDDI.d145.s6"}, "annotations": [{"start": 6, "end": 13, "tag": "drug"}, {"start": 55, "end": 65, "tag": "drug"}, {"start": 66, "end": 78, "tag": "drug"}, {"start": 79, "end": 89, "tag": "drug"}, {"start": 90, "end": 104, "tag": "drug"}, {"start": 105, "end": 119, "tag": "drug"}, {"start": 123, "end": 138, "tag": "drug"}]}, {"content": "Hepatotoxicity Asymptomatic increases in liver transaminases have been observed in TARCEVA treated patients;", "metadata": {"original_id": "DrugDDI.d145.s7"}, "annotations": [{"start": 47, "end": 61, "tag": "drug"}, {"start": 83, "end": 91, "tag": "drug"}]}, {"content": "therefore, periodic liver function testing (transaminases, bilirubin, and alkaline phosphatase) should be considered.", "metadata": {"original_id": "DrugDDI.d145.s8"}, "annotations": [{"start": 44, "end": 58, "tag": "drug"}, {"start": 59, "end": 69, "tag": "drug"}, {"start": 74, "end": 95, "tag": "drug"}]}, {"content": "Dose reduction or interruption of TARCEVA should be considered if changes in liver function are severe.", "metadata": {"original_id": "DrugDDI.d145.s9"}, "annotations": [{"start": 34, "end": 42, "tag": "drug"}]}, {"content": "Patients with Hepatic Impairment In vitro and in vivo evidence suggest that erlotinib is cleared primarily by the liver.", "metadata": {"original_id": "DrugDDI.d145.s10"}, "annotations": [{"start": 76, "end": 86, "tag": "drug"}, {"start": 114, "end": 120, "tag": "drug"}]}, {"content": "Therefore, erlotinib exposure may be increased in patients with hepatic dysfunction.", "metadata": {"original_id": "DrugDDI.d145.s11"}, "annotations": [{"start": 11, "end": 21, "tag": "drug"}]}, {"content": "Elevated International Normalized Ratio and Potential Bleeding International Normalized Ratio (INR) elevations and infrequent reports of bleeding events including gastrointestinal and non-gastrointestinal bleedings have been reported in clinical studies, some associated with concomitant warfarin administration.", "metadata": {"original_id": "DrugDDI.d145.s12"}, "annotations": [{"start": 288, "end": 297, "tag": "drug"}]}, {"content": "Patients taking warfarin or other coumarin-derivative anticoagulants should be monitored regularly for changes in prothrombin time or INR", "metadata": {"original_id": "DrugDDI.d145.s13"}, "annotations": [{"start": 16, "end": 25, "tag": "drug"}, {"start": 34, "end": 69, "tag": "drug"}]}, {"content": ".", "metadata": {"original_id": "DrugDDI.d145.s14"}, "annotations": []}, {"content": "? ?", "metadata": {"original_id": "DrugDDI.d145.s15"}, "annotations": []}, {"content": "Although BETAGAN used alone has little or no effect on pupil size, mydriasis resulting from concomitant therapy with BETAGAN and epinephrine may occur.", "metadata": {"original_id": "DrugDDI.d484.s0"}, "annotations": [{"start": 9, "end": 17, "tag": "drug"}, {"start": 117, "end": 125, "tag": "drug"}, {"start": 129, "end": 141, "tag": "drug"}]}, {"content": "Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may produce vertigo, syncope or postural hypotension.", "metadata": {"original_id": "DrugDDI.d484.s1"}, "annotations": [{"start": 55, "end": 68, "tag": "drug"}, {"start": 130, "end": 136, "tag": "drug"}, {"start": 144, "end": 154, "tag": "drug"}]}, {"content": "Patients receiving beta-adrenergic blocking agents along with either oral or intravenous calcium antagonists should be monitored for possible atrioventricular conduction disturbances, left ventricular failure and hypotension.", "metadata": {"original_id": "DrugDDI.d484.s2"}, "annotations": [{"start": 19, "end": 51, "tag": "drug"}, {"start": 89, "end": 108, "tag": "drug"}]}, {"content": "In patients with impaired cardiac function, simultaneous use should be avoided altogether.", "metadata": {"original_id": "DrugDDI.d484.s3"}, "annotations": []}, {"content": "The concomitant use of beta-adrenergic blocking agents with digitalis and calcium antagonists may have additive effects on prolonging atrioventricular conduction time.", "metadata": {"original_id": "DrugDDI.d484.s4"}, "annotations": [{"start": 23, "end": 55, "tag": "drug"}, {"start": 60, "end": 70, "tag": "drug"}, {"start": 74, "end": 93, "tag": "drug"}]}, {"content": "Phenothiazine-related compounds and beta-adrenergic blocking agents may have additive hypotensite effects due to the inhibition of each other?s metabolism.", "metadata": {"original_id": "DrugDDI.d484.s5"}, "annotations": [{"start": 0, "end": 14, "tag": "drug"}, {"start": 36, "end": 68, "tag": "drug"}]}, {"content": "Beta-adrenergic Blocking Agents: Experience in over 1400 patients in a non-comparative clinical trial has shown that concomitant administration of nifedipine and beta-blocking agents is usually well tolerated, but there have been occasional literature reports suggesting that the combination may increase the likelihood of congestive heart failure, severe hypotension or exacerbation of angina.", "metadata": {"original_id": "DrugDDI.d266.s0"}, "annotations": [{"start": 0, "end": 32, "tag": "drug"}, {"start": 147, "end": 158, "tag": "drug"}, {"start": 162, "end": 182, "tag": "drug"}]}, {"content": "Long Acting Nitrates: Nifedipine may be safely co-administered with nitrates, but there have been no controlled studies to evaluate the antianginal effectiveness of this combination.", "metadata": {"original_id": "DrugDDI.d266.s1"}, "annotations": [{"start": 12, "end": 21, "tag": "drug"}, {"start": 22, "end": 33, "tag": "drug"}, {"start": 68, "end": 77, "tag": "drug"}]}, {"content": "Digitalis: Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between digoxin and nifedipine, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.", "metadata": {"original_id": "DrugDDI.d266.s2"}, "annotations": [{"start": 0, "end": 10, "tag": "drug"}, {"start": 164, "end": 172, "tag": "drug"}, {"start": 176, "end": 187, "tag": "drug"}, {"start": 285, "end": 296, "tag": "drug"}]}, {"content": "Extended Release Tablets: Administration of nifedipine with digoxin increased digoxin levels in 9 of 12 normal volunteers.", "metadata": {"original_id": "DrugDDI.d266.s3"}, "annotations": [{"start": 44, "end": 55, "tag": "drug"}, {"start": 60, "end": 68, "tag": "drug"}]}, {"content": "The average increase was 45%.", "metadata": {"original_id": "DrugDDI.d266.s4"}, "annotations": []}, {"content": "Another investigator found no increase in digoxin levels in 13 patients with coronary artery disease.", "metadata": {"original_id": "DrugDDI.d266.s5"}, "annotations": []}, {"content": "In an uncontrolled study of over 200 patients with congestive heart failure during which digoxin blood levels were not measured, digitalis toxicity was not observed.", "metadata": {"original_id": "DrugDDI.d266.s6"}, "annotations": []}, {"content": "Since there have been isolated reports of patients with elevated digoxin levels, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.", "metadata": {"original_id": "DrugDDI.d266.s7"}, "annotations": [{"start": 178, "end": 189, "tag": "drug"}]}, {"content": "Quinidine: Immediate Release Capsules: There have been rare reports of an interaction between quinidine and nifedipine (with a decreased plasma level of quinidine).", "metadata": {"original_id": "DrugDDI.d266.s8"}, "annotations": [{"start": 0, "end": 10, "tag": "drug"}, {"start": 94, "end": 104, "tag": "drug"}, {"start": 108, "end": 119, "tag": "drug"}, {"start": 153, "end": 163, "tag": "drug"}]}, {"content": "Coumarin Anticoagulants: There have been rare reports of increased prothrombin time in patients taking coumarin anticoagulants to whom nifedipine was administered.", "metadata": {"original_id": "DrugDDI.d266.s9"}, "annotations": [{"start": 0, "end": 23, "tag": "drug"}, {"start": 103, "end": 126, "tag": "drug"}, {"start": 135, "end": 146, "tag": "drug"}]}, {"content": "However, the relationship to nifedipine therapy is uncertain.", "metadata": {"original_id": "DrugDDI.d266.s10"}, "annotations": [{"start": 29, "end": 40, "tag": "drug"}]}, {"content": "Cimetidine: A study in 6 healthy volunteers has shown a significant increase in peak nifedipine plasma levels (80%) and area-under-the-curve (74%) after a 1 week course of cimetidine at 1000 mg per day and nifedipine at 40 mg per day.", "metadata": {"original_id": "DrugDDI.d266.s11"}, "annotations": [{"start": 0, "end": 11, "tag": "drug"}, {"start": 85, "end": 96, "tag": "drug"}, {"start": 172, "end": 183, "tag": "drug"}, {"start": 206, "end": 217, "tag": "drug"}]}, {"content": "Ranitidine produced smaller, non-significant increases.", "metadata": {"original_id": "DrugDDI.d266.s12"}, "annotations": [{"start": 0, "end": 11, "tag": "drug"}]}, {"content": "The effect may be mediated by the known inhibition of cimetidine on hepatic cytochrome P-450, the enzyme system probably responsible for the first-pass metabolism of nifedipine.", "metadata": {"original_id": "DrugDDI.d266.s13"}, "annotations": [{"start": 54, "end": 65, "tag": "drug"}, {"start": 76, "end": 93, "tag": "drug"}, {"start": 166, "end": 177, "tag": "drug"}]}, {"content": "If nifedipine therapy is initiated in a patient currently receiving cimetidine, cautious titration is advised.", "metadata": {"original_id": "DrugDDI.d266.s14"}, "annotations": [{"start": 3, "end": 14, "tag": "drug"}, {"start": 68, "end": 79, "tag": "drug"}]}, {"content": "Zidovudine: There is no significant pharmacokinetic interaction between ZDV and zalcitabine which has been confirmed clinically.", "metadata": {"original_id": "DrugDDI.d528.s0"}, "annotations": [{"start": 0, "end": 11, "tag": "drug"}, {"start": 72, "end": 76, "tag": "drug"}, {"start": 80, "end": 92, "tag": "drug"}]}, {"content": "Zalcitabine also has no significant effect on the intracellular phosphorylation of ZDV, as shown in vitro in peripheral blood mononuclear cells or in two other cell lines (U937 and Molt-4).", "metadata": {"original_id": "DrugDDI.d528.s1"}, "annotations": [{"start": 0, "end": 12, "tag": "drug"}, {"start": 83, "end": 87, "tag": "drug"}]}, {"content": "In the same study it was shown that didanosine and stavudine had no significant effect on the intracellular phosphorylation of zalcitabine in peripheral blood mononuclear cells.", "metadata": {"original_id": "DrugDDI.d528.s2"}, "annotations": [{"start": 36, "end": 47, "tag": "drug"}, {"start": 51, "end": 61, "tag": "drug"}, {"start": 127, "end": 139, "tag": "drug"}]}, {"content": "Lamivudine: In vitro studies in peripheral blood mononuclear cells, U937 and Molt-4 cells revealed that lamivudine significantly inhibited zalcitabine phosphorylation in a dose dependent manner.", "metadata": {"original_id": "DrugDDI.d528.s3"}, "annotations": [{"start": 0, "end": 11, "tag": "drug"}, {"start": 104, "end": 115, "tag": "drug"}, {"start": 139, "end": 151, "tag": "drug"}]}, {"content": "Effects were already seen with doses corresponding to relevant plasma levels in humans, and the intracellular phosphorylation of zalcitabine to its three metabolites (including the active zalcitabine triphosphate metabolite) was significantly inhibited.", "metadata": {"original_id": "DrugDDI.d528.s4"}, "annotations": [{"start": 129, "end": 141, "tag": "drug"}, {"start": 154, "end": 166, "tag": "drug"}, {"start": 188, "end": 200, "tag": "drug"}]}, {"content": "Zalcitabine inhibited lamivudine phosphorylation at high concentration ratios (10 and 100);", "metadata": {"original_id": "DrugDDI.d528.s5"}, "annotations": [{"start": 0, "end": 12, "tag": "drug"}, {"start": 22, "end": 33, "tag": "drug"}]}, {"content": "however, it is considered to be unlikely that this decrease of phosphorylated lamivudine concentration is of clinical significance, as lamivudine is a more efficient substrate for deoxycytidine kinase than zalcitabine.", "metadata": {"original_id": "DrugDDI.d528.s6"}, "annotations": [{"start": 78, "end": 89, "tag": "drug"}, {"start": 135, "end": 146, "tag": "drug"}, {"start": 180, "end": 201, "tag": "drug"}, {"start": 206, "end": 218, "tag": "drug"}]}, {"content": "These in vitro studies suggest that concomitant administration of zalcitabine and lamivudine in humans may result in sub-therapeutic concentrations of active phosphorylated zalcitabine, which may lead to a decreased antiretroviral effect of zalcitabine.", "metadata": {"original_id": "DrugDDI.d528.s7"}, "annotations": [{"start": 66, "end": 78, "tag": "drug"}, {"start": 82, "end": 93, "tag": "drug"}, {"start": 173, "end": 185, "tag": "drug"}, {"start": 241, "end": 253, "tag": "drug"}]}, {"content": "It is unknown how the effect seen in these in vitro studies translates into clinical consequences.", "metadata": {"original_id": "DrugDDI.d528.s8"}, "annotations": []}, {"content": "Concomitant use of zalcitabine and lamivudine is not recommended.", "metadata": {"original_id": "DrugDDI.d528.s9"}, "annotations": [{"start": 19, "end": 31, "tag": "drug"}, {"start": 35, "end": 46, "tag": "drug"}]}, {"content": "Saquinavir: The combination of HIVID, saquinavir, and ZDV has been studied (as triple combination) in adults.", "metadata": {"original_id": "DrugDDI.d528.s10"}, "annotations": [{"start": 0, "end": 11, "tag": "drug"}, {"start": 31, "end": 37, "tag": "drug"}, {"start": 38, "end": 49, "tag": "drug"}, {"start": 54, "end": 58, "tag": "drug"}]}, {"content": "Pharmacokinetic data suggest that absorption, metabolism, and elimination of each of these drugs are unchanged when they are used together.", "metadata": {"original_id": "DrugDDI.d528.s11"}, "annotations": [{"start": 91, "end": 97, "tag": "drug"}]}, {"content": "Drugs Associated With Peripheral Neuropathy: The concomitant use of HIVID with drugs that have the potential to cause peripheral neuropathy should be avoided where possible.", "metadata": {"original_id": "DrugDDI.d528.s12"}, "annotations": [{"start": 0, "end": 6, "tag": "drug"}, {"start": 68, "end": 74, "tag": "drug"}, {"start": 79, "end": 85, "tag": "drug"}]}, {"content": "Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.", "metadata": {"original_id": "DrugDDI.d528.s13"}, "annotations": [{"start": 0, "end": 6, "tag": "drug"}, {"start": 67, "end": 104, "tag": "drug"}, {"start": 104, "end": 120, "tag": "drug"}, {"start": 121, "end": 131, "tag": "drug"}, {"start": 132, "end": 140, "tag": "drug"}, {"start": 141, "end": 152, "tag": "drug"}, {"start": 153, "end": 165, "tag": "drug"}, {"start": 166, "end": 179, "tag": "drug"}, {"start": 180, "end": 185, "tag": "drug"}, {"start": 186, "end": 198, "tag": "drug"}, {"start": 199, "end": 210, "tag": "drug"}, {"start": 211, "end": 221, "tag": "drug"}, {"start": 222, "end": 236, "tag": "drug"}, {"start": 237, "end": 252, "tag": "drug"}, {"start": 253, "end": 263, "tag": "drug"}, {"start": 264, "end": 274, "tag": "drug"}, {"start": 279, "end": 291, "tag": "drug"}]}, {"content": "Concomitant use of HIVID with didanosine is not recommended.", "metadata": {"original_id": "DrugDDI.d528.s14"}, "annotations": [{"start": 19, "end": 25, "tag": "drug"}, {"start": 30, "end": 41, "tag": "drug"}]}, {"content": "Intravenous Pentamidine: Treatment with HIVID should be interrupted when the use of a drug that has the potential to cause pancreatitis is required.", "metadata": {"original_id": "DrugDDI.d528.s15"}, "annotations": [{"start": 12, "end": 23, "tag": "drug"}, {"start": 40, "end": 46, "tag": "drug"}, {"start": 86, "end": 91, "tag": "drug"}]}, {"content": "Death due to fulminant pancreatitis possibly related to intravenous pentamidine and HIVID has been reported.", "metadata": {"original_id": "DrugDDI.d528.s16"}, "annotations": [{"start": 68, "end": 79, "tag": "drug"}, {"start": 84, "end": 90, "tag": "drug"}]}, {"content": "If intravenous pentamidine is required to treat Pneumocystis carinii pneumonia, treatment with HIVID should be interrupted.", "metadata": {"original_id": "DrugDDI.d528.s17"}, "annotations": [{"start": 15, "end": 26, "tag": "drug"}, {"start": 95, "end": 101, "tag": "drug"}]}, {"content": "Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).", "metadata": {"original_id": "DrugDDI.d528.s18"}, "annotations": [{"start": 0, "end": 13, "tag": "drug"}, {"start": 14, "end": 24, "tag": "drug"}, {"start": 29, "end": 45, "tag": "drug"}, {"start": 46, "end": 52, "tag": "drug"}, {"start": 60, "end": 73, "tag": "drug"}, {"start": 74, "end": 84, "tag": "drug"}, {"start": 89, "end": 105, "tag": "drug"}, {"start": 172, "end": 178, "tag": "drug"}, {"start": 247, "end": 259, "tag": "drug"}]}, {"content": "Patients who require the use of one of these drugs with HIVID should have frequent clinical and laboratory monitoring with dosage adjustment for any significant change in renal function.", "metadata": {"original_id": "DrugDDI.d528.s19"}, "annotations": [{"start": 45, "end": 51, "tag": "drug"}, {"start": 56, "end": 62, "tag": "drug"}]}, {"content": "Probenecid or Cimetidine: Concomitant administration of probenecid or cimetidine decreases the elimination of zalcitabine, most likely by inhibition of renal tubular secretion of zalcitabine.", "metadata": {"original_id": "DrugDDI.d528.s20"}, "annotations": [{"start": 0, "end": 11, "tag": "drug"}, {"start": 14, "end": 25, "tag": "drug"}, {"start": 56, "end": 67, "tag": "drug"}, {"start": 70, "end": 81, "tag": "drug"}, {"start": 110, "end": 122, "tag": "drug"}, {"start": 179, "end": 191, "tag": "drug"}]}, {"content": "Patients receiving these drugs in combination with zalcitabine should be monitored for signs of toxicity and the dose of zalcitabine reduced if warranted.", "metadata": {"original_id": "DrugDDI.d528.s21"}, "annotations": [{"start": 25, "end": 31, "tag": "drug"}, {"start": 51, "end": 63, "tag": "drug"}, {"start": 121, "end": 133, "tag": "drug"}]}, {"content": "Magnesium/Aluminum-containing Antacid Products: Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with magnesium/aluminum-containing antacid products.", "metadata": {"original_id": "DrugDDI.d528.s22"}, "annotations": [{"start": 0, "end": 10, "tag": "drug"}, {"start": 9, "end": 39, "tag": "drug"}, {"start": 62, "end": 74, "tag": "drug"}, {"start": 141, "end": 151, "tag": "drug"}, {"start": 150, "end": 180, "tag": "drug"}]}, {"content": "The clinical significance of this reduction is not known, hence zalcitabine is not recommended to be ingested simultaneously with magnesium/aluminum-containing antacids.", "metadata": {"original_id": "DrugDDI.d528.s23"}, "annotations": [{"start": 64, "end": 76, "tag": "drug"}, {"start": 130, "end": 140, "tag": "drug"}, {"start": 140, "end": 169, "tag": "drug"}]}, {"content": "Metoclopramide: Bioavailability is mildly reduced (approximately 10%) when zalcitabine and metoclopramide are coadministered.", "metadata": {"original_id": "DrugDDI.d528.s24"}, "annotations": [{"start": 0, "end": 15, "tag": "drug"}, {"start": 75, "end": 87, "tag": "drug"}, {"start": 91, "end": 106, "tag": "drug"}]}, {"content": "Doxorubicin: Doxorubicin caused a decrease in zalcitabine phosphorylation ( 50% inhibition of total phosphate formation) in U937/Molt 4 cells.", "metadata": {"original_id": "DrugDDI.d528.s25"}, "annotations": [{"start": 0, "end": 12, "tag": "drug"}, {"start": 13, "end": 25, "tag": "drug"}, {"start": 46, "end": 58, "tag": "drug"}]}, {"content": "Although there may be decreased zalcitabine activity because of lessened active metabolite formation, the clinical relevance of these in vitro results are not known.", "metadata": {"original_id": "DrugDDI.d528.s26"}, "annotations": [{"start": 32, "end": 44, "tag": "drug"}, {"start": 73, "end": 91, "tag": "drug"}]}, {"content": "Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents.", "metadata": {"original_id": "DrugDDI.d40.s0"}, "annotations": [{"start": 0, "end": 12, "tag": "drug"}, {"start": 106, "end": 136, "tag": "drug"}]}, {"content": "Therefore, it should be used with caution in patients receiving such agents.", "metadata": {"original_id": "DrugDDI.d40.s1"}, "annotations": []}, {"content": "Antagonism has been demonstrated between clindamycin and erythromycin in vitro.", "metadata": {"original_id": "DrugDDI.d40.s2"}, "annotations": [{"start": 41, "end": 53, "tag": "drug"}, {"start": 57, "end": 70, "tag": "drug"}]}, {"content": "Because of possible clinical significance, these two drugs should not be administered concurrently.", "metadata": {"original_id": "DrugDDI.d40.s3"}, "annotations": [{"start": 53, "end": 59, "tag": "drug"}]}, {"content": "When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine.", "metadata": {"original_id": "DrugDDI.d39.s0"}, "annotations": [{"start": 5, "end": 14, "tag": "drug"}, {"start": 18, "end": 30, "tag": "drug"}, {"start": 194, "end": 203, "tag": "drug"}, {"start": 225, "end": 237, "tag": "drug"}, {"start": 266, "end": 275, "tag": "drug"}]}, {"content": "The following precautions should be kept in mind in the treatment of anticholinesterase poisoning although they do not bear directly on the use of atropine and pralidoxime.", "metadata": {"original_id": "DrugDDI.d39.s1"}, "annotations": [{"start": 147, "end": 156, "tag": "drug"}, {"start": 160, "end": 172, "tag": "drug"}]}, {"content": "Since barbiturates are potentiated by the anticholinesterases, they should be used cautiously in the treatment of convulsions.", "metadata": {"original_id": "DrugDDI.d39.s2"}, "annotations": [{"start": 6, "end": 19, "tag": "drug"}, {"start": 42, "end": 62, "tag": "drug"}]}, {"content": "Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).", "metadata": {"original_id": "DrugDDI.d500.s0"}, "annotations": [{"start": 0, "end": 12, "tag": "drug"}, {"start": 30, "end": 44, "tag": "drug"}, {"start": 51, "end": 59, "tag": "drug"}, {"start": 61, "end": 77, "tag": "drug"}, {"start": 84, "end": 98, "tag": "drug"}, {"start": 100, "end": 118, "tag": "drug"}, {"start": 125, "end": 136, "tag": "drug"}, {"start": 140, "end": 150, "tag": "drug"}, {"start": 152, "end": 175, "tag": "drug"}, {"start": 176, "end": 181, "tag": "drug"}, {"start": 213, "end": 224, "tag": "drug"}, {"start": 233, "end": 247, "tag": "drug"}, {"start": 249, "end": 262, "tag": "drug"}, {"start": 269, "end": 279, "tag": "drug"}, {"start": 281, "end": 294, "tag": "drug"}, {"start": 295, "end": 301, "tag": "drug"}, {"start": 313, "end": 332, "tag": "drug"}, {"start": 346, "end": 356, "tag": "drug"}, {"start": 445, "end": 456, "tag": "drug"}]}, {"content": "Aminosalicylic acid may decrease the amount of digoxin (Lanoxin, Lanoxicaps) that gets absorbed into your body.", "metadata": {"original_id": "DrugDDI.d342.s0"}, "annotations": [{"start": 0, "end": 20, "tag": "drug"}, {"start": 47, "end": 55, "tag": "drug"}, {"start": 56, "end": 65, "tag": "drug"}, {"start": 65, "end": 76, "tag": "drug"}, {"start": 82, "end": 88, "tag": "drug"}]}, {"content": "In the case that you are taking digoxin while taking aminosalicylic acid, higher doses of digoxin may be needed.", "metadata": {"original_id": "DrugDDI.d342.s1"}, "annotations": [{"start": 32, "end": 40, "tag": "drug"}, {"start": 53, "end": 73, "tag": "drug"}, {"start": 90, "end": 98, "tag": "drug"}]}, {"content": "Aminosalicylic acid may also decrease the absorption of vitamin B12, which can lead to a deficiency.", "metadata": {"original_id": "DrugDDI.d342.s2"}, "annotations": [{"start": 0, "end": 20, "tag": "drug"}, {"start": 56, "end": 68, "tag": "drug"}]}, {"content": "Therefore you may need to take a vitamin B12 supplement while taking aminosalicylic acid.", "metadata": {"original_id": "DrugDDI.d342.s3"}, "annotations": [{"start": 69, "end": 89, "tag": "drug"}]}, {"content": "No drug-drug interaction studies in human subjects have been conducted.", "metadata": {"original_id": "DrugDDI.d28.s0"}, "annotations": []}, {"content": "Toxicologic and toxicokinetic studies in rats did not demonstrate any alterations in the clearance or toxicologic profile of either methotrexate or Kineret? when the two agents were administered together.", "metadata": {"original_id": "DrugDDI.d28.s1"}, "annotations": [{"start": 132, "end": 145, "tag": "drug"}]}, {"content": "In a study in which patients with active RA were treated for up to 24 weeks with concurrent Kineret? and etanercept therapy, a 7% rate of serious infections was observed, which was higher than that observed with etanercept alone (0%).", "metadata": {"original_id": "DrugDDI.d28.s2"}, "annotations": [{"start": 105, "end": 116, "tag": "drug"}, {"start": 212, "end": 223, "tag": "drug"}]}, {"content": "Two percent of patients treated concurrently with Kineret? and etanercept developed neutropenia (ANC  1 x 109/L).", "metadata": {"original_id": "DrugDDI.d28.s3"}, "annotations": [{"start": 63, "end": 74, "tag": "drug"}, {"start": 97, "end": 113, "tag": "drug"}]}, {"content": "Oxcarbazepine can inhibit CYP2C19 and induce CYP3A4/5 with potentially important effects on plasma concentrations of other drugs.", "metadata": {"original_id": "DrugDDI.d20.s0"}, "annotations": [{"start": 0, "end": 14, "tag": "drug"}, {"start": 26, "end": 34, "tag": "drug"}, {"start": 45, "end": 52, "tag": "drug"}, {"start": 123, "end": 129, "tag": "drug"}]}, {"content": "In addition, several AED?s that are cytochrome P450 inducers can decrease plasma concentrations of oxcarbazepine and MHD.", "metadata": {"original_id": "DrugDDI.d20.s1"}, "annotations": [{"start": 36, "end": 52, "tag": "drug"}, {"start": 99, "end": 113, "tag": "drug"}]}, {"content": "Oxcarbazepine was evaluated in human liver microsomes to determine its capacity to inhibit the major cytochrome P450 enzymes responsible for the metabolism of other drugs.", "metadata": {"original_id": "DrugDDI.d20.s2"}, "annotations": [{"start": 0, "end": 14, "tag": "drug"}, {"start": 101, "end": 117, "tag": "drug"}, {"start": 165, "end": 171, "tag": "drug"}]}, {"content": "Results demonstrate that oxcarbazepine and its pharmacologically active 10-monohydroxy metabolite (MHD) have little or no capacity to function as inhibitors for most of the human cytochrome P450 enzymes evaluated (CYP1A2, CYP2A6, CYP2C9, CYP2D6, CYP2E1, CYP4A9 and CYP4A11) with the exception of CYP2C19 and CYP3A4/5.", "metadata": {"original_id": "DrugDDI.d20.s3"}, "annotations": [{"start": 25, "end": 39, "tag": "drug"}, {"start": 65, "end": 98, "tag": "drug"}, {"start": 179, "end": 195, "tag": "drug"}, {"start": 214, "end": 221, "tag": "drug"}, {"start": 222, "end": 229, "tag": "drug"}, {"start": 230, "end": 237, "tag": "drug"}, {"start": 238, "end": 245, "tag": "drug"}, {"start": 246, "end": 253, "tag": "drug"}, {"start": 265, "end": 273, "tag": "drug"}, {"start": 296, "end": 304, "tag": "drug"}, {"start": 308, "end": 315, "tag": "drug"}]}, {"content": "Although inhibition of CYP 3A4/5 by OXC and MHD did occur at high concentrations, it is not likely to be of clinical significance.", "metadata": {"original_id": "DrugDDI.d20.s4"}, "annotations": [{"start": 23, "end": 27, "tag": "drug"}]}, {"content": "The inhibition of CYP-2C19 by OXC and MHD, however, is clinically relevant.", "metadata": {"original_id": "DrugDDI.d20.s5"}, "annotations": [{"start": 18, "end": 28, "tag": "drug"}]}, {"content": "In vitro, the UDP-glucuronyl transferase level was increased, indicating induction of this enzyme.", "metadata": {"original_id": "DrugDDI.d20.s6"}, "annotations": [{"start": 14, "end": 42, "tag": "drug"}]}, {"content": "Increases of 22% with MHD and 47% with oxcarbazepine were observed.", "metadata": {"original_id": "DrugDDI.d20.s7"}, "annotations": [{"start": 39, "end": 53, "tag": "drug"}]}, {"content": "As MHD, the predominant plasma substrate, is only a weak inducer of UDP-glucuronyl transferase, it is unlikely to have an effect on drugs that are mainly eliminated by conjugation through UDP-glucuronyl transferase (e.g., valproic acid, lamotrigine).", "metadata": {"original_id": "DrugDDI.d20.s8"}, "annotations": [{"start": 68, "end": 96, "tag": "drug"}, {"start": 132, "end": 138, "tag": "drug"}, {"start": 188, "end": 216, "tag": "drug"}, {"start": 222, "end": 236, "tag": "drug"}, {"start": 237, "end": 249, "tag": "drug"}]}, {"content": "In addition, oxcarbazepine and MHD induce a subgroup of the cytochrome P450 3A family (CYP3A4 and CYP3A5) responsible for the metabolism of dihydropyridine calcium antagonists and oral contraceptives, resulting in a lower plasma concentration of these drugs.", "metadata": {"original_id": "DrugDDI.d20.s9"}, "annotations": [{"start": 13, "end": 27, "tag": "drug"}, {"start": 60, "end": 79, "tag": "drug"}, {"start": 87, "end": 94, "tag": "drug"}, {"start": 98, "end": 105, "tag": "drug"}, {"start": 156, "end": 175, "tag": "drug"}, {"start": 180, "end": 200, "tag": "drug"}, {"start": 252, "end": 258, "tag": "drug"}]}, {"content": "As binding of MHD to plasma proteins is low (40%), clinically significant interactions with other drugs through competition for protein binding sites are unlikely.", "metadata": {"original_id": "DrugDDI.d20.s10"}, "annotations": [{"start": 21, "end": 37, "tag": "drug"}, {"start": 98, "end": 104, "tag": "drug"}, {"start": 128, "end": 136, "tag": "drug"}]}, {"content": "Antiepileptic drugs Potential interactions between Trileptal and other AEDs were assessed in clinical studies.", "metadata": {"original_id": "DrugDDI.d20.s11"}, "annotations": [{"start": 0, "end": 20, "tag": "drug"}, {"start": 51, "end": 61, "tag": "drug"}]}, {"content": "The effect of these interactions on mean AUCs and Cmin are summarized in Table 2: Table 2: Summary of AED interactions with Trileptal", "metadata": {"original_id": "DrugDDI.d20.s12"}, "annotations": [{"start": 124, "end": 134, "tag": "drug"}]}, {"content": "AED Co-administered", "metadata": {"original_id": "DrugDDI.d20.s13"}, "annotations": []}, {"content": "Dose of AED (mg/day)", "metadata": {"original_id": "DrugDDI.d20.s14"}, "annotations": []}, {"content": "Trileptal dose (mg/day)", "metadata": {"original_id": "DrugDDI.d20.s15"}, "annotations": [{"start": 0, "end": 10, "tag": "drug"}]}, {"content": "Influence of Trileptal on AED Concentration (Mean change, 90% Confidence Interval)", "metadata": {"original_id": "DrugDDI.d20.s16"}, "annotations": [{"start": 13, "end": 23, "tag": "drug"}]}, {"content": "Influence of AED On MHD Concentration (Mean change, 90% Confidence Interval)", "metadata": {"original_id": "DrugDDI.d20.s17"}, "annotations": []}, {"content": "Carbamazepine", "metadata": {"original_id": "DrugDDI.d20.s18"}, "annotations": [{"start": 0, "end": 14, "tag": "drug"}]}, {"content": "400-2000", "metadata": {"original_id": "DrugDDI.d20.s19"}, "annotations": []}, {"content": "900", "metadata": {"original_id": "DrugDDI.d20.s20"}, "annotations": []}, {"content": "nc1 40% decrease [CI: 17% decrease, 57% decrease]", "metadata": {"original_id": "DrugDDI.d20.s21"}, "annotations": []}, {"content": "Phenobarbital", "metadata": {"original_id": "DrugDDI.d20.s22"}, "annotations": [{"start": 0, "end": 14, "tag": "drug"}]}, {"content": "100-150", "metadata": {"original_id": "DrugDDI.d20.s23"}, "annotations": []}, {"content": "600-1800", "metadata": {"original_id": "DrugDDI.d20.s24"}, "annotations": []}, {"content": "14% increase [CI: 2% increase, 24% increase] 25% decrease [CI: 12% decrease, 51% decrease]", "metadata": {"original_id": "DrugDDI.d20.s25"}, "annotations": []}, {"content": "Phenytoin", "metadata": {"original_id": "DrugDDI.d20.s26"}, "annotations": [{"start": 0, "end": 10, "tag": "drug"}]}, {"content": "250-500", "metadata": {"original_id": "DrugDDI.d20.s27"}, "annotations": []}, {"content": "600-1800", "metadata": {"original_id": "DrugDDI.d20.s28"}, "annotations": []}, {"content": "nc1,2 30% decrease [CI: 3% decrease, 48 % decrease]", "metadata": {"original_id": "DrugDDI.d20.s29"}, "annotations": []}, {"content": "1200-2400 up to 40% increase3 [CI: 12% increase, 60 % increase]", "metadata": {"original_id": "DrugDDI.d20.s30"}, "annotations": []}, {"content": "Valproic acid", "metadata": {"original_id": "DrugDDI.d20.s31"}, "annotations": [{"start": 0, "end": 14, "tag": "drug"}]}, {"content": "400-2800", "metadata": {"original_id": "DrugDDI.d20.s32"}, "annotations": []}, {"content": "600-1800", "metadata": {"original_id": "DrugDDI.d20.s33"}, "annotations": []}, {"content": "nc1 18% decrease [CI: 13% decrease, 40 % decrease]", "metadata": {"original_id": "DrugDDI.d20.s34"}, "annotations": []}, {"content": "1- nc denotes a mean change of less than 10% 2- Pediatrics 3- Mean increase in adults at high Trileptal doses In vivo, the plasma levels of phenytoin increased by up to 40%, when Trileptal was given at doses above 1200 mg/day.", "metadata": {"original_id": "DrugDDI.d20.s35"}, "annotations": [{"start": 94, "end": 104, "tag": "drug"}, {"start": 140, "end": 150, "tag": "drug"}, {"start": 179, "end": 189, "tag": "drug"}]}, {"content": "Therefore, when using doses of Trileptal greater than 1200 mg/day during adjunctive therapy, a decrease in the dose of phenytoin may be required.", "metadata": {"original_id": "DrugDDI.d20.s36"}, "annotations": [{"start": 31, "end": 41, "tag": "drug"}, {"start": 119, "end": 129, "tag": "drug"}]}, {"content": "The increase of phenobarbital level, however, is small (15%) when given with Trileptal.", "metadata": {"original_id": "DrugDDI.d20.s37"}, "annotations": [{"start": 77, "end": 87, "tag": "drug"}]}, {"content": "Strong inducers of cytochrome P450 enzymes (i.e. carbamazepine, phenytoin and phenobarbital) have been shown to decrease the plasma levels of MHD (29-40%).", "metadata": {"original_id": "DrugDDI.d20.s38"}, "annotations": [{"start": 19, "end": 35, "tag": "drug"}, {"start": 49, "end": 63, "tag": "drug"}, {"start": 64, "end": 74, "tag": "drug"}, {"start": 78, "end": 92, "tag": "drug"}]}, {"content": "No autoinduction has been observed with Trileptal.", "metadata": {"original_id": "DrugDDI.d20.s39"}, "annotations": [{"start": 40, "end": 50, "tag": "drug"}]}, {"content": "Hormonal contraceptives Co-administration of Trileptal with an oral contraceptive has been shown to influence the plasma concentrations of the two hormonal components, ethinylestradiol (EE) and levonorgestrel (LNG).", "metadata": {"original_id": "DrugDDI.d20.s40"}, "annotations": [{"start": 45, "end": 55, "tag": "drug"}, {"start": 63, "end": 82, "tag": "drug"}, {"start": 168, "end": 185, "tag": "drug"}, {"start": 194, "end": 209, "tag": "drug"}]}, {"content": "The mean AUC values of EE were decreased by 48% [90% CI: 22-65] in one study and 52% [90% CI: 38-52] in another study [1,2].", "metadata": {"original_id": "DrugDDI.d20.s41"}, "annotations": []}, {"content": "The mean AUC values of LNG were decreased by 32% [90% CI: 20-45] in one study and 52% [90% CI: 42-52] in another study.", "metadata": {"original_id": "DrugDDI.d20.s42"}, "annotations": []}, {"content": "Therefore, concurrent use of Trileptal with hormonal contraceptives may render these contraceptives less effective.", "metadata": {"original_id": "DrugDDI.d20.s43"}, "annotations": [{"start": 29, "end": 39, "tag": "drug"}, {"start": 53, "end": 68, "tag": "drug"}, {"start": 85, "end": 100, "tag": "drug"}]}, {"content": "Studies with other oral or implant contraceptives have not been conducted.", "metadata": {"original_id": "DrugDDI.d20.s44"}, "annotations": [{"start": 35, "end": 50, "tag": "drug"}]}, {"content": "Calcium Antagonists After repeated co-administration of Trileptal, the AUC of felodipine was lowered by 28% [90% CI: 20-33].", "metadata": {"original_id": "DrugDDI.d20.s45"}, "annotations": [{"start": 0, "end": 19, "tag": "drug"}, {"start": 56, "end": 66, "tag": "drug"}, {"start": 78, "end": 89, "tag": "drug"}]}, {"content": "Verapamil produced a decrease of 20% [90% CI: 18-27] of the plasma levels of MHD.", "metadata": {"original_id": "DrugDDI.d20.s46"}, "annotations": [{"start": 0, "end": 10, "tag": "drug"}]}, {"content": "Other drug interactions Cimetidine, erythromycin and dextropropoxyphene had no effect on the pharmacokinetics of MHD.", "metadata": {"original_id": "DrugDDI.d20.s47"}, "annotations": [{"start": 24, "end": 35, "tag": "drug"}, {"start": 36, "end": 49, "tag": "drug"}, {"start": 53, "end": 72, "tag": "drug"}]}, {"content": "Results with warfarin wshow no evidence of interaction with either single or repeated doses of Trileptal.", "metadata": {"original_id": "DrugDDI.d20.s48"}, "annotations": [{"start": 13, "end": 22, "tag": "drug"}, {"start": 95, "end": 105, "tag": "drug"}]}, {"content": "Inhibitors of CYP2D6;", "metadata": {"original_id": "DrugDDI.d348.s0"}, "annotations": [{"start": 14, "end": 21, "tag": "drug"}]}, {"content": "poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .", "metadata": {"original_id": "DrugDDI.d348.s1"}, "annotations": [{"start": 21, "end": 33, "tag": "drug"}, {"start": 50, "end": 61, "tag": "drug"}, {"start": 87, "end": 94, "tag": "drug"}, {"start": 103, "end": 113, "tag": "drug"}, {"start": 114, "end": 125, "tag": "drug"}, {"start": 126, "end": 137, "tag": "drug"}, {"start": 142, "end": 154, "tag": "drug"}, {"start": 188, "end": 194, "tag": "drug"}, {"start": 249, "end": 260, "tag": "drug"}, {"start": 263, "end": 274, "tag": "drug"}]}, {"content": "Retrospective analysis of side effects in clinical trials showed that poor 2D6 metabolizers had a higher rate of dizziness during up-titration, presumably resulting from vasodilating effects of the higher concentrations of the a-blocking R(+) enantiomer.", "metadata": {"original_id": "DrugDDI.d348.s2"}, "annotations": [{"start": 243, "end": 254, "tag": "drug"}]}, {"content": "Catecholamine-depleting Agents: Patients taking both agents with b-blocking properties and a drug that can deplete catecholamines (e.g., reserpine and monoamine oxidase inhibitors) should be observed closely for signs of hypotension and/or severe bradycardia.", "metadata": {"original_id": "DrugDDI.d348.s3"}, "annotations": [{"start": 93, "end": 98, "tag": "drug"}, {"start": 137, "end": 147, "tag": "drug"}, {"start": 151, "end": 180, "tag": "drug"}]}, {"content": "Clonidine: Concomitant administration of clonidine with agents with b-blocking properties may potentiate blood-pressure- and heart-rate-lowering effects.", "metadata": {"original_id": "DrugDDI.d348.s4"}, "annotations": [{"start": 0, "end": 10, "tag": "drug"}, {"start": 41, "end": 51, "tag": "drug"}]}, {"content": "When concomitant treatment with agents with b-blocking properties and clonidine is to be terminated, the b-blocking agent should be discontinued first.", "metadata": {"original_id": "DrugDDI.d348.s5"}, "annotations": [{"start": 70, "end": 80, "tag": "drug"}]}, {"content": "Clonidine therapy can then be discontinued several days later by gradually decreasing the dosage.", "metadata": {"original_id": "DrugDDI.d348.s6"}, "annotations": [{"start": 0, "end": 10, "tag": "drug"}]}, {"content": "Cyclosporine: Modest increases in mean trough cyclosporine concentrations were observed following initiation of carvedilol treatment in 21 renal transplant patients suffering from chronic vascular rejection.", "metadata": {"original_id": "DrugDDI.d348.s7"}, "annotations": [{"start": 0, "end": 13, "tag": "drug"}, {"start": 46, "end": 59, "tag": "drug"}, {"start": 112, "end": 123, "tag": "drug"}]}, {"content": "In about 30% of patients, the dose of cyclosporine had to be reduced in order to maintain cyclosporine concentrations within the therapeutic range, while in the remainder no adjustment was needed.", "metadata": {"original_id": "DrugDDI.d348.s8"}, "annotations": [{"start": 38, "end": 51, "tag": "drug"}, {"start": 90, "end": 103, "tag": "drug"}]}, {"content": "On the average for the group, the dose of cyclosporine was reduced about 20% in these patients.", "metadata": {"original_id": "DrugDDI.d348.s9"}, "annotations": [{"start": 42, "end": 55, "tag": "drug"}]}, {"content": "Due to wide interindividual variability in the dose adjustment required, it is recommended that cyclosporine concentrations be monitored closely after initiation of carvedilol therapy and that the dose of cyclosporine be adjusted as appropriate.", "metadata": {"original_id": "DrugDDI.d348.s10"}, "annotations": [{"start": 96, "end": 109, "tag": "drug"}, {"start": 165, "end": 176, "tag": "drug"}, {"start": 205, "end": 218, "tag": "drug"}]}, {"content": "Digoxin: Digoxin concentrations are increased by about 15% when digoxin and carvedilol are administered concomitantly.", "metadata": {"original_id": "DrugDDI.d348.s11"}, "annotations": [{"start": 0, "end": 8, "tag": "drug"}, {"start": 9, "end": 17, "tag": "drug"}, {"start": 64, "end": 72, "tag": "drug"}, {"start": 76, "end": 87, "tag": "drug"}]}, {"content": "Both digoxin and COREG slow AV conduction.", "metadata": {"original_id": "DrugDDI.d348.s12"}, "annotations": [{"start": 5, "end": 13, "tag": "drug"}, {"start": 17, "end": 23, "tag": "drug"}]}, {"content": "Therefore, increased monitoring of digoxin is recommended when initiating, adjusting, or discontinuing COREG.", "metadata": {"original_id": "DrugDDI.d348.s13"}, "annotations": [{"start": 35, "end": 43, "tag": "drug"}, {"start": 103, "end": 109, "tag": "drug"}]}, {"content": "Inducers and Inhibitors of Hepatic Metabolism: Rifampin reduced plasma concentrations of carvedilol by about 70%.", "metadata": {"original_id": "DrugDDI.d348.s14"}, "annotations": [{"start": 47, "end": 56, "tag": "drug"}, {"start": 89, "end": 100, "tag": "drug"}]}, {"content": "Cimetidine increased AUC by about 30% but caused no change in Cmax.", "metadata": {"original_id": "DrugDDI.d348.s15"}, "annotations": [{"start": 0, "end": 11, "tag": "drug"}]}, {"content": "Calcium Channel Blockers: Isolated cases of conduction disturbance (rarely with hemodynamic compromise) have been observed when COREG is co-administered with diltiazem.", "metadata": {"original_id": "DrugDDI.d348.s16"}, "annotations": [{"start": 0, "end": 25, "tag": "drug"}, {"start": 128, "end": 134, "tag": "drug"}, {"start": 158, "end": 168, "tag": "drug"}]}, {"content": "As with other agents with b-blocking properties, if COREG is to be administered orally with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored.", "metadata": {"original_id": "DrugDDI.d348.s17"}, "annotations": [{"start": 52, "end": 58, "tag": "drug"}, {"start": 92, "end": 117, "tag": "drug"}, {"start": 124, "end": 134, "tag": "drug"}, {"start": 137, "end": 147, "tag": "drug"}]}, {"content": "Insulin or Oral Hypoglycemics: Agents with b-blocking properties may enhance the blood-sugar-reducing effect of insulin and oral hypoglycemics.", "metadata": {"original_id": "DrugDDI.d348.s18"}, "annotations": [{"start": 0, "end": 8, "tag": "drug"}, {"start": 11, "end": 30, "tag": "drug"}, {"start": 112, "end": 120, "tag": "drug"}, {"start": 124, "end": 143, "tag": "drug"}]}, {"content": "Therefore, in patients taking insulin or oral hypoglycemics, regular monitoring of blood glucose is recommended.", "metadata": {"original_id": "DrugDDI.d348.s19"}, "annotations": [{"start": 30, "end": 38, "tag": "drug"}, {"start": 41, "end": 60, "tag": "drug"}]}, {"content": "Oral Contraceptives Multiple doses of cefditoren pivoxil had no effect on the pharmacokinetics of ethinyl estradiol, the estrogenic component in most oral contraceptives.", "metadata": {"original_id": "DrugDDI.d152.s0"}, "annotations": [{"start": 0, "end": 20, "tag": "drug"}, {"start": 38, "end": 57, "tag": "drug"}, {"start": 98, "end": 116, "tag": "drug"}, {"start": 121, "end": 132, "tag": "drug"}, {"start": 150, "end": 170, "tag": "drug"}]}, {"content": "Antacids Co-administration of a single dose of an antacid which contained both magnesium (800 mg) and aluminum (900 mg) hydroxides reduced the oral absorption of a single 400 mg dose of cefditoren pivoxil administered following a meal, as evidenced by a 14% decrease in mean Cmax and an 11% decrease in mean AUC.", "metadata": {"original_id": "DrugDDI.d152.s1"}, "annotations": [{"start": 0, "end": 9, "tag": "drug"}, {"start": 50, "end": 58, "tag": "drug"}, {"start": 79, "end": 89, "tag": "drug"}, {"start": 186, "end": 205, "tag": "drug"}]}, {"content": "Although the clinical significance is not known, it is not recommended that cefditoren pivoxil be taken concomitantly with antacids.", "metadata": {"original_id": "DrugDDI.d152.s2"}, "annotations": [{"start": 76, "end": 95, "tag": "drug"}, {"start": 123, "end": 132, "tag": "drug"}]}, {"content": "H2-Receptor Antagonists Co-administration of a single dose of intravenously administered famotidine (20 mg) reduced the oral absorption of a single 400 mg dose of cefditoren pivoxil administered following a meal, as evidenced by a 27% decrease in mean Cmax and a 22% decrease in mean AUC.", "metadata": {"original_id": "DrugDDI.d152.s3"}, "annotations": [{"start": 0, "end": 24, "tag": "drug"}, {"start": 89, "end": 100, "tag": "drug"}, {"start": 163, "end": 182, "tag": "drug"}]}, {"content": "Although the clinical significance is not known, it is not recommended that cefditoren pivoxil be taken concomitantly with H2 receptor antagonists.", "metadata": {"original_id": "DrugDDI.d152.s4"}, "annotations": [{"start": 76, "end": 95, "tag": "drug"}, {"start": 123, "end": 135, "tag": "drug"}]}, {"content": "Probenecid As with other b-lactam antibiotics, co-administration of probenecid with cefditoren pivoxil resulted in an increase in the plasma exposure of cefditoren, with a 49% increase in mean Cmax, a 122% increase in mean AUC, and a 53% increase in half-life.", "metadata": {"original_id": "DrugDDI.d152.s5"}, "annotations": [{"start": 0, "end": 11, "tag": "drug"}, {"start": 25, "end": 46, "tag": "drug"}, {"start": 68, "end": 79, "tag": "drug"}, {"start": 84, "end": 103, "tag": "drug"}, {"start": 153, "end": 164, "tag": "drug"}]}, {"content": "Drug/Laboratory Test Interactions Cephalosporins are known to occasionally induce a positive direct Coombs test.", "metadata": {"original_id": "DrugDDI.d152.s6"}, "annotations": [{"start": 0, "end": 5, "tag": "drug"}, {"start": 34, "end": 49, "tag": "drug"}]}, {"content": "A false-positive reaction for glucose in the urine may occur with copper reduction tests (Benedicts or Fehlings solution or with CLINITEST tablets), but not with enzyme-based tests for glycosuria (e.g., CLINISTIX, TES-TAPE).", "metadata": {"original_id": "DrugDDI.d152.s7"}, "annotations": [{"start": 30, "end": 38, "tag": "drug"}]}, {"content": "As a false-negative result may occur in the ferricyanide test, it is recommended that either the glucose oxidase or hexokinase method be used to determine blood/plasma glucose levels in patients receiving cefditoren pivoxil.", "metadata": {"original_id": "DrugDDI.d152.s8"}, "annotations": [{"start": 97, "end": 113, "tag": "drug"}, {"start": 116, "end": 127, "tag": "drug"}, {"start": 205, "end": 224, "tag": "drug"}]}, {"content": "The renal effects of nephrotoxic compounds may be potentiated by Carboplatin.", "metadata": {"original_id": "DrugDDI.d506.s0"}, "annotations": [{"start": 65, "end": 77, "tag": "drug"}]}, {"content": "There have been no formal clinical studies to evaluate the drug interactions of TAXOTERE with other medications.", "metadata": {"original_id": "DrugDDI.d106.s0"}, "annotations": [{"start": 80, "end": 89, "tag": "drug"}, {"start": 94, "end": 112, "tag": "drug"}]}, {"content": "In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, terfenadine, ketoconazole, erythromycin, and troleandomycin.", "metadata": {"original_id": "DrugDDI.d106.s1"}, "annotations": [{"start": 51, "end": 61, "tag": "drug"}, {"start": 168, "end": 188, "tag": "drug"}, {"start": 197, "end": 210, "tag": "drug"}, {"start": 211, "end": 223, "tag": "drug"}, {"start": 224, "end": 237, "tag": "drug"}, {"start": 238, "end": 251, "tag": "drug"}, {"start": 256, "end": 271, "tag": "drug"}]}, {"content": "Caution should be exercised with these drugs when treating patients receiving TAXOTERE as there is a potential for a significant interaction.", "metadata": {"original_id": "DrugDDI.d106.s2"}, "annotations": [{"start": 39, "end": 45, "tag": "drug"}, {"start": 78, "end": 87, "tag": "drug"}]}, {"content": "Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital, phenytoin and primidone, and increase the frequency of seizures in susceptible pediatric patients.", "metadata": {"original_id": "DrugDDI.d341.s0"}, "annotations": [{"start": 0, "end": 11, "tag": "drug"}, {"start": 47, "end": 61, "tag": "drug"}, {"start": 71, "end": 85, "tag": "drug"}, {"start": 86, "end": 96, "tag": "drug"}, {"start": 100, "end": 110, "tag": "drug"}, {"start": 165, "end": 175, "tag": "drug"}]}, {"content": "Preliminary animal and human studies have shown that small quantities of systemically administered leucovorin enter the CSF primarily as 5-methyltetrahydro-folate and, in humans, remain 1 to 3 orders of magnitude lower than the usual methotrexate concentrations following intrathecal administration.", "metadata": {"original_id": "DrugDDI.d341.s1"}, "annotations": [{"start": 99, "end": 110, "tag": "drug"}, {"start": 234, "end": 247, "tag": "drug"}]}, {"content": "However, high doses of leucovorin may reduce the efficacy of intrathecally administered methotrexate.", "metadata": {"original_id": "DrugDDI.d341.s2"}, "annotations": [{"start": 23, "end": 34, "tag": "drug"}, {"start": 88, "end": 101, "tag": "drug"}]}, {"content": "Leucovorin may enhance the toxicity of 5-fluorouracil.", "metadata": {"original_id": "DrugDDI.d341.s3"}, "annotations": [{"start": 0, "end": 11, "tag": "drug"}, {"start": 41, "end": 54, "tag": "drug"}]}, {"content": "1.", "metadata": {"original_id": "DrugDDI.d392.s0"}, "annotations": []}, {"content": "Drugs Metabolized by P450 2D6: The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the caucasian population (about 7 to 10% of caucasians are so called poor metabolizers);", "metadata": {"original_id": "DrugDDI.d392.s1"}, "annotations": [{"start": 0, "end": 6, "tag": "drug"}, {"start": 21, "end": 31, "tag": "drug"}, {"start": 63, "end": 68, "tag": "drug"}, {"start": 110, "end": 135, "tag": "drug"}]}, {"content": "reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available.", "metadata": {"original_id": "DrugDDI.d392.s2"}, "annotations": [{"start": 48, "end": 66, "tag": "drug"}]}, {"content": "Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses.", "metadata": {"original_id": "DrugDDI.d392.s3"}, "annotations": [{"start": 69, "end": 95, "tag": "drug"}]}, {"content": "Depending on the traction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA).", "metadata": {"original_id": "DrugDDI.d392.s4"}, "annotations": [{"start": 29, "end": 34, "tag": "drug"}, {"start": 49, "end": 59, "tag": "drug"}]}, {"content": "In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble p.o.", "metadata": {"original_id": "DrugDDI.d392.s5"}, "annotations": [{"start": 21, "end": 27, "tag": "drug"}, {"start": 56, "end": 64, "tag": "drug"}]}, {"content": "metabolizers.", "metadata": {"original_id": "DrugDDI.d392.s6"}, "annotations": []}, {"content": "An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy.", "metadata": {"original_id": "DrugDDI.d392.s7"}, "annotations": [{"start": 112, "end": 118, "tag": "drug"}]}, {"content": "The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine;", "metadata": {"original_id": "DrugDDI.d392.s8"}, "annotations": [{"start": 4, "end": 10, "tag": "drug"}, {"start": 23, "end": 43, "tag": "drug"}, {"start": 96, "end": 106, "tag": "drug"}]}, {"content": "cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythrnics propatenone and flecainide).", "metadata": {"original_id": "DrugDDI.d392.s9"}, "annotations": [{"start": 0, "end": 11, "tag": "drug"}, {"start": 45, "end": 55, "tag": "drug"}, {"start": 66, "end": 82, "tag": "drug"}, {"start": 83, "end": 98, "tag": "drug"}, {"start": 148, "end": 159, "tag": "drug"}]}, {"content": "While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, seriraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.", "metadata": {"original_id": "DrugDDI.d392.s10"}, "annotations": [{"start": 24, "end": 54, "tag": "drug"}, {"start": 69, "end": 80, "tag": "drug"}, {"start": 97, "end": 108, "tag": "drug"}, {"start": 117, "end": 127, "tag": "drug"}]}, {"content": "The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.", "metadata": {"original_id": "DrugDDI.d392.s11"}, "annotations": []}, {"content": "Nevertheless, caution is indicated in the co-administration of T.A. with any of the SSRIs and also in switching from one class to the other.", "metadata": {"original_id": "DrugDDI.d392.s12"}, "annotations": [{"start": 63, "end": 66, "tag": "drug"}]}, {"content": "Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).", "metadata": {"original_id": "DrugDDI.d392.s13"}, "annotations": [{"start": 120, "end": 131, "tag": "drug"}, {"start": 175, "end": 193, "tag": "drug"}]}, {"content": "Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug.", "metadata": {"original_id": "DrugDDI.d392.s14"}, "annotations": [{"start": 19, "end": 45, "tag": "drug"}, {"start": 50, "end": 56, "tag": "drug"}, {"start": 73, "end": 93, "tag": "drug"}, {"start": 156, "end": 181, "tag": "drug"}, {"start": 194, "end": 199, "tag": "drug"}]}, {"content": "Furthermore, whenever one of these other drugs is withdrawn from co-therapy, an increased dose of tricyclic antidepressant may be required.", "metadata": {"original_id": "DrugDDI.d392.s15"}, "annotations": [{"start": 41, "end": 47, "tag": "drug"}, {"start": 98, "end": 123, "tag": "drug"}]}, {"content": "It is desirable to monitor TCA plasma levels whenever a TCA is going to be co-administered with another drug known to be an inhibitor of P450 2D6.", "metadata": {"original_id": "DrugDDI.d392.s16"}, "annotations": [{"start": 104, "end": 109, "tag": "drug"}, {"start": 137, "end": 147, "tag": "drug"}]}, {"content": "2.", "metadata": {"original_id": "DrugDDI.d392.s17"}, "annotations": []}, {"content": "Close supervision and careful adjustment of dosage are required when this drug is given concomitantly with anticholinergic or sympathomimetic drugs.", "metadata": {"original_id": "DrugDDI.d392.s18"}, "annotations": [{"start": 74, "end": 79, "tag": "drug"}, {"start": 107, "end": 123, "tag": "drug"}, {"start": 126, "end": 148, "tag": "drug"}]}, {"content": "3.", "metadata": {"original_id": "DrugDDI.d392.s19"}, "annotations": []}, {"content": "Clinical experience in the concurrent administration of ECT and antidepressant drugs is limited.", "metadata": {"original_id": "DrugDDI.d392.s20"}, "annotations": [{"start": 64, "end": 85, "tag": "drug"}]}, {"content": "Thus, if such treatment is essential, the possibility of increased risk relative to benefits should be considered.", "metadata": {"original_id": "DrugDDI.d392.s21"}, "annotations": []}, {"content": "4.", "metadata": {"original_id": "DrugDDI.d392.s22"}, "annotations": []}, {"content": "If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.", "metadata": {"original_id": "DrugDDI.d392.s23"}, "annotations": [{"start": 3, "end": 29, "tag": "drug"}, {"start": 58, "end": 78, "tag": "drug"}, {"start": 86, "end": 100, "tag": "drug"}, {"start": 103, "end": 112, "tag": "drug"}, {"start": 112, "end": 122, "tag": "drug"}, {"start": 214, "end": 223, "tag": "drug"}, {"start": 234, "end": 246, "tag": "drug"}, {"start": 250, "end": 266, "tag": "drug"}, {"start": 273, "end": 290, "tag": "drug"}, {"start": 293, "end": 302, "tag": "drug"}]}, {"content": "Both the sedative and anticholinergic effects of the major tranquilizers are also additive to those of desipramine.", "metadata": {"original_id": "DrugDDI.d392.s24"}, "annotations": [{"start": 9, "end": 18, "tag": "drug"}, {"start": 22, "end": 38, "tag": "drug"}, {"start": 53, "end": 73, "tag": "drug"}, {"start": 103, "end": 115, "tag": "drug"}]}, {"content": "5.", "metadata": {"original_id": "DrugDDI.d392.s25"}, "annotations": []}, {"content": "Concurrent administration of cimetidine and tricyclic antidepressants can produce clinically significant increases in the plasma levels of the tricyclic antidepressants.", "metadata": {"original_id": "DrugDDI.d392.s26"}, "annotations": [{"start": 29, "end": 40, "tag": "drug"}, {"start": 44, "end": 70, "tag": "drug"}, {"start": 143, "end": 169, "tag": "drug"}]}, {"content": "Conversely, decreases in plasma levels of the tricyclic antidepressants have been reported upon discontinuation of cimetidine which may result in the loss of the therapeutic efficacy of the tricyclic antidepressant 6.", "metadata": {"original_id": "DrugDDI.d392.s27"}, "annotations": [{"start": 46, "end": 72, "tag": "drug"}, {"start": 115, "end": 126, "tag": "drug"}, {"start": 190, "end": 215, "tag": "drug"}]}, {"content": "There have been greater than two-fold increases of previously stable plasma levels of tricyclic antidepressants when fluoxetine has been administered in combination with these agents.", "metadata": {"original_id": "DrugDDI.d392.s28"}, "annotations": [{"start": 86, "end": 112, "tag": "drug"}, {"start": 117, "end": 128, "tag": "drug"}]}, {"content": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "metadata": {"original_id": "DrugDDI.d38.s0"}, "annotations": [{"start": 61, "end": 71, "tag": "drug"}, {"start": 76, "end": 85, "tag": "drug"}, {"start": 87, "end": 102, "tag": "drug"}, {"start": 103, "end": 117, "tag": "drug"}, {"start": 120, "end": 134, "tag": "drug"}, {"start": 135, "end": 149, "tag": "drug"}, {"start": 150, "end": 163, "tag": "drug"}, {"start": 197, "end": 207, "tag": "drug"}, {"start": 263, "end": 273, "tag": "drug"}, {"start": 278, "end": 291, "tag": "drug"}, {"start": 315, "end": 330, "tag": "drug"}, {"start": 340, "end": 358, "tag": "drug"}, {"start": 359, "end": 373, "tag": "drug"}, {"start": 386, "end": 396, "tag": "drug"}, {"start": 401, "end": 414, "tag": "drug"}, {"start": 446, "end": 456, "tag": "drug"}, {"start": 483, "end": 503, "tag": "drug"}, {"start": 514, "end": 524, "tag": "drug"}, {"start": 525, "end": 538, "tag": "drug"}, {"start": 578, "end": 598, "tag": "drug"}, {"start": 649, "end": 663, "tag": "drug"}]}, {"content": "Drug/Laboratory Interactions No formal drug interaction studies have been performed with Campath.", "metadata": {"original_id": "DrugDDI.d167.s0"}, "annotations": [{"start": 0, "end": 5, "tag": "drug"}, {"start": 89, "end": 97, "tag": "drug"}]}, {"content": "An immune response to Campath may interfere with subsequent diagnostic serum tests that utilize antibodies", "metadata": {"original_id": "DrugDDI.d167.s1"}, "annotations": [{"start": 22, "end": 30, "tag": "drug"}, {"start": 96, "end": 107, "tag": "drug"}]}, {"content": ".", "metadata": {"original_id": "DrugDDI.d167.s2"}, "annotations": []}, {"content": "? ?", "metadata": {"original_id": "DrugDDI.d167.s3"}, "annotations": []}, {"content": "Elevated plasma levels of theophylline have been reported with concomitant quinolone use.", "metadata": {"original_id": "DrugDDI.d485.s0"}, "annotations": [{"start": 26, "end": 39, "tag": "drug"}, {"start": 75, "end": 86, "tag": "drug"}]}, {"content": "There have been reports of theophylline-related side effects in patients on concomitant therapy with quinolones and theophylline.", "metadata": {"original_id": "DrugDDI.d485.s1"}, "annotations": [{"start": 27, "end": 40, "tag": "drug"}, {"start": 101, "end": 112, "tag": "drug"}, {"start": 116, "end": 129, "tag": "drug"}]}, {"content": "Therefore, monitoring of theophylline plasma levels should be considered and dosage of theophylline adjusted, as required.", "metadata": {"original_id": "DrugDDI.d485.s2"}, "annotations": [{"start": 25, "end": 38, "tag": "drug"}]}, {"content": "Quinolones have been shown to interfere with the metabolism of caffeine.", "metadata": {"original_id": "DrugDDI.d485.s3"}, "annotations": [{"start": 0, "end": 11, "tag": "drug"}, {"start": 63, "end": 72, "tag": "drug"}]}, {"content": "This may lead to reduced clearance of caffeine and the prolongation of its plasma half-life.", "metadata": {"original_id": "DrugDDI.d485.s4"}, "annotations": [{"start": 38, "end": 47, "tag": "drug"}]}, {"content": "Quinolones, including nalidixic acid, may enhance the effects of the oral anticoagulant warfarin or its derivatives.", "metadata": {"original_id": "DrugDDI.d485.s5"}, "annotations": [{"start": 0, "end": 11, "tag": "drug"}, {"start": 22, "end": 37, "tag": "drug"}, {"start": 69, "end": 98, "tag": "drug"}, {"start": 104, "end": 116, "tag": "drug"}]}, {"content": "When these products are administered concomitantly, prothrombin time or other suitable coagulation test should be closely monitored.", "metadata": {"original_id": "DrugDDI.d485.s6"}, "annotations": []}, {"content": "Nitrofurantoin interferes with the therapeutic action of nalidixic acid.", "metadata": {"original_id": "DrugDDI.d485.s7"}, "annotations": [{"start": 0, "end": 15, "tag": "drug"}, {"start": 57, "end": 72, "tag": "drug"}]}, {"content": "Antacids containing magnesium, aluminum, or calcium;", "metadata": {"original_id": "DrugDDI.d485.s8"}, "annotations": [{"start": 0, "end": 9, "tag": "drug"}, {"start": 20, "end": 30, "tag": "drug"}, {"start": 44, "end": 52, "tag": "drug"}]}, {"content": "sucralfate or divalent or trivalent cations such as iron;", "metadata": {"original_id": "DrugDDI.d485.s9"}, "annotations": [{"start": 0, "end": 11, "tag": "drug"}, {"start": 36, "end": 44, "tag": "drug"}, {"start": 52, "end": 57, "tag": "drug"}]}, {"content": "multivitamins containing zinc;", "metadata": {"original_id": "DrugDDI.d485.s10"}, "annotations": [{"start": 0, "end": 14, "tag": "drug"}, {"start": 25, "end": 30, "tag": "drug"}]}, {"content": "and Videx?, (Didanosine), chewable/buffered tablets or the pediatric powder for oral solution may substantially interfere with the absorption of quinolones, resulting in systemic levels considerably lower than desired.", "metadata": {"original_id": "DrugDDI.d485.s11"}, "annotations": [{"start": 13, "end": 24, "tag": "drug"}, {"start": 35, "end": 42, "tag": "drug"}, {"start": 59, "end": 69, "tag": "drug"}, {"start": 145, "end": 156, "tag": "drug"}]}, {"content": "These agents should not be taken within the two hour period before or within the two-hour period after nalidixic acid administration.", "metadata": {"original_id": "DrugDDI.d485.s12"}, "annotations": [{"start": 103, "end": 118, "tag": "drug"}]}, {"content": "Elevated serum levels of cyclosporine have been reported with the concomitant use of some quinolones and cyclosporine.", "metadata": {"original_id": "DrugDDI.d485.s13"}, "annotations": [{"start": 25, "end": 38, "tag": "drug"}, {"start": 90, "end": 101, "tag": "drug"}, {"start": 105, "end": 118, "tag": "drug"}]}, {"content": "Therefore, cyclosporine serum levels should be monitored and appropriate cyclosporine dosage adjustments made when these drugs are used concomitantly.", "metadata": {"original_id": "DrugDDI.d485.s14"}, "annotations": [{"start": 11, "end": 24, "tag": "drug"}, {"start": 73, "end": 86, "tag": "drug"}, {"start": 121, "end": 127, "tag": "drug"}]}, {"content": ")", "metadata": {"original_id": "DrugDDI.d57.s0"}, "annotations": []}, {"content": "?", "metadata": {"original_id": "DrugDDI.d57.s1"}, "annotations": []}, {"content": "?Clinical Laboratory", "metadata": {"original_id": "DrugDDI.d57.s2"}, "annotations": []}, {"content": "?", "metadata": {"original_id": "DrugDDI.d57.s3"}, "annotations": []}, {"content": "increased creatine", "metadata": {"original_id": "DrugDDI.d57.s4"}, "annotations": [{"start": 10, "end": 19, "tag": "drug"}]}, {"content": "positive antinuclear", "metadata": {"original_id": "DrugDDI.d57.s5"}, "annotations": []}, {"content": "?", "metadata": {"original_id": "DrugDDI.d57.s6"}, "annotations": []}, {"content": "phosphokinase", "metadata": {"original_id": "DrugDDI.d57.s7"}, "annotations": [{"start": 0, "end": 14, "tag": "drug"}]}, {"content": "antibody", "metadata": {"original_id": "DrugDDI.d57.s8"}, "annotations": [{"start": 0, "end": 9, "tag": "drug"}]}, {"content": "?", "metadata": {"original_id": "DrugDDI.d57.s9"}, "annotations": []}, {"content": "increased bilirubin", "metadata": {"original_id": "DrugDDI.d57.s10"}, "annotations": [{"start": 10, "end": 20, "tag": "drug"}]}, {"content": "?", "metadata": {"original_id": "DrugDDI.d57.s11"}, "annotations": []}, {"content": "?", "metadata": {"original_id": "DrugDDI.d57.s12"}, "annotations": []}, {"content": "increased liver", "metadata": {"original_id": "DrugDDI.d57.s13"}, "annotations": [{"start": 10, "end": 16, "tag": "drug"}]}, {"content": "?", "metadata": {"original_id": "DrugDDI.d57.s14"}, "annotations": []}, {"content": "?", "metadata": {"original_id": "DrugDDI.d57.s15"}, "annotations": []}, {"content": "transaminases (AST", "metadata": {"original_id": "DrugDDI.d57.s16"}, "annotations": [{"start": 0, "end": 14, "tag": "drug"}, {"start": 15, "end": 19, "tag": "drug"}]}, {"content": "?", "metadata": {"original_id": "DrugDDI.d57.s17"}, "annotations": []}, {"content": "?", "metadata": {"original_id": "DrugDDI.d57.s18"}, "annotations": []}, {"content": "(SGOT), ALT (SGPT)", "metadata": {"original_id": "DrugDDI.d57.s19"}, "annotations": []}, {"content": "?", "metadata": {"original_id": "DrugDDI.d57.s20"}, "annotations": []}, {"content": "?", "metadata": {"original_id": "DrugDDI.d57.s21"}, "annotations": []}, {"content": "increased alkaline", "metadata": {"original_id": "DrugDDI.d57.s22"}, "annotations": []}, {"content": "?", "metadata": {"original_id": "DrugDDI.d57.s23"}, "annotations": []}, {"content": "?", "metadata": {"original_id": "DrugDDI.d57.s24"}, "annotations": []}, {"content": "phophatase", "metadata": {"original_id": "DrugDDI.d57.s25"}, "annotations": []}, {"content": "?", "metadata": {"original_id": "DrugDDI.d57.s26"}, "annotations": []}, {"content": "?Hematopoietic", "metadata": {"original_id": "DrugDDI.d57.s27"}, "annotations": []}, {"content": "anemia", "metadata": {"original_id": "DrugDDI.d57.s28"}, "annotations": []}, {"content": "thrombocytopenia", "metadata": {"original_id": "DrugDDI.d57.s29"}, "annotations": []}, {"content": "?", "metadata": {"original_id": "DrugDDI.d57.s30"}, "annotations": []}, {"content": "leukopenia", "metadata": {"original_id": "DrugDDI.d57.s31"}, "annotations": []}, {"content": "?", "metadata": {"original_id": "DrugDDI.d57.s32"}, "annotations": []}, {"content": "?", "metadata": {"original_id": "DrugDDI.d57.s33"}, "annotations": []}, {"content": "bone marrow hypoplasia", "metadata": {"original_id": "DrugDDI.d57.s34"}, "annotations": []}, {"content": "?", "metadata": {"original_id": "DrugDDI.d57.s35"}, "annotations": []}, {"content": "?", "metadata": {"original_id": "DrugDDI.d57.s36"}, "annotations": []}, {"content": "eosinophilia", "metadata": {"original_id": "DrugDDI.d57.s37"}, "annotations": []}, {"content": "?", "metadata": {"original_id": "DrugDDI.d57.s38"}, "annotations": []}, {"content": "?Immunologic", "metadata": {"original_id": "DrugDDI.d57.s39"}, "annotations": []}, {"content": "angioedema", "metadata": {"original_id": "DrugDDI.d57.s40"}, "annotations": []}, {"content": "anaphylaxis", "metadata": {"original_id": "DrugDDI.d57.s41"}, "annotations": []}, {"content": "?", "metadata": {"original_id": "DrugDDI.d57.s42"}, "annotations": []}, {"content": "laryngeal edema", "metadata": {"original_id": "DrugDDI.d57.s43"}, "annotations": []}, {"content": "Lupus-like syndrome", "metadata": {"original_id": "DrugDDI.d57.s44"}, "annotations": []}, {"content": "?", "metadata": {"original_id": "DrugDDI.d57.s45"}, "annotations": []}, {"content": "urticaria", "metadata": {"original_id": "DrugDDI.d57.s46"}, "annotations": []}, {"content": "vasculitis", "metadata": {"original_id": "DrugDDI.d57.s47"}, "annotations": []}, {"content": "?Integumentary", "metadata": {"original_id": "DrugDDI.d57.s48"}, "annotations": []}, {"content": "exfoliative dermatitis", "metadata": {"original_id": "DrugDDI.d57.s49"}, "annotations": []}, {"content": "alopecia", "metadata": {"original_id": "DrugDDI.d57.s50"}, "annotations": []}, {"content": "?", "metadata": {"original_id": "DrugDDI.d57.s51"}, "annotations": []}, {"content": "rash", "metadata": {"original_id": "DrugDDI.d57.s52"}, "annotations": []}, {"content": "?", "metadata": {"original_id": "DrugDDI.d57.s53"}, "annotations": []}, {"content": "?", "metadata": {"original_id": "DrugDDI.d57.s54"}, "annotations": []}, {"content": "dermatitis", "metadata": {"original_id": "DrugDDI.d57.s55"}, "annotations": []}, {"content": "?", "metadata": {"original_id": "DrugDDI.d57.s56"}, "annotations": []}, {"content": "?", "metadata": {"original_id": "DrugDDI.d57.s57"}, "annotations": []}, {"content": "pruritus", "metadata": {"original_id": "DrugDDI.d57.s58"}, "annotations": []}, {"content": "?", "metadata": {"original_id": "DrugDDI.d57.s59"}, "annotations": []}, {"content": "The adverse effects of CAMPTOSAR, such as myelosuppression and diarrhea, would be expected to be exacerbated by other antineoplastic agents having similar adverse effects.", "metadata": {"original_id": "DrugDDI.d177.s0"}, "annotations": [{"start": 23, "end": 33, "tag": "drug"}, {"start": 112, "end": 140, "tag": "drug"}]}, {"content": "Patients who have previously received pelvic/ abdominal irradiation are at increased risk of severe myelosuppression following the administration of CAMPTOSAR.", "metadata": {"original_id": "DrugDDI.d177.s1"}, "annotations": [{"start": 149, "end": 159, "tag": "drug"}]}, {"content": "The concurrent administration of CAMPTOSAR with irradiation has not been adequately studied and is not recommended.", "metadata": {"original_id": "DrugDDI.d177.s2"}, "annotations": [{"start": 33, "end": 43, "tag": "drug"}]}, {"content": "Lymphocytopenia has been reported in patients receiving CAMPTOSAR, and it is possible that the administration of dexamethasone as antiemetic prophylaxis may have enhanced the likelihood of this effect.", "metadata": {"original_id": "DrugDDI.d177.s3"}, "annotations": [{"start": 56, "end": 66, "tag": "drug"}, {"start": 113, "end": 127, "tag": "drug"}, {"start": 130, "end": 141, "tag": "drug"}]}, {"content": "However, serious opportunistic infections have not been observed, and no complications have specifically been attributed to lymphocytopenia.", "metadata": {"original_id": "DrugDDI.d177.s4"}, "annotations": []}, {"content": "Hyperglycemia has also been reported in patients receiving CAMPTOSAR.", "metadata": {"original_id": "DrugDDI.d177.s5"}, "annotations": [{"start": 59, "end": 69, "tag": "drug"}]}, {"content": "Usually, this has been observed in patients with a history of diabetes mellitus or evidence of glucose intolerance prior to administration of CAMPTOSAR.", "metadata": {"original_id": "DrugDDI.d177.s6"}, "annotations": [{"start": 142, "end": 152, "tag": "drug"}]}, {"content": "It is probable that dexamethasone, given as antiemetic prophylaxis, contributed to hyperglycemia in some patients.", "metadata": {"original_id": "DrugDDI.d177.s7"}, "annotations": [{"start": 20, "end": 34, "tag": "drug"}, {"start": 44, "end": 55, "tag": "drug"}]}, {"content": "The incidence of akathisia in clinical trials of the weekly dosage schedule was greater (8.5%, 4/47 patients) when prochlorperazine was administered on the same day as CAMPTOSAR than when these drugs were given on separate days (1.3%, 1/80 patients).", "metadata": {"original_id": "DrugDDI.d177.s8"}, "annotations": [{"start": 115, "end": 132, "tag": "drug"}, {"start": 168, "end": 178, "tag": "drug"}, {"start": 194, "end": 200, "tag": "drug"}]}, {"content": "The 8.5% incidence of akathisia, however, is within the range reported for use of prochlorperazine when given as a premedication for other chemotherapies.", "metadata": {"original_id": "DrugDDI.d177.s9"}, "annotations": [{"start": 82, "end": 99, "tag": "drug"}]}, {"content": "It would be expected that laxative use during therapy with CAMPTOSAR would worsen the incidence or severity of diarrhea, but this has not been studied.", "metadata": {"original_id": "DrugDDI.d177.s10"}, "annotations": [{"start": 26, "end": 35, "tag": "drug"}, {"start": 59, "end": 69, "tag": "drug"}]}, {"content": "In view of the potential risk of dehydration secondary to vomiting and/or diarrhea induced by CAMPTOSAR, the physician may wish to withhold diuretics during dosing with CAMPTOSAR and, certainly, during periods of active vomiting or diarrhea.", "metadata": {"original_id": "DrugDDI.d177.s11"}, "annotations": [{"start": 94, "end": 104, "tag": "drug"}, {"start": 140, "end": 150, "tag": "drug"}, {"start": 169, "end": 179, "tag": "drug"}]}, {"content": "Drug-Laboratory Test Interactions There are no known interactions between CAMPTOSAR and laboratory tests.", "metadata": {"original_id": "DrugDDI.d177.s12"}, "annotations": [{"start": 74, "end": 84, "tag": "drug"}]}, {"content": "Colchicine is inhibited by acidifying agents.", "metadata": {"original_id": "DrugDDI.d474.s0"}, "annotations": [{"start": 0, "end": 11, "tag": "drug"}, {"start": 27, "end": 45, "tag": "drug"}]}, {"content": "The action of colchicine is potentiated by alkalinizing agents.", "metadata": {"original_id": "DrugDDI.d474.s1"}, "annotations": [{"start": 14, "end": 25, "tag": "drug"}, {"start": 43, "end": 63, "tag": "drug"}]}, {"content": "Colchicine may increase sensitivity to the CNS depressants.", "metadata": {"original_id": "DrugDDI.d474.s2"}, "annotations": [{"start": 0, "end": 11, "tag": "drug"}, {"start": 43, "end": 59, "tag": "drug"}]}, {"content": "Response to sympathomimetic agents may be enhanced by colchicine.", "metadata": {"original_id": "DrugDDI.d474.s3"}, "annotations": [{"start": 12, "end": 35, "tag": "drug"}, {"start": 54, "end": 65, "tag": "drug"}]}, {"content": "No significant drug interactions have been reported in studies of candesartan cilexetil given with other drugs such as glyburide, nifedipine, digoxin, warfarin, hydrochlorothiazide, and oral contraceptives in healthy volunteers, or given with enalapril to patients with heart failure (NYHA class II and III).", "metadata": {"original_id": "DrugDDI.d349.s0"}, "annotations": [{"start": 66, "end": 88, "tag": "drug"}, {"start": 105, "end": 111, "tag": "drug"}, {"start": 119, "end": 129, "tag": "drug"}, {"start": 130, "end": 141, "tag": "drug"}, {"start": 142, "end": 150, "tag": "drug"}, {"start": 151, "end": 160, "tag": "drug"}, {"start": 161, "end": 181, "tag": "drug"}, {"start": 186, "end": 206, "tag": "drug"}, {"start": 243, "end": 253, "tag": "drug"}]}, {"content": "Because candesartan is not significantly metabolized by the cytochrome P450 system and at therapeutic concentrations has no effects on P450 enzymes, interactions with drugs that inhibit or are metabolized by those enzymes would not be expected.", "metadata": {"original_id": "DrugDDI.d349.s1"}, "annotations": [{"start": 8, "end": 20, "tag": "drug"}, {"start": 60, "end": 76, "tag": "drug"}, {"start": 135, "end": 140, "tag": "drug"}, {"start": 167, "end": 173, "tag": "drug"}]}, {"content": "Lithium? Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors, and with some angiotensin II receptor antagonists.", "metadata": {"original_id": "DrugDDI.d349.s2"}, "annotations": [{"start": 39, "end": 47, "tag": "drug"}, {"start": 131, "end": 139, "tag": "drug"}, {"start": 144, "end": 159, "tag": "drug"}, {"start": 174, "end": 210, "tag": "drug"}]}, {"content": "An increase in serum lithium concentration has been reported during concomitant administration of lithium with ATACAND, so careful monitoring of serum lithium levels is recommended during concomitant use.", "metadata": {"original_id": "DrugDDI.d349.s3"}, "annotations": [{"start": 21, "end": 29, "tag": "drug"}, {"start": 98, "end": 106, "tag": "drug"}, {"start": 111, "end": 119, "tag": "drug"}]}, {"content": "Use of Cerubidine in a patient who has previously received doxorubicin increases the risk of cardiotoxicity.", "metadata": {"original_id": "DrugDDI.d51.s0"}, "annotations": [{"start": 7, "end": 18, "tag": "drug"}, {"start": 59, "end": 71, "tag": "drug"}]}, {"content": "Cerubidine should not be used in patients who have previously received the recommended maximum cumulative doses of doxorubicin or Cerubidine.", "metadata": {"original_id": "DrugDDI.d51.s1"}, "annotations": [{"start": 0, "end": 11, "tag": "drug"}, {"start": 115, "end": 127, "tag": "drug"}, {"start": 130, "end": 141, "tag": "drug"}]}, {"content": "Cyclophosphamide used concurrently with Cerubidine may also result in increased cardiotoxicity.", "metadata": {"original_id": "DrugDDI.d51.s2"}, "annotations": [{"start": 0, "end": 17, "tag": "drug"}, {"start": 40, "end": 51, "tag": "drug"}]}, {"content": "Dosage reduction of Cerubidine may be required when used concurrently with other myelosuppressive agents.", "metadata": {"original_id": "DrugDDI.d51.s3"}, "annotations": [{"start": 20, "end": 31, "tag": "drug"}]}, {"content": "Hepatotoxic medications, such as high-dose methotrexate, may impair liver function and increase the risk of toxicity.", "metadata": {"original_id": "DrugDDI.d51.s4"}, "annotations": [{"start": 12, "end": 24, "tag": "drug"}, {"start": 43, "end": 56, "tag": "drug"}]}, {"content": "The use of codeine may result in additive CNS depressant effects when coadministered with alcohol, antihistamines, psychotropics or other drugs that produce CNS depression.", "metadata": {"original_id": "DrugDDI.d244.s0"}, "annotations": [{"start": 11, "end": 19, "tag": "drug"}, {"start": 42, "end": 57, "tag": "drug"}, {"start": 90, "end": 98, "tag": "drug"}, {"start": 99, "end": 114, "tag": "drug"}, {"start": 138, "end": 144, "tag": "drug"}]}, {"content": "Serious toxicity may result if dextromethorphan is coadministered with monoamine oxidase inhibitors (MAOIs).", "metadata": {"original_id": "DrugDDI.d244.s1"}, "annotations": [{"start": 31, "end": 48, "tag": "drug"}, {"start": 71, "end": 100, "tag": "drug"}]}, {"content": "The use of dextromethorphan hydrobromide may result in additive CNS depressant effects when coadministered with alcohol, antihistamines, psychotropics or other drugs that produce CNS depression.", "metadata": {"original_id": "DrugDDI.d244.s2"}, "annotations": [{"start": 11, "end": 41, "tag": "drug"}, {"start": 64, "end": 79, "tag": "drug"}, {"start": 112, "end": 120, "tag": "drug"}, {"start": 121, "end": 136, "tag": "drug"}, {"start": 160, "end": 166, "tag": "drug"}]}, {"content": "Known drug interactions include barbiturates, tranquilizers, and alcohol.", "metadata": {"original_id": "DrugDDI.d448.s0"}, "annotations": [{"start": 32, "end": 45, "tag": "drug"}, {"start": 46, "end": 60, "tag": "drug"}, {"start": 65, "end": 73, "tag": "drug"}]}, {"content": "Diphenoxylate HCl and atropine sulfate may interact with MAO inhibitors In studies with male rats, diphenoxylate hydrochloride was found to inhibit the hepatic microsomal enzyme system at a dose of 2 mg/kg/day.", "metadata": {"original_id": "DrugDDI.d448.s1"}, "annotations": [{"start": 0, "end": 18, "tag": "drug"}, {"start": 22, "end": 39, "tag": "drug"}, {"start": 57, "end": 72, "tag": "drug"}, {"start": 99, "end": 127, "tag": "drug"}, {"start": 160, "end": 178, "tag": "drug"}]}, {"content": "Therefore, diphenoxylate has the potential to prolong the biological half-lives of drugs for which the rate of elimination is dependent on the microsomal drug metabolizing enzyme system.", "metadata": {"original_id": "DrugDDI.d448.s2"}, "annotations": [{"start": 11, "end": 25, "tag": "drug"}, {"start": 83, "end": 89, "tag": "drug"}, {"start": 143, "end": 159, "tag": "drug"}]}, {"content": "No formal drug interaction studies have been conducted with Cyanokit.", "metadata": {"original_id": "DrugDDI.d523.s0"}, "annotations": []}, {"content": "Catecholamine-depleting drugs, such as reserpine, may have an additive effect when given with beta-blocking agents.", "metadata": {"original_id": "DrugDDI.d518.s0"}, "annotations": [{"start": 24, "end": 30, "tag": "drug"}, {"start": 39, "end": 49, "tag": "drug"}, {"start": 94, "end": 114, "tag": "drug"}]}, {"content": "Patients treated with acebutolol plus catecholamine depletors should, therefore, be observed closely for evidence of marked bradycardia or hypotension which may present as vertigo, syncope/presyncope, or orthostatic changes in blood pressure without compensatory tachycardia.", "metadata": {"original_id": "DrugDDI.d518.s1"}, "annotations": [{"start": 22, "end": 33, "tag": "drug"}]}, {"content": "Exaggerated hypertensive responses have been reported from the combined use of beta-adrenergic antagonists and alpha-adrenergic stimulants, including those contained in proprietary cold remedies and vasoconstrictive nasal drops.", "metadata": {"original_id": "DrugDDI.d518.s2"}, "annotations": [{"start": 79, "end": 106, "tag": "drug"}, {"start": 128, "end": 139, "tag": "drug"}]}, {"content": "Patients receiving beta-blockers should be warned of this potential hazard.", "metadata": {"original_id": "DrugDDI.d518.s3"}, "annotations": [{"start": 19, "end": 34, "tag": "drug"}]}, {"content": "Blunting of the antihypertensive effect of beta-adrenoceptor blocking agents by nonsteroidal anti-inflammatory drugs has been reported.", "metadata": {"original_id": "DrugDDI.d518.s4"}, "annotations": [{"start": 16, "end": 33, "tag": "drug"}, {"start": 43, "end": 76, "tag": "drug"}, {"start": 80, "end": 117, "tag": "drug"}]}, {"content": "No significant interactions with digoxin, hydrochlorothiazide, hydralazine, sulfinpyrazone, oral contraceptives, tolbutamide, or warfarin have been observed.", "metadata": {"original_id": "DrugDDI.d518.s5"}, "annotations": [{"start": 33, "end": 41, "tag": "drug"}, {"start": 42, "end": 62, "tag": "drug"}, {"start": 63, "end": 75, "tag": "drug"}, {"start": 76, "end": 91, "tag": "drug"}, {"start": 92, "end": 112, "tag": "drug"}, {"start": 113, "end": 125, "tag": "drug"}, {"start": 129, "end": 138, "tag": "drug"}]}, {"content": "Efavirenz has been shown in vivo to induce CYP3A4.", "metadata": {"original_id": "DrugDDI.d496.s0"}, "annotations": [{"start": 0, "end": 10, "tag": "drug"}, {"start": 43, "end": 50, "tag": "drug"}]}, {"content": "Other compounds that are substrates of CYP3A4 may have decreased plasma concentrations when coadministered with SUSTIVA (efavirenz).", "metadata": {"original_id": "DrugDDI.d496.s1"}, "annotations": [{"start": 39, "end": 46, "tag": "drug"}, {"start": 112, "end": 120, "tag": "drug"}, {"start": 121, "end": 131, "tag": "drug"}]}, {"content": "In vitro studies have demonstrated that efavirenz inhibits 2C9, 2C19, and 3A4 isozymes in the range of observed efavirenz plasma concentrations.", "metadata": {"original_id": "DrugDDI.d496.s2"}, "annotations": [{"start": 40, "end": 50, "tag": "drug"}, {"start": 78, "end": 87, "tag": "drug"}, {"start": 112, "end": 122, "tag": "drug"}]}, {"content": "Coadministration of efavirenz with drugs primarily metabolized by these isozymes may result in altered plasma concentrations of the coadministered drug.", "metadata": {"original_id": "DrugDDI.d496.s3"}, "annotations": [{"start": 20, "end": 30, "tag": "drug"}, {"start": 35, "end": 41, "tag": "drug"}, {"start": 72, "end": 81, "tag": "drug"}, {"start": 147, "end": 152, "tag": "drug"}]}, {"content": "Therefore, appropriate dose adjustments may be necessary for these drugs.", "metadata": {"original_id": "DrugDDI.d496.s4"}, "annotations": [{"start": 67, "end": 73, "tag": "drug"}]}, {"content": "Drugs which induce CYP3A4 activity (eg, phenobarbital, rifampin, rifabutin) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.", "metadata": {"original_id": "DrugDDI.d496.s5"}, "annotations": [{"start": 0, "end": 6, "tag": "drug"}, {"start": 19, "end": 26, "tag": "drug"}, {"start": 40, "end": 54, "tag": "drug"}, {"start": 55, "end": 64, "tag": "drug"}, {"start": 65, "end": 75, "tag": "drug"}, {"start": 123, "end": 133, "tag": "drug"}]}, {"content": "Drug interactions with SUSTIVA are summarized in Table 5.", "metadata": {"original_id": "DrugDDI.d496.s6"}, "annotations": [{"start": 23, "end": 31, "tag": "drug"}]}, {"content": "Table 5a: Drugs That Should Not Be Coadministered With SUSTIVA", "metadata": {"original_id": "DrugDDI.d496.s7"}, "annotations": [{"start": 10, "end": 16, "tag": "drug"}, {"start": 55, "end": 63, "tag": "drug"}]}, {"content": "Drug Class", "metadata": {"original_id": "DrugDDI.d496.s8"}, "annotations": [{"start": 0, "end": 5, "tag": "drug"}]}, {"content": "Drugs Within Class Not To Be Coadministered With SUSTIVA", "metadata": {"original_id": "DrugDDI.d496.s9"}, "annotations": [{"start": 0, "end": 6, "tag": "drug"}, {"start": 49, "end": 57, "tag": "drug"}]}, {"content": "Antihistamines Benzodiazepines GI Motility Agents Anti-Migraine Antifungal", "metadata": {"original_id": "DrugDDI.d496.s10"}, "annotations": [{"start": 0, "end": 15, "tag": "drug"}]}, {"content": "astemizole midazolam, triazolam cisapride ergot derivatives voriconazole", "metadata": {"original_id": "DrugDDI.d496.s11"}, "annotations": [{"start": 0, "end": 11, "tag": "drug"}, {"start": 22, "end": 32, "tag": "drug"}, {"start": 60, "end": 73, "tag": "drug"}]}, {"content": "Established Drug Interactions", "metadata": {"original_id": "DrugDDI.d496.s12"}, "annotations": []}, {"content": "?", "metadata": {"original_id": "DrugDDI.d496.s13"}, "annotations": []}, {"content": "Drug Name", "metadata": {"original_id": "DrugDDI.d496.s14"}, "annotations": [{"start": 0, "end": 5, "tag": "drug"}]}, {"content": "Effect", "metadata": {"original_id": "DrugDDI.d496.s15"}, "annotations": []}, {"content": "Clinical Comment", "metadata": {"original_id": "DrugDDI.d496.s16"}, "annotations": []}, {"content": "Atazanavir", "metadata": {"original_id": "DrugDDI.d496.s17"}, "annotations": [{"start": 0, "end": 11, "tag": "drug"}]}, {"content": "?atazanavir", "metadata": {"original_id": "DrugDDI.d496.s18"}, "annotations": []}, {"content": "When coadministered with SUSTIVA in treatment-naive patients, the recommended dose of atazanavir is 300 mg with ritonavir 100 mg and SUSTIVA 600 mg (all once daily).", "metadata": {"original_id": "DrugDDI.d496.s19"}, "annotations": [{"start": 25, "end": 33, "tag": "drug"}, {"start": 86, "end": 97, "tag": "drug"}, {"start": 112, "end": 129, "tag": "drug"}, {"start": 133, "end": 141, "tag": "drug"}]}, {"content": "Dosing recommendations for SUSTIVA and atazanavir in treatment-experienced patients have not been established.", "metadata": {"original_id": "DrugDDI.d496.s20"}, "annotations": [{"start": 27, "end": 35, "tag": "drug"}, {"start": 39, "end": 50, "tag": "drug"}]}, {"content": "Established Drug Interactions (continued)", "metadata": {"original_id": "DrugDDI.d496.s21"}, "annotations": []}, {"content": "Drug Name", "metadata": {"original_id": "DrugDDI.d496.s22"}, "annotations": [{"start": 0, "end": 5, "tag": "drug"}]}, {"content": "Effect", "metadata": {"original_id": "DrugDDI.d496.s23"}, "annotations": []}, {"content": "Clinical Comment", "metadata": {"original_id": "DrugDDI.d496.s24"}, "annotations": []}, {"content": "Clarithromycin", "metadata": {"original_id": "DrugDDI.d496.s25"}, "annotations": [{"start": 0, "end": 15, "tag": "drug"}]}, {"content": "??clarithromycin concentration", "metadata": {"original_id": "DrugDDI.d496.s26"}, "annotations": [{"start": 2, "end": 17, "tag": "drug"}]}, {"content": "Plasma concentrations decreased by SUSTIVA;", "metadata": {"original_id": "DrugDDI.d496.s27"}, "annotations": [{"start": 35, "end": 43, "tag": "drug"}]}, {"content": "clinical significance unknown.", "metadata": {"original_id": "DrugDDI.d496.s28"}, "annotations": []}, {"content": "In uninfected volunteers, 46% developed rash while receiving SUSTIVA and clarithromycin.", "metadata": {"original_id": "DrugDDI.d496.s29"}, "annotations": [{"start": 61, "end": 69, "tag": "drug"}, {"start": 73, "end": 88, "tag": "drug"}]}, {"content": "No dose adjustment of SUSTIVA is recommended when given with clarithromycin.", "metadata": {"original_id": "DrugDDI.d496.s30"}, "annotations": [{"start": 22, "end": 30, "tag": "drug"}, {"start": 61, "end": 76, "tag": "drug"}]}, {"content": "Alternatives to clarithromycin, such as azithromycin, should be considered.", "metadata": {"original_id": "DrugDDI.d496.s31"}, "annotations": [{"start": 16, "end": 31, "tag": "drug"}, {"start": 40, "end": 53, "tag": "drug"}]}, {"content": "Other macrolide antibiotics, such as erythromycin, have not been studied in combination with SUSTIVA.", "metadata": {"original_id": "DrugDDI.d496.s32"}, "annotations": [{"start": 6, "end": 28, "tag": "drug"}, {"start": 37, "end": 50, "tag": "drug"}, {"start": 93, "end": 101, "tag": "drug"}]}, {"content": "??", "metadata": {"original_id": "DrugDDI.d496.s33"}, "annotations": []}, {"content": "14-OH metabolite concentration", "metadata": {"original_id": "DrugDDI.d496.s34"}, "annotations": []}, {"content": "Indinavir", "metadata": {"original_id": "DrugDDI.d496.s35"}, "annotations": [{"start": 0, "end": 10, "tag": "drug"}]}, {"content": "??indinavir concentration", "metadata": {"original_id": "DrugDDI.d496.s36"}, "annotations": [{"start": 2, "end": 12, "tag": "drug"}]}, {"content": "The optimal dose of indinavir, when given in combination with SUSTIVA, is not known.", "metadata": {"original_id": "DrugDDI.d496.s37"}, "annotations": [{"start": 20, "end": 30, "tag": "drug"}, {"start": 62, "end": 70, "tag": "drug"}]}, {"content": "Increasing the indinavir dose to 1000 mg every 8 hours does not compensate for the increased indinavir metabolism due to SUSTIVA.", "metadata": {"original_id": "DrugDDI.d496.s38"}, "annotations": [{"start": 15, "end": 25, "tag": "drug"}, {"start": 93, "end": 103, "tag": "drug"}, {"start": 121, "end": 129, "tag": "drug"}]}, {"content": "When indinavir at an increased dose (1000 mg every 8 hours) was given with SUSTIVA (600 mg once daily), the indinavir AUC and Cmin were decreased on average by 33-46% and 39-57%, respectively, compared to when indinavir (800 mg every 8 hours) was given alone.", "metadata": {"original_id": "DrugDDI.d496.s39"}, "annotations": [{"start": 5, "end": 15, "tag": "drug"}, {"start": 75, "end": 83, "tag": "drug"}, {"start": 108, "end": 118, "tag": "drug"}, {"start": 210, "end": 220, "tag": "drug"}]}, {"content": "Lopinavir/ritonavir", "metadata": {"original_id": "DrugDDI.d496.s40"}, "annotations": [{"start": 0, "end": 10, "tag": "drug"}, {"start": 10, "end": 20, "tag": "drug"}]}, {"content": "??lopinavir concentration", "metadata": {"original_id": "DrugDDI.d496.s41"}, "annotations": [{"start": 2, "end": 12, "tag": "drug"}]}, {"content": "A dose increase of lopinavir/ritonavir to 533/133 mg (4 capsules or 6.5 mL) twice daily taken with food is recommended when used in combination with SUSTIVA.", "metadata": {"original_id": "DrugDDI.d496.s42"}, "annotations": [{"start": 19, "end": 29, "tag": "drug"}, {"start": 29, "end": 39, "tag": "drug"}, {"start": 149, "end": 157, "tag": "drug"}]}, {"content": "Methadone", "metadata": {"original_id": "DrugDDI.d496.s43"}, "annotations": [{"start": 0, "end": 10, "tag": "drug"}]}, {"content": "??methadone concentration", "metadata": {"original_id": "DrugDDI.d496.s44"}, "annotations": [{"start": 2, "end": 12, "tag": "drug"}]}, {"content": "Coadministration in HIV-infected individuals with a history of injection drug use resulted in decreased plasma levels of methadone and signs of opiate withdrawal.", "metadata": {"original_id": "DrugDDI.d496.s45"}, "annotations": [{"start": 121, "end": 131, "tag": "drug"}, {"start": 144, "end": 151, "tag": "drug"}]}, {"content": "Methadone dose was increased by a mean of 22% to alleviate withdrawal symptoms.", "metadata": {"original_id": "DrugDDI.d496.s46"}, "annotations": []}, {"content": "Patients should be monitored for signs of withdrawal and their methadone dose increased as required to alleviate withdrawal symptoms.", "metadata": {"original_id": "DrugDDI.d496.s47"}, "annotations": []}, {"content": "Ethinyl estradiol", "metadata": {"original_id": "DrugDDI.d496.s48"}, "annotations": [{"start": 0, "end": 18, "tag": "drug"}]}, {"content": "??ethinyl estradiol concentration", "metadata": {"original_id": "DrugDDI.d496.s49"}, "annotations": [{"start": 2, "end": 20, "tag": "drug"}]}, {"content": "Plasma concentrations increased by SUSTIVA (efavirenz);", "metadata": {"original_id": "DrugDDI.d496.s50"}, "annotations": [{"start": 35, "end": 43, "tag": "drug"}, {"start": 44, "end": 54, "tag": "drug"}]}, {"content": "clinical significance unknown.", "metadata": {"original_id": "DrugDDI.d496.s51"}, "annotations": []}, {"content": "Because the potential interaction of efavirenz with oral contraceptives has not been fully characterized, a reliable method of barrier contraception should be used in addition to oral contraceptives.", "metadata": {"original_id": "DrugDDI.d496.s52"}, "annotations": [{"start": 37, "end": 47, "tag": "drug"}, {"start": 52, "end": 72, "tag": "drug"}, {"start": 179, "end": 199, "tag": "drug"}]}, {"content": "Rifabutin", "metadata": {"original_id": "DrugDDI.d496.s53"}, "annotations": [{"start": 0, "end": 10, "tag": "drug"}]}, {"content": "??rifabutin concentration", "metadata": {"original_id": "DrugDDI.d496.s54"}, "annotations": [{"start": 2, "end": 12, "tag": "drug"}]}, {"content": "Increase daily dose of rifabutin by 50%.", "metadata": {"original_id": "DrugDDI.d496.s55"}, "annotations": [{"start": 23, "end": 33, "tag": "drug"}]}, {"content": "Consider doubling the rifabutin dose in regimens where rifabutin is given 2 or 3 times a week.", "metadata": {"original_id": "DrugDDI.d496.s56"}, "annotations": [{"start": 22, "end": 32, "tag": "drug"}, {"start": 55, "end": 65, "tag": "drug"}]}, {"content": "Rifampin", "metadata": {"original_id": "DrugDDI.d496.s57"}, "annotations": [{"start": 0, "end": 9, "tag": "drug"}]}, {"content": "??efavirenz concentration", "metadata": {"original_id": "DrugDDI.d496.s58"}, "annotations": [{"start": 2, "end": 12, "tag": "drug"}]}, {"content": "Clinical significance of reduced efavirenz concentrations unknown.", "metadata": {"original_id": "DrugDDI.d496.s59"}, "annotations": [{"start": 33, "end": 43, "tag": "drug"}]}, {"content": "Ritonavir", "metadata": {"original_id": "DrugDDI.d496.s60"}, "annotations": [{"start": 0, "end": 10, "tag": "drug"}]}, {"content": "??ritonavir concentration", "metadata": {"original_id": "DrugDDI.d496.s61"}, "annotations": [{"start": 2, "end": 12, "tag": "drug"}]}, {"content": "Combination was associated with a higher frequency of adverse clinical experiences (eg, dizziness, nausea, paresthesia) and laboratory abnormalities (elevated liver enzymes).", "metadata": {"original_id": "DrugDDI.d496.s62"}, "annotations": []}, {"content": "Monitoring of liver enzymes is recommended when SUSTIVA is used in combination with ritonavir.", "metadata": {"original_id": "DrugDDI.d496.s63"}, "annotations": [{"start": 14, "end": 28, "tag": "drug"}, {"start": 48, "end": 56, "tag": "drug"}, {"start": 84, "end": 94, "tag": "drug"}]}, {"content": "??efavirenz concentration", "metadata": {"original_id": "DrugDDI.d496.s64"}, "annotations": [{"start": 2, "end": 12, "tag": "drug"}]}, {"content": "Saquinavir", "metadata": {"original_id": "DrugDDI.d496.s65"}, "annotations": [{"start": 0, "end": 11, "tag": "drug"}]}, {"content": "??saquinavir concentration", "metadata": {"original_id": "DrugDDI.d496.s66"}, "annotations": [{"start": 2, "end": 13, "tag": "drug"}]}, {"content": "Should not be used as sole protease inhibitor in combination with SUSTIVA.", "metadata": {"original_id": "DrugDDI.d496.s67"}, "annotations": [{"start": 27, "end": 46, "tag": "drug"}, {"start": 66, "end": 74, "tag": "drug"}]}, {"content": "Sertraline", "metadata": {"original_id": "DrugDDI.d496.s68"}, "annotations": [{"start": 0, "end": 11, "tag": "drug"}]}, {"content": "??sertraline concentration", "metadata": {"original_id": "DrugDDI.d496.s69"}, "annotations": [{"start": 2, "end": 13, "tag": "drug"}]}, {"content": "Increases in sertraline dose should be guided by clinical response.", "metadata": {"original_id": "DrugDDI.d496.s70"}, "annotations": []}, {"content": "Other Potentially Clinically Significant Drug or Herbal Product Interactions With SUSTIVAb", "metadata": {"original_id": "DrugDDI.d496.s71"}, "annotations": [{"start": 41, "end": 46, "tag": "drug"}]}, {"content": "Anticoagulants: Warfarin", "metadata": {"original_id": "DrugDDI.d496.s72"}, "annotations": [{"start": 0, "end": 15, "tag": "drug"}, {"start": 16, "end": 25, "tag": "drug"}]}, {"content": "Plasma concentrations and effects potentially increased or decreased by SUSTIVA.", "metadata": {"original_id": "DrugDDI.d496.s73"}, "annotations": [{"start": 72, "end": 80, "tag": "drug"}]}, {"content": "Anticonvulsants: Phenytoin Phenobarbital Carbamazepine", "metadata": {"original_id": "DrugDDI.d496.s74"}, "annotations": [{"start": 0, "end": 16, "tag": "drug"}, {"start": 27, "end": 41, "tag": "drug"}]}, {"content": "Potential for reduction in anticonvulsant and/or efavirenz plasma levels;", "metadata": {"original_id": "DrugDDI.d496.s75"}, "annotations": [{"start": 27, "end": 42, "tag": "drug"}, {"start": 49, "end": 59, "tag": "drug"}]}, {"content": "periodic monitoring of anticonvulsant plasma levels should be conducted.", "metadata": {"original_id": "DrugDDI.d496.s76"}, "annotations": [{"start": 23, "end": 38, "tag": "drug"}]}, {"content": "Antifungals: Itraconazole Ketoconazole", "metadata": {"original_id": "DrugDDI.d496.s77"}, "annotations": [{"start": 0, "end": 12, "tag": "drug"}, {"start": 13, "end": 26, "tag": "drug"}]}, {"content": "Drug interaction studies with SUSTIVA and these imidazole and triazole antifungals have not been conducted.", "metadata": {"original_id": "DrugDDI.d496.s78"}, "annotations": [{"start": 30, "end": 38, "tag": "drug"}, {"start": 48, "end": 58, "tag": "drug"}, {"start": 62, "end": 83, "tag": "drug"}]}, {"content": "SUSTIVA has the potential to decrease plasma concentrations of itraconazole and ketoconazole.", "metadata": {"original_id": "DrugDDI.d496.s79"}, "annotations": [{"start": 0, "end": 8, "tag": "drug"}, {"start": 63, "end": 76, "tag": "drug"}, {"start": 80, "end": 93, "tag": "drug"}]}, {"content": "Anti-HIV protease inhibitors: Saquinavir/ritonavir combination", "metadata": {"original_id": "DrugDDI.d496.s80"}, "annotations": [{"start": 0, "end": 29, "tag": "drug"}, {"start": 30, "end": 41, "tag": "drug"}, {"start": 41, "end": 51, "tag": "drug"}]}, {"content": "No pharmacokinetic data are available.", "metadata": {"original_id": "DrugDDI.d496.s81"}, "annotations": []}, {"content": "Amprenavir", "metadata": {"original_id": "DrugDDI.d496.s82"}, "annotations": [{"start": 0, "end": 11, "tag": "drug"}]}, {"content": "SUSTIVAhas the potential to decrease serum concentrations of amprenavir.", "metadata": {"original_id": "DrugDDI.d496.s83"}, "annotations": [{"start": 61, "end": 72, "tag": "drug"}]}, {"content": "Non-nucleoside reverse transcriptase inhibitors", "metadata": {"original_id": "DrugDDI.d496.s84"}, "annotations": [{"start": 0, "end": 48, "tag": "drug"}]}, {"content": "No studies have been performed with other NNRTIs.", "metadata": {"original_id": "DrugDDI.d496.s85"}, "annotations": []}, {"content": "St. John?s wort (Hypericum perforatum)", "metadata": {"original_id": "DrugDDI.d496.s86"}, "annotations": [{"start": 17, "end": 38, "tag": "drug"}]}, {"content": "Expected to substantially decrease plasma levels of efavirenz;has not been studied in combination with SUSTIVA.", "metadata": {"original_id": "DrugDDI.d496.s87"}, "annotations": [{"start": 52, "end": 62, "tag": "drug"}, {"start": 103, "end": 111, "tag": "drug"}]}, {"content": "a See Tables 1 and 2.", "metadata": {"original_id": "DrugDDI.d496.s88"}, "annotations": []}, {"content": "b This table is not all-inclusive.", "metadata": {"original_id": "DrugDDI.d496.s89"}, "annotations": []}, {"content": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.", "metadata": {"original_id": "DrugDDI.d496.s90"}, "annotations": [{"start": 6, "end": 12, "tag": "drug"}, {"start": 104, "end": 112, "tag": "drug"}, {"start": 113, "end": 123, "tag": "drug"}, {"start": 162, "end": 182, "tag": "drug"}, {"start": 192, "end": 205, "tag": "drug"}, {"start": 206, "end": 217, "tag": "drug"}, {"start": 218, "end": 229, "tag": "drug"}, {"start": 230, "end": 242, "tag": "drug"}, {"start": 243, "end": 254, "tag": "drug"}, {"start": 255, "end": 265, "tag": "drug"}, {"start": 266, "end": 277, "tag": "drug"}, {"start": 278, "end": 289, "tag": "drug"}, {"start": 294, "end": 305, "tag": "drug"}]}, {"content": "Specific drug interaction studies have not been performed with SUSTIVA and NRTIs other than lamivudine and zidovudine.", "metadata": {"original_id": "DrugDDI.d496.s91"}, "annotations": [{"start": 63, "end": 71, "tag": "drug"}, {"start": 92, "end": 103, "tag": "drug"}, {"start": 107, "end": 118, "tag": "drug"}]}, {"content": "Clinically significant interactions would not be expected since the NRTIs are metabolized via a different route than efavirenz and would be unlikely to compete for the same metabolic enzymes and elimination pathways.", "metadata": {"original_id": "DrugDDI.d496.s92"}, "annotations": [{"start": 117, "end": 127, "tag": "drug"}, {"start": 152, "end": 160, "tag": "drug"}]}, {"content": "Many other medicines may increase or decrease the effects of glimepiride or affect your condition.", "metadata": {"original_id": "DrugDDI.d465.s0"}, "annotations": [{"start": 11, "end": 21, "tag": "drug"}, {"start": 61, "end": 73, "tag": "drug"}]}, {"content": "Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);", "metadata": {"original_id": "DrugDDI.d465.s1"}, "annotations": [{"start": 14, "end": 26, "tag": "drug"}, {"start": 83, "end": 93, "tag": "drug"}, {"start": 96, "end": 104, "tag": "drug"}, {"start": 115, "end": 126, "tag": "drug"}, {"start": 134, "end": 144, "tag": "drug"}, {"start": 144, "end": 163, "tag": "drug"}, {"start": 164, "end": 174, "tag": "drug"}, {"start": 176, "end": 186, "tag": "drug"}, {"start": 187, "end": 196, "tag": "drug"}, {"start": 206, "end": 225, "tag": "drug"}, {"start": 226, "end": 236, "tag": "drug"}, {"start": 238, "end": 259, "tag": "drug"}, {"start": 260, "end": 266, "tag": "drug"}, {"start": 271, "end": 293, "tag": "drug"}, {"start": 294, "end": 307, "tag": "drug"}]}, {"content": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "metadata": {"original_id": "DrugDDI.d465.s2"}, "annotations": [{"start": 4, "end": 40, "tag": "drug"}, {"start": 41, "end": 47, "tag": "drug"}, {"start": 56, "end": 66, "tag": "drug"}, {"start": 67, "end": 74, "tag": "drug"}, {"start": 75, "end": 81, "tag": "drug"}, {"start": 82, "end": 89, "tag": "drug"}, {"start": 99, "end": 110, "tag": "drug"}, {"start": 111, "end": 118, "tag": "drug"}, {"start": 119, "end": 129, "tag": "drug"}, {"start": 130, "end": 138, "tag": "drug"}, {"start": 140, "end": 151, "tag": "drug"}, {"start": 152, "end": 161, "tag": "drug"}, {"start": 162, "end": 171, "tag": "drug"}, {"start": 173, "end": 182, "tag": "drug"}, {"start": 183, "end": 190, "tag": "drug"}, {"start": 192, "end": 205, "tag": "drug"}, {"start": 206, "end": 214, "tag": "drug"}, {"start": 216, "end": 227, "tag": "drug"}, {"start": 228, "end": 236, "tag": "drug"}, {"start": 238, "end": 248, "tag": "drug"}, {"start": 249, "end": 256, "tag": "drug"}, {"start": 262, "end": 271, "tag": "drug"}, {"start": 272, "end": 280, "tag": "drug"}, {"start": 281, "end": 290, "tag": "drug"}, {"start": 291, "end": 297, "tag": "drug"}]}, {"content": "- a sulfa-based drug such as sulfamethoxazole-trimethoprim (Bactrim, Septra), sulfisoxazole (Gantrisin), or sulfasalazine (Azulfidine);", "metadata": {"original_id": "DrugDDI.d465.s3"}, "annotations": [{"start": 4, "end": 21, "tag": "drug"}, {"start": 29, "end": 59, "tag": "drug"}, {"start": 60, "end": 68, "tag": "drug"}, {"start": 69, "end": 76, "tag": "drug"}, {"start": 78, "end": 92, "tag": "drug"}, {"start": 93, "end": 103, "tag": "drug"}, {"start": 108, "end": 122, "tag": "drug"}, {"start": 123, "end": 135, "tag": "drug"}]}, {"content": "- a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil);", "metadata": {"original_id": "DrugDDI.d465.s4"}, "annotations": [{"start": 4, "end": 32, "tag": "drug"}, {"start": 47, "end": 61, "tag": "drug"}, {"start": 62, "end": 70, "tag": "drug"}, {"start": 72, "end": 88, "tag": "drug"}, {"start": 89, "end": 97, "tag": "drug"}, {"start": 102, "end": 113, "tag": "drug"}, {"start": 114, "end": 121, "tag": "drug"}]}, {"content": "- a beta-blocker such as propranolol (Inderal), atenolol (Tenormin), acebutolol (Sectral), metoprolol (Lopressor), and others;", "metadata": {"original_id": "DrugDDI.d465.s5"}, "annotations": [{"start": 4, "end": 17, "tag": "drug"}, {"start": 25, "end": 37, "tag": "drug"}, {"start": 38, "end": 46, "tag": "drug"}, {"start": 48, "end": 57, "tag": "drug"}, {"start": 58, "end": 67, "tag": "drug"}, {"start": 69, "end": 80, "tag": "drug"}, {"start": 81, "end": 89, "tag": "drug"}, {"start": 91, "end": 102, "tag": "drug"}, {"start": 103, "end": 113, "tag": "drug"}]}, {"content": "- a diuretic (water pill) such as hydrochlorothiazide (HCTZ, Hydrodiuril), chlorothiazide (Diuril), and others;", "metadata": {"original_id": "DrugDDI.d465.s6"}, "annotations": [{"start": 4, "end": 13, "tag": "drug"}, {"start": 14, "end": 20, "tag": "drug"}, {"start": 34, "end": 54, "tag": "drug"}, {"start": 55, "end": 60, "tag": "drug"}, {"start": 61, "end": 73, "tag": "drug"}, {"start": 75, "end": 90, "tag": "drug"}, {"start": 91, "end": 98, "tag": "drug"}]}, {"content": "- a steroid medicine such as prednisone (Deltasone, Orasone, others), methylprednisolone (Medrol, others), prednisolone (Prelone, Pediapred, others), and others;", "metadata": {"original_id": "DrugDDI.d465.s7"}, "annotations": [{"start": 4, "end": 21, "tag": "drug"}, {"start": 29, "end": 40, "tag": "drug"}, {"start": 41, "end": 51, "tag": "drug"}, {"start": 52, "end": 60, "tag": "drug"}, {"start": 70, "end": 89, "tag": "drug"}, {"start": 90, "end": 97, "tag": "drug"}, {"start": 107, "end": 120, "tag": "drug"}, {"start": 121, "end": 129, "tag": "drug"}, {"start": 130, "end": 140, "tag": "drug"}]}, {"content": "- a phenothiazine such as chlorpromazine (Thorazine), fluphenazine (Prolixin, Permitil), prochlorperazine (Compazine), promethazine (Phenergan), and others;", "metadata": {"original_id": "DrugDDI.d465.s8"}, "annotations": [{"start": 4, "end": 18, "tag": "drug"}, {"start": 26, "end": 41, "tag": "drug"}, {"start": 42, "end": 52, "tag": "drug"}, {"start": 54, "end": 67, "tag": "drug"}, {"start": 68, "end": 77, "tag": "drug"}, {"start": 78, "end": 87, "tag": "drug"}, {"start": 89, "end": 106, "tag": "drug"}, {"start": 107, "end": 117, "tag": "drug"}, {"start": 119, "end": 132, "tag": "drug"}, {"start": 133, "end": 143, "tag": "drug"}]}, {"content": "- phenytoin (Dilantin);", "metadata": {"original_id": "DrugDDI.d465.s9"}, "annotations": [{"start": 2, "end": 12, "tag": "drug"}, {"start": 13, "end": 22, "tag": "drug"}]}, {"content": "- isoniazid (Nydrazid);", "metadata": {"original_id": "DrugDDI.d465.s10"}, "annotations": [{"start": 2, "end": 12, "tag": "drug"}, {"start": 13, "end": 22, "tag": "drug"}]}, {"content": "- rifampin (Rifadin, Rifamate);", "metadata": {"original_id": "DrugDDI.d465.s11"}, "annotations": [{"start": 2, "end": 11, "tag": "drug"}, {"start": 12, "end": 20, "tag": "drug"}, {"start": 21, "end": 30, "tag": "drug"}]}, {"content": "or - over-the-counter cough, cold, allergy, or weight loss medications.", "metadata": {"original_id": "DrugDDI.d465.s12"}, "annotations": [{"start": 59, "end": 71, "tag": "drug"}]}, {"content": "You may require a dosage adjustment or special monitoring if you are taking any of the medicines listed above.", "metadata": {"original_id": "DrugDDI.d465.s13"}, "annotations": [{"start": 87, "end": 97, "tag": "drug"}]}, {"content": "Drugs other than those listed here may also interact with glimepiride or affect your condition.", "metadata": {"original_id": "DrugDDI.d465.s14"}, "annotations": [{"start": 0, "end": 6, "tag": "drug"}, {"start": 58, "end": 70, "tag": "drug"}]}, {"content": "Talk to your doctor and pharmacist before taking any prescription or over-the-counter medicines, including herbal products.", "metadata": {"original_id": "DrugDDI.d465.s15"}, "annotations": [{"start": 69, "end": 96, "tag": "drug"}]}, {"content": "Specific drug interaction studies have not been conducted with ENBREL?.", "metadata": {"original_id": "DrugDDI.d217.s0"}, "annotations": []}, {"content": "However, it was observed that the pharmacokinetics of ENBREL? was unaltered by concomitant methotrexate in rheumatoid arthritis patients.", "metadata": {"original_id": "DrugDDI.d217.s1"}, "annotations": [{"start": 91, "end": 104, "tag": "drug"}]}, {"content": "In a study in which patients with active RA were treated for up to 24 weeks with concurrent ENBREL? and anakinra therapy, a 7% rate of serious infections was observed, which was higher than that observed with ENBREL? alone (0%).", "metadata": {"original_id": "DrugDDI.d217.s2"}, "annotations": [{"start": 104, "end": 113, "tag": "drug"}]}, {"content": "Two percent of patients treated concurrently with ENBREL? and anakinra developed neutropenia (ANC   1 x 109/L).", "metadata": {"original_id": "DrugDDI.d217.s3"}, "annotations": [{"start": 62, "end": 71, "tag": "drug"}, {"start": 94, "end": 111, "tag": "drug"}]}, {"content": "Patients in a clinical study who were on established therapy with sulfasalazine, to which ENBREL was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either ENBREL CI or sulfasalazine alone.", "metadata": {"original_id": "DrugDDI.d217.s4"}, "annotations": [{"start": 66, "end": 80, "tag": "drug"}, {"start": 90, "end": 97, "tag": "drug"}, {"start": 216, "end": 223, "tag": "drug"}, {"start": 229, "end": 243, "tag": "drug"}]}, {"content": "The clinical significance of this observation is unknown.", "metadata": {"original_id": "DrugDDI.d217.s5"}, "annotations": []}, {"content": "Androgens may increase sensitivity to oral anticoagulahts.", "metadata": {"original_id": "DrugDDI.d433.s0"}, "annotations": [{"start": 0, "end": 10, "tag": "drug"}]}, {"content": "Dosage of the anticoagulant may require reduction in order to maintain satisfactory therapeutic hypoprothrombinemia.", "metadata": {"original_id": "DrugDDI.d433.s1"}, "annotations": [{"start": 14, "end": 28, "tag": "drug"}]}, {"content": "Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone.", "metadata": {"original_id": "DrugDDI.d433.s2"}, "annotations": [{"start": 29, "end": 45, "tag": "drug"}, {"start": 49, "end": 59, "tag": "drug"}, {"start": 98, "end": 114, "tag": "drug"}]}, {"content": "In diabetic patients, the metabolic effects of androgens may decrease blood glucose and therefore, insulin requirements.", "metadata": {"original_id": "DrugDDI.d433.s3"}, "annotations": [{"start": 47, "end": 57, "tag": "drug"}, {"start": 99, "end": 107, "tag": "drug"}]}, {"content": "No information available", "metadata": {"original_id": "DrugDDI.d494.s0"}, "annotations": []}, {"content": ".", "metadata": {"original_id": "DrugDDI.d494.s1"}, "annotations": []}, {"content": "?", "metadata": {"original_id": "DrugDDI.d494.s2"}, "annotations": []}, {"content": "The CNS effects of butalbital may be enhanced by monoamine oxidase (MAO) inhibitors.", "metadata": {"original_id": "DrugDDI.d223.s0"}, "annotations": [{"start": 19, "end": 30, "tag": "drug"}, {"start": 49, "end": 67, "tag": "drug"}]}, {"content": "Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.", "metadata": {"original_id": "DrugDDI.d223.s1"}, "annotations": [{"start": 0, "end": 11, "tag": "drug"}, {"start": 30, "end": 39, "tag": "drug"}, {"start": 67, "end": 92, "tag": "drug"}, {"start": 94, "end": 102, "tag": "drug"}, {"start": 103, "end": 123, "tag": "drug"}, {"start": 124, "end": 138, "tag": "drug"}, {"start": 146, "end": 163, "tag": "drug"}, {"start": 164, "end": 183, "tag": "drug"}, {"start": 193, "end": 209, "tag": "drug"}]}, {"content": "Drug/Laboratory Test Interactions Acetaminophen may produce false-positive test results for urinary 5-hydroxyindoleacetic acid.", "metadata": {"original_id": "DrugDDI.d223.s2"}, "annotations": [{"start": 0, "end": 5, "tag": "drug"}, {"start": 34, "end": 48, "tag": "drug"}, {"start": 92, "end": 128, "tag": "drug"}]}, {"content": "Tablet If a patient receiving clonidine hydrochloride is also taking tricyclic antidepressants, the effect of clonidine may be reduced, thus necessitating an increase in dosage.", "metadata": {"original_id": "DrugDDI.d467.s0"}, "annotations": [{"start": 30, "end": 54, "tag": "drug"}, {"start": 69, "end": 95, "tag": "drug"}, {"start": 110, "end": 120, "tag": "drug"}]}, {"content": "Clonidine hydrochloride may enhance the CNS-depressive effects of alcohol, barbiturates or other sedatives.", "metadata": {"original_id": "DrugDDI.d467.s1"}, "annotations": [{"start": 0, "end": 24, "tag": "drug"}, {"start": 66, "end": 74, "tag": "drug"}, {"start": 75, "end": 88, "tag": "drug"}, {"start": 97, "end": 107, "tag": "drug"}]}, {"content": "Amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats Epidural Injection Clonidine may potentiate the CNS-depressive effect of alcohol, barbiturates or other sedating drugs.", "metadata": {"original_id": "DrugDDI.d467.s2"}, "annotations": [{"start": 0, "end": 14, "tag": "drug"}, {"start": 34, "end": 44, "tag": "drug"}, {"start": 117, "end": 127, "tag": "drug"}, {"start": 171, "end": 179, "tag": "drug"}, {"start": 180, "end": 193, "tag": "drug"}, {"start": 211, "end": 217, "tag": "drug"}]}, {"content": "Narcotic analgesics may potentiate the hypotensive effects of clonidine.", "metadata": {"original_id": "DrugDDI.d467.s3"}, "annotations": [{"start": 0, "end": 20, "tag": "drug"}, {"start": 62, "end": 72, "tag": "drug"}]}, {"content": "Tricyclic antidepressants may antagonize the hypotensive effects of clonidine.", "metadata": {"original_id": "DrugDDI.d467.s4"}, "annotations": [{"start": 0, "end": 26, "tag": "drug"}, {"start": 68, "end": 78, "tag": "drug"}]}, {"content": "The effects of tricyclic antidepressants on clonidines analgesic actions are not known.", "metadata": {"original_id": "DrugDDI.d467.s5"}, "annotations": [{"start": 15, "end": 41, "tag": "drug"}, {"start": 44, "end": 54, "tag": "drug"}, {"start": 55, "end": 65, "tag": "drug"}]}, {"content": "Beta blockers may exacerbate the hypertensive response seen with clonidine withdrawl.", "metadata": {"original_id": "DrugDDI.d467.s6"}, "annotations": [{"start": 0, "end": 14, "tag": "drug"}, {"start": 65, "end": 75, "tag": "drug"}]}, {"content": "Also, due to the potential for additive effects such as bradycardia and AV block, caution is warranted in patients receiving clonidine with agents known to affect sinus node function or AV nodal conduction (e.g., digitalis, calcium channel blockers, and beta-blockers.)", "metadata": {"original_id": "DrugDDI.d467.s7"}, "annotations": [{"start": 125, "end": 135, "tag": "drug"}, {"start": 213, "end": 223, "tag": "drug"}, {"start": 224, "end": 249, "tag": "drug"}, {"start": 254, "end": 269, "tag": "drug"}]}, {"content": "There is one reported case of a patient with acute delirium associated with the simultaneous use of fluphenazine and oral clonidine.", "metadata": {"original_id": "DrugDDI.d467.s8"}, "annotations": [{"start": 100, "end": 113, "tag": "drug"}, {"start": 122, "end": 132, "tag": "drug"}]}, {"content": "Symptoms resolved when clonidine was withdrawn and recurred when the patient was rechallenged with clonidine.", "metadata": {"original_id": "DrugDDI.d467.s9"}, "annotations": [{"start": 23, "end": 33, "tag": "drug"}, {"start": 99, "end": 109, "tag": "drug"}]}, {"content": "Epidural clonidine may prolong the duration of pharmacologic effects of epidural local anesthetics, including both sensory and motor blockade.", "metadata": {"original_id": "DrugDDI.d467.s10"}, "annotations": [{"start": 9, "end": 19, "tag": "drug"}, {"start": 81, "end": 99, "tag": "drug"}]}, {"content": "Because alosetron is metabolized by a variety of hepatic CYP drug-metabolizing enzymes, inducers or inhibitors of these enzymes may change the clearance of alosetron.", "metadata": {"original_id": "DrugDDI.d450.s0"}, "annotations": [{"start": 8, "end": 18, "tag": "drug"}, {"start": 156, "end": 166, "tag": "drug"}]}, {"content": "Fluvoxamine is a known strong inhibitor of CYP1A2 and also inhibits CYP3A4, CYP2C9, and CYP2C19.", "metadata": {"original_id": "DrugDDI.d450.s1"}, "annotations": [{"start": 0, "end": 12, "tag": "drug"}, {"start": 43, "end": 50, "tag": "drug"}, {"start": 68, "end": 75, "tag": "drug"}, {"start": 76, "end": 83, "tag": "drug"}, {"start": 88, "end": 96, "tag": "drug"}]}, {"content": "In a pharmacokinetic study, 40 healthy female subjects received fluvoxamine in escalating doses from 50 to 200 mg per day for 16 days, with coadministration of alosetron 1 mg on the last day.", "metadata": {"original_id": "DrugDDI.d450.s2"}, "annotations": [{"start": 64, "end": 76, "tag": "drug"}, {"start": 160, "end": 175, "tag": "drug"}]}, {"content": "Fluvoxamine increased mean alosetron plasma concentrations (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold.", "metadata": {"original_id": "DrugDDI.d450.s3"}, "annotations": [{"start": 0, "end": 12, "tag": "drug"}, {"start": 27, "end": 37, "tag": "drug"}]}, {"content": "Concomitant administration of alosetron and fluvoxamine is contraindicated.", "metadata": {"original_id": "DrugDDI.d450.s4"}, "annotations": [{"start": 30, "end": 40, "tag": "drug"}, {"start": 44, "end": 56, "tag": "drug"}]}, {"content": "Concomitant administration of alosetron and moderate CYP1A2 inhibitors, including quinolone antibiotics and cimetidine, has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions.", "metadata": {"original_id": "DrugDDI.d450.s5"}, "annotations": [{"start": 30, "end": 40, "tag": "drug"}, {"start": 53, "end": 60, "tag": "drug"}, {"start": 82, "end": 103, "tag": "drug"}, {"start": 108, "end": 119, "tag": "drug"}]}, {"content": "Ketoconazole is a known strong inhibitor of CYP3A4.", "metadata": {"original_id": "DrugDDI.d450.s6"}, "annotations": [{"start": 0, "end": 13, "tag": "drug"}, {"start": 44, "end": 51, "tag": "drug"}]}, {"content": "In a pharmacokinetic study, 38 healthy female subjects received ketoconazole 200 mg twice daily for 7 days, with coadministration of alosetron 1 mg on the last day.", "metadata": {"original_id": "DrugDDI.d450.s7"}, "annotations": [{"start": 64, "end": 84, "tag": "drug"}, {"start": 133, "end": 148, "tag": "drug"}]}, {"content": "Ketoconazole increased mean alosetron plasma concentrations (AUC) by 29%.", "metadata": {"original_id": "DrugDDI.d450.s8"}, "annotations": [{"start": 0, "end": 13, "tag": "drug"}, {"start": 28, "end": 38, "tag": "drug"}]}, {"content": "Caution should be used when alosetron and ketoconazole are administered concomitantly.", "metadata": {"original_id": "DrugDDI.d450.s9"}, "annotations": [{"start": 28, "end": 38, "tag": "drug"}, {"start": 42, "end": 55, "tag": "drug"}]}, {"content": "Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.", "metadata": {"original_id": "DrugDDI.d450.s10"}, "annotations": [{"start": 20, "end": 30, "tag": "drug"}, {"start": 41, "end": 48, "tag": "drug"}, {"start": 68, "end": 83, "tag": "drug"}, {"start": 84, "end": 98, "tag": "drug"}, {"start": 99, "end": 119, "tag": "drug"}, {"start": 120, "end": 133, "tag": "drug"}, {"start": 138, "end": 151, "tag": "drug"}]}, {"content": "The effect of induction or inhibition of other pathways on exposure to alosetron and its metabolites is not known.", "metadata": {"original_id": "DrugDDI.d450.s11"}, "annotations": [{"start": 71, "end": 81, "tag": "drug"}, {"start": 89, "end": 101, "tag": "drug"}]}, {"content": "In vitro human liver microsome studies and an in vivo metabolic probe study demonstrated that alosetron did not inhibit CYP enzymes 2D6, 3A4, 2C9, or 2C19.", "metadata": {"original_id": "DrugDDI.d450.s12"}, "annotations": [{"start": 94, "end": 104, "tag": "drug"}, {"start": 120, "end": 131, "tag": "drug"}]}, {"content": "In vitro, at total drug concentrations 27-fold higher than peak plasma concentrations observed with the 1-mg dosage, alosetron inhibited CYP enzymes 1A2 (60%) and 2E1 (50%).", "metadata": {"original_id": "DrugDDI.d450.s13"}, "annotations": [{"start": 117, "end": 127, "tag": "drug"}, {"start": 137, "end": 148, "tag": "drug"}]}, {"content": "In an in vivo metabolic probe study, alosetron did not inhibit CYP2E1 but did produce 30% inhibition of both CYP1A2 and N-acetyltransferase.", "metadata": {"original_id": "DrugDDI.d450.s14"}, "annotations": [{"start": 37, "end": 47, "tag": "drug"}, {"start": 63, "end": 70, "tag": "drug"}, {"start": 109, "end": 116, "tag": "drug"}, {"start": 120, "end": 140, "tag": "drug"}]}, {"content": "Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine.", "metadata": {"original_id": "DrugDDI.d450.s15"}, "annotations": [{"start": 26, "end": 36, "tag": "drug"}, {"start": 53, "end": 71, "tag": "drug"}, {"start": 117, "end": 123, "tag": "drug"}, {"start": 131, "end": 141, "tag": "drug"}, {"start": 142, "end": 155, "tag": "drug"}, {"start": 160, "end": 172, "tag": "drug"}]}, {"content": "The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed.", "metadata": {"original_id": "DrugDDI.d450.s16"}, "annotations": [{"start": 14, "end": 21, "tag": "drug"}, {"start": 79, "end": 92, "tag": "drug"}]}, {"content": "Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates).", "metadata": {"original_id": "DrugDDI.d450.s17"}, "annotations": [{"start": 26, "end": 36, "tag": "drug"}, {"start": 105, "end": 130, "tag": "drug"}, {"start": 153, "end": 168, "tag": "drug"}, {"start": 169, "end": 176, "tag": "drug"}]}, {"content": "A clinical interaction study was also conducted with alosetron and the CYP3A4 substrate cisapride.", "metadata": {"original_id": "DrugDDI.d450.s18"}, "annotations": [{"start": 53, "end": 63, "tag": "drug"}, {"start": 88, "end": 98, "tag": "drug"}]}, {"content": "No significant effects on cisapride metabolism or QT interval were noted.", "metadata": {"original_id": "DrugDDI.d450.s19"}, "annotations": [{"start": 26, "end": 36, "tag": "drug"}]}, {"content": "The effect of alosetron on monoamine oxidases and on intestinal first pass secondary to high intraluminal concentrations have not been examined.", "metadata": {"original_id": "DrugDDI.d450.s20"}, "annotations": [{"start": 14, "end": 24, "tag": "drug"}, {"start": 27, "end": 46, "tag": "drug"}]}, {"content": "Based on the above data from in vitro and in vivo studies, it is unlikely that alosetron will inhibit the hepatic metabolic clearance of drugs metabolized by the major CYP enzyme 3A4, as well as the CYP enzymes 2D6, 2C9, 2C19, 2E1, or 1A2.", "metadata": {"original_id": "DrugDDI.d450.s21"}, "annotations": [{"start": 79, "end": 89, "tag": "drug"}, {"start": 137, "end": 143, "tag": "drug"}, {"start": 168, "end": 172, "tag": "drug"}, {"start": 199, "end": 210, "tag": "drug"}]}, {"content": "Alosetron does not appear to induce the major cytochrome P450 (CYP) drug metabolizing enzyme 3A.", "metadata": {"original_id": "DrugDDI.d450.s22"}, "annotations": [{"start": 0, "end": 10, "tag": "drug"}, {"start": 46, "end": 62, "tag": "drug"}, {"start": 63, "end": 67, "tag": "drug"}, {"start": 68, "end": 73, "tag": "drug"}]}, {"content": "Alosetron also does not appear to induce CYP enzymes 2E1 or 2C19.", "metadata": {"original_id": "DrugDDI.d450.s23"}, "annotations": [{"start": 0, "end": 10, "tag": "drug"}, {"start": 41, "end": 52, "tag": "drug"}]}, {"content": "It is not known whether alosetron might induce other enzymes.", "metadata": {"original_id": "DrugDDI.d450.s24"}, "annotations": [{"start": 24, "end": 34, "tag": "drug"}]}, {"content": "Corticotropin may accentuate the electrolyte loss associated with diuretic therapy.", "metadata": {"original_id": "DrugDDI.d469.s0"}, "annotations": [{"start": 0, "end": 14, "tag": "drug"}]}, {"content": "Disulfiram appears to decrease the rate at which certain drugs are metabolized and therefore may increase the blood levels and the possibility of clinical toxicity of drugs given concomitantly.", "metadata": {"original_id": "DrugDDI.d383.s0"}, "annotations": [{"start": 0, "end": 11, "tag": "drug"}, {"start": 57, "end": 63, "tag": "drug"}, {"start": 167, "end": 173, "tag": "drug"}]}, {"content": "DISULFIRAM SHOULD BE USED WITH CAUTION IN THOSE PATIENTS REVEIVING PHENYTOIN AND ITS CONGENERS.", "metadata": {"original_id": "DrugDDI.d383.s1"}, "annotations": [{"start": 0, "end": 11, "tag": "drug"}, {"start": 67, "end": 77, "tag": "drug"}, {"start": 85, "end": 94, "tag": "drug"}]}, {"content": "SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO PHENYTOIN INTOXICATION, PRIOR TO ADMINISTERING DISULFIRAM TO A PATIENT ON PHENYTOIN THERAPY, A BASELINE PHENYTOIN SERUM LEVEL SHOULD BE OBTAINED.", "metadata": {"original_id": "DrugDDI.d383.s2"}, "annotations": [{"start": 50, "end": 56, "tag": "drug"}, {"start": 115, "end": 126, "tag": "drug"}, {"start": 142, "end": 152, "tag": "drug"}]}, {"content": "SUBSEQUENT TO INITIATION OF DISULFIRAM THERAPY.", "metadata": {"original_id": "DrugDDI.d383.s3"}, "annotations": []}, {"content": "SERUM LEVELS OF PHENYTOIN SHOULD BE DETERMINED ON DIFFERENT DAYS FOR EVIDENCE OF AN INCREASE OR FOR A CONTINUING RISE IN LEVELS.", "metadata": {"original_id": "DrugDDI.d383.s4"}, "annotations": [{"start": 16, "end": 26, "tag": "drug"}]}, {"content": "INCREASED PHENYTOIN LEVELS SHOULD BE TREATED WITH APPROPRIATE DOSAGE ADJUSTMENT.", "metadata": {"original_id": "DrugDDI.d383.s5"}, "annotations": []}, {"content": "It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping disulfiram. since disulfiram may prolong prothrombin time.", "metadata": {"original_id": "DrugDDI.d383.s6"}, "annotations": [{"start": 44, "end": 64, "tag": "drug"}, {"start": 91, "end": 102, "tag": "drug"}, {"start": 109, "end": 120, "tag": "drug"}]}, {"content": "Patients taking isoniazid when disulfiram is given should be observed for the appearance of unsteady gait or marked changes in mental status;", "metadata": {"original_id": "DrugDDI.d383.s7"}, "annotations": [{"start": 16, "end": 26, "tag": "drug"}, {"start": 31, "end": 42, "tag": "drug"}]}, {"content": "the disulfiram should be discontinued if such signs appear.", "metadata": {"original_id": "DrugDDI.d383.s8"}, "annotations": [{"start": 4, "end": 15, "tag": "drug"}]}, {"content": "In rats, simultaneous ingestion of disulfiram and nitrite in the diet for 78 weeks has been reported to cause tumors, and it has been suggested that disulfiram may react with nitrites in the rat stomach to form a nitrosamine, which is tumorigenic.", "metadata": {"original_id": "DrugDDI.d383.s9"}, "annotations": [{"start": 35, "end": 46, "tag": "drug"}, {"start": 50, "end": 58, "tag": "drug"}, {"start": 149, "end": 160, "tag": "drug"}, {"start": 175, "end": 184, "tag": "drug"}]}, {"content": "Disulfiram alone in the rat?s diet did not lead to such tumors.", "metadata": {"original_id": "DrugDDI.d383.s10"}, "annotations": [{"start": 0, "end": 11, "tag": "drug"}]}, {"content": "The relevance of this finding to humans is not known at this time.", "metadata": {"original_id": "DrugDDI.d383.s11"}, "annotations": []}, {"content": "In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, TAXOL before cisplatin).", "metadata": {"original_id": "DrugDDI.d480.s0"}, "annotations": [{"start": 45, "end": 51, "tag": "drug"}, {"start": 71, "end": 81, "tag": "drug"}, {"start": 169, "end": 175, "tag": "drug"}, {"start": 191, "end": 201, "tag": "drug"}, {"start": 239, "end": 245, "tag": "drug"}, {"start": 252, "end": 262, "tag": "drug"}]}, {"content": "Pharmacokinetic data from these patients demonstrated a decrease in paclitaxel clearance of approximately 33% when TAXOL was administered following cisplatin.", "metadata": {"original_id": "DrugDDI.d480.s1"}, "annotations": [{"start": 68, "end": 79, "tag": "drug"}, {"start": 115, "end": 121, "tag": "drug"}, {"start": 148, "end": 158, "tag": "drug"}]}, {"content": "The metabolism of TAXOL is catalyzed by cytochrome P450 isoen-zymes CYP2C8 and CYP3A4.", "metadata": {"original_id": "DrugDDI.d480.s2"}, "annotations": [{"start": 18, "end": 24, "tag": "drug"}, {"start": 40, "end": 56, "tag": "drug"}, {"start": 79, "end": 86, "tag": "drug"}]}, {"content": "In the absence of formal clinical drug interaction studies, caution should be exercised when administering TAXOL concomitantly with known substrates or inhibitors of the cytochrome P450 isoenzymes CYP2C8 and CYP3A4.", "metadata": {"original_id": "DrugDDI.d480.s3"}, "annotations": [{"start": 107, "end": 113, "tag": "drug"}, {"start": 170, "end": 186, "tag": "drug"}, {"start": 208, "end": 215, "tag": "drug"}]}, {"content": "Potential interactions between TAXOL, a substrate of CYP3A4, and protease inhibitors (ritonavir, saquinavir, indinavir, and nelfinavir), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.", "metadata": {"original_id": "DrugDDI.d480.s4"}, "annotations": [{"start": 31, "end": 37, "tag": "drug"}, {"start": 53, "end": 60, "tag": "drug"}, {"start": 65, "end": 85, "tag": "drug"}, {"start": 86, "end": 96, "tag": "drug"}, {"start": 97, "end": 108, "tag": "drug"}, {"start": 109, "end": 119, "tag": "drug"}, {"start": 124, "end": 135, "tag": "drug"}, {"start": 179, "end": 186, "tag": "drug"}]}, {"content": "Reports in the literature suggest that plasma levels of doxorubicin (and its active metabolite doxorubicinol) may be increased when paclitaxel and doxorubicin are used in combination.", "metadata": {"original_id": "DrugDDI.d480.s5"}, "annotations": [{"start": 56, "end": 68, "tag": "drug"}, {"start": 77, "end": 95, "tag": "drug"}, {"start": 132, "end": 143, "tag": "drug"}, {"start": 147, "end": 159, "tag": "drug"}]}, {"content": "Hematology: TAXOL therapy should not be administered to patients with baseline neutrophil counts of less than 1,500 cells/mm3.", "metadata": {"original_id": "DrugDDI.d480.s6"}, "annotations": [{"start": 12, "end": 18, "tag": "drug"}]}, {"content": "In order to monitor the occurrence of myelotoxicity, it is recommended that frequent peripheral blood cell counts be performed on all patients receiving TAXOL.", "metadata": {"original_id": "DrugDDI.d480.s7"}, "annotations": [{"start": 153, "end": 159, "tag": "drug"}]}, {"content": "Patients should not be re-treated with subsequent cycles of TAXOL until neutrophils recover to a level  1500 cells/mm3 and platelets recover to a level  100,000 cells/mm3.", "metadata": {"original_id": "DrugDDI.d480.s8"}, "annotations": [{"start": 60, "end": 66, "tag": "drug"}]}, {"content": "In the case of severe neutropenia ( 500 cells/mm3 for seven days or more) during a course of TAXOL therapy, a 20% reduction in dose for subsequent courses of therapy is recommended.", "metadata": {"original_id": "DrugDDI.d480.s9"}, "annotations": [{"start": 93, "end": 99, "tag": "drug"}]}, {"content": "For patients with advanced HIV disease and poor-risk AIDS-related Kaposi?s sarcoma, TAXOL, at the recommended dose for this disease, can be initiated and repeated if the neutrophil count is at least 1000 cells/mm3.", "metadata": {"original_id": "DrugDDI.d480.s10"}, "annotations": [{"start": 27, "end": 31, "tag": "drug"}, {"start": 84, "end": 90, "tag": "drug"}]}, {"content": "Hypersensitivity Reactions: Patients with a history of severe hypersensitivity reactions to products containing Cremophor? EL (eg, cyclosporin for injection concentrate and teniposide for injection concentrate) should not be treated with TAXOL.", "metadata": {"original_id": "DrugDDI.d480.s11"}, "annotations": [{"start": 131, "end": 143, "tag": "drug"}, {"start": 173, "end": 184, "tag": "drug"}, {"start": 238, "end": 244, "tag": "drug"}]}, {"content": "In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should be premedicated with corticosteroids (such as dexamethasone), diphen-hydramine and H2 antagonists (such as cimetidine or ranitidine).", "metadata": {"original_id": "DrugDDI.d480.s12"}, "annotations": [{"start": 97, "end": 103, "tag": "drug"}, {"start": 131, "end": 147, "tag": "drug"}, {"start": 156, "end": 170, "tag": "drug"}, {"start": 172, "end": 179, "tag": "drug"}, {"start": 217, "end": 228, "tag": "drug"}, {"start": 231, "end": 242, "tag": "drug"}]}, {"content": "Minor symptoms such as flushing, skin reactions, dyspnea, hypotension, or tachycardia do not require interruption of therapy.", "metadata": {"original_id": "DrugDDI.d480.s13"}, "annotations": []}, {"content": "However, severe reactions, such as hypotension requiring treatment, dyspnea requiring bronchodilators, angioedema, or generalized urticaria require immediate discontinuation of TAXOL and aggressive symptomatic therapy.", "metadata": {"original_id": "DrugDDI.d480.s14"}, "annotations": [{"start": 86, "end": 102, "tag": "drug"}, {"start": 177, "end": 183, "tag": "drug"}]}, {"content": "Patients who have developed severe hypersensitivity reactions should not be rechallenged with TAXOL.", "metadata": {"original_id": "DrugDDI.d480.s15"}, "annotations": [{"start": 94, "end": 100, "tag": "drug"}]}, {"content": "Cardiovascular: Hypotension, bradycardia, and hypertension have been observed during administration of TAXOL, but generally do not require treatment.", "metadata": {"original_id": "DrugDDI.d480.s16"}, "annotations": [{"start": 103, "end": 109, "tag": "drug"}]}, {"content": "Occasionally TAXOL infusions must be interrupted or discontinued because of initial or recurrent hypertension.", "metadata": {"original_id": "DrugDDI.d480.s17"}, "annotations": [{"start": 13, "end": 19, "tag": "drug"}]}, {"content": "Frequent vital sign monitoring, particularly during the first hour of TAXOL infusion, is recommended.", "metadata": {"original_id": "DrugDDI.d480.s18"}, "annotations": [{"start": 70, "end": 76, "tag": "drug"}]}, {"content": "Continuous cardiac monitoring is not required except for patients with serious conduction abnormalities.", "metadata": {"original_id": "DrugDDI.d480.s19"}, "annotations": []}, {"content": "Nervous System: Although the occurrence of peripheral neuropathy is frequent, the development of severe symptomatology is unusual and requires a dose reduction of 20% for all subsequentcourses of TAXOL.", "metadata": {"original_id": "DrugDDI.d480.s20"}, "annotations": [{"start": 196, "end": 202, "tag": "drug"}]}, {"content": "TAXOL contains dehydrated alcohol USP, 396 mg/mL;", "metadata": {"original_id": "DrugDDI.d480.s21"}, "annotations": [{"start": 0, "end": 6, "tag": "drug"}, {"start": 15, "end": 39, "tag": "drug"}]}, {"content": "consideration should be given to possible CNS and other effects of alcohol.", "metadata": {"original_id": "DrugDDI.d480.s22"}, "annotations": [{"start": 67, "end": 75, "tag": "drug"}]}, {"content": "Hepatic: There is limited evidence that the myelotoxicity of TAXOL may be exacerbated in patients with serum total bilirubin  2 times ULN.", "metadata": {"original_id": "DrugDDI.d480.s23"}, "annotations": [{"start": 61, "end": 67, "tag": "drug"}]}, {"content": "Extreme caution should be exercised when administering TAXOL to such patients, with dose reduction as recommended in DOSAGE AND ADMINISTRATION, Table 17.", "metadata": {"original_id": "DrugDDI.d480.s24"}, "annotations": [{"start": 55, "end": 61, "tag": "drug"}]}, {"content": "InjectionSite Reaction: Injection site reactions, including reactions secondary to extravasation, were usually mild and consisted of erythema, tenderness, skin discoloration, or swelling at the injection site.", "metadata": {"original_id": "DrugDDI.d480.s25"}, "annotations": []}, {"content": "These reactions have been observed more frequently with the 24-hour infusion than with the 3-hour infusion.", "metadata": {"original_id": "DrugDDI.d480.s26"}, "annotations": []}, {"content": "Recurrence of skin reactions at a site of previous extravasation following administration of TAXOL at a different site, ie, recall, has been reported rarely.", "metadata": {"original_id": "DrugDDI.d480.s27"}, "annotations": [{"start": 93, "end": 99, "tag": "drug"}]}, {"content": "Rare reports of more severe events such as phlebitis, cellulitis, induration, skin exfoliation, necrosis, and fibrosis have been received as part of the continuing surveillance of TAXOL safety.", "metadata": {"original_id": "DrugDDI.d480.s28"}, "annotations": [{"start": 180, "end": 186, "tag": "drug"}]}, {"content": "In some cases the onset of the injection site reaction either occurred during a prolonged infusion or was delayed by a week to ten days.", "metadata": {"original_id": "DrugDDI.d480.s29"}, "annotations": []}, {"content": "A specific treatment for extravasation reactions is unknown at this time.", "metadata": {"original_id": "DrugDDI.d480.s30"}, "annotations": []}, {"content": "Given the possibility of extravasation, it is advisable to closely monitor the infusion site for possible infiltration during drug administration.", "metadata": {"original_id": "DrugDDI.d480.s31"}, "annotations": []}, {"content": "When given concurrently the following drugs may interact with thiazide diuretics.", "metadata": {"original_id": "DrugDDI.d354.s0"}, "annotations": [{"start": 38, "end": 44, "tag": "drug"}, {"start": 62, "end": 81, "tag": "drug"}]}, {"content": "- Alcohol, barbiturates, or narcotics: Potentiation of otthostatic hypotension may occur", "metadata": {"original_id": "DrugDDI.d354.s1"}, "annotations": [{"start": 2, "end": 10, "tag": "drug"}, {"start": 11, "end": 24, "tag": "drug"}, {"start": 28, "end": 38, "tag": "drug"}]}, {"content": ".", "metadata": {"original_id": "DrugDDI.d354.s2"}, "annotations": []}, {"content": "- Antidiabetic drugs: (Oral agents and insulin) Dosage adjustment of the antidiabetic drug may be required", "metadata": {"original_id": "DrugDDI.d354.s3"}, "annotations": [{"start": 2, "end": 21, "tag": "drug"}, {"start": 39, "end": 47, "tag": "drug"}, {"start": 73, "end": 91, "tag": "drug"}]}, {"content": ".", "metadata": {"original_id": "DrugDDI.d354.s4"}, "annotations": []}, {"content": "- Other antihypertensive drugs: Additive effect or potentiation", "metadata": {"original_id": "DrugDDI.d354.s5"}, "annotations": [{"start": 8, "end": 31, "tag": "drug"}]}, {"content": ".", "metadata": {"original_id": "DrugDDI.d354.s6"}, "annotations": []}, {"content": "- Cholestyramine and colestipol resins: Cholestytamine and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract", "metadata": {"original_id": "DrugDDI.d354.s7"}, "annotations": [{"start": 2, "end": 17, "tag": "drug"}, {"start": 21, "end": 32, "tag": "drug"}, {"start": 59, "end": 70, "tag": "drug"}, {"start": 107, "end": 126, "tag": "drug"}, {"start": 139, "end": 148, "tag": "drug"}]}, {"content": ".", "metadata": {"original_id": "DrugDDI.d354.s8"}, "annotations": []}, {"content": "- Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia", "metadata": {"original_id": "DrugDDI.d354.s9"}, "annotations": [{"start": 2, "end": 18, "tag": "drug"}, {"start": 19, "end": 24, "tag": "drug"}]}, {"content": ".", "metadata": {"original_id": "DrugDDI.d354.s10"}, "annotations": []}, {"content": "- Pressor amines (e.g., norepinephrine): Possible decreased response to pressor amines but not sufficient to preclude their use", "metadata": {"original_id": "DrugDDI.d354.s11"}, "annotations": [{"start": 2, "end": 17, "tag": "drug"}, {"start": 24, "end": 39, "tag": "drug"}, {"start": 72, "end": 87, "tag": "drug"}]}, {"content": ".", "metadata": {"original_id": "DrugDDI.d354.s12"}, "annotations": []}, {"content": "- Skeletal muscle relaxants, nondepolarizing (e.g., tubocurarine): Possible increased responsiveness to the muscle relaxant", "metadata": {"original_id": "DrugDDI.d354.s13"}, "annotations": [{"start": 2, "end": 28, "tag": "drug"}, {"start": 52, "end": 65, "tag": "drug"}, {"start": 108, "end": 124, "tag": "drug"}]}, {"content": ".", "metadata": {"original_id": "DrugDDI.d354.s14"}, "annotations": []}, {"content": "- Lithium: Generally should not be given with diuretics.", "metadata": {"original_id": "DrugDDI.d354.s15"}, "annotations": [{"start": 2, "end": 10, "tag": "drug"}, {"start": 46, "end": 56, "tag": "drug"}]}, {"content": "Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.", "metadata": {"original_id": "DrugDDI.d354.s16"}, "annotations": [{"start": 0, "end": 9, "tag": "drug"}, {"start": 46, "end": 54, "tag": "drug"}]}, {"content": "Refer to the package insert for lithium preparations before use of such preparations with chlorothiazide", "metadata": {"original_id": "DrugDDI.d354.s17"}, "annotations": [{"start": 32, "end": 52, "tag": "drug"}, {"start": 90, "end": 105, "tag": "drug"}]}, {"content": ".", "metadata": {"original_id": "DrugDDI.d354.s18"}, "annotations": []}, {"content": "- Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.", "metadata": {"original_id": "DrugDDI.d354.s19"}, "annotations": [{"start": 2, "end": 40, "tag": "drug"}, {"start": 83, "end": 121, "tag": "drug"}, {"start": 136, "end": 145, "tag": "drug"}, {"start": 163, "end": 180, "tag": "drug"}, {"start": 197, "end": 207, "tag": "drug"}, {"start": 219, "end": 238, "tag": "drug"}]}, {"content": "Therefore, when chlorothiazide and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained", "metadata": {"original_id": "DrugDDI.d354.s20"}, "annotations": [{"start": 16, "end": 31, "tag": "drug"}, {"start": 35, "end": 74, "tag": "drug"}, {"start": 179, "end": 188, "tag": "drug"}]}, {"content": ".", "metadata": {"original_id": "DrugDDI.d354.s21"}, "annotations": []}, {"content": "- Drug/Laboratory Test Interactions: Thiazides should be discontinued before carrying out tests for parathyroid function.", "metadata": {"original_id": "DrugDDI.d354.s22"}, "annotations": [{"start": 2, "end": 7, "tag": "drug"}, {"start": 37, "end": 47, "tag": "drug"}, {"start": 100, "end": 112, "tag": "drug"}]}, {"content": "A 30 to 45% increase in AUC and Cmax of nisoldipine was observed with concomitant administration of cimetidine 400 mg twice daily.", "metadata": {"original_id": "DrugDDI.d234.s0"}, "annotations": [{"start": 40, "end": 52, "tag": "drug"}, {"start": 100, "end": 118, "tag": "drug"}]}, {"content": "Ranitidine 150 mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15-20 %).", "metadata": {"original_id": "DrugDDI.d234.s1"}, "annotations": [{"start": 0, "end": 18, "tag": "drug"}, {"start": 66, "end": 78, "tag": "drug"}]}, {"content": "No pharmacodynamic effects of either histamine H2 receptor antagonist were observed.", "metadata": {"original_id": "DrugDDI.d234.s2"}, "annotations": [{"start": 37, "end": 71, "tag": "drug"}]}, {"content": "Coadministration of phenytoin with 40 mg SULAR tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.", "metadata": {"original_id": "DrugDDI.d234.s3"}, "annotations": [{"start": 20, "end": 30, "tag": "drug"}, {"start": 41, "end": 47, "tag": "drug"}, {"start": 89, "end": 101, "tag": "drug"}]}, {"content": "Coadministration of SULAR with phenytoin or any known CYP3A4 inducer should be avoided and alternative antihypertensive therapy should be considered.", "metadata": {"original_id": "DrugDDI.d234.s4"}, "annotations": [{"start": 20, "end": 26, "tag": "drug"}, {"start": 31, "end": 41, "tag": "drug"}, {"start": 54, "end": 61, "tag": "drug"}, {"start": 103, "end": 120, "tag": "drug"}]}, {"content": "Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.", "metadata": {"original_id": "DrugDDI.d234.s5"}, "annotations": [{"start": 37, "end": 49, "tag": "drug"}, {"start": 53, "end": 68, "tag": "drug"}, {"start": 68, "end": 77, "tag": "drug"}, {"start": 78, "end": 90, "tag": "drug"}]}, {"content": "Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.", "metadata": {"original_id": "DrugDDI.d234.s6"}, "annotations": [{"start": 0, "end": 12, "tag": "drug"}, {"start": 93, "end": 105, "tag": "drug"}]}, {"content": "The blood pressure effect of SULAR tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.", "metadata": {"original_id": "DrugDDI.d234.s7"}, "annotations": [{"start": 29, "end": 35, "tag": "drug"}, {"start": 71, "end": 80, "tag": "drug"}, {"start": 109, "end": 126, "tag": "drug"}]}, {"content": "Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.", "metadata": {"original_id": "DrugDDI.d234.s8"}, "annotations": [{"start": 0, "end": 10, "tag": "drug"}, {"start": 20, "end": 24, "tag": "drug"}, {"start": 63, "end": 75, "tag": "drug"}]}, {"content": "The immediate release, but not the coat-core formulation of nisoldipine increased plasma quinidine concentrations by about 20%.", "metadata": {"original_id": "DrugDDI.d234.s9"}, "annotations": [{"start": 60, "end": 72, "tag": "drug"}]}, {"content": "This interaction was not accompanied by ECG changes and its clinical significance is not known.", "metadata": {"original_id": "DrugDDI.d234.s10"}, "annotations": []}, {"content": "No significant interactions were found between nisoldipine and warfarin or digoxin.", "metadata": {"original_id": "DrugDDI.d234.s11"}, "annotations": [{"start": 47, "end": 59, "tag": "drug"}, {"start": 63, "end": 72, "tag": "drug"}, {"start": 75, "end": 83, "tag": "drug"}]}, {"content": "The pharmacokinetic interactions listed below are potentially clinically important.", "metadata": {"original_id": "DrugDDI.d191.s0"}, "annotations": []}, {"content": "Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.", "metadata": {"original_id": "DrugDDI.d191.s1"}, "annotations": [{"start": 0, "end": 6, "tag": "drug"}, {"start": 42, "end": 56, "tag": "drug"}, {"start": 57, "end": 67, "tag": "drug"}, {"start": 71, "end": 80, "tag": "drug"}, {"start": 110, "end": 126, "tag": "drug"}, {"start": 155, "end": 170, "tag": "drug"}]}, {"content": "Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance.", "metadata": {"original_id": "DrugDDI.d191.s2"}, "annotations": [{"start": 0, "end": 6, "tag": "drug"}, {"start": 14, "end": 29, "tag": "drug"}, {"start": 33, "end": 46, "tag": "drug"}, {"start": 76, "end": 92, "tag": "drug"}]}, {"content": "Therefore, the dose of corticosteroid should be titrated to avoid steroid toxicity.", "metadata": {"original_id": "DrugDDI.d191.s3"}, "annotations": [{"start": 23, "end": 38, "tag": "drug"}]}, {"content": "Corticosteroids may increase the clearance of chronic high dose aspirin.", "metadata": {"original_id": "DrugDDI.d191.s4"}, "annotations": [{"start": 0, "end": 16, "tag": "drug"}, {"start": 64, "end": 72, "tag": "drug"}]}, {"content": "This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn.", "metadata": {"original_id": "DrugDDI.d191.s5"}, "annotations": [{"start": 102, "end": 117, "tag": "drug"}]}, {"content": "Aspirin should be used cautiously in conjunction with cortico-steroids in patients suffering from hypopro-thrombinemia.", "metadata": {"original_id": "DrugDDI.d191.s6"}, "annotations": [{"start": 0, "end": 8, "tag": "drug"}, {"start": 54, "end": 72, "tag": "drug"}]}, {"content": "The effect of corticosteroids on oral anticoagulants is variable.", "metadata": {"original_id": "DrugDDI.d191.s7"}, "annotations": [{"start": 14, "end": 30, "tag": "drug"}, {"start": 33, "end": 53, "tag": "drug"}]}, {"content": "There are reports of enhanced as well as diminished effects of anticoagulants when given concurrently with corticosteroids.", "metadata": {"original_id": "DrugDDI.d191.s8"}, "annotations": [{"start": 63, "end": 78, "tag": "drug"}, {"start": 107, "end": 123, "tag": "drug"}]}, {"content": "Therefore, coagulation indices should be monitored to maintain the desired anticoagulant effect.", "metadata": {"original_id": "DrugDDI.d191.s9"}, "annotations": []}, {"content": "The interaction of Activase with other cardioactive or cerebroactive drugs has not been studied.", "metadata": {"original_id": "DrugDDI.d503.s0"}, "annotations": [{"start": 19, "end": 28, "tag": "drug"}, {"start": 69, "end": 75, "tag": "drug"}]}, {"content": "In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole and Abciximab) may increase the risk of bleeding if administered prior to, during, or after Activase therapy.", "metadata": {"original_id": "DrugDDI.d503.s1"}, "annotations": [{"start": 40, "end": 48, "tag": "drug"}, {"start": 75, "end": 81, "tag": "drug"}, {"start": 119, "end": 140, "tag": "drug"}, {"start": 141, "end": 154, "tag": "drug"}, {"start": 158, "end": 168, "tag": "drug"}, {"start": 246, "end": 255, "tag": "drug"}]}, {"content": "Use of Antithrombotics Aspirin and heparin have been administered concomitantly with and following infusions of Activase in the management of acute myocardial infarction or pulmonary embolism.", "metadata": {"original_id": "DrugDDI.d503.s2"}, "annotations": [{"start": 23, "end": 31, "tag": "drug"}, {"start": 35, "end": 43, "tag": "drug"}, {"start": 112, "end": 121, "tag": "drug"}]}, {"content": "Because heparin, aspirin, or Activase may cause bleeding complications, careful monitoring for bleeding is advised, especially at arterial puncture sites.", "metadata": {"original_id": "DrugDDI.d503.s3"}, "annotations": [{"start": 8, "end": 16, "tag": "drug"}, {"start": 17, "end": 25, "tag": "drug"}, {"start": 29, "end": 38, "tag": "drug"}]}, {"content": "The concomitant use of heparin or aspirin during the first 24 hours following symptom onset were prohibited in The NINDS t-PA Stroke Trial.", "metadata": {"original_id": "DrugDDI.d503.s4"}, "annotations": [{"start": 23, "end": 31, "tag": "drug"}, {"start": 34, "end": 42, "tag": "drug"}, {"start": 97, "end": 106, "tag": "drug"}]}, {"content": "The safety of such concomitant use with Activase for the management of acute ischemic stroke is unknown.", "metadata": {"original_id": "DrugDDI.d503.s5"}, "annotations": [{"start": 40, "end": 49, "tag": "drug"}]}]